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ABSTRACT	  
Genome-­‐wide	  association	  studies	  have	  been	  used	  extensively	  to	  study	  hundreds	  
of	   phenotypes	   and	   have	   determined	   thousands	   of	   associated	   SNPs	   whose	  
underlying	   biology	   and	   causation	   is	   as	   yet	   largely	   unknown.	   Many	   previous	  
studies	  attempted	  to	  clarify	  the	  causal	  biology	  by	  investigating	  overlaps	  of	  trait-­‐
associated	  variants	  with	  functional	  annotations,	  but	  lacked	  statistical	  rigor	  and	  
examined	   incomplete	  subsets	  of	  available	   functional	  annotations.	  Additionally,	  
it	   has	   been	   difficult	   to	   disentangle	   the	   relative	   contributions	   of	   different	  
annotations	  that	  may	  show	  strong	  correlations	  with	  one	  another.	  In	  this	  thesis,	  
we	  address	  these	  shortcomings	  and	  strengthen	  and	  extend	  the	  obtained	  results.	  
Two	  methods,	  permutations	  and	   logistic	  regression,	  are	  applied	   in	  statistically	  
rigorous	   analyses	   of	   genomic	   annotations	   and	   their	   observed	   enrichment	   or	  
depletion	  of	   trait-­‐associated	   SNPs.	  The	   genomic	   annotations	   range	   from	  genic	  
regions	   and	   regulatory	   features	   to	   measures	   of	   conservation	   and	   aspects	   of	  
chromatin	   structure.	   Logistic	   regressions	   in	   a	   number	   of	   trait-­‐specific	   subsets	  
identify	   genomic	   annotations	   influencing	   SNPs	   associated	   with	   both	   normal	  
variation	  (e.g.,	  eye	  or	  hair	  colour)	  and	  diseases,	  suggesting	  some	  generalities	  in	  
the	  biological	  underpinnings	  of	  phenotypes.	  SNPs	  associated	  with	  phenotypes	  of	  
the	   immune	   system	   are	   investigated	   and	   the	   results	   highlight	   the	   distinct	  
aetiology	  for	  this	  subset.	  Despite	  the	  heterogeneity	  of	  the	  studied	  cancers,	  SNPs	  
associated	  to	  different	  cancers	  are	  particularly	  enriched	  for	  conserved	  regions,	  
unlike	   all	   other	   trait-­‐subsets.	   Nonetheless,	   chromatin	   states	   are,	   perhaps	  
surprisingly,	   among	   the	   most	   influential	   genomic	   annotations	   in	   all	   trait-­‐
subsets.	   Evolutionary	   conserved	   regions	   are	   rarely	   within	   the	   top	   genomic	  
annotations	  despite	   their	  widespread	  use	   in	  prioritisation	  methods	   for	   follow-­‐
up	   studies.	   We	   identify	   a	   common	   set	   of	   enriched	   or	   depleted	   genomic	  
annotations	  that	  significantly	  influence	  all	  traits,	  but	  also	  highlight	  trait-­‐specific	  
differences.	  These	  annotations	  may	  be	  used	  for	  the	  computational	  prioritisation	  
of	  variants	  implicated	  in	  phenotypes	  of	  interest.	  The	  approaches	  developed	  for	  
this	   thesis	   are	   further	   applied	   to	   studies	   of	   a	   specific	   human	   complex	   trait	  
(height)	  and	  gene	  expression	  in	  atherosclerosis.	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  Trait-­‐associated	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TABs	  –	  Trait-­‐associated	  Blocks	  














	   8	  
	  
TABLE	  OF	  CONTENTS	  
FIGURES.................................................................................................................12	  
TABLES ..................................................................................................................14	  
1	   INTRODUCTION ..................................................................................................16	  
1.1	   Phenotypes	  and	  heredity ................................................................................................................16	  
1.2	   Genomics	  and	  complex	  traits ........................................................................................................17	  
1.3	   Genomic	  studies..................................................................................................................................19	  
1.4	   Function	  of	  genome...........................................................................................................................27	  
1.5	   Future	  outlook.....................................................................................................................................29	  
1.6	   Scope	  of	  this	  thesis ............................................................................................................................29	  
2	   MATERIALS	  AND	  METHODS ...................................................................................31	  
2.1	   SNP	  datasets .........................................................................................................................................31	  
2.1.1	   Hindorff	  SNPs .................................................................................................................................. 31	  
2.1.2	   Reconstructed	  Hindorff	  SNPs ................................................................................................... 31	  
2.1.3	   Significant	  SNPs	  (2011) .............................................................................................................. 32	  
2.1.4	   Suggestive	  SNPs	  (2011) .............................................................................................................. 32	  
2.1.5	   Significant	  SNPs	  (2013) .............................................................................................................. 33	  
2.1.6	   Significant	  SNPs	  (Difference) ................................................................................................... 33	  
2.1.7	   Trait-­subsets .................................................................................................................................... 33	  
2.1.8	   STAGE	  eQTLs.................................................................................................................................... 35	  
2.1.9	   GIANT	  SNPs ...................................................................................................................................... 35	  
2.1.10	   Defining	  linkage	  disequilibrium	  partners ........................................................................ 36	  
2.1.11	   Scoring	  LD	  blocks	  and	  definition	  of	  odds	  ratios ............................................................ 37	  
2.1.12	   Two-­tailed	  two-­sample	  t-­test................................................................................................. 37	  
2.2	   Genomic	  annotations........................................................................................................................38	  
2.2.1	   Genome	  build	  and	  sources ......................................................................................................... 38	  
2.2.2	   Categories	  of	  genomic	  annotations ....................................................................................... 38	  
2.3	   Distribution	  of	  genomic	  annotations.........................................................................................46	  
3	   GETTING	  IT	  RIGHT:	  REPLICATION	  OF	  A	  PREVIOUS	  STUDY ................................................48	  
3.1	   Introduction..........................................................................................................................................48	  
3.2	   Method ....................................................................................................................................................50	  
	   9	  
3.2.1	   Sampling	  genotyping	  arrays..................................................................................................... 50	  
3.2.2	   Odds	  ratios ........................................................................................................................................ 50	  
3.3	   Results.....................................................................................................................................................51	  
3.3.1	   Preliminary	  work........................................................................................................................... 51	  
3.3.2	   Replicating	  significant	  enrichment	  results......................................................................... 55	  
3.3.3	   Comparison	  of	  Reconstructed	  Hindorff	  SNPs	  and	  Significant	  SNPs	  (2011) ........ 59	  
3.4	   Discussion..............................................................................................................................................63	  
3.4.1	   Comparison	  of	  Hindorff	  results	  with	  Reconstructed	  Hindorff	  SNPs........................ 63	  
3.4.2	   Expansion	  of	  analysis	  to	  more	  annotations	  and	  trait-­associated	  variants.......... 64	  
3.4.3	   Reconstructed	  Hindorff	  SNPs	  vs.	  Significant	  SNPs	  (2011) .......................................... 65	  
4	   CIRCULAR	  PERMUTATIONS ....................................................................................66	  
4.1	   Introduction..........................................................................................................................................66	  
4.2	   Materials	  and	  method ......................................................................................................................67	  
4.2.1	   Data	  structure................................................................................................................................. 67	  
4.2.2	   Circular	  permutation	  strategy................................................................................................. 68	  
4.2.3	   Odds	  ratios	  and	  confidence	  intervals .................................................................................... 69	  
4.2.4	   Calculating	  P-­values ..................................................................................................................... 71	  
4.3	   Results.....................................................................................................................................................71	  
4.3.1	   Comparison	  of	  permutations	  and	  sampling	  in	  Significant	  SNPs	  (2011)............... 71	  
4.3.2	   Comparison	  of	  different	  significant	  thresholds ................................................................ 76	  
4.3.3	   Results	  of	  Significant	  SNPs	  (2011)	  vs.	  Significant	  SNPs	  (2013) ................................ 80	  
4.3.4	   Results	  of	  Significant	  SNPs	  (2011)	  vs.	  Significant	  SNPs	  (Difference) ..................... 84	  
4.3.5	   Comparison	  of	  different	  LD	  thresholds	  in	  Significant	  SNPs	  (2011)......................... 88	  
4.4	   Discussion..............................................................................................................................................92	  
4.4.1	   Permutations	  vs.	  sampling ........................................................................................................ 92	  
4.4.2	   Modest	  functional	  enrichment	  in	  Suggestive	  SNPs	  (2011) ......................................... 94	  
4.4.3	   Analysis	  of	  trait-­associated	  variants	  identified	  since	  2011......................................... 95	  
4.4.4	   Comparison	  of	  different	  LD	  thresholds ................................................................................ 97	  
4.4.5	   Conclusion......................................................................................................................................... 98	  
5	   LOGISTIC	  REGRESSION ..........................................................................................99	  
5.1	   Introduction..........................................................................................................................................99	  
5.2	   Method .................................................................................................................................................101	  
5.2.1	   Stepwise	  multivariate	  logistic	  regression .........................................................................102	  
5.2.2	   Pseudo-­r2	  values ...........................................................................................................................104	  
	   10	  
5.3	   Results..................................................................................................................................................105	  
5.3.1	   Significant	  SNPs	  (2011) ............................................................................................................105	  
5.3.2	   Suggestive	  SNPs	  (2011) ............................................................................................................116	  
5.3.3	   Significant	  SNPs	  (2013) ............................................................................................................119	  
5.3.4	   Subsets	  of	  Significant	  SNPs	  (2013) ......................................................................................123	  
5.3.5	   Pseudo-­r2	  values ...........................................................................................................................137	  
5.4	   Discussion...........................................................................................................................................138	  
5.4.1	   Immune	  SNPs	  vs.	  Non-­immune	  SNPs ..................................................................................141	  
5.4.2	   Cancer	  SNPs	  vs.	  Non-­cancer	  SNPs ........................................................................................142	  
5.4.3	   Normal	  Variation	  SNPs	  vs.	  Disease	  SNPs ..........................................................................143	  
5.4.4	   Pseudo-­r2	  values ...........................................................................................................................143	  
5.4.5	   Method	  discussion	  and	  future	  work.....................................................................................144	  
6	   APPLICATION	  OF	  METHODS	  TO	  OTHER	  DATA ............................................................146	  
6.1	   Introduction.......................................................................................................................................146	  
6.2	   Methods...............................................................................................................................................147	  
6.2.1	   STAGE	  eSNPs..................................................................................................................................147	  
6.2.2	   GIANT	  SNPs ....................................................................................................................................149	  
6.3	   Results..................................................................................................................................................151	  
6.3.1	   STAGE	  eSNPs..................................................................................................................................151	  
6.3.2	   GIANT	  consortium	  data ............................................................................................................160	  
6.4	   Discussion...........................................................................................................................................164	  
6.4.1	   STAGE	  eSNPs..................................................................................................................................164	  
6.4.2	   GIANT	  height	  consortium.........................................................................................................167	  
6.4.3	   Conclusion.......................................................................................................................................168	  
7	   DISCUSSION ....................................................................................................169	  
7.1	   Summary	  of	  sampling	  method...................................................................................................169	  
7.2	   Summary	  of	  permutation	  method ...........................................................................................170	  
7.3	   Summary	  of	  regression	  models ................................................................................................171	  
7.4	   Recommendation	  of	  methods....................................................................................................173	  
7.5	   Summary	  of	  application	  to	  other	  data ...................................................................................174	  
7.6	   Discussion	  of	  genomic	  annotations.........................................................................................174	  
7.7	   Other	  studies	  investigating	  functional	  annotations .........................................................176	  
7.8	   Future	  work	  and	  developments	  and	  their	  impacts ..........................................................178	  
	   11	  
8	   BIBLIOGRAPHY.................................................................................................181	  
9	   APPENDIX.......................................................................................................203	  
9.1	   Traits	  divided	  into	  four	  different	  subsets.............................................................................203	  
9.1.1	   Immune	  traits................................................................................................................................203	  
9.1.2	   Cancer	  traits ..................................................................................................................................210	  
9.1.3	   Normal	  Variation	  traits ............................................................................................................211	  
9.1.4	   Disease	  traits .................................................................................................................................218	  
9.2	   R	  code	  for	  LogReg2	  model...........................................................................................................222	  
	  
	  
	   12	  
FIGURES	  
Figure	  3-­‐1	  –	  Risk	  allele	  frequencies	  in	  published	  studies.............................................52	  
Figure	  3-­‐2	  –	  Study	  populations	  of	  Significant	  SNPs	  (2011)	  and	  Significant	  SNPs	  
(2013) ........................................................................................................................................53	  
Figure	   3-­‐3	   –	   Diagram	   of	   Trait-­‐associated	   SNP	   partners	   (TASPs)	   and	   Trait-­‐
associated	  blocks	  (TABs)...................................................................................................55	  
Figure	  3-­‐4	  –	  Comparison	  of	  sampling	  results	  with	  published	  results.....................56	  
Figure	  3-­‐5	  –	  Fold	  enrichment	  vs.	  odds	  ratios .....................................................................57	  
Figure	  3-­‐6	  –	  Comparing	  published	  results	  with	  larger	  dataset..................................58	  
Figure	   3-­‐7	   –	   Comparing	   Reconstructed	   Hindorff	   SNPs	   and	   Significant	   SNPs	  
(2011) ........................................................................................................................................60	  
Figure	  4-­‐1	  –	  Diagram	  of	  permutations	  on	  virtually	  circularised	  chromosome...69	  
Figure	  4-­‐2	  –	  Comparison	  of	  sampling	  vs.	  permutation	  results	  of	  Significant	  SNPs	  
(2011) ........................................................................................................................................74	  
Figure	   4-­‐3	   –	   Comparison	   of	   significant	   and	   suggestive	   variants	   in	   a	   subset	   of	  
genomic	  annotations...........................................................................................................77	  
Figure	   4-­‐4	   –	   All	   annotations	   compared	   for	   Significant	   SNPs	   (2011)	   and	  
Suggestive	  SNPs	  (2011) .....................................................................................................78	  
Figure	  4-­‐5	  –	  Comparison	  of	  Significant	  SNPs	  (2011)	  and	  Significant	  SNPs	  (2013)	  
in	  all	  annotations ..................................................................................................................81	  
Figure	  4-­‐6	  –	  Correlations	  between	  datasets	  and	  methods...........................................82	  
Figure	   4-­‐7	   –	   Comparing	   Significant	   SNPs	   (2011)	   with	   Significant	   SNPs	  
(Difference) .............................................................................................................................85	  
Figure	   4-­‐8	   –	   Correlation	   of	   Significant	   SNPs	   (2011)	   with	   Significant	   SNPs	  
(Difference) .............................................................................................................................86	  
Figure	  4-­‐9	  –	  Comparison	  of	  r2>0.9	  with	  r2>0.7	  in	  Significant	  SNPs	  (2011)..........89	  
Figure	  4-­‐10	  –	  Correlation	  of	  the	  odds	  ratios	  in	  the	  analyses	  of	  the	  LD	  partners	  of	  
r2LD>0.9	  and	  r2LD>0.7	  in	  Significant	  SNPs	  (2011) ...................................................90	  
Figure	  5-­‐1	  –	  Odds	  ratios	  of	  univariate	  logistic	  regression	  vs.	  permutations ..... 107	  
Figure	  5-­‐2	  –	  Permutations	  vs.	  univariate	  logistic	  regression ................................... 108	  
	   13	  
Figure	   5-­‐3	   –	   Odds	   ratios	   of	   the	   final	   multivariate	   model	   for	   Significant	   SNPs	  
(2011) ..................................................................................................................................... 111	  
Figure	   5-­‐4	   –	   Odds	   ratios	   of	   the	   final	   multivariate	   model	   for	   Significant	   SNPs	  
(2011)	  including	  Distance	  to	  TSS ............................................................................... 114	  
Figure	   5-­‐5	   –	   Genomic	   annotations	   for	   Significant	   SNPs	   vs.	   Suggestive	   SNPs	  
(2011) ..................................................................................................................................... 116	  
Figure	  5-­‐6	  –	  Histogram	  of	  distance	  to	  TSS	  of	  significant	  and	  suggestive	  variants	  
(<	  20	  Kb)................................................................................................................................ 117	  
Figure	  5-­‐7	  -­‐	  Histogram	  of	  distance	  to	  TSS	  of	  significant	  and	  suggestive	  variants	  
(≤	  420	  Kb) ............................................................................................................................. 117	  
Figure	   5-­‐8	   –	   Correlation	   of	   odds	   ratios	   for	   Significant	   SNPs	   (2011)	   and	  
Significant	  SNPs	  (2013) .................................................................................................. 120	  
Figure	  5-­‐9	  –	  Significant	  genomic	  annotations	  for	  Significant	  SNPs	  (2013) ....... 121	  
Figure	   5-­‐10	   –	   Common	   genomic	   annotations	   for	   Significant	   SNPs	   (2011)	   and	  
Significant	  SNPs	  (Difference)........................................................................................ 124	  
Figure	  5-­‐11	  –	  Effect	  of	  genomic	  annotations	   in	   Immune	  vs.	  Non-­‐immune	  SNPs
.................................................................................................................................................... 127	  
Figure	  5-­‐12	  –	  Cancer	  SNPs	  vs.	  Non-­‐cancer	  SNPs ........................................................... 131	  
Figure	  5-­‐13	  –	  Normal	  Variation	  SNPs	  vs.	  Disease	  SNPs.............................................. 134	  
Figure	  6-­‐1	  –	  Comparison	  of	  odds	  ratios	  obtained	   for	  GWAS	  hits	  and	  All	  eSNPs
.................................................................................................................................................... 153	  
Figure	  6-­‐2	  –	  Shared	  eSNPs	  vs.	  Tissue-­‐specific	  eSNPs .................................................. 157	  
Figure	  6-­‐3	  –	  Odds	  ratios	  for	  GIANT	  height	  data............................................................. 162	  
	  
	   14	  
TABLES	  	  
Table	  2-­‐1	  –	  Summary	  statistics	  of	  the	  three	  classes	  of	  genomic	  annotations......47	  
Table	  3-­‐1	  –	  Sampling	  results	  for	  Reconstructed	  Hindorff	  SNPs ................................61	  
Table	  3-­‐2	  –	  Sampling	  results	  for	  Significant	  SNPs	  (2011)............................................62	  
Table	  4-­‐1	  –	  Permutation	  results	  for	  Significant	  SNPs	  (2011)	  at	  r2	  >	  0.9	  threshold
.......................................................................................................................................................75	  
Table	  4-­‐2	  –	  Permutation	  results	  for	  Suggestive	  SNPs	  (2011).....................................79	  
Table	  4-­‐3	  –	  Permutation	  results	  for	  Significant	  SNPs	  (2013).....................................83	  
Table	  4-­‐4	  –	  Permutation	  results	  for	  Significant	  SNPs	  (Difference) ..........................87	  
Table	  4-­‐5	  –	  Permutations	  for	  Significant	  SNPs	  (2011)	  at	  r2LD	  >	  0.7	  LD	  threshold
.......................................................................................................................................................91	  
Table	  5-­‐1	  –	  Univariate	  logistic	  regression	  for	  Significant	  SNPs	  (2011) .............. 109	  
Table	   5-­‐2	   –	   Stepwise	   logistic	   regression	   results	   for	   Significant	   SNPs	   (2011)	  
without	  Distance	  to	  TSS .................................................................................................. 112	  
Table	  5-­‐3	  –	  Stepwise	  logistic	  regression	  results	  for	  Significant	  SNPs	  (2011)	  with	  
Distance	  to	  TSS ................................................................................................................... 115	  
Table	  5-­‐4	  –	  Stepwise	  logistic	  regression	  results	  for	  Suggestive	  SNPs	  (2011)	  with	  
Distance	  to	  TSS ................................................................................................................... 118	  
Table	  5-­‐5	  –	  Stepwise	  logistic	  regression	  results	  for	  Significant	  SNPs	  (2013) .. 122	  
Table	  5-­‐6	  –	  Stepwise	  logistic	  regression	  results	  for	  Significant	  SNPs	  (Difference)
.................................................................................................................................................... 125	  
Table	  5-­‐7	  –	  Stepwise	  logistic	  regression	  results	  for	  Immune	  SNPs ...................... 128	  
Table	  5-­‐8	  –	  Stepwise	  logistic	  regression	  results	  for	  Non-­‐immune	  SNPs ............ 129	  
Table	  5-­‐9	  –	  Stepwise	  logistic	  regression	  results	  for	  Cancer	  SNPs ......................... 132	  
Table	  5-­‐10	  –	  Stepwise	  logistic	  regression	  results	  for	  Non-­‐cancer	  SNPs ............. 133	  
Table	  5-­‐11	  –	  Stepwise	  logistic	  regression	  results	  for	  Normal	  Variation	  SNPs. 135	  
Table	  5-­‐12	  –	  Stepwise	  logistic	  regression	  results	  for	  Disease	  SNPs ..................... 136	  
Table	  5-­‐13	  –	  McKelvey	  and	  Zavoina’s	  pseudo-­‐r2	  values	  for	  different	  SNP	  sets137	  
Table	  6-­‐1	  –	  Distribution	  of	  SNPs	  and	  eSNPs	  across	  chromosomes ....................... 149	  
	   15	  
Table	  6-­‐2	  –	  Permutation	  results	  for	  the	  GWAS	  hits	  for	  the	  comparison	  with	  All	  
STAGE	  eSNPs ....................................................................................................................... 154	  
Table	  6-­‐3	  –	  Permutation	  results	  for	  All	  STAGE	  eSNPs ................................................ 155	  
Table	  6-­‐4	  –	  Permutation	  results	  for	  Shared	  STAGE	  eSNPs ....................................... 158	  
Table	  6-­‐5	  –	  Permutation	  results	  for	  Tissue-­‐specific	  STAGE	  eSNPs ....................... 159	  
Table	  6-­‐6	  –	  GIANT	  height	  linear	  regression	  results ..................................................... 163	  
	  
	  
	   16	  
1 INTRODUCTION	  
	  
A policeman sees a drunken man searching for something under a streetlight and asks what the 
drunk has lost. He says he lost his keys and they both look under the streetlight together. After a 
few minutes the policeman asks if he is sure he lost them here, and the drunk replies, no, that he 
lost them in the park. The policeman asks why he is searching here, and the drunk replies, "This 
is where the light is." -- David H. Freedman (2010)  
	  
1.1 Phenotypes	  and	  heredity	  
Every	   living	   organism	   exhibits	   certain	   traits	   or	   phenotypes,	   which	   determine	  
their	  ability	  to	  survive	  in	  any	  given	  environment.	  If	  the	  organism	  is	  successful	  in	  
surviving	   and	   producing	   offspring,	   then	   these	   traits	  will	   get	   passed	   on	   to	   the	  
next	  generation.	  This	  phenomenon	  is	  heredity	  and	  Gregor	  Johann	  Mendel,	  a	  19th	  
century	  Austrian	  monk,	  was	  the	  first	  to	  observe	  and	  describe	  heredity	  patterns	  
of	  seven	  discreet	  traits,	  which	  existed	  in	  one	  of	  two	  forms,	  in	  garden	  pea	  plants	  
(Pisum	  sativum)	  [1].	  	  
	  
One	  of	  the	  traits	  he	   investigated	  was	  the	  colour	  of	  peas,	  which	  could	  be	  either	  
yellow	  or	  green.	   In	  a	   crossing	  of	   two	  plants	  with	  yellow	  peas,	  which	  emerged	  
from	   a	   cross	   of	   a	   plant	   with	   yellow	   peas	   and	   a	   plant	   with	   green	   peas,	   he	  
observed	  a	  distinct	  3:1	  ratio	  of	  yellow	  to	  green	  peas.	  He	  was	  able	  to	  draw	  three	  
conclusions	   based	   on	   the	   observed	   patterns.	   The	   first	   of	   these	   was	   that	   the	  
determining	   factors	   of	   inheritance	  were	   “units”,	  which	  had	  been	  passed	  on	   to	  
the	  descendants	  unchanged	  if	  the	  same	  trait	  was	  observed.	  The	  second	  was	  that	  
each	   individual	   had	   two	   of	   these	   units,	   where	   one	   was	   obtained	   from	   each	  
parent.	  The	  third	  conclusion	  was	  that,	  while	  the	  units	  were	  passed	  on,	  the	  trait	  
did	  not	  have	   to	  be	  displayed.	  From	  these	  conclusions,	   two	   laws	  of	   inheritance	  
were	   established	  much	   later	   [2],	  which	   are	   now	   called	   the	  Mendelian	   laws	   of	  
inheritance.	   The	   Law	   of	   Segregation	   states	   that	   a	   parent	   only	   passes	   on	   one	  
allele	  for	  any	  given	  trait,	  while	  the	  Law	  of	  Independent	  Assortment	  dictates	  that	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different	   pairs	   of	   alleles	   are	   passed	   on	   independently	   of	   each	   other	   to	   the	  
descendants.	  	  
	  
Mendel’s	  work	   defined	  many	   of	   the	   terms	   used	   today.	  Mendel	   described	   two	  
versions	   of	   the	   inherited	   units	   as	   alleles.	   Today,	   we	   know	   that	   these	   alleles	  
describe	  different	  versions	  of	  genes	  or	  mutations.	  The	  terms	  heterozygous	  and	  
homozygous	   define	   if	   an	   individual	   carries	   different	   or	   the	   same	   alleles,	  
respectively.	  A	  recessive	  trait	  is	  only	  exhibited	  if	  the	  same	  alleles	  of	  a	  gene	  are	  
inherited,	  while	  only	  one	  allele	  is	  necessary	  for	  a	  dominant	  trait	  as	  the	  state	  or	  
version	   of	   the	   other	   is	   irrelevant	   in	   the	   development	   of	   the	   trait.	   Traits	   that	  
follow	   the	   laws	   of	   inheritance	   are	   called	  Mendelian	   traits	   and	  while	  Mendel’s	  
conclusions	  were	  based	  on	  experiments	  in	  pea	  plants,	  the	  laws	  and	  conclusions	  
are	   true	   for	   all	   diploid	   organisms,	   i.e.,	   organisms	   with	   two	   copies	   of	   genetic	  
information	  in	  their	  cells.	  	  
	  
1.2 Genomics	  and	  complex	  traits	  
Human	  DNA	   consists	   of	  ~3	   billion	   nucleotides	   arranged	   into	   23	   chromosome	  
pairs,	  which	  contain	  genes	  and	  regulatory	  elements	  controlling	  their	  expression.	  
There	  are	   four	  nucleotides	   (Arginine,	  Thymine,	  Cytosine,	   and	  Guanine),	  which	  
can	  be	  found	  in	  DNA,	  whose	  order	  encodes	  the	  information	  that	  determines	  the	  
characteristics	   of	   the	   individual	   carrying	   the	   genes	   and	   regulatory	   elements.	  
Expressed	   genes	   are	   transcribed	   into	   ribonucleic	   acid,	   or	   RNA,	   which	   is	   then	  
translated	   into	   proteins.	   RNA	   contains	   three	   of	   the	   above-­‐mentioned	  
nucleotides	  and	  Uracil,	  which	  replaces	  Thymine.	  	  
	  
The	  first	  working	  drafts	  of	  the	  human	  genome	  sequence	  were	  published	  in	  2001	  
[3,	   4]	   and	   announced	   finished	   in	   2004	   [5].	   The	   sequencing	  was	   accomplished	  
through	  a	   large	   international	   cooperation	  of	  many	   laboratories	  worldwide	   [3]	  
and	   Celera	   [4,	   6,	   7],	   a	   privately	   owned	   company,	   and	   has	   been	   refined	   and	  
improved	  several	  times.	  It	   is	  now	  in	  its	  19th	  release	  [8]	  and	  its	  37th	  release	  for	  
the	  Genome	  Reference	   Consortium	   (GRC),	  with	   a	   38th	   release	   planned	   for	   the	  
	   18	  
end	  of	  summer	  of	  2013	  [9].	  Each	  refinement	   improved	  the	  available	  reference	  
genome	  but	   the	  working	  drafts	   or	   reference	   assemblies	  have	  never	   contained	  
100%	   of	   the	   genomic	   sequence	   due	   to	   sequencing	   and	   alignment	   problems	  
particularly	  in	  repetitive	  regions	  [10].	  	  
	  
Despite	   these	   problems,	   researchers	   were	   able	   to	   identify	   several	   types	   of	  
variation	   between	   the	   sequences	   of	   individuals.	   These	   variations	   were	   either	  
single	  base	  changes	  of	  the	  sequence,	  or	  insertions	  and	  deletions	  (Indels)	  of	  one	  
or	   multiple	   bases,	   which	   can	   have	   effects	   on	   phenotypes.	   The	   effect	   can	   be	  
caused	   by	   either	   changes	   within	   a	   gene’s	   product	   (RNA	   or	   protein)	   or	  
disruptions	  to	  a	  regulatory	  element	  controlling	  the	  expression	  of	  the	  gene.	  The	  
mutations	   causing	   diseases	   such	   as	   Huntington’s	   or	   sickle	   cell	   anaemia	   were	  
identified	   within	   the	   protein	   coding	   part	   of	   a	   gene,	   either	   truncating	   or	  
deforming	   the	   resulting	   protein	   and	   thus	   diminishing	   its	   function	   [11].	  
Mutations	   affecting	   the	   regulation	   of	   genes	   can	   also	   be	   detrimental	   and	   are	  
therefore	  correspondingly	  selected	  against	  [12].	  	  
	  
Mutations	  can	  occur	  during	  meiosis,	  mitosis	  or	  through	  exposure	  to	  mutational	  
triggers	   such	   as	   UV	   radiation	   or	   exposure	   to	   certain	   chemicals.	   Base	  
substitutions	   tend	   to	  affect	  only	  single	  base	  pairs,	   changing	   the	   identity	  of	   the	  
local	   nucleotide.	   In	   rare	   events,	   it	   can	   affect	  more	   than	   one	   base	   pair	   during	  
gene	   conversions.	  Deletions	  or	   insertions	  of	  nucleotides	   can	  vary	   in	   size	   from	  
one	  to	  several	  nucleotides	  as	  a	  result	  of	   frame	  shift	  mutations	  or	  transposable	  
elements.	   The	   mutational	   rate	   in	   humans	   across	   generations	   was	   recently	  
estimated	   ~1.20	   ×	   10-­‐8	   per	   base	   pair	   per	   generation	   [13-­‐15],	   which	   is	  
considered	   to	   be	   unexpectedly	   low	   [15].	   Deleterious	   mutations,	   which	   either	  
affect	  survival	  or	  reproduction	  of	   the	  carrier,	  are	  selected	  against,	  while	   those	  
mutations	  offering	  an	  advantage	  can	  become	   fixed	   in	   the	  population.	  Selective	  
pressures	   are	   determined	   by	   the	   environment	   and	   can	   be	   quite	   different	  
between	  different	  populations.	  Mutations	  may	  therefore	  exhibit	  different	  allele	  
frequencies	   in	   different	   populations	   or	   population	   groups,	   as	   selection	  
pressures	  are	  different	  between	  populations	  depending	  on	  their	  environments.	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This	  can	  cause	  stable	  genomic	  differences	  between	  groups	  of	  individuals	  within	  
or	   across	   populations	   at	   certain	   points	   in	   the	   DNA	   called	   polymorphisms.	   A	  
distinct	  and	  systematic	  difference	   in	  allele	   frequencies	  between	  populations	   is	  
called	  population	  stratification.	  Admixture	  is	  the	  result	  of	  such	  two	  populations	  
mixing,	  which	  results	  in	  new	  genetic	  lineages	  in	  a	  population.	  These	  are	  issues,	  
which	   need	   to	   be	   taken	   into	   account	   in	   genetic	   studies,	   which	   are	   described	  
later.	   Single	   nucleotide	   polymorphisms	   (SNPs)	   are	   DNA	   sequence	   variants	  
where	   a	   single	   nucleotide	   has	   a	   different	   identity	   when	   compared	   to	   either	  
other	  members	   of	   the	   same	   species	   or	   the	   paired	   chromosome.	   The	   different	  
identities	  of	  a	  SNP	  are	  called	  alleles,	  where	  the	  majority	  of	  common	  SNPs	  have	  
two	   alleles,	   although	   tri-­‐	   or	   quadri-­‐allelic	   SNPs	   can	   also	   be	   found.	   The	  minor	  
allele	  of	  a	  SNP	  is	  defined	  as	  the	  allele	  with	  a	  frequency	  of	   less	  than	  0.5	  (minor	  
allele	   frequency	   (MAF))	   in	   a	   population	   or	   sample.	   To	   date	   (10th	   July	   2013)	  
53,567,890	   SNPs	   have	   been	   identified	   in	   the	   human	   genome,	   of	   which	  
38,072,522	   have	   been	   validated	   according	   to	   the	   National	   Center	   for	  
Biotechnology	  Information	  (NCBI)	  [16].	  The	  genome	  contains	  highly	  specialized	  
regions,	   which	   are	   associated	  with	   regulatory	   features	   or	   can	   contain	   a	   large	  
number	  of	  genes.	  The	  distributions	  of	  genes,	  regulatory	   features	  and	  SNPs	  are	  
far	  from	  homogenous	  with	  certain	  regions	  in	  the	  genome	  showing	  a	  higher	  SNP	  
density	   than	   others	   [17,	   18],	   with	   particular	   preference	   for	   areas	   outside	   of	  
coding	   regions.	   An	   impediment	   to	   the	   reliable	   use	   of	   SNP	   data,	   or	   any	   DNA	  
sequence	  data	  in	  further	  analyses,	  was	  the	  difficulty	  in	  genotyping	  certain	  areas	  
of	  the	  genome.	  For	  instance,	  areas	  high	  in	  GC	  content	  are	  comparatively	  difficult	  
to	   sequence	   or	   genotype	   accurately	   [19].	   Furthermore,	   repetitive	   elements	  
cause	   problems	   in	   the	   mapping	   and	   alignment	   of	   those	   sequences	   which	  
hindered	  the	  identification	  of	  SNPs	  in	  these	  regions	  [20].	  	  
1.3 Genomic	  studies	  
Before	  nucleic	  acids	  were	   identified	  as	   the	   carriers	  of	  heritable	   traits,	   and	   the	  
molecular	   structure	   of	   nucleic	   acids	  was	   identified	   [21,	   22],	   researchers	  were	  
continually	   observing	   phenotypes	   to	   further	   deduce	   conclusions	   about	   the	  
molecule	   that	  determines	  our	  characteristics.	  They	  measured	  the	   frequency	  of	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alleles	   of	   genes	   by	   observing	   the	   frequency	   of	   traits	   in	   the	   population	   and	  
calculated	   the	   expected	   and	   observed	   frequencies	   of	   certain	   traits	   to	   appear.	  
They	   discovered	   a	   deviance	   in	   frequency	   of	   two	   alleles	   from	   the	   expected	  
frequency	  as	  defined	  by	  the	  product	  of	  their	  individual	  frequencies,	  and	  termed	  
it	   linkage	   disequilibrium	   (LD)	   [23].	   LD	   is	   a	   measure	   of	   the	   genetic	   linkage	  
between	   loci.	   It	  was	   hypothesized	   that	   as	   distance	   decreased	   alleles	   or	   genes	  
would	   segregate	   together	   more	   often	   than	   expected	   by	   chance,	   so	   that	   a	  
distance	  between	  the	  two	  loci	  could	  be	  estimated	  by	  calculating	  the	  number	  of	  
recombinants	  in	  each	  cross.	  This	  greatly	  facilitated	  the	  identification	  of	  genetic	  
components,	   as	   traits	   were	   analysed	   in	   relation	   to	   each	   other	   where	   the	  
probability	   of	   segregation	   acted	   as	   a	  proxy	   for	  distance.	  With	   this	   knowledge,	  
the	  first	  linkage	  or	  genetic	  maps	  were	  created	  in	  Drosophila	  ten	  years	  later	  [24],	  
which	  aided	  discovering	  genes	   in	   that	  species.	  However,	   it	  was	  not	  until	  1980	  
that	   linkage	   was	   used	   to	   create	   the	   first	   genetic	   maps	   in	   humans	   [25].	   The	  
genetic	  maps	  of	  human	  DNA	  sequence	  enabled	  the	  first	  linkage	  analyses,	  which	  
identified	  disease-­‐associated	  genomic	  regions	  solely	  through	  positional	  cloning	  
or	   LD	  mapping	   [26].	   Linkage	   analysis	   studies	   aim	   to	   associate	   genes	   to	   their	  
locations	   in	   the	   genome	   and	   are	   performed	   by	   investigating	   genetic	   markers	  
that	   are	   co-­‐inherited	  with	   the	   analysed	   trait	   in	   related	   individuals.	   The	   rough	  
location	  of	  the	  underlying	  genetics	  of	  the	  investigated	  trait	  is	  thereby	  identified	  
and	  can	  be	  researched	  further	  to	  find	  the	  causal	  gene.	  	  
	  
Linkage	  analyses	  or	  LD	  mapping	  were	  successful	  for	  Mendelian	  traits,	  i.e.,	  traits	  
caused	   by	   single	   genes,	   which	   followed	   the	   Mendelian	   laws	   of	   inheritance.	  
Among	  the	  first	  of	  the	  diseases,	  whose	  causal	  genes	  were	  successfully	  mapped	  
was	   Huntington’s	   disease.	   In	   1993	   [27]	   a	  mutation	  was	   identified	   in	   a	   single	  
gene,	   hence	   named	   Huntingtin.	   More	   specifically,	   this	   mutation	   was	   the	  
multiplication	  of	   a	   codon,	  within	   the	   coding	   region	  of	   that	  gene.	  The	   resulting	  
protein	   functions	   differently	   depending	   on	   the	   number	   of	   repeats	   of	   a	   codon	  
(CAG,	   coding	   for	   glutamate)	  where	   36	   or	  more	   codons	   result	   in	   Huntington’s	  
disease	  [28].	  The	  number	  of	  codons	  within	  the	  gene	  is	  highly	  correlated	  with	  the	  
age	   of	   onset	   and	   severity	   of	   the	   disease,	   where	   higher	   codon	   numbers	   cause	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more	   severe	   phenotypes.	   Parents	  with	   normal	   codon	   numbers	   can	   pass	   on	   a	  
defect	   gene	   to	   their	   children	   due	   to	   a	   random	   multiplication	   event	   during	  
meiosis.	  The	  clear	  separation	  between	  patient	  and	  healthy	  control	  and	  the	  large	  
effect	   caused	   by	   the	   mutation	   in	   a	   single	   gene	   enabled	   the	   relatively	   easy	  
identification	  of	  the	  causal	  gene.	  	  
	  
However,	  not	  all	  genetic	  causes	   for	   traits	  were	  as	  detectable	  as	   the	  Huntingtin	  
gene,	   as	   the	  majority	   of	   traits	   are	   not	   caused	   by	   a	  mutation	   in	   a	   single	   gene,	  
which	   has	   a	   large	   effect	   on	   a	   phenotype.	   There	   are	   hundreds	   of	   examples	   of	  
traits	  influencing	  behaviour	  or	  characteristics	  in	  humans	  that	  are	  not	  caused	  by	  
a	  single	  gene	  with	  large	  effect	  [29].	  Such	  complex	  traits	  can	  be	  caused	  by	  one	  or	  
more	   genes	   acting	   either	   independently	   or	   in	   interactions	   with	   other	   genes,	  
and/or	   the	  environment	   [29].	   In	   complex	   traits,	   a	  mutation	  or	   genetic	   variant	  
underlying	  certain	  the	  phenotype	  may	  also	  have	  only	  a	  very	  small	  effect	  on	  the	  
trait	  making	  detection	  difficult.	  These	  genetic	  loci	  contributing	  towards	  complex	  
traits	  are	  called	  quantitative	  trait	  loci	  (QTLs).	  The	  polygenic	  nature	  of	  complex	  
traits	  means	   that	   they	  do	  not	   follow	  the	  Mendelian	   laws	  of	   inheritance,	  as	   the	  
causal	  genes	  may	  not	  segregate	  together.	  This	  combined	  with	  the	  small	  effects	  
of	   the	   causal	   variants	   means	   that	   it	   can	   be	   quite	   challenging	   to	   identify	   all	  
genetic	   factors	   of	   complex	   traits	   [29-­‐32],	   especially	   when	   limited	   by	   low-­‐
resolution	  methods	  such	  as	  linkage	  analyses.	  
	  
The	   search	   for	   trait-­‐associated	   genetic	   variants	   advanced	   substantially	   in	   the	  
last	   decade	   with	   the	   implementation	   of	   genome-­‐wide	   association	   studies	  
(GWAS).	   These	   studies	   are	  designed	   to	   analyse	   the	   entire	   genome	   for	   regions	  
associated	   to	   the	   trait	   under	   investigation	   [31]	   using	   an	   essentially	   blind	  
approach	  and	  do	  not	  require	  a	  previously	  identified	  area	  of	  interest.	  GWAS	  test	  
alleles	  of	  SNPs	   for	  associations	  with	  diseases	  or	  other	  measurable	  phenotypes	  
returning	  a	  P-­value	  of	  association,	  which	  reflects	  the	  strength	  of	  the	  association.	  
The	   first	   GWAS	  were	   performed	   in	   2005	   and	   2006	   and	   identified	   SNPs	   with	  
significantly	   different	   allele	   frequencies	   in	   healthy	   controls	   and	   patients	   with	  
age-­‐related	  macular	  degeneration	  [33,	  34].	  The	  era	  of	  GWAS	  truly	  began	  in	  2007	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with	   the	  Wellcome	   Trust	   Case	   Control	   Consortium	   (WTCCC),	   which	   analysed	  
seven	   common	   diseases	   in	   14,000	   patients	   and	   3,000	   controls	   [35]	   and	  
discovered	  several	  significantly	  associated	  SNPs.	  A	  SNP	  is	  said	  to	  be	  significantly	  
associated	   with	   the	   trait,	   if	   its	   P-­value	   of	   association	   was	   less	   than	   the	  
commonly	   accepted	   genome-­‐wide	   threshold	   of	   significance	   (P	   ≤	   5	   ×	   10-­‐08),	  
which	  is	  based	  on	  testing	  1	  million	  SNPs	  [36].	  This	  P-­value	  takes	  the	  number	  of	  
performed	   tests	   into	   account	   to	   eliminate	   spurious	   associations	   caused	   by	  
multiple	   testing.	   The	   success	   of	   a	   study,	   as	   measured	   by	   the	   number	   of	  
identified	  significantly	  trait-­‐associated	  variants,	  varied	  for	  different	  traits.	  This	  
demonstrated	   two	   major	   difficulties	   encountered	   by	   GWAS	   performed	   since	  
then.	  First,	  the	  cost	  of	  obtaining	  sufficiently	  large	  numbers	  of	  samples	  to	  detect	  
variants	  of	  small	  effect	  can	  be	  prohibitive	  [31].	  Second,	  certain	  traits	  may	  also	  
be	   poorly	   defined,	   which	   makes	   the	   identification	   of	   the	   underlying	   genetics	  
difficult.	  Bipolar	  affective	  disorder,	  for	  example,	  can	  be	  difficult	  to	  diagnose	  as	  it	  
can	   be	   mistaken	   for	   other	   psychoses	   or	   unipolar	   depression	   with	   re-­‐current	  
episodes	   [37].	   Other	   problems	   of	   GWAS	   include	   the	   lack	   of	   power	   to	   identify	  
associations	   with	   rare	   SNPs	   and	   SNPs	  with	   small	   effect	   sizes.	   GWAS	   are	   also	  
highly	  sensitive	  to	  admixture	  and	  population	  stratification,	  which	  could	  result	  in	  
false	   positive	   associations	   as	   alleles	   segregated	   at	   different	   frequencies	   in	  
different	   populations.	   The	   heritability	   estimate	   of	   any	   given	   trait	   may	   also	  
influence	  the	  success	  of	  a	  GWAS,	  as	  high	  heritability	  estimates	   indicate	  a	   large	  
genetic	   component.	   The	   assumption	   is	   that	   genome-­‐wide	   association	   studies	  
would	   be	   more	   successful	   at	   detecting	   associated	   genomic	   regions	   for	   these	  
highly	   heritability	   traits	   than	   for	   traits	   which	   have	   a	   higher	   environmental	  
component.	  	  
	  
Despite	  all	   these	   issues,	  as	  of	  25th	   June	  2013	  1,640	  GWAS	  had	  been	  published,	  
reporting	   a	   total	   of	   10,876	   trait-­‐associated	   SNPs	   [38].	   SNPs	   tested	   for	  
association	   to	  a	   trait	  are	  said	   to	  be	  significantly	  associated	  with	  a	   trait,	   if	   they	  
are	  found	  to	  co-­‐occur	  with	  the	  trait	  more	  often	  than	  expected	  by	  chance.	  This	  is	  
usually	  at	  a	  significance	  level	  of	  less	  than	  0.05.	  However,	  since	  many	  hundreds	  
of	  thousands	  of	  SNPs	  are	  analysed	  in	  each	  study,	  the	  significance	  threshold	  must	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be	  corrected	  for	  multiple	  testing	  to	  take	  into	  account	  spurious	  associations.	  One	  
method	  often	  used	   to	  correct	   for	  multiple	   testing	   is	   the	  Bonferroni	  correction.	  
An	  association	  P-­value	  of	  P	  ≤	  0.05/n,	  where	  n	  is	  the	  number	  of	  tests	  performed,	  
i.e.,	   the	   number	   of	   SNPs	   on	   a	   genotyping	   array,	   is	   generally	   accepted	   as	  
significant	  evidence	  that	  the	  SNP	  is	  associated	  to	  the	  disease	  [39].	  	  
	  
According	   to	   some,	   GWAS	   produced	   relatively	   little	   understanding	   of	   the	  
underlying	   biology	   [40,	   41],	   and	   has	   even	   been	   characterized	   as	   a	   waste	   of	  
money	   by	   some	   of	   the	   supporters	   for	   effectively	   the	   same	   reasons	   [31].	  
Regardless	  of	  the	  validity	  of	  these	  criticisms,	  the	  fact	  is	  that	  GWAS	  have	  greatly	  
advanced	  our	  understanding	  of	   the	   genetics	   of	   complex	   traits	   [31],	   increasing	  
our	  knowledge	  by	  a	  factor	  only	  previously	  matched	  by	  	  epidemiological	  studies	  
[42].	  	  
	  
When	   GWAS	  were	   first	   carried	   out	   it	  was	   hoped	   that	   trait-­‐associated	   regions	  
contained	   functional	  elements,	  which	  could	  explain	  some,	   if	  not	  all,	  of	  a	   trait’s	  
observed	   heritability	   [31].	   Heritability	   is	   a	   calculated	   estimate	   of	   the	   genetic	  
proportion	  of	  traits	  and	  is	  the	  ratio	  of	  the	  variance	  of	  a	  trait	  across	  generations	  
and	   the	   total	   phenotypic	   variance	   in	   a	   population,	   which	   is	   the	   interaction	  
between	  genetics	  and	  environment	  [43].	  The	  identified	  variants	  have	  explained	  
little	   of	   the	   estimated	   total	   heritability	   of	   the	   analysed	   traits,	   a	   phenomenon	  
dubbed	  “missing	  heritability”	  [36,	  38,	  44].	  Studies	  have	  since	  suggested	  that	  the	  
heritability	  is	  not	  missing	  but	  that	  researchers	  either	  do	  not	  know	  how	  to	  look	  
for	   it	   or	   that	   it	   was	   estimated	   incorrectly	   [30,	   45,	   46].	   Several	  methods	   have	  
been	  published	  which	  improve	  the	  heritability	  estimates	  by	  employing	  methods	  
that	   analyse	   more	   than	   just	   the	   associated	   variants	   [30,	   36,	   46-­‐48].	   It	   is	  
therefore	  possible	  that	  the	  “missing	  heritability”	  is	  not	  missing	  at	  all,	  but	  that	  it	  
is	  calculated	  wrongly	  after	  the	  results	  are	  obtained.	  Furthermore,	  it	  is	  possible	  
that	  the	  causal	  variant	  is	  not	  only	  not	  included	  on	  the	  genotyping	  array	  used	  for	  
the	   study,	  but	   that	   the	   represented	  variants	   are	  not	   in	   full	   LD	  with	   the	   causal	  
variant.	  Other	  reasons	  for	  the	  apparently	  missing	  heritability	  could	  be,	  as	  of	  yet	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unaccounted	  for,	  epistatic	  effects,	  epigenetic	  factors	  or	  use	  of	  models	  that	  only	  
investigate	  significant	  SNPs	  rather	  than	  all	  effect	  sizes.	  
	  
The	  genotypes	  of	  the	  SNPs	  used	  for	  GWAS	  are	  obtained	  using	  genotyping	  array	  
technologies,	  which	  allow	  the	  simultaneous	  analysis	  of	  a	  large	  number	  of	  SNPs.	  
Most	  GWAS	  use	  commercially	  available	  and	  standard	  genotyping	  arrays,	  which	  
measure	   between	   300,000	   and	   1.8	  million	   genetic	  markers	   at	   the	   same	   time,	  
although	   earlier	   arrays	  were	   less	   dense.	   The	   entire	   genome	   can	   be	   examined	  
using	  small	  numbers	  of	  SNPs	   in	  comparison	  to	  the	  number	  present	  within	  the	  
entire	  genome	  because	  of	  LD.	  The	  underlying	  assumption	  of	  GWAS	   is	   that	   the	  
analysed	  SNPs	  are	  either	  the	  causal	  mutation	  or	  in	  LD	  with	  the	  causal	  mutation	  
and	   can	   therefore	   ‘tag’	   the	   causal	  mutation.	   Those	   tag	   SNPs,	  which	   are	   in	   LD	  
with	  a	  large	  number	  of	  SNPs	  and	  are	  therefore	  the	  most	  informative	  SNPs,	  are	  
included	   on	   the	   arrays	   to	   produce	  maximum	   coverage	   of	   the	   genome	  with	   a	  
minimum	   number	   of	   genotyped	   variants	   [49].	   The	   different	   genotype	   array	  
producers	  use	  different	  criteria	  to	  choose	  the	  SNPs	  that	  were	  incorporated	  into	  
arrays.	  For	  example,	  the	  Illumina	  HumanHap300	  array	  included	  an	  intentional	  
bias	  towards	  non-­‐synonymous	  variants	  [50],	  due	  to	  their	  high	  impact	  on	  protein	  
function.	   After	   performing	   quality	   control	   on	   the	   genotyped	   SNPs,	   badly	  
genotyped	   or	   missing	   markers	   are	   often	   imputed	   to	   boost	   the	   numbers	   of	  
analysed	  markers	  [51].	  	  
	  
Imputation	   is	  a	  method,	  which	   is	  used	  to	   infer	   the	  genotypes	  of	  untyped	  SNPs	  
based	  on	  the	  identity	  of	  genotyped	  SNPs	  and	  a	  reference	  population	  [52].	  This	  
adds	  statistical	  power	  to	  GWAS	  by	  adding	  more	  SNPs	  to	  the	  analysis,	  which	  can	  
then	   be	   tested	   for	   an	   association	   with	   analysed	   traits	   in	   the	   same	   way	   as	  
genotyped	   SNPs.	   Several	   algorithms,	   such	   as	   IMPUTE2	   [53],	   MACH	   [54]	   or	  
BEAGLE	   [55]	   to	   name	   but	   a	   few,	   are	   available	   for	   imputations.	  Meta-­‐analyses	  
routinely	   use	   imputation	   to	   combine	   different	   studies,	   which	   may	   have	   used	  
different	  genotyping	  arrays,	  to	  infer	  the	  genotypes	  of	  untyped	  SNPs	  in	  the	  used	  
studies.	  The	  imputed	  SNPs	  can	  be	  tested	  for	  association	  in	  the	  same	  way	  as	  the	  
genotyped	   SNPs	   are.	  While	   imputations	   greatly	   boost	   the	   number	   of	   variants	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available	   for	   analysis,	   they	   can	   take	   a	   very	   long	   time	   to	   perform.	   It	   is	  
additionally	  possible	   that	   imputations	   introduce	  errors	   into	   the	  analysis	   if	   the	  
wrong	  reference	  genome	  is	  used.	  However,	  if	  the	  reference	  genome	  is	  matched	  
appropriately	   to	   the	   population	   under	   investigation,	   the	   results	   can	   be	   quite	  
reliable.	   As	  most	   studies	   now	   use	   imputations	   to	   boost	   the	   numbers	   of	   SNPs	  
available	  for	  analysis	  [38],	  any	  study	  investigating	  trait-­‐associated	  variants	  will	  
have	  to	  consider	  SNPs	  resulting	  from	  imputations.	  	  
	  
Several	  study	  designs	  are	  available	  for	  GWAS.	  One	  common	  design	  is	  the	  cohort	  
study,	  where	  one	  group	  of	  people	  is	  analysed	  for	  a	  common	  quantitative	  trait,	  to	  
identify	  a	  common	  genetic	  factor.	  A	  study	  using	  this	  design	  led	  to	  the	  discovery	  
of	   the	   involvement	   of	   a	   urate	   transporter	   gene	   in	   gout	   [56].	   Another	   popular	  
design	   is	   the	   patient	   (‘case’)	   and	   control	   group	   study,	   where	   SNPs	   are	  
investigated	   for	   a	   difference	   in	   allele	   frequencies	   in	   the	   two	   groups.	   In	   these	  
types	  of	  studies,	   it	   is	   important	   to	  match	   the	  sampled	  populations	  properly	   to	  
take	   population	   stratification	   and	   admixture	   into	   account.	   If	   these	   are	   not	  
considered	  properly,	  spurious	  associations	  will	  result	   from	  the	  analysis,	  which	  
are	   only	   indicative	   of	   a	   recent	   mixing	   of	   the	   populations	   than	   real	   trait-­‐
associations.	   The	   above	   mentioned	   WTCCC	   study	   in	   2007	   [35]	   was	   a	   case-­‐
control	   study	  which	   analysed	   seven	   different	   traits.	   Usually	   a	   discrete	   trait	   is	  
analysed	  (i.e.,	  a	  trait	  which	  simply	  is	  present	  or	  not,	  for	  instance	  the	  presence	  or	  
lack	   of	   the	   defining	   symptoms	   of	   the	   disease	   under	   investigation),	   although	  
continuous	  traits	  such	  as	  e.g.,	  height	  can	  also	  be	  examined	  [57].	  The	  majority	  of	  
the	   trait-­‐associated	   variants	   identified	   so	   far	   are	   common	   alleles,	  which	   have	  
allele	   frequencies	  greater	   than	  0.05,	  with	  modest	  effect	  sizes	  on	   the	   trait	   [58].	  
This	   directly	   reflects	   the	   biases	   in	   the	   variants	   that	   were	   chosen	   for	   the	  
genotyping	  arrays	  towards	  those	  with	  common	  alleles.	  These	  were	  selected,	  as	  
the	  minor	   alleles	  will	   be	   present	   in	   a	   larger	   number	   of	   people,	   increasing	   the	  
power	   to	   detect	   a	   given	   size	   of	   genetic	   effect	   for	   a	   fixed	   sample	   size.	  
Furthermore,	  the	  cost	  of	  studies	  using	  the	  number	  of	  people	  needed	  to	  analyse	  
small	  effects	  has	  so	  far	  been	  prohibitively	  large.	  However,	  this	  will	  likely	  change	  
as	  the	  cost	  to	  genotype	  and	  sequence	  the	  genome	  is	  ever-­‐decreasing.	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Despite	   the	   shortcomings	   of	   GWAS,	   when	   results	   are	   produced	   it	   can	   have	  
profound	   impact	   on	   our	   understanding	   of	   biology.	   For	   instance,	   when	   the	  
underlying	   biology	   was	   verified	   through	   follow-­‐up	   studies,	   the	   results	   were	  
sometimes	  surprising.	  For	  example,	  the	  genes	  associated	  with	  multiple	  sclerosis	  
were	   all	   found	   to	   have	   an	   autoimmune	   role	   rather	   than	   a	   neurodegenerative	  
role	  as	  previously	  hypothesized	  [59].	  The	  new	  biology	  introduced	  by	  GWAS	  has	  
therefore	   shed	   light	   onto	   the	   aetiology	   of	   the	   investigated	   traits.	   The	  
identification	   of	   new	   candidate	   treatment	   options	   as	   a	   consequence	   of	  GWAS,	  
perhaps	  in	  the	  form	  of	  novel	  drug	  targets,	   is	  the	  best-­‐case	  scenario	  and	  but	  so	  
far	   has	   happened	   only	   rarely	   [31].	   While	   we	   know	   only	   10-­‐20%	   of	   genetic	  
variability	   contributing	   to	   certain	   diseases,	   we	   know	   10-­‐20%	   more	   of	   the	  
underlying	   genetics	   than	   we	   did	   five	   years	   ago	   [31].	   GWAS	   have	   therefore	  
contributed	   substantially	   to	   our	  understanding	  of	   complex	   traits	   and	  diseases	  
[31].	  	  
	  
GWAS	   identifies	   SNPs	   that	   are	  only	   associated	   to	   traits,	  which	  does	  not	   imply	  
that	   the	   associations	   really	   are	   the	   mutations	   causing	   the	   trait.	   A	   distinction	  
therefore	  needs	  to	  be	  made	  between	  trait-­‐associated	  variants	  and	  trait	  causing	  
variants.	  A	  trait-­‐associated	  variant	  will	  highlight	  areas	  of	  interest	  for	  follow-­‐up	  
studies,	   while	   causal	   mutations	   will	   clarify	   the	   aetiology	   of	   traits.	   The	   causal	  
mutations	   are	   known	   for	   only	   a	   fraction	   of	   the	   10,876	   reported	   trait-­‐
associations.	   This	   is	   at	   least	   partly	   due	   to	   the	  majority	   of	   the	   trait-­‐associated	  
variants	  lying	  outside	  coding	  regions	  [50]	  and	  only	  a	  small	  fraction	  of	  the	  trait-­‐
associations	   are	   near	   or	   within	   genes	   [60].	   This	   was	   surprising	   when	   first	  
discovered	   and	   is	   contributing	   to	   the	   bottleneck	   in	   elucidating	   the	  molecular	  
processes	   and	   pathways	   underlying	   these	   associations	   [36,	   38,	   50,	   61]	   and	  
hence	  in	  gaining	  new	  biological	  knowledge.	  Experiments	  identifying	  the	  causal	  
underlying	   biology	   for	   confirmed	   associations	   are	   expensive	   and	   time-­‐
consuming.	   There	   has	   therefore	   been	   much	   interest	   in	   computational	  
prioritisation	   of	   candidate	   variants,	   both	   to	   accelerate	   the	   search	   for	   causal	  
variants,	  and	  to	  provide	  insights	  into	  the	  biology	  underlying	  disease	  states	  [62-­‐
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65].	  Although	  confirmed	  trait-­‐associated	  SNPs	  will	  most	  often	  not	  be	  the	  causal	  
variants,	   the	   surrounding	   genomic	   regions	   in	   LD	   with	   associated	   SNPs	   are	  
expected	   to	   contain	   causal	   variants	  with	   biological	   function.	   This	   triggers	   the	  
question:	   what	   do	   the	   trait-­‐associations	   coincide	   with,	   if	   not	   with	   coding	  
regions?	  	  
1.4 Function	  of	  genome	  
Back	   in	   1972	   it	   was	   hypothesized	   that	   6%	   of	   the	   genome	  was	  within	   coding	  
regions	  and	  what	  remained	  was	  defined	  as	  “junk	  DNA”	  [66],	   i.e.,	  DNA	  that	  had	  
no	   function	   as	   it	   was	   not	   under	   selection.	   Junk	   DNA	   has	   since	   been	   a	   highly	  
disputed	   concept.	   However,	   the	   fact	   remains	   that	   a	   very	   small	   proportion	   of	  
DNA	  is	  coding.	  The	  latest	  estimate	  of	  the	  number	  of	  coding	  genes	  in	  the	  human	  
genome	  stood	  at	  20,806	  according	  to	  ENSEMBL	  (date	  of	  access:	  13	  May	  2013),	  
which	   corresponds	   to	   about	   1.5%	   of	   the	   genome,	   a	   quarter	   of	   what	   was	  
previously	   hypothesized.	   In	   the	  meantime,	   it	   was	   realized	   that	   the	   remaining	  
98.5%	  harbours	   important	   functional	  elements	  such	  as	  non-­‐coding	  enhancers,	  
silencers	   and	   promoters.	   Yet,	   not	   all	   the	   non-­‐coding	   DNA	   has	   function	  
associated	   with	   it.	   So,	   the	   right	   question	   is:	   how	   much	   of	   the	   genome	   is	  
functional?	  	  
	  
The	   recent	   ENCODE	   consortium	   estimated	   that	   ~80%	   of	   the	   genome	   is	  
‘functional’	   in	   the	   sense	   that	   it	   possesses	   some	   biochemical	   activity	   [67],	  
thereby	  effectively	  eliminating	  the	  term	  junk	  DNA.	  This	  percentage	  was	  highly	  
disputed	  the	  moment	  it	  was	  announced	  [68,	  69]	  and	  continues	  to	  be	  challenged	  
[70].	  Specifically,	  Graur	  et	  al.	  [71]	  declared	  that	  the	  ENCODE	  consortium	  did	  not	  
estimate	  function	  correctly,	  blatantly	  refused	  to	  look	  at	  the	  evidence	  in	  front	  of	  
them	  and	  grabbed	  a	  good	  sounding	  number	  out	  of	  the	  hat.	  The	  ENCODE	  authors	  
themselves	  gave	  different	  functional	  genomic	  estimates	  ranging	  between	  20%-­‐
80%,	  depending	  on	  which	  author	  was	  asked	  [71].	  The	  death	  of	   the	  term	  “junk	  
DNA”	  was	  therefore	  contestable.	  While	  the	  debate	  on	  how	  much	  of	  the	  genome	  
contains	   functional	   elements	   is	  not	  yet	   resolved,	   it	   is	   indisputable	   that	  a	  wide	  
range	  of	  functional	  elements	  has	  been	  identified	  over	  the	  years.	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There	   are	  many	   regulatory	   and	   functional	   elements	   in	   the	   genome.	   Here,	   we	  
separate	  them	  into	  three	  main	  classes.	  The	  first	  class	  includes	  some	  of	  the	  many	  
identified	  genic	  annotations	  in	  the	  genome,	  such	  as	  gained	  stop	  codons	  5’	  and	  3’	  
UTRs	  and	  pseudo	  genes	  as	  well	  as	  genes	  but	  also	  regulatory	  regions	  like	  eQTLs	  
[72].	  Previous	  studies	  had	  shown	  that	  distance	  to	  transcriptional	  start	  site	  (TSS)	  
was	  very	  important	  for	  predicting	  eQTLs	  [72],	  so	  in	  chapter	  5	  onwards,	  we	  also	  
included	   this	   quantitative	   variable	   in	   our	   logistic	   regression	  modelling	   in	   this	  
class.	  The	  second	  class	  consists	  of	  other	  candidates	  for	  functional	  elements	  such	  
as	  regions,	  which	  are	  highly	  conserved	  across	  multiple	  species	  or	  transcription	  
factor	  binding	  sites	  [73,	  74],	  enhancers	  identified	  through	  conserved	  sequences	  
[75]	   and	   insulators.	   They	   are	   suspected	   to	   be	   important	   during	   development	  
and	  contribute	  to	  the	  accurate	  function	  of	  the	  cell	  and	  have	  also	  been	  used	  as	  a	  
proxy	  for	  functional	  elements	  [64,	  76].	  	  
	  
Yet	   a	   third	   class	   of	   potential	   functional	   elements	   is	   derived	   from	   a	   range	   of	  
dynamic	   chromatin	   features	   that	   are	   associated	  with	   biological	   functions	   like	  
promoters,	   enhancers,	   silencers	   or	   heterochromatin	   states.	   The	   epigenome	   is	  
the	   set	   of	   heritable	   features	   that	   can	   alter	   gene	   expression	   or	   the	   cellular	  
phenotype	  independently	  of	  the	  DNA	  sequence	  itself	  [77].	  Epigenomic	  features	  
include	   DNA	   methylations,	   histone	   modifications	   and	   the	   binding	   of	  
transcription	   factors	   [77].	   DNA	   methylations	   most	   commonly	   occur	   on	   a	  
cytosine	  nucleotide	  when	  a	  guanine	  residue	  follows	  it	  on	  the	  same	  DNA	  strand.	  
DNA	  methylations	  are	  necessary	   for	   the	   correct	   function	  of	   a	   cell,	   as	   aberrant	  
methylation	   is	   highly	   associated	   with	   cancer	   [78,	   79].	   Certain	   amino	   acid	  
residues	  within	  histone	  proteins,	  around	  which	  DNA	  molecules	  are	  wrapped	  for	  
safe	   storage	   in	   the	   cell,	   are	   the	   targets	   of	   a	   variety	   of	   different	   biochemical	  
modifications.	   The	   identity	   and	   location	   of	   the	   modification	   is	   strongly	  
associated	  with	   their	   function.	  Presence	  of	  acetylations,	   for	  example,	   is	  almost	  
always	  associated	  with	  transcriptionally	  active	  regions	  in	  the	  genome,	  whereas	  
absence	  of	  these	  modifications	  may	  indicate	  inactive	  regions	  [80].	  Methylations	  
can	  be	  associated	  with	  repressed	  or	  active	  regions	  depending	  on	  their	  location	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on	  the	  histone	  protein	  [80].	  Epigenomic	  mechanisms	  are	  not	  only	  crucial	  for	  cell	  
differentiation	  during	  development	  but	  also	  seem	  to	  respond	  to	  environmental	  
stimuli,	   such	   as	   diet	   [81].	   A	   landmark	   paper	   investigated	   epigenomic	  
modifications	   and	   their	   distribution	   across	   nine	   cell	   lines	   and	   identified	   a	  
reproducible	   pattern	   of	   histone	   modifications	   for	   15	   genomic	   features	   [82].	  
These	   features	   ranged	   from	   promoters	   and	   enhancers	   to	   insulators	   and	  
repressed	  regions,	  and	  showed	  varying	  degrees	   in	  strength	  of	   function	  as	  well	  
as	   significant	   odds	   ratios	   for	   enrichment	   of	   specific	   trait	   associated	   variants.	  
However,	  they	  did	  not	  investigate	  all	  available	  trait-­‐associated	  variants.	  	  
1.5 Future	  outlook	  
Trait-­‐associated	   variants	   are	   assumed	   to	   highlight	   the	   functional	   variants,	  
which	  cause	  the	  investigated	  traits.	  The	  number	  of	  these	  associated	  variants	  is	  
set	   to	   increase	  not	  only	  through	  more	  powerful	  GWA	  studies	  but	  also	  through	  
next	  generation	  sequencing.	  In	  order	  to	  gain	  any	  insights	  into	  what	  drives	  these	  
associations	  we	  will	  have	  to	  investigate	  where	  these	  trait-­‐associated	  variants	  lie	  
and	  what	  causes	  the	  associations.	  However,	  gathering	  the	  data	  is	  only	  the	  first	  
part	   and	   in	   order	   to	   validate	   the	   associations,	   follow-­‐up	   studies	   need	   to	   be	  
performed.	   The	   cost	   of	   these	   in	   time	   and	   money	   is	   restrictive	   limiting	   the	  
number	  of	  results	  that	  can	  be	  analysed.	  Given	  that	  trait-­‐association	  data	  is	  going	  
to	  continue	  to	  accumulate,	  ways	  of	  prioritizing	  the	  associated	  variants	  are	  going	  
to	  become	  ever	  more	   important.	  We	  have	   therefore	  developed	   the	  project	   for	  
this	  thesis,	  the	  scope	  of	  which	  we	  outline	  next.	  	  
	  
1.6 Scope	  of	  this	  thesis	  
This	  thesis	  deals	  with	  the	  number	  and	  nature	  of	  the	  functional	  elements	  found	  
to	  be	  overlapping	  with	  trait-­‐associated	  variants,	  which	  were	  the	  results	  of	  GWA	  
studies	  investigating	  a	  large	  number	  of	  traits.	  These	  SNPs	  may	  not	  be	  the	  causal	  
mutations	   themselves,	   but	   it	   is	   the	   assumption	   that	   they	   are	   nonetheless	   in	  
association	   with	   the	   underlying	   causal	   mutation,	   which	   might	   not	   be	   an	  
identified	  SNP	  [36].	  The	   introduction	  of	   this	   thesis	  sets	  out	   to	  define	   the	  most	  
	   30	  
important	   concepts	   used	   in	   this	   study.	   Chapter	   2	   describes	   the	   SNP	   sets	   and	  
genomic	   feature	  datasets	  we	  use	  throughout	  the	  thesis.	   In	  Chapters	  3,	  4	  and	  5	  
we	  explore	  three	  methods	  for	  the	  identification	  of	  sets	  of	  genomic	  annotations	  
that	  were	  either	  significantly	  enriched	  or	  depleted	  for	  trait-­‐associated	  variants	  
in	  humans.	  First	  we	  investigate	  a	  sampling	  based	  method	  employed	  by	  Hindorff	  
et	   al.	   [50]	   in	   Chapter	   3.	   We	   then	   analyse	   a	   permutation-­‐based	   method	   and	  
compare	   the	   permutation	   results	   to	   the	   sampling	   results	   in	   Chapter	   4.	   The	  
permutations	  were	  investigated	  as	  an	  alternative	  to	  the	  sampling	  method,	  in	  the	  
hope	   it	   would	   allow	   a	   more	   rapid,	   comprehensive,	   and	   statistically	   rigorous	  
analysis.	   Chapter	   5	   details	   the	   third	   method	   we	   applied.	   This	   was	   logistic	  
regression,	  a	  method	  that	  allowed	  estimates	  of	  the	  relative	  contributions	  of	  all	  
genomic	  annotations	  to	  trait-­‐association	  status,	  thereby	  eliminating	  redundant	  
information.	  Here,	  we	  also	  included	  an	  additional	  annotation,	  distance	  to	  TSS,	  as	  
suggested	  by	  a	   reviewer	  of	   our	  paper	   (following	   [72]).	   In	  Chapter	  6	  we	  apply	  
two	  methods,	  permutations	  and	  regression,	   to	   two	  differently	  obtained	  sets	  of	  
SNPs	   to	   see	   if	   the	  methods	   are	   adaptable.	   The	   first	   of	   these	   datasets	  was	   the	  
result	  of	  the	  Stockholm	  Atherosclerosis	  Gene	  Expression	  (STAGE)	  study	  aimed	  
at	   identifying	  eQTLs	  and	  contained	  26,546	  SNPs	   [83].	  The	  second	  dataset	  was	  
obtained	   from	   the	   Genetic	   Investigation	   of	   Anthropometric	   Traits	   (GIANT)	  
consortium	   and	   contained	   P-­values	   of	   association	   for	   ~2.5	   million	   SNPs	  
investigated	  for	  associations	  with	  height	  [57].	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2 MATERIALS	  AND	  METHODS	  
2.1 SNP	  datasets	  
2.1.1 Hindorff	  SNPs	  
This	   data	   consisted	   of	   465	   unique	   trait-­‐associated	   SNPs,	   with	   associations	  
significant	  at	  the	  Bonferroni	  corrected	  genome-­‐wide	  significance	  threshold	  of	  5	  
×	  10-­‐8.	   The	   significant	   SNPs	  originated	   from	  151	  of	   the	  237	  published	   studies	  
until	  December	  2008	  [50].	  This	  dataset	  of	  Hindorff	  SNPs	  was	  used	  only	   in	   the	  
original	  paper	  in	  2009.	  We	  attempted	  to	  reconstruct	  this	  set	  of	  trait-­‐associated	  
SNPs.	   All	   reported	   studies	   used	   at	   least	   one	   of	   the	   several	   commercially	  
available	  genotyping	  arrays	  by	  different	  companies,	  and	  most	  studies	  ended	  up	  
with	  ~2.5	  million	  imputed	  SNPs.	  Imputation	  of	  unknown	  SNPs	  using	  a	  reference	  
population	  is	  a	  cost	  and	  time	  efficient	  method	  for	  increasing	  the	  number	  of	  SNPs	  
available	  for	  analyses	  [84].	  	  
2.1.2 Reconstructed	  Hindorff	  SNPs	  
The	  original	  GWAS	  catalogue,	  detailing	  all	  GWAS	  performed	  until	  31st	  December	  
2008,	   was	   obtained	   through	   personal	   communication	   with	   the	   authors	   [50].	  
This	   GWAS	   catalogue	   reported	   1,104	   SNPs	   identified	   as	   trait-­‐associated	   at	  
various	  levels	  of	  significance	  in	  237	  studies	  for	  165	  different	  traits.	  Of	  these,	  476	  
SNPs	   were	   unique,	   trait-­‐associated	   SNPs	   significant	   at	   5	   ×	   10-­‐8	   for	   95	   traits	  
identified	  in	  151	  studies.	  The	  final	  analysed	  dataset	  included	  468	  SNPs,	  as	  SNPs	  
from	  the	  Y-­‐chromosome	  or	  non-­‐assigned	  chromosomes	  were	  removed	  from	  the	  
data.	  It	  was	  impossible	  to	  identify	  the	  exact	  set	  of	  465	  SNPs	  used	  for	  the	  analysis	  
by	  Hindorff	   et	   al.,	   as	   following	   their	  method	   to	   identify	   the	   significantly	   trait-­‐
associated	   SNPs	   resulted	   in	   a	   number	   of	   trait-­‐associated	   SNPs	   that	   was	   far	  
lower	  than	  they	  originally	  reported.	  It	  is	  possible	  that	  further	  steps	  were	  either	  
not	   published	   or	   that	   their	   methodology	   was	   not	   clear.	   However,	   several	  
approaches	  at	   replicating	   the	  data	  were	  attempted.	  The	  dataset	  analysed	  here	  
was	  the	  closest	  approximation.	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2.1.3 Significant	  SNPs	  (2011)	  
The	  National	  Human	  Genome	  Research	  Institute	  (NHGRI)	  GWAS	  catalogue	  [85]	  
reports	   genome-­‐wide	   association	   studies	   if	   they	  meet	   their	   inclusion	   criteria.	  
The	   first	   one	   is	   that	   any	   included	   study	   must	   analyse	   at	   least	   100,000	   SNPs	  
before	   the	   quality	   control	   was	   applied.	   Secondly,	   the	   catalogue	   only	   reports	  
SNPs	   with	   P-­‐values	   of	   association	   of	   <	   1.00	   ×	   10-­‐5	   in	   the	   total	   analysed	  
population,	   which	   includes	   any	   initial	   and	   replication	   studies.	   There	   is	   no	  
exclusion	  criterion	  based	  on	  minimum	  sample	  size,	  but	  the	  curators	  did	  exclude	  
any	   studies	   that	   focussed	   only	   on	   SNPs	   in	   candidate	   regions.	   Trait-­‐associated	  
SNPs	  significant	  at	  the	  genome-­‐wide	  significance	  threshold	  (P	  ≤	  5	  ×	  10-­‐8)	  were	  
extracted	   from	   the	   NHGRI	   GWAS	   catalogue	   [85],	   downloaded	   on	   25	   August	  
2011.	  The	  catalogue	  reported	  5,800	  associations	  from	  764	  studies	  in	  total.	  After	  
the	  removal	  of	  SNPs	  on	  the	  Y-­‐chromosome	  or	  non-­‐assigned	  chromosomes	  1,974	  
were	   significantly	   associated	   in	   576 studies	   and	   1,909	   of	   these	   significantly	  
trait-­‐associated	   SNPs	   were	   analysed.	   The	   remainder	   either	   had	   rare	   allele	  
frequencies	  in	  the	  study	  populations	  and	  were	  not	  present	  in	  the	  HapMap	  CEU	  
II	   reference	  data,	  or	  were	   lost	  due	   to	  updated	   rs	  numbers	  when	   the	  positions	  
were	  updated	  to	  build	  37.	  	  
2.1.4 Suggestive	  SNPs	  (2011)	  
Suggestive	   SNPs	   (2011)	   consisted	   of	   the	   suggestively	   trait-­‐associated	   SNPs	  
derived	  from	  the	  NHGRI	  GWAS	  catalogue,	  which	  was	  accessed	  25	  August	  2011	  
[86].	   The	   significantly	   associated	   SNPs	   were	   also	   extracted	   from	   this	   set,	   as	  
detailed	  in	  the	  paragraph	  above.	  The	  suggestively	  trait-­‐associated	  SNP	  set	  was	  
defined	  as	  SNPs	  with	  association	  P-­values	  between	  5	  ×	  10-­‐8	  and	  5	  ×	  10-­‐5.	  SNPs	  
that	  were	  located	  on	  either	  the	  Y-­‐chromosome	  or	  unassigned	  to	  chromosomes	  
were	   removed	   from	   all	   analyses.	   SNPs	   in	   the	   suggestively	   associated	   SNP	   set	  
found	   to	   be	   in	   LD	   (r2	   >	   0.9)	   with	   significant	   SNPs	   were	   removed	   from	   the	  
dataset,	   resulting	   in	  2,410	  unique	  rs	  numbers	   from	  412	  studies	  present	   in	   the	  
data.	  The	  remainder	  either	  had	  rare	  allele	  frequencies	  in	  the	  study	  populations,	  
and	  were	  not	  present	  in	  the	  HapMap	  CEU	  II	  reference	  data,	  or	  were	  lost	  due	  to	  
updated	  rs	  numbers	  when	  the	  positions	  were	  updated	  to	  build	  37.	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2.1.5 Significant	  SNPs	  (2013)	  
The	   NHGRI	   catalogue	   was	   accessed	   again	   on	   18	   January	   2013	   and	   the	   most	  
recent	  version	  of	  the	  GWAS	  catalogue	  was	  downloaded,	  which	  incorporated	  all	  
trait-­‐associated	  SNPs	  known	  to	  that	  date.	  This	  dataset	  contained	  3,421	  unique	  
SNPs	   that	  were	  associated	  with	  492	   individual	   traits	   identified	   in	  929	  studies.	  
The	   total	   number	   of	   SNPs	   present	   in	   the	   background	   list	   of	   SNPs	   was	   3,283	  
SNPs.	  As	  before,	   the	   remainder	  either	  had	   rare	  allele	   frequencies	   in	   the	   study	  
populations,	  or	  were	  not	  present	  in	  the	  HapMap	  CEU	  II	  reference	  data,	  or	  were	  
lost	  due	  to	  updated	  rs	  numbers	  when	  the	  positions	  were	  updated	  to	  build	  37.	  	  
	  
2.1.6 Significant	  SNPs	  (Difference)	  
This	   dataset	   consisted	   of	   the	   difference	   of	   Significant	   SNPs	   (2013)	   and	  
Significant	  SNPs	  (2011).	  This	  set	  was	  analysed	  to	  see	  the	  impact	  of	  only	  the	  new	  
variants	  when	  compared	  to	  the	  older	  variants.	  It	  comprised	  1,477	  significantly	  
trait-­‐associated	   SNPs	   that	   were	   identified	   in	   the	   period	   between	   25	   August	  
2011	   and	   18	   January	   2013.	   Three	   Japanese	   studies	   [87-­‐89]	   that	  were	   part	   of	  
Significant	   SNPs	   (2011)	   had	   been	   removed	   from	   the	   NHGRI	   catalogue	   by	   the	  
time	   Significant	   SNPs	   (2013)	   was	   downloaded.	   No	   official	   reason	   has	   been	  
found	  for	  the	  removal	  of	  the	  SNPs.	  However,	  this	  increased	  the	  total	  amount	  of	  
analysed	  SNPs	  by	  153	  in	  the	  Significant	  SNPs	  (Difference).	  This	  set	  was	  analysed	  
as	   the	  SNPs	  were	  expected	   to	  have	  a	   slightly	  different	  distribution	   to	  all	  SNPs	  
from	  2013,	  as	  the	  2011	  SNPs	  contributed	  to	  the	  overall	  set.	  The	  difference	  of	  the	  
sets	  was	  expected	  to	  have	  a	  slightly	  different	  distribution	  due	  to	   the	  design	  of	  
the	  newer	  GWAS,	  which	  tend	  to	  analyse	  comparatively	  larger	  populations.	  	  
2.1.7 Trait-­‐subsets	  
The	   traits	   (phenotypes)	   associated	   with	   the	   Significant	   SNPs	   (2013)	   were	  
divided	  into	  four	  subsets:	  Cancer	  traits,	   immune-­‐related	  traits,	  general	  disease	  
traits	   and	   normal	   variation	   traits.	   This	   was	   previously	   not	   possible,	   as	   the	  
number	   of	   SNPs	   within	   the	   subsets	   was	   prohibitive	   for	   a	   reliable	   result.	   The	  
SNPs	   that	   overlapped	   between	   the	   disease	   category	   and	   the	   normal	   variation	  
category	   were	   classified	   as	   disease	   SNPs.	   Please	   refer	   to	   Section	   9.1	   for	   an	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overall	  view	  of	  all	  traits	   in	  each	  subset.	  We	  downloaded	  data	  from	  the	  Genetic	  
Association	  Database	  (GaD,	  [90])	  which	  has	  a	  detailed	  breakdown	  of	  traits	  into	  
categories.	   The	   traits	  were	   separated	   into	   subsets	  using	   the	   information	   from	  
the	  GaD.	  For	  those	  traits,	  which	  were	  not	  listed	  in	  GaD,	  we	  searched	  across	  the	  
publicly	   available	   data	   online	   to	   sort	   them	   into	   their	   respective	   subsets	  
according	  to	  the	  results	  of	  that	  investigation.	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2.1.8 STAGE	  eQTLs	  
One	  dataset	  used	  for	  analysis	  was	  an	  eQTL	  dataset	  generated	  by	  the	  Stockholm	  
Atherosclerosis	   Gene	   Expression	   (STAGE)	   study	   [83].	   This	   study	   investigated	  
gene	   expression	   levels	   in	   seven	   tissue	   types	   of	   147	   coronary	   artery	   disease	  
patients	   eligible	   for	   coronary	   artery	   bypass	   grafting	   and/or	   carotid	  
atherectomy.	  Tissue	  biopsies	  were	  extracted	   from	  atherosclerotic	  arterial	  wall	  
(n	  =	  68),	  internal	  mammary	  artery	  (n	  =	  79),	  liver	  (n	  =	  77),	  whole	  blood	  (n	  =	  102)	  
and	  subcutaneous	  (n	  =	  63)	  and	  visceral	  fat	  (n	  =	  88).	  The	  gene	  expression	  levels,	  
as	  measured	  by	  RNA	  levels	  in	  the	  biopsies,	  were	  treated	  as	  traits	  in	  a	  correlation	  
study	  with	  the	  SNP	  genotypes	  of	  the	  109	  patients,	  which	  had	  sufficient	  levels	  of	  
DNA.	   Multiple	   testing	   was	   corrected	   for	   using	   false-­‐discovery	   rate	   in	   each	  
individual	   tissue.	  These	  SNPs	  were	   located	  within	  1	  Mb	  of	  6,450	  genes	  whose	  
gene	  expression	  was	  used	  as	   the	   investigated	   trait.	  The	   total	  number	  of	  SNPs,	  
identified	  as	  significantly	  associated	  with	  gene	  expression	  levels	  were	  referred	  
to	   as	   eSNPs,	   was	   29,530.	   Collaborators	   at	   the	   Karolinski	   Institute,	   Sweden,	  
performed	  all	  the	  gene	  expression	  analyses.	  Here,	  we	  analysed	  26,546	  SNPs	  of	  
29,530	   SNPs.	   The	   remainder	  were	   lost	   due	   to	   updated	   rs	   numbers	  when	   the	  
positions	  were	  updated	  to	  build	  37.	  The	  data	  could	  be	  separated	  into	  different	  
subsets	   according	   to	   the	   tissue	   whose	   gene	   expression	   correlated	   with	   the	  
genotyped	  SNPs.	  	  
2.1.9 GIANT	  SNPs	  
The	  Genetic	   Investigation	   of	   Anthropometric	   Traits	   (GIANT)	   consortium	   is	   an	  
international	   genome-­‐wide	   association	  meta-­‐analysis	   consortium	   that	   focused	  
on	  the	  identification	  of	  loci	  affecting	  measures	  for	  human	  body	  size	  and	  shape.	  
This	  consortium	  has	  made	  datasets	  available	  to	  the	  public,	   including	  the	  meta-­‐
analyses	  for	  three	  traits:	  Height,	  BMI	  and	  Waist/Hip	  ratio	  adjusted	  for	  BMI.	  The	  
height	   dataset	   was	   downloaded	   and	   analysed	   to	   identify	   genomic	   signature	  
patterns	   of	   associated	   SNPs,	   and	   consisted	   of	   2,469,635	   SNPs	  with	   a	   range	   of	  
association	  P-­values	  [57].	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2.1.10 Defining	  linkage	  disequilibrium	  partners	  
Linkage	   disequilibrium	   (LD)	   underlies	   the	   design	   and	   success	   of	   GWAS.	   The	  
design	   of	   GWAS	   was	   based	   on	   genotyping	   arrays,	   which	   could	   capture	   a	  
substantial	   proportion	   of	   genomic	   variation	   [91].	   LD	   between	   two	   alleles	   is	  
defined	   as	   the	   deviation	   (denoted	   D)	   of	   the	   observed	   frequency	   of	   two	  
combined	   loci	   from	   the	  expected,	  where	   the	  expected	   frequency	  of	   two	   loci	   is	  
the	   product	   of	   their	   allele	   frequencies	   [43].	  While	  D	   is	   easy	   to	   calculate,	   it	   is	  
highly	  dependent	  on	  allele	   frequencies,	   so	  usually	  D’	   is	   calculated	  which	   takes	  
the	   allele	   frequencies	   into	   account.	   An	   alternate	  measure	   to	  D’	   is	   r2,	  which	   is	  
defined	  as	   the	   square	  of	   the	   correlation	   coefficient	  between	  pairs	  of	   loci.	  This	  
measure	  also	  takes	  allele	  frequencies	  into	  account.	  It	  was	  the	  optimal	  choice	  for	  
our	  work,	  as	   it	   is	  a	  commonly	  used	  measure	  and	  Hindorff	  et	  al.	  also	  used	  r2	   in	  
their	   analysis	   [50].	   SNPs	   in	   LD	   were	   referred	   to	   as	   LD	   partners	   and	   were	  
important	   for	   the	  analysis	  of	   the	  underlying	  genomic	  structure	  of	  phenotypes.	  
LD	  partners	  were	  characterized	  as	  SNPs	  from	  the	  HapMap	  CEU	  II	  data	  that	  were	  
in	   LD	   above	   the	   chosen	   cut-­‐off	   threshold	   (r2	   >	   0.9)	  with	   a	   trait-­‐associated	   or	  
sampled	  SNP	  [92,	  93].	  Since	  only	  a	  fraction	  of	  the	  known	  SNPs	  were	  included	  on	  
genotyping	   arrays,	   it	   was	   unlikely	   that	   causal	   mutations	   were	   genotyped.	  
However,	  it	  is	  assumed	  that	  they	  were	  in	  LD	  with	  associated	  SNPs	  [50].	  The	  LD	  
threshold	   of	   r2	   >	   0.9,	   a	   highly	   stringent	   threshold	   [50],	   was	   chosen	   in	  
compliance	  with	  previous	  literature	  [50].	  This	  cut-­‐off	  point	  was	  also	  chosen	  for	  
all	   our	   analyses,	   unless	   otherwise	   stated.	   The	   HapMap	   CEU	   II	   data	   on	   LD	  
(release	   #24,	   phase	   I	   and	   II,	   http://hapmap.ncbi.nlm.nih.gov/downloads/	  
ld_data/2009-­‐02_rel24/)	  between	  SNPs	  was	  used	   to	  define	   the	  LD	  partners	  of	  
all	   analysed	   SNPs	   (trait-­‐associated	   and	   non-­‐associated).	   HapMap	   CEU	   II	   data	  
contained	   information	   on	   LD	   calculated	   for	   pairs	   of	   SNPs	   up	   to	   250	  Kb	   apart	  
from	  each	  other	  [92].	  This	  resulted	  in	  theoretical	  LD	  blocks	  of	  up	  to	  500	  Kb	  long	  
for	   any	   one	   SNP.	   An	   additional	   cut-­‐off	   point	   of	   r2	   >	   0.7	   was	   analysed	   to	  
investigate	   reducing	   the	   LD	   threshold,	   capturing	   more	   LD	   SNP	   partners	   and	  
therefore	  potentially	  more	  causal	  variants	  but	  also	  noise.	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2.1.11 Scoring	  LD	  blocks	  and	  definition	  of	  odds	  ratios	  
The	   applied	   scoring	   system	   for	   the	   calculation	   of	   depletion/enrichment	   odds	  
ratios	   was	   binary.	   An	   LD	   block	   of	   trait-­‐associated	   SNPs	   and	   its	   partners	   was	  
defined	  as	  overlapping	  with	  a	  particular	  genomic	   feature	   if	   at	   least	  one	  of	   the	  
SNP	   variants	   in	   that	   block	   coincided	   with	   the	   genomic	   feature.	   Multiple	   hits	  
within	   an	   LD	   block	   were	   not	   counted.	   Sample	   and	   permutation	   SNPs	   were	  
treated	   the	   same	   as	   the	   trait-­‐associated	   SNPs	   to	   enable	   a	   solid	   comparison	  
between	  the	  expected	  and	  the	  observed	  data.	  	  
	  
Odds	  ratios	  were	  calculated	  to	  enable	  comparisons	  with	  previous	  studies	  [50],	  
where	  an	  odds	  ratio	  was	  defined	  as	  shown	  below.	  Here,	  the	  observed	  data	  are	  
the	  number	  of	  overlaps	  of	   trait-­‐associated	  SNPs	  and	  the	  expected	  data	  are	  the	  
mean	  number	  overlaps	  of	  the	  background	  data.	  	  
€ 
Overlaps Observed Data( ) * Non - Overlaps Expected Data( )
Non - Overlaps Observed Data( ) * Overlaps Expected Data( ) 	  
	  
2.1.12 Two-­‐tailed	  two-­‐sample	  t-­‐test	  
In	  order	  to	  test	  for	  a	  significant	  difference	  between	  two	  odds-­‐ratios	  of	  datasets,	  
which	   had	   no	   common	   SNPs,	   a	   two-­‐tailed	   two-­‐sample	   t-­‐test	   was	   applied	  
assuming	  unequal	   variances	  of	   the	   two	   compared	  SNP	   sets.	   The	   test	   used	   the	  
natural	  logarithm	  of	  the	  odds	  ratios,	  the	  natural	  logarithm	  of	  the	  standard	  error	  
of	  the	  odds	  ratio,	  and	  the	  number	  of	  SNPs	  per	  analysed	  set	  to	  calculate	  a	  P-­value	  
for	  the	  difference	  of	  the	  odds	  ratios.	  The	  total	  number	  of	  analysed	  SNPs	  divided	  
by	   two	   determined	   the	   degrees	   of	   freedom.	   The	   P-­value	   was	   corrected	   for	  
multiple	   testing	   using	   the	   Bonferroni	   correction,	   i.e.,	   for	   the	   number	   of	  
annotations	  that	  were	  analysed.	  The	  P-­value	  was	  significant	  if	  it	  was	  below	  the	  
adjusted	  threshold	  of	  significance.	  The	  annotations,	  for	  which	  the	  difference	  of	  
odds	  ratios	  was	  significant,	  were	  identified	  using	  a	  red	  star	  in	  all	  graphs.	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2.2 	  Genomic	  annotations	  
2.2.1 Genome	  build	  and	  sources	  
Details	  on	   the	  genomic	  annotations	  sources	  are	   included	   in	   the	  corresponding	  
paragraphs.	   All	   genomic	   annotations	   were	   downloaded	   in	   hg18,	   where	  
available.	  The	  hg18	  build	  was	   chosen,	   as	  more	  annotations	  were	  available	   for	  
that	  build	  at	  the	  beginning	  of	  the	  project,	  than	  either	  the	  previous	  (hg17)	  or	  the	  
later	  one	  (hg19).	  If	  they	  were	  not	  available	  in	  hg18,	  the	  UCSC	  liftOver	  tool	  [94]	  
was	   used	   to	   transfer	   the	   annotated	   regions	   into	   hg18.	   The	   majority	   of	   the	  
genome	   annotations	   were	   downloaded	   from	   the	   UCSC	   genome	   browser	   and	  
were	   publicly	   available	   at	   the	   time	   of	   download.	   Other	   sources	   included	   the	  
ENSEMBL	   webpage,	   which	   allowed	   selective	   download	   of	   a	   number	   of	  
variations	   with	   specified	   biological	   functions.	   These	   were	   only	   available	   for	  
download	  in	  hg19	  and	  were	  transferred	  to	  hg18.	  The	  remainder	  of	  the	  sources	  
were	   laboratory	   web	   pages	   which	   had	   made	   their	   data	   available	   online.	   If	  
necessary,	  they	  were	  converted	  into	  the	  appropriate	  build	  to	  ensure	  the	  correct	  
relative	  map	  positions.	  	  
2.2.2 Categories	  of	  genomic	  annotations	  
The	  final	  analysed	  data	  included	  58	  genomic	  features	  for	  which	  the	  genome	  was	  
annotated.	   These	   were	   separated	   into	   three	   major	   categories	   to	   enable	  
appropriate	   representation	   of	   the	   different	   underlying	   biology.	   The	   genomic	  
annotations	   chosen	   for	   analysis	   were	   similar	   to,	   if	   not	   the	   same	   as,	   the	   20	  
annotations	   previously	   published	   in	   the	   analysis	   we	   are	   replicating	   [50].	  
However,	  some	  of	  the	  annotations	  were	  no	  longer	  publicly	  available	  at	  the	  time	  
of	   download	   (e.g.,	   the	   regions	   under	   accelerated	   rates	   of	   substitution	   in	   the	  
human	  genome).	  For	   these	  annotations,	  we	  used	  either	  approximations	  of	   the	  
annotations,	   or,	   based	   on	   the	   significance	   of	   the	   odds	   ratios	   calculated	   by	  
Hindorff	   et	   al.,	   were	   not	   included	   in	   this	   analysis.	   Of	   the	   20	   published	  
annotations,	   14	   were	   downloaded	   and	   results	   obtained	   in	   theses	   categories	  
were	  compared	  to	  the	  published	  results.	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Genomic	  annotations	  that	  were	  added	  to	  the	  genomic	  annotation	  set	  included	  a	  
range	  of	  conserved	  regions,	  areas	  with	  signs	  of	  purifying	  selection,	  and	  a	  large	  
number	   of	   distinct	   and	   replicable	   histone	   modification	   patterns.	   The	   latter	  
replaced	  a	   large	  number	  of	   individual	  histone	  modifications	  that	  were	  used	  as	  
proxy	  for	  the	  different	  underlying	  biological	  functions.	  	  
	  
A	   detailed	   description	   of	   the	   58	   genomic	   annotations	   and	   their	   sources	   are	  
outlined	   below	   according	   to	   the	   category	   they	   belonged	   into.	   The	   three	  
categories	   were	   genic	   and	   regulatory	   features,	   conserved	   and	   regulatory	  
regions,	  and	  chromatin	  states.	  	  
2.2.2.1 Genic	  and	  regulatory	  features	  
This	   category	   contained	   all	   genomic	   annotations	   that	   were	   within	   genes,	  
defined	  by	  their	  proximity	  to	  genes,	  or	  identified	  through	  sequence	  analyses	  as	  
a	   regulatory	   element	   of	   transcription	   factor	   binding	   site.	   The	   text	   reflects	   the	  
order	   of	   the	   genomic	   annotations	   as	   they	   are	   shown	   on	   the	   corresponding	  
graphs	  in	  each	  figure.	  	  
	  
The	   region	  upstream	  of	   the	   transcription	   start	   site	   (TSS)	  of	   a	   gene	  has	   strong	  
literature	  evidence	  of	  containing	  putative	  promoters.	  In	  order	  to	  analyse	  these	  
regions	   and	   identify	   long-­‐range	   vs.	   short-­‐range	   regulatory	   elements,	   two	  
distances	  upstream	  of	  the	  TSS	  were	  analysed:	  1	  Kb	  and	  5	  Kb	  upstream	  of	  TSS.	  
These	   two	   genomic	   annotations	   were	   derived	   from	   the	   RefSeq	   dataset	  
downloaded	   from	   the	   UCSC	   table	   browser	   (accessed	   15th	   November	   2010),	  
which	  details	  the	  position	  of	  the	  TSS	  and	  the	  strand	  on	  which	  the	  gene	  is	  found	  
[95].	  	  
	  
CpG	   islands	   are	   areas	   in	   the	   genome	   with	   a	   large	   proportion	   (larger	   than	  
expected	   by	   chance)	   than	   expected	   by	   chance	   of	   unmethylated	   cytosines	  
followed	   immediately	   by	   a	   guanine,	  where	   only	   a	   phosphate	   group	   separates	  
the	  two.	  The	  unmethylated	  state	  of	  a	  single	  CpG	  is	  rare	  and	  will	  only	  be	  present	  
if	   there	   is	   selective	   pressure	   to	   keep	   it	   unmethylated	   [96].	   The	   methylated	  
	   40	  
cytosine	  tends	  to	  turn	  into	  thymines	  due	  to	  spontaneous	  de-­‐amination.	  The	  CpG	  
islands	   are	   associated	   with	   promoter	   functions	   and	   –	   in	   vertebrates	   –	   in	  
particular	   with	   housekeeping	   genes	   [97].	   This	   annotation	   set	   was	   also	  
downloaded	  on	  15th	  November	  2010	  from	  the	  UCSC	  table	  browser.	  	  
	  
The	   ORegAnno	   annotation	   reports	   regulatory	   regions,	   regulatory	  
polymorphisms	  and	  transcription	  factor	  binding	  sites	  and	  was	  downloaded	  on	  
15th	  November	  2010	  from	  the	  UCSC	  table	  browser.	  It	  originates	  from	  the	  Open	  
Regulatory	  Annotation	  database,	  which	   is	  an	  online	  repository	   that	   is	  publicly	  
curated	  containing	  information	  validated	  through	  experiments	  [73,	  98].	  	  
	  
The	   Vertebrate	   Genome	   Annotation	   (vega)	   database	   contains	   frequently	  
manually	   annotated	   regions	   with	   information	   on	   protein-­‐coding	   genomic	  
regions	   as	   well	   as	   pseudo	   genes	   and	   immunoglobulin	   segments.	   These	   were	  
divided	  into	  the	  vegaGenes	  annotation	  and	  the	  vega	  PseudoGenes	  annotation,	  
which	  were	  downloaded	  from	  the	  UCSC	  table	  browser	  on	  15th	  November	  2010.	  	  
The	  OMIM	  genes	  and	  OMIM	  morbid	  regions	  are	  no	  longer	  publicly	  available,	  
but	  were	  available	  at	  the	  time	  of	  download.	  The	  Online	  Mendelian	  Inheritance	  in	  
Man	  is	  a	  continuously	  updated	  catalogue	  of	  human	  genes	  and	  genetic	  disorders	  
which	   incorporates	   all	   genes	   and	   genomic	   regions	   that	   have	   been	   identified	  
through	  experiments.	  The	  OMIM	  morbid	  map	  shows	  the	  cytogenetic	  locations	  of	  
specific	  diseases	  identified	  by	  previous	  studies	  [99].	  	  
	  
The	  Exons	  annotation	  was	  derived	  from	  the	  RefSeq	  gene	  annotation	  [95],	  at	  the	  
same	  time	  as	   the	  1	  Kb	  and	  5	  Kb	  upstream	  TSS	  annotations	  were	  created.	  This	  
category	   included	   all	   exons	   possible	   through	   different	   splicing	   to	   take	   all	  
isoforms	   into	   account.	   A	   number	   of	   SNP	   annotations,	   i.e.,	   intronic,	   non-­
synonymous,	   synonymous,	   intergenic,	   splice	   sites	   and	   sites	   in	   the	   3’	   and	  
5’UTRs,	   were	   extracted	   from	   the	   dbSNP	   129	   dataset	   [16],	   accessed	   on	   20	  
January	  2011.	  The	  non-­‐synonymous	  and	  synonymous	  SNPs	  were	  combined	   to	  
create	  the	  coding	  SNPs	  annotation.	  Non-­‐synonymous	  SNPs	  resulting	  in	  gained	  
or	  lost	  stop	  codons	  were	  downloaded	  from	  the	  ENSEMBL	  webpage.	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The	  locations	  of	  RNA	  genes,	  which	  are	  genes	  that	  were	  expressed	  but	  were	  not	  
coding	   for	   proteins	   and	   pseudo	   genes	   [100,	   101],	  were	   downloaded	   from	   the	  
UCSC	  Table	  browser	  on	  25	  November	  2010.	  The	  genomic	  locations	  which	  were	  
known	  to	  correspond	  to	  totally	  intronic	  non-­coding	  RNAs	  were	  downloaded	  
from	  the	  RNA	  database	  on	  15	  November	  2010	  [102].	  The	  regulatory	  target	  sites	  
for	   conserved	   mammalian	   microRNA	   families	   in	   the	   3’UTRs	   of	   RefSeq	   Genes	  
were	  predicted	  by	  an	  algorithm	  called	  TargetScanS	  [103-­‐105].	  These	  sites	  were	  
downloaded	  from	  the	  UCSC	  Table	  Browser	  on	  15	  November	  2010.	  	  
	  
The	  eQTLs	  are	  defined	  as	  SNPs	  that	  have	  been	  associated	  to	  variation	   in	  gene	  
expression	   levels.	   The	   SNPs	   represented	   in	   this	   annotation	  were	   downloaded	  
from	   the	   eQTL	   web	   browser	   [106]	   and	   originate	   from	   a	   number	   of	   different	  
studies	  [72,	  107-­‐110].	  	  
	  
DNase	   Clusters	   represent	   DNase	   hypersensitive	   areas	   assayed	   in	   a	   large	  
collection	  of	  cell	  types	  and	  have	  been	  shown	  to	  play	  a	  major	  role	  in	  human	  traits	  
[111].	   The	   dataset	   was	   downloaded	   from	   the	   UCSC	   Table	   Browser	   on	   15	  
November	  2010	  [112].	  	  
	  
Insulators	   in	   the	  human	  genome	  are	  necessary	  boundaries	  between	  different	  
areas	   of	   the	   genome,	   which	   are	   translated	   or	   silenced.	   Genomic	   locations	   for	  
human	   insulators	   were	   downloaded	   using	   the	   ENSEMBL	   biomart	   on	   15	  
November	  2010.	  	  
SNP	   sites	   found	   within	   mature	   microRNAs	   were	   downloaded	   using	   the	  
ENSEMBL	  biomart	   to	   investigate	   if	   trait-­‐associated	   SNPs	   can	  be	  preferentially	  
found	  within	  microRNAs.	  The	  sites	  were	  downloaded	  on	  15	  November	  2010.	  	  
	  
Regions	  with	   sequences	   of	   at	   least	   15	  perfect	   di-­‐nucleotide	   and	   tri-­‐nucleotide	  
repeats	  are	  likely	  to	  be	  useful	  as	  microsatellite	  markers	  and	  are	  usually	  highly	  
polymorphic	  between	  populations	  [113].	  This	  annotation	  was	  downloaded	  from	  
the	  UCSC	  Table	  browser	  on	  15	  November	  2010.	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2.2.2.2 Conserved	  regions	  and	  evolutionary	  signatures	  
The	   conserved	   and	   evolutionary	   signatures	   category	  was	   chosen	   to	   represent	  
genomic	   locations,	  which	  were	   either	   conserved	  between	  different	   species,	   or	  
have	   been	   shown	   to	   be	   under	   selective	   pressures.	   The	   evofold	   annotation	  
corresponded	   to	   RNA	   secondary	   structure	   predictions	  made	  with	   the	   evofold	  
program.	   This	   program	   compared	   multiple-­‐sequence	   alignments	   to	   identify	  
conserved	  functional	  RNA	  structures	  [114].	  This	  annotation	  was	  downloaded	  on	  
15	  November	  2010	  from	  the	  UCSC	  Table	  browser.	  	  
	  
The	   identity	   and	   genomic	   locations	   of	   16,529	   high-­‐confidence	   orthologues	  
showing	   tested	   for	   positive	   selection	   were	   downloaded	   from	   the	   UCSC	   Table	  
browser	  on	  15	  November	  2010.	  The	  high-­‐confidence	  orthologues	  were	   from	  a	  
multiple	   mammal	   alignment	   using	   the	   genome	   assemblies	   of	   human	   (hg18),	  
chimp	   (panTro2),	   macaque	   (rheMac2),	   mouse	   (mm8),	   rat	   (rn4),	   and	   dog	  
(canFam2).	   These	   genes	   were	   analysed	   in	   different	   evolutionary	   lineages	   to	  
investigate	   mammalian	   positive	   selection	   [115].	   However,	   here	   only	   the	  
orthologues	  were	  used	  without	  restriction	  to	  the	  positive	  selection	  score.	  
	  
A	   set	   of	   enhancers	   identified	   through	   a	   number	   of	   computational	   and	  
experimental	  analyses	  to	   identify	  possible	  enhancers	   in	  human	  and	  mice	  were	  
downloaded	  on	  15	  November	  2010	  from	  the	  VISTA	  enhancer	  browser	  [116].	  
 
Exapted	  repeats	   are	   conserved	  non-­‐exonic	   sites	   that	  have	  been	  deposited	  by	  
mobile	  sites	  (repeats)	  in	  a	  process	  called	  exaptation.	  These	  repeats	  are	  possible	  
distal	   enhancers	   and	   were	   downloaded	   from	   the	   UCSC	   Table	   browser	   on	   15	  
November	  2010	  [117-­‐121].	  	  
	  
Predicted	  cis-­‐acting	  regulatory	  modules	  are	  presented	  in	  the	  PREMOD	  genomic	  
annotations,	  which	  were	   downloaded	   from	   the	   PREMOD	  database	   [122,	   123].	  
The	   location	   and	   score	   of	   transcription	   factor	   binding	   sites	   that	   are	  
conserved	   in	   a	   human/mouse/rat	   alignment,	   based	   on	   computational	  
predictions,	  were	  downloaded	   from	  the	  UCSC	  Table	  browser	  on	  15	  November	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2010.	  The	  data	  were	  generated	  using	  the	  Transfac	  Matrix	  and	  Factor	  databases	  
on	  Biobase,	  while	  Matt	  Weirauch	  and	  Brian	  Raney	  at	  the	  University	  of	  California	  
at	  Santa	  Cruz	  created	  the	  track	  for	  the	  UCSC	  Table	  browser.	  Regions	  significant	  
for	  purifying	  selection	  with	  respect	  to	  mutations	  involving	  sequence	  insertions	  
and	  deletions	  have	  been	  implicated	  as	  possibly	  identifying	  long	  intergenic	  non-­‐
coding	   RNAs,	   which	   may	   have	   an	   impact	   on	   phenotypes	   [124].	   This	   dataset,	  
referred	   to	   as	   Indels,	  was	  downloaded	  on	  15	  November	  2010	   from	   the	  UCSC	  
Table	  browser.	  	  
	  
Conserved	  sites,	  identified	  using	  a	  number	  of	  different	  species	  alignments,	  may	  
have	   a	   larger	   than	   expected	   chance	   of	   containing	   trait-­‐associated	   variants,	   as	  
conserved	   sites	   are	   thought	   to	   have	   an	   important	   biological	   function.	   The	  
phastCons	   program	   was	   used	   for	   the	   different	   species	   alignments	   [76].	   The	  
species	   used	   for	   the	   17	   species	   alignment	   were	   human	   (March	   2006	  
(NCBI36/hg18),	   hg18),	   chimp	   (November	   2003,	   panTro1),	   macaque	   (January	  
2006,	   rheMac2),	   mouse	   (February	   2006,	   mm8),	   rat	   (November	   2004,	   rn4),	  
rabbit	   (May	   2005,	   oryCun1),	   dog	   (May	   2005,	   canFam2),	   cow	   (March	   2005,	  
bosTau2),	  armadillo	  (May	  2005,	  dasNov1),	  elephant	  (May	  2005,	  loxAfr1),	  tenrec	  
(July	   2005,	   echTel1),	   opossum	   (January	   2006,	   monDom4),	   chicken	   (February	  
2004,	   galGal2),	   frog	   (October	  2004,	   xenTro1),	   zebrafish	   (May	  2005,	  danRer3),	  
tetraodon	  (February	  2004,	  tetNig1)	  and	  fugu	  (August	  2002,	  fr1).	  	  
	  
The	  28	  species	  alignment	   includes	  all	  species	   from	  the	  17	  species	  alignment,	  
six	  of	  which	  use	  updated	  sequences,	  and	  11	  new	  species.	  The	  updated	  species	  
are	  for	  the	  chimp	  (March	  2006,	  panTro2),	  cow	  (August	  2006,	  bosTau3),	  chicken	  
(May	  2006,	  galGal3),	  frog	  (August	  2005,	  xenTro2),	  fugu	  (October	  2004,	  fr2)	  and	  
zebrafish	  (March	  2006,	  danRer4).	  Five	  of	  the	  new	  species	  are	  high-­‐coverage	  (5-­‐
8.5X)	   assemblies	   of	   horse	   (February	   2007,	   equCab1),	   platypus	   (March	   2007,	  
ornAna1),	   lizard	   (February	   2007,	   anoCar1),	   stickleback	   (February	   2006,	  
gasAcu1)	  and	  medaka	  (Apr	  2006,	  oryLat1),	  while	   the	  remaining	  six	  were	   low-­‐
coverage	   assemblies	   (2X)	   from	   bush	   baby	   (December	   2006,	   otoGar1),	   tree	  
shrew	   (December	   2006,	   tupBel1),	   guinea	   pig	   (October	   2005,	   cavPor2),	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hedgehog	   (June	  2006,	   eriEur1),	   common	   shrew	   (June	  2006,	   sorAra1),	   and	   cat	  
(March	   2006,	   felCat3).	   These	   28	   species	   were	   aligned	   and	   a	   subgroup	   of	   the	  
species	  was	  used	   to	   identify	  elements	  conserved	  between	  placental	  mammals.	  
The	   placental	   mammals	   excluded	   the	   sequences	   of	   the	   opossum,	   platypus,	  
chicken,	   lizard,	   and	   frog	   as	   well	   as	   the	   following	   fish:	   tetraodon,	   fugu,	  
stickleback,	  medaka	  and	  zebrafish	  [125]	  from	  the	  28	  species	  set	  above.	  	  
	  
The	  44	  species	  alignment	   is	   composed	  of	   the	  28	  species	   listed	  above	  and	  an	  
additional	  16	  new	  ones.	  Eight	  of	  the	  28	  previous	  species	  were	  updated.	  The	  new	  
assemblies	  are	  mouse	  (July	  2007,	  mm9),	  cow	  (October	  2007,	  bosTau4),	  guinea	  
pig	  (February	  2008,	  cavPor3),	  horse	  (Sep	  2007,	  equCab2),	  elephant	  (July	  2008,	  
loxArr2),	  zebrafish	  (July	  2007,	  danRer5),	  and	  medaka	  (October	  2005,	  oryLat2).	  
The	   orang-­‐utan	   (July	   2007,	   ponAbe2)	   and	   zebra	   finch	   (July	   2007,	   danRer5)	  
were	   high-­‐coverage	   (5-­‐8.5X)	   assemblies,	   and	   gorilla	   (October	   2008,	   gorGor1),	  
marmoset	   (June	   2007,	   calJac1),	   tarsier	   (August	   2008,	   tarSyr1),	   mouse	   lemur	  
(June	   2003,	  micMur1),	   kangaroo	   rat	   (July	   2008,	   dipOrd1),	   squirrel	   (February	  
2008,	  February	  2008,	  speTri1),	  pika	  (July	  2008,	  ochPri2),	  mega	  bat	  (July	  2008,	  
pteVam1),	   micro	   bat	   (March	   2006,	   myoLuc1),	   dolphin	   (February	   2008,	  
turTru1),	  alpaca	  (July	  2008,	  viPac1),	  sloth	  (July	  2008,	  choHof1),	  rock	  hyrax	  (July	  
2008,	   proCap1),	   and	   lamprey	   (March	   2007,	   petMar1).	   The	   subsets	   were	  
obtained	  from	  the	  total	  alignments	  of	   the	  44	  species	   from	  which	  some	  species	  
were	   selected.	   The	  placental	  mammals	   included	   the	   sloth,	   armadillo,	   tenrec,	  
rock	  hyrax,	  elephant,	  common	  shrew,	  hedgehog,	  mega	  bat,	  micro	  bat,	  dog,	  cat,	  
horse,	  cow,	  dolphin,	  alpaca,	  pika,	  rabbit,	  squirrel,	  guinea	  pig,	  kangaroo	  rat,	  rat,	  
mouse,	  tree	  shrew,	  bush	  baby,	  mouse	  lemur,	  tarsier,	  marmoset,	  rhesus	  monkey,	  
orang-­‐utan,	  gorilla,	  chimp	  and	  human.	  The	  primates’	  subset	  included	  the	  latter	  
species	  from	  bush	  baby	  to	  human.	  	  
	  
Overlaps	  of	  any	  of	  the	  above	  conserved,	  regulatory	  or	  genic	  sites	  were	  removed	  
from	   the	   intergenic	   SNP	   set.	   This	   created	   a	  negative	   genomic	   feature,	   which	  
was	   depleted	   of	   any	   regulatory	   elements,	   irrespective	   of	   chromatin	   states	   or	  
histone	  modifications.	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2.2.2.3 Chromatin	  states	  and	  histone	  modifications	  	  
Two	  higher	  order	  structures	  of	  chromatin	  were	  included	  in	  the	  analysis,	  which	  
were	  established	  in	  a	  karyotypically	  normal	  lymphoblastoid	  cell	  line,	  GM06990	  
[126].	   These	   chromatin	   states	  were	   downloaded	   on	   15	  November	   2010	   from	  
the	  GO	  website	  (accession	  number:	  19815776).	  The	  data	  identified	  two	  regions	  
chromatin	  regions	  with	  different	  interaction	  patterns.	  The	  chromatin	  in	  a	  more	  
“open”	   and	   more	   accessible	   state	   was	   associated	   with	   active	   genes	   and	  
transcription	   patterns,	   while	   chromatin	   in	   a	  more	   “closed”	   conformation	  was	  
associated	   with	   inactive	   genes.	   These	   were	   included	   in	   the	   analysis	   with	   the	  
names	  Open	  Chromatin	   and	  Closed	  Chromatin,	   respectively.	  Additionally	   to	  
these	   higher	   order	   structures,	   the	   lower	   order	   structures	  were	   also	   analysed.	  
Initially,	  these	  consisted	  of	  a	  large	  number	  of	  individual	  histone	  modifications	  in	  
different	  cell	  lines.	  However,	  the	  identification	  of	  15	  different	  replicable	  histone	  
modification	   patterns	   in	   nine	   different	   cell	   lines	   made	   the	   set	   of	   individual	  
modifications	   obsolete.	   These	   15	   different	   patterns	   were	   associated	   with	  
underlying	  15	  biological	   functions	   in	   the	   genome	   [82].	   The	   authors	  used	  nine	  
different	   cell	   lines,	   out	   of	   which	   we	   used	   the	   GM12878	   cell	   line	   to	   ease	  
comparison	   with	   the	   open	   and	   closed	   chromatin	   states.	   The	   biological	  
functions	   associated	   with	   the	   histone	   modifications	   were	   promoter,	  
enhancer	   and	   insulator	   activities.	   The	   former	   two	   could	   be	   separated	   into	  
different	   subcategories,	   which	   for	   the	   promoters	   were	   active,	   weak	   and	  
inactive/poised.	   The	   active,	   weak	   and	   poised	   promoter	   labels	   were	   highly	  
interchangeable	  between	  different	  cell	  lines,	  so	  that	  overall	  these	  labels	  pointed	  
to	   regions	  with	   transcribed	   genes.	   The	   same	   can	  be	   said	   for	   strong	   and	  weak	  
enhancers	  and	  transcribed	  regions.	  However,	  the	  identity	  of	  these	  regions	  only	  
changed	  within	   their	   classes,	   so	   that	   it	   can	   be	   said	   that	   these	   regions	   tend	   to	  
preserve	  their	  regulatory	  potential,	  still	  retaining	  their	  biological	  functions	  [82].	  
The	   enhancer	   and	   repetitive	   regions	   showed	   different	   positional	   enrichment	  
along	  transcripts,	  where	  some	  elements	  acted	  on	  distal	  or	  rather	  more	  proximal	  
genes	  [82].	  These	  histone	  modifications	  were	  downloaded	  from	  the	  UCSC	  Table	  
browser	  on	  09	  June	  2011	  (“wgEncodeBroadHmmGm12878HMM”).	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2.3 Distribution	  of	  genomic	  annotations	  
Table	  2-­‐1	   shows	   the	  descriptive	   statistics	   of	   the	  58	   genomic	   annotations.	   The	  
distribution	  of	  the	  genomic	  annotations	  was	  important	  for	  the	  analysis,	  as	  a	  low	  
number	   of	   annotated	   SNPs	   caused	   odds	   ratios	   and	   confidence	   intervals	   with	  
values	  of	  infinity.	  The	  table	  includes	  information	  on	  coverage	  of	  the	  annotations	  
in	   number	   of	   sites	   in	   nucleotides	   (i.e.,	   genome	   coverage)	   and	   SNPs	   (i.e.,	   SNPs	  
genotyped	   or	   imputed	   in	   the	  GWA	   studies	   surveyed),	   and	   the	  mean	   length	   of	  
each	  annotation	  in	  the	  entire	  genome.	  Four	  (within	  mature	  miRNA,	  splice	  sites,	  
lost	  stops	  and	  microsatellites)	  of	  the	  annotations	  had	  a	  very	  low	  coverage	  of	  the	  
SNPs	  and	  were	  excluded	  from	  all	  graphs,	  as	  the	  odds	  ratios	  were	  undefined	  due	  
to	  a	  division	  by	  zero.	  The	  mean	  allele	   frequency	  of	  647,776	  SNPs	   identified	   in	  
the	  Human	  Genome	  Diversity	  Project	  overlapping	  with	   the	  annotations	   is	  also	  
shown	  in	  Table	  2-­‐1.	  The	  MAFs	  are	  very	  stable	  across	  the	  annotations,	  so	  that	  a	  
possible	  selection	  effect	  is	  unlikely	  to	  have	  influenced	  the	  results.	  	  
	  
Table	  2-­1	  –	  Summary	  statistics	  of	  the	  three	  classes	  of	  genomic	  annotations	  
This	   table	   shows	   the	   number	   of	   annotation	   sites	   (Sites),	   their	   mean	   length	   in	   base	   pairs	   (Mean	  
Length	  (bp)),	  the	  percentage	  of	  nucleotides	  coinciding	  with	  them	  (Nucleotides	  (%)),	  the	  percentage	  
of	  SNPs	  coinciding	  with	  them	  (SNPs	  (%))	  and	  the	  mean	  minor	  allele	  frequency	  of	  SNPs	  in	  the	  HGDP	  
overlapping	  with	  annotations	  (Mean	  MAF.).	  	  
Annotations	   Sites	   Mean	  Length	  (bp)	   Nucleotides	  (%)	   SNPs	  (%)	   Mean	  MAF	  
TSS	  1	  Kb	  upstream	   22624	   1069.60	   0.79	   3.40	   0.23	  
TSS	  5	  Kb	  upstream	   20592	   5533.29	   3.70	   8.83	   0.23	  
CpG	  Islands	   27458	   764.28	   0.68	   1.76	   0.23	  
ORegAnno	   17903	   627.89	   0.37	   1.97	   0.23	  
Vega	  Genes	   14651	   64881.51	   30.90	   37.89	   0.22	  
OMIM	  Genes	   12307	   64852.28	   25.90	   32.74	   0.22	  
OMIM	  Morbid	  Regions	   2532	   69311.51	   5.70	   7.82	   0.22	  
Exons	   212325	   245.31	   1.69	   7.14	   0.22	  
Intronic	  SNPs	   5125999	   1.76	   0.29	   43.61	   0.22	  
Non-­‐Syn.	  SNPs	   117692	   55.54	   0.21	   3.73	   0.22	  
Coding	  SNPs	   186247	   35.59	   0.22	   5.74	   0.22	  
Syn.	  SNPs	   72933	   1.50	   3.54	  ×	  10-­‐3	   2.99	   0.13	  
Gained	  Stops	   4186	   1.01	   1.37	  ×	  10-­‐4	   0.05	   0.20	  
3’UTR	   131649	   1.63	   0.01	   3.81	   0.22	  
5’UTR	   27693	   1.41	   1.27	  ×	  10-­‐3	   0.94	   0.27	  
RNA	  Genes	   6936	   132.54	   0.03	   0.25	   0.23	  
ncRNA	   890	   15355.22	   0.44	   0.83	   0.22	  
TS	  miRNA	   40648	   7.69	   0.01	   0.03	   0.23	  
eQTLs	   68619	   1.00	   2.23	  ×	  10-­‐3	   4.50	   0.25	  
Vega	  PseudoGenes	   6999	   3094.04	   0.70	   1.78	   0.22	  
Intergenic	  SNPs	   8250331	   1.73	   0.46	   63.71	   0.22	  
DNase	  Clusters	   969313	   243.90	   7.67	   31.25	   0.23	  
Insulators	  (sequence)	   25546	   1095.15	   0.91	   4.29	   0.23	  
Within	  miRNA	   395	   1.09	   1.39	  ×	  10-­‐5	   0.00	   0.23	  
Splice	  Sites	   1718	   4.44	   2.48	  ×	  10-­‐4	   0.04	   0.23	  
Lost	  Stops	   278	   1.02	   9.19	  ×	  10-­‐6	   0.02	   0.25	  
Microsatellites	   40186	   40.56	   0.05	   0.08	   0.25	  
Evofold	   47244	   38.81	   0.06	   0.21	   0.23	  
Pos.	  Sel.	  Genes	   16384	   39030.69	   20.80	   28.43	   0.22	  
Enhancers	   1295	   1526.59	   0.06	   0.32	   0.22	  
Exapted	  Repeats	   10400	   99.50	   0.03	   0.29	   0.22	  
PREMOD	   122979	   482.55	   1.93	   10.39	   0.23	  
tfbsConsSites	   2345848	   16.45	   1.25	   8.48	   0.23	  
Indels	   2596839	   82.23	   6.93	   32.61	   0.23	  
17	  spc.	  algmt	   2201980	   66.24	   4.74	   21.74	   0.23	  
28	  spc.	  algmt,	  plc.mmls	   2028316	   54.65	   3.60	   17.23	   0.23	  
28	  spc.	  algmt	   2873612	   48.33	   4.51	   20.30	   0.23	  
44	  spc.	  algmt	   4846954	   29.02	   4.57	   20.52	   0.23	  
44	  spc.	  algmt,	  plc.mmls	   3945677	   31.31	   4.01	   18.75	   0.23	  
44	  spc.	  algmt,	  prim	   806524	   150.28	   3.93	   17.85	   0.22	  
Negative	  (sequence)	   5277572	   509.71	   97.90	   54.81	   0.22	  
Open	  Chromatin	   13843	   99999.00	   44.90	   46.77	   0.22	  
Closed	  Chromatin	   13469	   99999.00	   43.70	   52.95	   0.22	  
Active	  promoter	   15279	   1440.81	   0.72	   2.82	   0.23	  
Weak	  promoter	   35076	   568.26	   0.65	   2.99	   0.23	  
Inactive/poised	  promoter	   5265	   891.55	   0.15	   0.35	   0.22	  
Strong	  enhancer	  (proximal)	   25486	   964.20	   0.80	   3.13	   0.23	  
Strong	  enhancer	  (distal)	   38612	   621.47	   0.78	   3.47	   0.23	  
Weak/poised	  enhancer	  
(proximal)	  
69144	   388.98	   0.87	   4.37	   0.23	  
Weak/poised	  enhancer	  (distal)	   109526	   555.25	   1.97	   8.14	   0.23	  
Insulator	   33311	   468.99	   0.51	   3.36	   0.23	  
Transcriptional	  transition	   16223	   1223.81	   0.65	   2.51	   0.22	  
Transcriptional	  elongation	   26473	   5975.22	   5.14	   9.13	   0.22	  
Weak	  transcribed	   82235	   3671.65	   9.80	   16.51	   0.22	  
Polycomb	  repressed	   25483	   3524.60	   2.92	   7.29	   0.22	  
Heterochrom;	  low	  signal	   10530	   891.55	   0.31	   81.79	   0.22	  
Repetitive/CNV	  (proximal)	   8033	   627.54	   0.16	   0.24	   0.24	  
Repetitive/CNV	  (distal)	   6122	   452.66	   0.09	   0.20	   0.25	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3 GETTING	  IT	  RIGHT:	  REPLICATION	  OF	  A	  PREVIOUS	  STUDY	  	  
3.1 	  Introduction	  	  
As	  mentioned	   in	   the	   introduction	   chapter	   of	   this	   thesis,	  most	   trait-­‐associated	  
GWAS	  hits	  are	  found	  outside	  of	  genic	  and	  usually	  coincide	  with	  genomic	  regions	  
whose	  functions	  have	  not	  yet	  been	  identified.	  This	  hinders	  the	  identification	  of	  
the	  causal	  underlying	  biology	  for	  the	  majority	  of	  GWAS	  hits	  [36,	  127],	  as	  a	  target	  
for	   follow-­‐up	   studies	   is	   not	   immediately	   obvious.	   An	   investigation	   into	   the	  
genomic	   environment	   of	   trait-­‐associated	   SNPs	   and	   their	   LD	   partners	   was	  
therefore	  warranted	   to	  aid	   the	  understanding	  of	   trait-­‐associated	  variants.	  The	  
question	   as	   to	   which	   genomic	   features	   underlie	   trait-­‐associated	   SNPs	   more	  
often	   (or	   less	   often)	   than	   expected	   by	   chance	   arises	   when	   GWAS	   hits	   are	  
investigated.	  The	  answer	  to	  that	  question	  is	  important	  for	  future	  research,	  as	  it	  
could	  be	  used	  in	  prediction	  mechanisms	  for	  trait-­‐associated	  variants.	  	  
	  
In	   2009	   Hindorff	   et	   al.	   published	   a	   study	   to	   answer	   the	   above	   question	   by	  
investigating	   genomic	   regions	   for	   enrichment	   or	   depletion	   of	   trait-­‐associated	  
SNPs	   to	   identify	   potential	   aetiological	   mechanisms	   [50].	   The	   20	   analysed	  
genomic	   regions	   or	   features	   were	   mainly	   genic	   and	   mutually	   non-­‐exclusive	  
annotations,	   i.e.,	   the	   annotations	  were	   coinciding	  with	   each	   other.	   The	   results	  
showed	   three	   annotations	   with	   significant	   odds	   ratios	   of	   enrichment	   and	  
depletion	  of	  trait-­‐associated	  variants.	  Non-­‐synonymous	  SNPs	  and	  regions	  1	  Kb	  
upstream	  of	   a	   transcription	   start	   site	   (TSS)	  were	   significantly	   enriched,	  while	  
intergenic	   SNPs	   were	   significantly	   depleted	   for	   trait-­‐associated	   SNPs.	   These	  
results	  were	  obtained	  by	   creating	  100	  samples	  of	  non-­‐associated	  SNPs,	  which	  
closely	  matched	   the	  genotype	  array	  composition	  of	   the	  observed	  data,	   i.e.,	   the	  
trait-­‐associated	  SNPs,	  as	  we	  explain	  shortly.	  The	  majority	  of	  genotyping	  arrays	  
were	   designed	  with	   a	   specific	   purpose	   in	  mind.	   The	   Illumina	  HumanHap	   300	  
genotyping	  array	  was	  enriched	  for	  non-­‐synonymous	  SNPs	  and	  targeted	  mainly	  
common	  SNPs	  [50].	  This	  inherent	  ascertainment	  bias	  present	  within	  all	  arrays	  
could	   cause	   problems	   in	   the	   sampling	   analysis,	   if	   GWAS	   hits	   were	   to	   be	  
compared	  with	  non-­‐associated	  SNPs.	  If,	  for	  example,	  one	  were	  to	  choose	  sample	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SNPs	  from	  the	  Illumina	  HumanHap	  300	  array	  only	  and	  the	  SNPs	  originated	  from	  
a	  different	  platform,	  one	  would	  erroneously	  find	  relative	  depletion	  in	  the	  non-­‐
synonymous	   SNPs	   in	   comparison.	   This	   bias	   of	   the	   genotyping	   arrays	   and	   any	  
imputed	   SNPs	   in	   the	  original	   trait-­‐associated	  dataset	   had	   to	  be	   considered	  by	  
any	   method	   aimed	   at	   obtaining	   random	   samples.	   This	   sampling	   with	   taking	  
account	  of	   the	  genotyping	  array	   composition	  produced	  a	  background,	  or	  null-­‐
distribution,	  of	  expected	  data	   to	  which	   the	  observed	  data	  were	  compared	  and	  
odds	   ratios	   of	   enrichment	   or	   depletion	   of	   the	   trait-­‐associated	   SNPs	   were	  
calculated.	  	  
	  
Hindorff	  et	  al.	   showed	   that	   trait-­‐associated	  SNPs	  had	  a	  distinct	  distribution	   in	  
the	   investigated	   genomic	   regions	   with	   significant	   results	   in	   three	   of	   20	  
annotations.	  However,	  since	  the	  study’s	  publication	  in	  2009	  many	  more	  GWAS	  
have	   been	   performed	   identifying	   many	   new	   trait-­‐associations.	   An	   additional	  
study	   into	   the	   new	   associations	   was	   therefore	   warranted.	   We	   began	   with	   a	  
replication	  of	  the	  results	  with	  the	  original	  data,	  which	  was	  needed	  to	  compare	  
the	   original	   results	   with	   the	   results	   from	   the	   more	   recent	   dataset.	   We	   also	  
included	   additional	   genomic	   annotations	   to	   investigate	   a	   broader	   range	   of	  
regulatory	   regions.	   Epigenetic	  modifications	  were	   also	   included,	   as	   they	   have	  
been	   shown	   to	   contribute	   to	   stress-­‐related	  phenotypes	   such	   as	   e.g.,	   cancer	   or	  
diabetes	  [77,	  128,	  129].	  	  
Here,	  we	  detail	  the	  steps	  taken	  to	  replicate	  the	  data,	  methods,	  and	  results	  of	  the	  
Hindorff	  et	   al.	   study.	  We	   then	  performed	   an	   investigation	  with	   a	   larger	   set	   of	  
SNPs,	  which	  were	   a	  more	   recent	   version	   of	   trait-­‐associated	   variants	   from	   the	  
NHGRI	   catalogue	   of	   GWAS	   results	   [86].	   The	   results	   of	   the	   two	   SNP	   sets,	   the	  
replicated	   set	   and	   the	  more	   recent	   set	  with	  more	  variants,	  were	   compared	   to	  
the	   results	   obtained	   by	   Hindorff	   et	   al.	   We	   additionally	   expanded	   the	  
investigation	  with	  more	  genomic	   features.	  Our	  results	  show	  that	   the	  sampling	  
method	   could	   be	   reproduced	   thereby	   validating	   the	   way	   we	   performed	   the	  
sampling	  method.	  This	  validation	  was	  necessary	  for	  an	  appropriate	  comparison	  
of	  the	  sampling	  results	  with	  results	  obtained	  by	  a	  novel	  method	  discussed	  later.	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3.2 Method	  
3.2.1 Sampling	  genotyping	  arrays	  	  
The	  study	  we	  aimed	  to	  replicate	  was	  published	  in	  2009	  by	  Hindorff	  et	  al.	  [50],	  
who	   used	   a	   sampling	   method	   to	   analyse	   the	   distribution	   of	   trait-­‐associated	  
variants	  in	  20	  genomic	  annotations.	  The	  method	  obtained	  sample	  sets	  of	  SNPs	  
of	   equal	   size	   to	   the	   set	   of	   trait-­‐associated	   SNPs	   represented	   on	   genotyping	  
platforms.	  We	  used	  weighted	  groups	  based	  on	  the	  manufacturer(s)	  of	   the	  SNP	  
platform(s)	   and	   the	  HapMap	  CEU	   II	   data	   to	  draw	   the	   samples,	   rather	   than	  on	  
individual	   genotyping	   arrays,	   as	   that	   information	   was	   often	   unavailable.	   The	  
numbers	   of	   SNPs	   drawn	   from	   each	  manufacturer	   group	  were	   proportional	   to	  
the	   number	   of	   SNPs	   observed	   in	   the	   real	   data.	   Groups	   were	   established	  
representing	   the	   union	   of	   varied	   combinations	   of	   genotyping	   arrays	   and	  
imputed	  data.	  These	  groups	  were	  randomly	  sampled	   in	   the	  proportions	  of	   the	  
observed	  data.	  Multiple	  entries	  of	   individual	  SNPs	  were	  possible	  and	  were	  not	  
removed.	  This	  takes	  into	  account	  the	  greater	  chance	  of	  a	  SNP	  to	  be	  identified	  as	  
a	  trait-­‐associated	  SNP,	  if	  it	  was	  present	  on	  more	  than	  one	  genotyping	  array.	  	  
3.2.2 Odds	  ratios	  	  
Odds	  ratios,	   confidence	   intervals	  and	  P-­values	  of	  significance	   for	   the	  observed	  
results	   were	   calculated	   using	   the	   oddsratio.wald	   function	   from	   the	   epitools R 
package	   [130]	  of	   the	   statistical	  program R version	  2.12.1	   [131].	  This	   function	  
calculated	  the	  odds	  ratios	  by	  comparing	  unconditional	  maximum	  likelihoods	  of	  
the	   observed	   value	   compared	   with	   the	   mean	   number	   of	   expected	   hits.	   Odds	  
ratios	  of	  enrichment/depletion	  were	  calculated	  by	  comparing	  overlaps	  between	  
genomic	   features	   and	   real	   trait-­‐associated	   data	   with	   overlaps	   of	   SNPs	  
determined	   by	   chance	   alone.	   The	   P-­values	   were	   defined	   as	   significant	   when	  
below	   the	  Bonferroni-­‐corrected	   significance	   threshold,	  which	   in	   our	   case	  was	  
calculated	  for	  58	  independent	  variables	  (P	  ≤	  8.62	  ×	  10-­‐4).	  The	  analysed	  genomic	  
annotations	   were	   not	   independent	   from	   each	   other,	   which	   means	   that	   the	  
Bonferroni	  corrected	  P-­value	  is	  conservative.	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3.3 	  Results	  	  
3.3.1 Preliminary	  work	  
3.3.1.1 Study	  populations	  
In	   order	   to	   ascertain	   the	   correct	   population	   for	   the	   establishment	   of	   the	   LD	  
blocks,	   an	   investigation	   was	   undertaken	   into	   which	   population	   was	   used	   the	  
most	   often	   in	   GWAS.	   Hindorff	   et	   al.	   already	   showed	   that	   populations	   from	  
European	  descent	  were	  the	  most	  numerous.	  However,	  for	  completeness	  we	  also	  
reinvestigated	   this.	   Three	   populations	   were	   analysed:	   European,	   Asian,	   and	  
African.	   The	   European	   category	   contained	   all	   studies	   specifying	   European	  
populations	  (e.g.,	  Croatian	  or	  Scottish)	  or	  those	  defining	  their	  study	  population	  
as	   Caucasian	   or	   white.	   The	   Asian	   category	   consisted	   of	   studies	   with	   several	  
populations	   with	   Asian	   background,	   such	   as	   Malaysian,	   Thai,	   Chinese	   or	  
Japanese.	   The	   African	   category	   included	   populations	   such	   as	   Ghanaians	   or	  
populations	  with	  African	  ancestry,	  e.g.,	  African	  Americans.	  Since	  Reconstructed	  
Hindorff	   SNPs	   were	   obtained	   from	   the	   authors	   of	   the	   original	   paper,	   it	   was	  
expected	   that	   its	   structure	   was	   as	   published.	   In	   the	   Significant	   SNPs	   (2011)	  
dataset	  374	  of	  576	  studies	  specified	  their	  study	  population	  in	  either	  the	  title	  or	  
the	  sample	  descriptions.	  	  
	  
Histograms	  of	  the	  risk	  allele	  frequencies	  in	  the	  entire	  dataset	  (A),	  the	  European	  
(B),	  Asian	  (C),	  and	  African	  (D)	  populations	  respectively	  are	  shown	  in	  Figure	  3-­‐1.	  
The	   histogram	   of	   the	   European	   population	   (green)	   matches	   that	   of	   the	   risk	  
allele	  frequencies	  of	  all	  significant	  trait-­‐associated	  SNPs	  the	  best.	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Figure	  3-­1	  –	  Risk	  allele	  frequencies	  in	  published	  studies	  
The	  risk	  allele	  frequencies	  of	  all	  reported	  trait-­‐associated	  SNPs	  are	  shown	  in	  the	  panel	  A	  (pink).	  Their	  
distribution	   closely	  matches	   the	   distribution	   of	   the	   risk	   allele	   frequencies	   of	   trait-­‐associated	   SNPs	  
from	  GWAS	  specifying	  their	  study	  population	  as	  either	  European	  or	  white	  (green,	  B).	  While	  the	  Asian	  
(turquoise,	   C)	   and	   African	   (purple,	   D)	   populations	   show	   similar	   trends,	   the	   numbers	   of	   observed	  
variants	  are	  much	  smaller.	  
	  
Additionally,	  the	  Euler	  diagram	  in	  Figure	  3-­‐2	  showing	  the	  number	  of	  studies	  for	  
each	  population	  and	  the	  overlap	  between	  all	  studies	  indicates	  that	  the	  majority	  
of	   studies	   specified	   the	   use	   of	   a	   European	   study	   population.	   The	   study	  
population	  for	  Significant	  SNPs	  (2013)	  was	  also	  the	  European	  population,	  as	  an	  
Euler	   diagram	   of	   the	   studies	   with	   specified	   populations	   showed	   the	   same	  
proportions	   as	   in	   Significant	   SNPs	   (2011).	   The	  definitions	   for	   the	  populations	  
were	   the	   same	   as	   outlined	  previously.	   Significant	   SNPs	   (2013)	   contains	  many	  
more	   studies	   than	   Significant	   SNPs	   (2011),	   and	   they	   are	   equally	   distributed	  
across	  all	  populations.	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Figure	  3-­2	  –	  Study	  populations	  of	  Significant	  SNPs	  (2011)	  and	  Significant	  SNPs	  (2013)	  
A)	  A	   total	  of	   374	  of	  576	  unique	   studies	   in	   the	   large	  dataset,	  which	   specified	   the	   study	  population	  
(202	  unspecified).	   There	  were	   four	   studies,	  which	   analysed	  all	   three	  populations	  but	   zero	   studies,	  
which	   compared	   Asian	   populations	   with	   African	   populations.	   B)	   The	   total	   number	   of	   studies	  
specifying	   the	   study	   populations	   was	   710.	   The	   number	   of	   studies	   using	   European	   or	   African	  
populations	  has	  increased	  by	  almost	  two-­‐fold	  when	  compared	  to	  the	  data	  from	  2011.	  However,	  the	  
number	  of	  studies	  using	  Asian	  populations	  has	  more	  than	  tripled.	  The	  majority	  of	  these	  studies	  were	  
performed	   in	   the	   Chinese	   population	   (data	   not	   shown).	   Of	   the	   929	   unique	   studies,	   219	   did	   not	  
specify	  the	  study	  population	  in	  either	  the	  sample	  descriptions	  or	  the	  study	  title.	  	  
	  
The	   results	   of	   this	   investigation	   led	   to	   the	   use	   of	   the	   HapMap	   CEPH	   LD	   data	  
(CEU,	  release	  #24)	   in	   this	  study	  to	  establish	  LD	  partners	  of	   trait-­‐associated	  or	  
sample	   SNPs,	   and	   to	  make	   up	   the	   groups	   for	   the	   sampling	   of	   the	   genotyping	  
arrays	   mixed	   with	   imputation	   results.	   The	   CEU	   data	   are	   obtained	   from	   Utah	  
residents	  with	  ancestry	  from	  Northern	  and	  Western	  Europe	  [132].	  Additionally,	  
the	   use	   of	   this	   data	   is	   in	   concordance	   with	   published	   studies.	   The	   African	  
population	   is	   known	   to	   be	   genetically	   the	   most	   diverse	   population	   with	  





















3.3.1.2 LD	  partners	  vs.	  LD	  Blocks	  
There	   were	   two	   ways	   of	   creating	   LD	   blocks	   surrounding	   the	   analysed	   SNPs,	  
which	  were	  available	  for	  our	  study.	  One	  way	  was	  using	  the	  Trait-­‐Associated	  SNP	  
Partners	   (TASPs),	   while	   the	   other	  way	  was	   using	   the	   Trait-­‐Associated	   Blocks	  
(TABs).	  The	  thesis	  was	  done	  using	  TASPs,	  as	  this	  analysis	  investigated	  only	  LD	  
partners,	   while	   TABs	   analysed	   all	   nucleotides	   enclosed	   by	   the	   furthest	   LD	  
partners	  of	  a	  SNP.	  Both	  ways	  had	  their	  benefits	  and	  drawbacks.	  The	  benefits	  of	  
the	  TABs	  method	  were	  that	  the	  regions	  of	  the	  genome	  between	  two	  SNPs	  were	  
included	  in	  the	  analysis,	  while	  the	  TASPs	  analysis	  only	  investigated	  those	  SNPs	  
for	  which	  LD	  was	  calculated	  and	  the	  LD	  passed	  the	  cut-­‐off	  point	  off.	  TABs	  would	  
be	   advantageous	   for	   the	   analysis	   of	   sparse	   genomic	   annotations	   that	   did	   not	  
often	  coincide	  with	  SNPs	  and	  even	  less	  often	  with	  trait-­‐associated	  variants.	  The	  
use	  of	  TASPs	  missed	  out	  those	  annotations	  that	  did	  not	  overlap	  with	  SNPs	  and	  
furthermore	   did	   not	   allow	   the	   analysis	   of	   regions,	   which	   were	   difficult	   to	  
genotype	  or	  sequence.	  However,	  it	  did	  guarantee	  that	  all	  analysed	  SNPs	  were	  in	  
LD	  at	  the	  required	  threshold.	  This	  was	  not	  guaranteed	  in	  the	  TABs	  analysis,	  as	  
LD	  varies	  across	  distances	  and	  with	  allele	  frequencies.	  Additionally,	  the	  value	  of	  
LD	   was	   unknown	   for	   the	   regions	   between	   two	   SNPs.	   Figure	   3-­‐3	   shows	   a	  
cartoon-­‐like	   representation	   of	   the	   same	   stretch	   of	   DNA	   for	   both	   TABs	   and	  
TASPs,	  highlighting	  the	  overlap	  of	  a	  genomic	  annotation	  with	  the	  TAB	  method,	  
but	  not	  with	  the	  TASP	  method.	   It	  was	  therefore	  decided	  that	  TASPs	  should	  be	  
used	   rather	   than	   TABs,	   since	   the	   LD	   threshold	   was	   known	   for	   all	   analysed	  
variants	  and	  because	  the	  TABs	  analysis	  included	  more	  noise	  in	  the	  results.	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Figure	  3-­3	  –	  Diagram	  of	  Trait-­associated	  SNP	  partners	  (TASPs)	  and	  Trait-­associated	  blocks	  (TABs)	  	  
This	   diagram	   highlights	   the	   differences	   between	   Trait-­‐associated	   SNP	   partners	   (TASPs)	   and	   Trait-­‐
associated	  blocks	  (TABs)	  for	  the	  genomic	  region.	  The	  block	  (brown)	  surrounding	  the	  trait-­‐associated	  
SNP	  (red)	  overlaps	  with	  both	  genomic	  annotation	  blocks	   (grey),	  however,	  only	  one	  block	  coincides	  
with	   TASPs.	   The	   smaller	   annotation	  block	   coincides	  with	   the	   genomic	   region	  between	   rs4	   and	   rs5	  
and	  is	  not	  counted	  as	  an	  overlap	  in	  the	  TASP	  analysis.	  
	  
3.3.2 Replicating	  significant	  enrichment	  results	  	  
Odds	   ratios	   of	   enrichment/depletion	   of	   trait-­‐associated	   SNPs	  were	   calculated	  
for	  each	  genomic	  annotation.	  An	  odds	  ratio	  equal	   to	  unity	   indicated	  that	   trait-­‐
associated	  SNPs	  were	  as	  likely	  to	  coincide	  with	  the	  analysed	  genomic	  feature	  as	  
non-­‐associated	   SNPs.	   An	   odds	   ratio	   above	   unity	   indicated	   that	   the	   genomic	  
feature	  was	   enriched	   for	   trait-­‐associated	   SNPs,	  while	   odds	   ratios	   below	   unity	  
were	   evidence	   for	   depletion.	   Figure	   3-­‐4	   compared	   the	   published	   results	  with	  
the	   results	   obtained	   for	   Reconstructed	   Hindorff	   SNPs.	   Our	   replication	   of	   the	  
sampling	   method	   compared	   well	   with	   the	   published	   data.	   The	   trend	   of	   the	  
enrichments	  and	  depletion	  were	  almost	  equivalent	  with	  enrichment	  in	  all	  of	  the	  
genomic	   annotations,	   except	   for	   the	   intergenic	   SNPs.	   The	   odds	   ratio	   was	   not	  
available	  for	  the	  TS	  annotation	  in	  the	  Reconstructed	  Hindorff	  SNPs,	  as	  none	  of	  
the	   analysed	   SNPs	   overlapped	   with	   it.	   The	   observed	   correlation	   for	   the	   two	  
datasets,	   once	   the	   not-­‐available	   annotation	  was	   removed	   from	   both	   sets,	  was	  
0.84	  with	  a	  P-­value	  of	  6.70	  ×	  10-­‐06.	  This	  meant,	  that	  where	  the	  information	  was	  
available,	  the	  two	  sets	  agreed	  well	  with	  each	  other.	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Figure	  3-­4	  –	  Comparison	  of	  sampling	  results	  with	  published	  results	  	  
The	   odds	   ratios	   for	   trait-­‐associated	   SNPs	   from	  Hindorff	   et	   al.	   (n	   =	  465	   SNPs;	  )	   and	   our	   analysis	  
using	  Reconstructed	  Hindorff	   SNPs	   (n	   =	  468	  SNPs;	  )	   in	   selected	  genomic	  annotations	  are	   shown	  
above.	   All	   results	   are	   displayed	   in	   odds	   ratios	   along	   with	   95%	   confidence	   intervals,	   where	   solid	  
symbols	  indicate	  significance	  at	  the	  Bonferroni	  corrected	  threshold.	  Odds	  ratios	  below	  or	  above	  one	  
show	   depletions	   or	   enrichments	   respectively.	   Red	   stars	   ()	   at	   the	   bottom	   of	   the	   graph	   indicate	  
significant	  differences	  between	  odds	  ratios.	  Grey	  symbols	  indicate	  that	  the	  odds	  ratio	  is	  undefined.	  	  
	  
The	   differences	   in	   significant	   odds	   ratios	  might	   be	   explained	   through	   author-­‐
specific	  differences	  in	  the	  genomic	  annotation	  datasets,	  which	  were	  discussed	  in	  
the	  Discussion	  sections	  of	  this	  chapter.	  Of	  the	  three	  significant	  results	  from	  the	  
Hindorff	  et	  al.	  study,	  we	  have	  replicated	  two.	  These	  replicated	  results	  are	  for	  the	  
non-­‐synonymous	   SNPs	   annotation,	   which	   was	   the	   most	   significant	   and	   most	  
enriched	  genomic	  annotation	   in	   the	  published	  data,	  and	   the	  1	  Kb	  upstream	  of	  
TSS.	   The	   latter	   identified	   putative	   promoter	   regions,	   as	  most	   promoters	  were	  
located	  upstream	  and	  in	  proximity	  to	  a	  TSS.	  The	  depletion	  observed	  by	  Hindorff	  
et	  al.	   in	   the	   intergenic	  SNPs	  was	  replicated,	  although	   in	  our	  analysis,	   the	  odds	  
ratio	   was	   no	   longer	   significant	   after	   correcting	   for	   multiple	   testing.	   In	   our	  
analysis,	   we	   saw	   significant	   odds	   ratios	   of	   enrichment	   for	   seven	   more	  
annotations.	  However,	  the	  95%	  confidence	  intervals	  of	  the	  odds	  ratios	  of	  either	  
study	   were	   overlapping	   with	   each	   other,	   indicating	   that	   they	   were	   not	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The	  differences	  between	  sets	  were	  discussed	  in	  further	  detail	  in	  the	  Discussion	  
of	  this	  chapter.	  Odds	  ratios	  could	  be	  interpreted	  in	  terms	  of	  fold	  enrichment,	  as	  
the	  measures	  were	  almost	  identical	  with	  a	  significant	  correlation	  of	  0.96	  (Figure	  
3-­‐5)	  when	  calculated	  for	  all	  annotations	  of	  Significant	  SNPs	  (2011).	  The	  P-­value	  





Figure	  3-­5	  –	  Fold	  enrichment	  vs.	  odds	  ratios	  
The	  odds	   ratios	  and	   the	   fold	  enrichment	   calculated	   for	   Significant	  SNPs	   (2011)	  are	  plotted	  against	  
each	  other.	   The	   red	   line	   indicates	   the	   line	  of	  best	   fit	   for	   the	  odds	   ratios	   and	   the	   fold	  enrichment.	  
There	   is	  a	  strong	  and	  significant	  correlation	  between	  fold	  enrichment	  and	  odds	  ratios	  (r2	  =	  0.96,	  P-­‐
value	  =	  8.33	  ×	  10-­‐42).	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Figure	  3-­6	  –	  Comparing	  published	  results	  with	  larger	  dataset	  	  
Enrichment	  of	  trait-­‐associated	  SNPs	  in	  selected	  genomic	  annotations	  for	  Significant	  SNPs	  (2011)	  and	  
Hindorff	  et	  al.	  (,	  respectively).	  All	  results	  are	  displayed	  in	  odds	  ratios	  along	  with	  95%	  confidence	  
intervals,	   where	   solid	   symbols	   indicate	   significance	   at	   the	   Bonferroni	   corrected	   threshold.	   Odds	  
ratios	   below	   or	   above	   one	   show	   depletions	   or	   enrichments,	   respectively.	   A	   red	   star	   ()	   at	   the	  
bottom	  of	  the	  graph	  indicates	  significance	  at	  the	  Bonferroni	  corrected	  P-­‐value.	  	  
	  
Figure	  3-­‐6	  shows	  the	  comparison	  of	  the	  results	  of	  the	  sampling	  strategy	  for	  the	  
Hindorff	  results	  with	  Significant	  SNPs	  (2011)	  containing	  more	  SNPs	  than	  shown	  
in	  Figure	  3-­‐4.	  This	  new	  set	  with	  more	  analysed	  SNPs	  is	  expected	  to	  have	  more	  
statistical	   power	   to	   detect	   enrichment	   or	   depletion	   of	   associated	   SNPs.	   The	  
coefficient	  of	   the	  regression	  of	  the	  odds	  ratios	  obtained	  by	  Hindorff	  et	  al.	  with	  
the	   two	   analysed	   SNP	   sets	   is	   very	   high	   (Reconstructed	   Hindorff	   SNPs:	   0.84,	  
Significant	  SNPs	  (2011):	  0.83)	  in	  the	  same	  annotations	  as	  above.	  The	  correlation	  
for	  the	  odds	  ratios	  of	  the	  Hindorff	  set	  with	  Significant	  SNPs	  (2011)	  is	  significant	  
with	  a	  P-­value	  of	  8.99	  ×	  10-­‐6.	  We	  observed	   two	  genomic	  annotations	   in	  which	  
the	  odds	  ratios	  differ	  significantly.	  The	  difference	   in	  the	   intronic	  SNPs	   is	  again	  
significantly	   different,	   as	   in	   the	   comparison	   shown	   previously.	   However,	   the	  
difference	   in	   the	   intergenic	   SNPs	   is	   unexpected.	   Since	   the	   trend	   of	   the	   odds	  
ratios	   remained	   the	   same,	   the	   observed	   difference	   in	   significance	   of	   the	   odds	  
ratios	  is	  most	  likely	  due	  to	  the	  decreased	  width	  in	  the	  confidence	  interval	  in	  the	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3.3.3 Comparison	   of	   Reconstructed	   Hindorff	   SNPs	   and	   Significant	   SNPs	  
(2011)	  
Of	   the	   58	   analysed	   annotations,	   four	   were	   too	   sparsely	   distributed	   in	   the	  
genome	   to	   obtain	   any	   odds	   ratios.	   Summary	   statistics	   for	   the	   analysed	  
annotations	   were	   calculated	   for	   all	   annotations	   (see	   Table	   2-­‐1).	   The	   table	  
summarised	   the	  number	  of	   sites,	   the	  percentage	  of	  nucleotides	  covered	   in	   the	  
analysed	  part	   of	   the	   genome,	   the	   percentage	   of	   SNPs	   covered	   in	   the	   analysed	  
part	  of	  the	  genome,	  and	  the	  average	  length	  of	  the	  annotated	  sites	  in	  base	  pairs.	  
Figure	   3-­‐7	   shows	   the	   comparison	   of	   Reconstructed	   Hindorff	   SNPs	   with	  
Significant	  SNPs	  (2011)	  and	  Table	  3-­‐1	  and	  Table	  3-­‐2	  present	  the	  results	  for	  the	  
two	   sets,	   respectively.	   The	   three	   subcategories	   are	   displayed	   in	   three	   panels:	  
The	  genic	  and	  regulatory	  regions	  are	  in	  the	  top	  panel,	  the	  conserved	  regions	  in	  
the	   middle	   panel,	   and	   the	   chromatin	   states	   and	   histone	   modifications	   are	  
included	  in	  the	  bottom	  panel.	  There	  were	  no	  significant	  differences	  between	  the	  
two	  SNP	  datasets	  in	  any	  of	  the	  genomic	  annotations.	  The	  regression	  line	  of	  the	  
available	  odds	  ratios	  of	  the	  two	  sets	  in	  all	  categories	  was	  0.61	  and	  significant	  (P-­
value	   =	   5.16	   ×	   10-­‐12).	   A	   number	   of	   annotations	   are	   significant	   for	   Significant	  
SNPs	   (2011),	   which	   are	   not	   significant	   for	   Reconstructed	   Hindorff	   SNPs.	   The	  
most	  prominent	  differences	  are	   the	  odds	  ratios	   for	   the	  synonymous	  SNPs	  and	  
the	  5’UTRs	  that	  were	  significant	  in	  our	  analysis.	  	  
SNPs	   in	   the	   HapMap	   CEU	   II	   data	   and	   all	   analysed	   genotyping	   arrays	   were	  
analysed	   for	   an	   overlap	   of	   genomic	   annotations.	   There	   were	   a	   number	   of	  
annotations,	  which	  rarely	  overlap	  with	  SNPs	  (see	  Table	  2-­‐1).	  These	  annotations	  
overlapped	   with	   trait-­‐associated	   SNPs	   at	   an	   even	   lower	   rate,	   as	   the	   trait-­‐
associated	  SNPs	  were	  a	  subset	  of	  the	  total	  set	  of	  analysed	  SNPs	  in	  the	  genome.	  
The	  Significant	  SNPs	  (2011)(n	  =	  1,909	  SNPs)	  resulted	  in	  a	  defined	  odds	  ratio	  for	  
these	   genomic	   annotations	   (e.g.,	   TS	   miRNA	   or	   evofold),	   while	   Reconstructed	  
Hindorff	  SNPs	  (n	  =	  468)	  did	  not.	  The	  odds	  ratios	   for	   these	  sparse	  annotations	  
were	  not	  significant	  and	  had	  large	  95%	  confidence	  intervals	  (see	  Table	  3-­‐1	  and	  
Table	  3-­‐2).	  	  
	   60	  
	  
Figure	  3-­7	  –	  Comparing	  Reconstructed	  Hindorff	  SNPs	  and	  Significant	  SNPs	  (2011)	  	  
The	   results	   of	   the	   sampling	  method	   for	   Reconstructed	   Hindorff	   SNPs	   (/)	   and	   Significant	   SNPs	  
(2011)	  (/)	  are	  shown	  here.	  All	  results	  are	  displayed	  in	  odds	  ratios	  with	  95%	  confidence	  intervals.	  
Solid	  symbols	  are	  significant	  at	   the	  Bonferroni	  corrected	  significance	  threshold.	  Not	  available	  odds	  
ratios	  (grey)	  and	  those	  with	  a	  value	  above	  the	  maximum	  of	  the	  graph	  are	  indicated	  ().	  Top:	  Genic	  
and	   regulatory	   features.	  Middle:	   Conserved	   regions	   and	   evolutionary	   regions.	   Bottom:	   Chromatin	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Table	  3-­1	  –	  Sampling	  results	  for	  Reconstructed	  Hindorff	  SNPs	  
This	   table	  summarises	   the	  number	  of	  overlaps	   in	   the	  observed	  set	   (Real),	   the	  mean	  of	   the	  sample	  
hits	   (Sample	   Mean),	   the	   calculated	   odds	   ratio	   and	   confidence	   interval	   (OR	   [LCI-­‐HCI])	   and	   the	  
obtained	  P-­‐value	  for	  each	  of	  the	  genomic	  annotations.	  Significant	  P-­‐values	  in	  bold.	  	  
Annotation	   Real	  	   Sample	  Mean	   P-­‐value	   OR	  [LCI	  -­‐	  HCI]	  
1	  Kb	  TSS	   57	   16.81	   1.35	  ×	  10-­‐06	   3.72	  [2.13-­‐6.52]	  
5	  Kb	  TSS	   118	   44.55	   3.09	  ×	  10-­‐10	   3.20	  [2.21-­‐4.65]	  
CpG	  Islands	   32	   8.17	   1.33	  ×	  10-­‐04	   4.13	  [1.89-­‐9.01]	  
ORegAnno	   30	   9.76	   1.78	  ×	  10-­‐03	   3.22	  [1.54-­‐6.70]	  
vega	  Genes	   260	   176.53	   7.20	  ×	  10-­‐08	   2.06	  [1.59-­‐2.68]	  
OMIM	  genes	   283	   154.13	   3.17	  ×	  10-­‐17	   3.12	  [2.38-­‐4.07]	  
OMIM	  morbid	  regions	   165	   36.67	   2.43	  ×	  10-­‐25	   6.41	  [4.35-­‐9.43]	  
Exons	   122	   35.90	   3.38	  ×	  10-­‐14	   4.24	  [2.85-­‐6.32]	  
Intronic	  SNPs	   286	   206.77	   3.09	  ×	  10-­‐07	   1.99	  [1.53-­‐2.58]	  
Non.Syn.	  SNPs	  (UCSC)	   81	   18.81	   2.76	  ×	  10-­‐11	   5.00	  [2.97-­‐8.40]	  
Coding	  SNPs	  (UCSC)	   101	   29.03	   6.43	  ×	  10-­‐12	   4.16	  [2.69-­‐6.43]	  
Syn.	  SNPs	  (UCSC)	   38	   15.05	   1.62	  ×	  10-­‐03	   2.66	  [1.44-­‐4.90]	  
Gained	  Stops	   6	   0.16	   3.08	  ×	  10-­‐02	   37.97	  [0.26-­‐5450.04]	  
3’UTR	   61	   19.51	   2.13	  ×	  10-­‐06	   3.45	  [2.03-­‐5.84]	  
5’UTR	   15	   4.33	   1.80	  ×	  10-­‐02	   3.55	  [1.21-­‐10.41]	  
RNA	  Genes	   3	   0.98	   6.24	  ×	  10-­‐01	   3.07	  [0.31-­‐30.18]	  
ncRNA	   10	   3.55	   1.76	  ×	  10-­‐01	   2.86	  [0.85-­‐9.65]	  
TS	  miRNA	   0	   0.13	   1.00	   0.00	  [0.00-­‐NA]	  
eQTLs	   108	   27.46	   1.92	  ×	  10-­‐14	   4.81	  [3.10-­‐7.48]	  
vega	  PseudoGenes	   11	   7.84	   6.44	  ×	  10-­‐01	   1.41	  [0.56-­‐3.56]	  
Intergenic	  SNPs	   258	   290.56	   3.36	  ×	  10-­‐02	   0.75	  [0.58-­‐0.97]	  
DNase	  Clusters	   274	   157.75	   3.47	  ×	  10-­‐14	   2.78	  [2.13-­‐3.62]	  
Insulators	  (sequence)	   44	   20.43	   2.64	  ×	  10-­‐03	   2.27	  [1.32-­‐3.91]	  
Within	  miRNA	   0	   0.01	   1.00	   0.00	  [0.00-­‐NA]	  
Splice	  Sites	   0	   0.15	   1.00	   0.00	  [0.00-­‐NA]	  
Lost	  Stops	   0	   0.10	   1.00	   0.00	  [0.00-­‐NA]	  
Microsatellites	   0	   0.31	   1.00	   0.00	  [0.00-­‐NA]	  
EvoFold	   0	   1.17	   1.00	   0.00	  [0.00-­‐NA]	  
Pos.	  Sel.	  Genes	   211	   134.83	   3.52	  ×	  10-­‐07	   2.03	  [1.55-­‐2.66]	  
Enhancers	  (sequence)	   4	   1.60	   6.86	  ×	  10-­‐01	   2.51	  [0.40-­‐15.79]	  
Exapted	  Repeats	   1	   1.28	   1.00	   0.78	  [0.06-­‐10.71]	  
PREMOD	   88	   50.96	   8.88	  ×	  10-­‐04	   1.90	  [1.31-­‐2.75]	  
tfbs	  Conserved	   79	   41.03	   2.71	  ×	  10-­‐04	   2.11	  [1.41-­‐3.16]	  
Indels	  Pure	  regions	   233	   163.02	   4.79	  ×	  10-­‐06	   1.85	  [1.43-­‐2.41]	  
17	  spc.	  algmt	   171	   104.91	   2.94	  ×	  10-­‐06	   1.99	  [1.49-­‐2.66]	  
28	  spc.	  algmt	  plc.mmls	   143	   83.62	   8.94	  ×	  10-­‐06	   2.02	  [1.49-­‐2.75]	  
28	  spc.	  algmt	   159	   97.40	   7.17	  ×	  10-­‐06	   1.96	  [1.46-­‐2.63]	  
44	  spc.	  algmt	   173	   98.15	   8.42	  ×	  10-­‐08	   2.21	  [1.65-­‐2.96]	  
44	  spc.	  algmt	  plc.mmls	   155	   90.29	   1.76	  ×	  10-­‐06	   2.07	  [1.54-­‐2.80]	  
44	  spc.	  algmt	  prim.	   145	   87.21	   1.48	  ×	  10-­‐05	   1.96	  [1.45-­‐2.66]	  
Negative	  (sequence)	   225	   253.42	   7.74	  ×	  10-­‐02	   0.78	  [0.61-­‐1.01]	  
Open	  Chromatin	   337	   224.43	   5.72	  ×	  10-­‐14	   2.79	  [2.13-­‐3.66]	  
Closed	  Chromatin	   128	   233.04	   2.20	  ×	  10-­‐12	   0.38	  [0.29-­‐0.50]	  
Active	  Promoter	   47	   13.44	   6.33	  ×	  10-­‐06	   3.78	  [2.03-­‐7.02]	  
Weak	  Promoter	   44	   14.38	   6.05	  ×	  10-­‐05	   3.27	  [1.78-­‐6.02]	  
Poised	  Promoter	   12	   1.97	   1.23	  ×	  10-­‐02	   6.23	  [1.37-­‐28.24]	  
Strong	  Enhancer	  (proximal)	   55	   15.92	   1.57	  ×	  10-­‐06	   3.78	  [2.13-­‐6.71]	  
Strong	  Enhancer	  (distal)	   42	   17.52	   1.92	  ×	  10-­‐03	   2.54	  [1.43-­‐4.50]	  
Weak	  Enhancer	  (proximal)	   57	   21.10	   2.62	  ×	  10-­‐05	   2.94	  [1.75-­‐4.93]	  
Weak	  Enhancer	  (distal)	   106	   40.79	   5.55	  ×	  10-­‐09	   3.07	  [2.08-­‐4.52]	  
Insulator	   35	   16.38	   8.93	  ×	  10-­‐03	   2.23	  [1.22-­‐4.07]	  
Txn	  Transition	   35	   12.27	   8.11	  ×	  10-­‐04	   3.00	  [1.55-­‐5.83]	  
Txn	  Elongation	   93	   43.29	   4.50	  ×	  10-­‐06	   2.43	  [1.65-­‐3.58]	  
Weak	  Txn	   150	   81.75	   3.41	  ×	  10-­‐07	   2.23	  [1.64-­‐3.03]	  
Repressed	   71	   39.53	   2.30	  ×	  10-­‐03	   1.94	  [1.28-­‐2.93]	  
Heterochrom/low	   331	   376.14	   8.00	  ×	  10-­‐04	   0.59	  [0.44-­‐0.80]	  
Repetitive/CNV	  (proximal)	   3	   1.04	   6.24	  ×	  10-­‐01	   2.90	  [0.31-­‐27.05]	  
Repetitive/CNV	  (distal)	   1	   1.01	   1.00	   0.99	  [0.06-­‐15.77]	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Table	  3-­2	  –	  Sampling	  results	  for	  Significant	  SNPs	  (2011)	  	  
This	   table	  summarises	   the	  number	  of	  overlaps	   in	   the	  observed	  set	   (Real),	   the	  mean	  of	   the	  sample	  
hits	   (Sample	   Mean),	   the	   calculated	   odds	   ratio	   and	   confidence	   interval	   (OR	   [LCI-­‐HCI])	   and	   the	  
obtained	  P-­‐value	  for	  each	  of	  the	  genomic	  annotations.	  Significant	  P-­‐values	  in	  bold.	  	  
Annotation	   Real	  	   Sample	  Mean	   P-­‐value	   OR	  [LCI	  -­‐	  HCI]	  
1	  Kb	  TSS	   191	   65.70	   3.46	  ×	  10-­‐16	   3.11	  [2.33-­‐4.15]	  
5	  Kb	  TSS	   461	   176.40	   1.07	  ×	  10-­‐35	   3.10	  [2.58-­‐3.74]	  
CpG	  Islands	   112	   32.81	   1.30	  ×	  10-­‐11	   3.56	  [2.40-­‐5.28]	  
ORegAnno	   100	   39.78	   2.58	  ×	  10-­‐07	   2.59	  [1.79-­‐3.77]	  
vega	  Genes	   1053	   733.24	   1.59	  ×	  10-­‐24	   1.93	  [1.70-­‐2.20]	  
OMIM	  genes	   1067	   644.30	   3.60	  ×	  10-­‐42	   2.43	  [2.13-­‐2.76]	  
OMIM	  morbid	  regions	   514	   154.73	   2.31	  ×	  10-­‐54	   4.14	  [3.41-­‐5.02]	  
Exons	   452	   139.10	   6.42	  ×	  10-­‐46	   3.92	  [3.20-­‐4.79]	  
Intronic	  SNPs	   1161	   857.23	   4.31	  ×	  10-­‐22	   1.86	  [1.64-­‐2.11]	  
Non.Syn.	  SNPs	  (UCSC)	   266	   72.27	   1.51	  ×	  10-­‐29	   4.10	  [3.13-­‐5.36]	  
Coding	  SNPs	  (UCSC)	   364	   111.50	   2.55	  ×	  10-­‐36	   3.78	  [3.02-­‐4.72]	  
Syn.	  SNPs	  (UCSC)	   166	   57.89	   6.25	  ×	  10-­‐14	   3.04	  [2.24-­‐4.13]	  
Gained	  Stops	   9	   1.11	   2.13	  ×	  10-­‐02	   8.14	  [1.13-­‐58.53]	  
3’UTR	   212	   73.29	   5.03	  ×	  10-­‐18	   3.12	  [2.37-­‐4.10]	  
5’UTR	   48	   16.99	   1.34	  ×	  10-­‐04	   2.87	  [1.64-­‐5.01]	  
RNA	  Genes	   7	   4.17	   5.48	  ×	  10-­‐01	   1.68	  [0.50-­‐5.66]	  
ncRNA	   25	   16.05	   2.09	  ×	  10-­‐01	   1.56	  [0.83-­‐2.94]	  
TS	  miRNA	   4	   0.49	   1.25	  ×	  10-­‐01	   8.18	  [0.42-­‐158.95]	  
eQTLs	   378	   104.46	   2.84	  ×	  10-­‐42	   4.24	  [3.38-­‐5.32]	  
vega	  PseudoGenes	   63	   31.99	   1.69	  ×	  10-­‐03	   2.00	  [1.30-­‐3.08]	  
Intergenic	  SNPs	   1114	   1208.31	   2.64	  ×	  10-­‐03	   0.82	  [0.72-­‐0.93]	  
DNase	  Clusters	   1057	   638.14	   1.71	  ×	  10-­‐41	   2.41	  [2.12-­‐2.75]	  
Insulators	  (sequence)	   163	   82.35	   1.03	  ×	  10-­‐07	   2.07	  [1.57-­‐2.72]	  
Within	  miRNA	   0	   0.04	   1.00	   0.00	  [0.00-­‐NA]	  
Splice	  Sites	   0	   0.78	   1.00	   0.00	  [0.00-­‐NA]	  
Lost	  Stops	   0	   0.39	   1.00	   0.00	  [0.00-­‐NA]	  
Microsatellites	   0	   1.31	   1.00	   0.00	  [0.00-­‐NA]	  
EvoFold	   8	   3.88	   3.87	  ×	  10-­‐01	   2.07	  [0.61-­‐6.96]	  
Pos.	  Sel.	  Genes	   831	   557.46	   7.46	  ×	  10-­‐20	   1.85	  [1.62-­‐2.11]	  
Enhancers	  (sequence)	   12	   6.19	   2.37	  ×	  10-­‐01	   1.94	  [0.74-­‐5.14]	  
Exapted	  Repeats	   9	   5.77	   6.07	  ×	  10-­‐01	   1.56	  [0.55-­‐4.45]	  
PREMOD	   303	   204.68	   3.80	  ×	  10-­‐06	   1.57	  [1.30-­‐1.89]	  
tfbs	  Conserved	   258	   162.70	   1.15	  ×	  10-­‐06	   1.67	  [1.36-­‐2.06]	  
Indels	  Pure	  regions	   905	   657.99	   1.08	  ×	  10-­‐15	   1.69	  [1.49-­‐1.93]	  
17	  spc.	  algmt	   614	   420.08	   2.54	  ×	  10-­‐12	   1.67	  [1.45-­‐1.93]	  
28	  spc.	  algmt	  plc.mmls	   545	   334.56	   1.04	  ×	  10-­‐15	   1.87	  [1.60-­‐2.18]	  
28	  spc.	  algmt	   618	   391.67	   1.83	  ×	  10-­‐16	   1.84	  [1.59-­‐2.13]	  
44	  spc.	  algmt	   641	   396.60	   1.19	  ×	  10-­‐18	   1.91	  [1.65-­‐2.21]	  
44	  spc.	  algmt	  plc.mmls	   578	   363.10	   1.06	  ×	  10-­‐15	   1.84	  [1.58-­‐2.13]	  
44	  spc.	  algmt	  prim.	   573	   348.80	   3.75	  ×	  10-­‐17	   1.91	  [1.64-­‐2.22]	  
Negative	  (sequence)	   932	   1051.01	   1.73	  ×	  10-­‐04	   0.79	  [0.69-­‐0.89]	  
Open	  Chromatin	   1458	   927.77	   2.26	  ×	  10-­‐67	   3.18	  [2.78-­‐3.64]	  
Closed	  Chromatin	   502	   981.98	   1.54	  ×	  10-­‐56	   0.34	  [0.30-­‐0.39]	  
Active	  Promoter	   155	   52.75	   2.15	  ×	  10-­‐13	   3.10	  [2.26-­‐4.27]	  
Weak	  Promoter	   164	   57.36	   7.36	  ×	  10-­‐14	   3.03	  [2.23-­‐4.12]	  
Poised	  Promoter	   28	   6.91	   4.81	  ×	  10-­‐04	   4.10	  [1.78-­‐9.44]	  
Strong	  Enhancer	  (proximal)	   231	   62.99	   2.27	  ×	  10-­‐25	   4.02	  [3.02-­‐5.35]	  
Strong	  Enhancer	  (distal)	   176	   68.18	   6.76	  ×	  10-­‐13	   2.74	  [2.05-­‐3.65]	  
Weak	  Enhancer	  (proximal)	   201	   85.04	   8.52	  ×	  10-­‐13	   2.52	  [1.94-­‐3.27]	  
Weak	  Enhancer	  (distal)	   367	   162.68	   9.54	  ×	  10-­‐22	   2.54	  [2.09-­‐3.09]	  
Insulator	   108	   65.21	   1.04	  ×	  10-­‐03	   1.69	  [1.24-­‐2.32]	  
Txn	  Transition	   144	   48.84	   1.46	  ×	  10-­‐12	   3.10	  [2.23-­‐4.32]	  
Txn	  Elongation	   360	   171.23	   8.63	  ×	  10-­‐19	   2.35	  [1.93-­‐2.85]	  
Weak	  Txn	   631	   323.36	   1.44	  ×	  10-­‐30	   2.40	  [2.06-­‐2.79]	  
Repressed	   289	   157.59	   5.01	  ×	  10-­‐11	   1.98	  [1.61-­‐2.43]	  
Heterochrom/low	   1314	   1576.96	   3.45	  ×	  10-­‐21	   0.50	  [0.43-­‐0.58]	  
Repetitive/CNV	  (proximal)	   6	   3.36	   5.07	  ×	  10-­‐01	   1.79	  [0.47-­‐6.81]	  
Repetitive/CNV	  (distal)	   1	   3.26	   6.25	  ×	  10-­‐01	   0.31	  [0.03-­‐2.88]	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3.4 Discussion	  
In	   this	   chapter,	   we	   represent	   the	   results	   of	   our	   attempt	   at	   replicating	   the	  
sampling	  method	   published	   by	   Hindorff	   et	   al.	   [50]	   as	   closely	   as	   possible.	  We	  
then	  expanded	  our	  analyses	  to	  incorporate	  more	  genomic	  annotations	  and	  more	  
trait-­‐associated	  SNPs.	  	  
3.4.1 Comparison	  of	  Hindorff	  results	  with	  Reconstructed	  Hindorff	  SNPs	  
The	   results	   of	   the	  Reconstructed	  Hindorff	   SNP	   set	   obtained	   in	  14	  annotations	  
common	  to	  Hindorff	  et	  al.	  and	  this	  analysis	  were	  compared	  to	  the	  results	  from	  
the	   original	   study	   [50].	   In	   our	   analysis	   we	   obtained	   nine	   odds	   ratios	   of	  
enrichment,	  which	  were	   significant	   at	   the	   significance	   threshold	   corrected	   for	  
14	  annotations.	  The	  nine	  annotations	  with	   significant	  odds	   ratios	   contain	   two	  
annotations,	   which	   replicated	   two	   of	   the	   significant	   results	   by	   Hindorff	   et	   al.	  
[50].	  These	   two	   annotations	   were	   the	   non-­‐synonymous	   SNPs	   annotation	   and	  
the	  1	  Kb	  upstream	  region	  of	  TSS	  annotation.	  The	  intergenic	  SNPs	  are	  depleted	  
in	   our	   analysis,	   although	   the	   P-­value	   was	   not	   significant	   after	   correcting	   for	  
multiple	  testing.	  	  
	  
Hindorff	   et	   al.	   [50]	   investigated	   the	   underlying	   genomic	   annotations	   of	   465	  
significantly	   trait-­‐associated	   SNPs	   and	   presented	   the	   results	   after	   taking	  
account	   of	   hitchhiking	   effects	   caused	  by	   SNPs	   in	   LD	  with	  possibly	  deleterious	  
non-­‐synonymous	   variants.	   The	   non-­‐synonymous	   variants	   were	   the	   most	  
enriched	  signal	  and	   the	  authors	   tested	   if	   the	  odds	   ratios	   in	   the	  other	  genomic	  
annotations	  were	  driven	  by	  non-­‐synonymous	  variants	  that	  were	  in	  LD	  with	  the	  
trait-­‐associated	  variants.	  However,	  correcting	  the	  rest	  of	  the	  results	  for	  the	  top	  
result,	  while	  not	  correcting	   the	   top	  result	  with	   the	  second	  highest	  enrichment	  
signal	   is	   close	   to	   biasing	   the	   results	   in	   favour	   of	   the	   strongest	   signal	   and	   the	  
difference	   between	   the	   corrected	   and	   not-­‐corrected	   odds	   ratios	   are	   not	  
significant	   [50].	   The	   correction	   furthermore	   did	   not	   change	   the	   odds	   ratios	  
significantly.	  For	  these	  reasons,	  we	  did	  not	  correct	  for	  hitchhiking	  effects	  in	  our	  
analyses.	   Thus,	   all	   our	   results	   are	   compared	   to	   the	   non-­‐corrected	   results	   by	  
Hindorff	   et	   al.	   [50].	   The	   differences	   between	   the	   published	   results	   and	   our	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analysis	  with	  the	  Reconstructed	  Hindorff	  SNPs	  could	  be	  due	  to	  author	  specific	  
definitions	  of	  the	  analysed	  genomic	  features,	  where	  the	  algorithms	  and	  methods	  
were	  not	  exactly	  matched.	  For	  example,	  different	  algorithms	   identify	  different	  
targets	   for	   the	   miRNA	   binding	   sites	   and	   the	   authors	   did	   not	   specify	   which	  
algorithms	   were	   chosen.	   Odds	   ratios	   of	   genomic	   annotations	   for	   which	   the	  
definition	  was	  clear,	  such	  as	  non-­‐synonymous	  SNPs,	  were	  very	  comparable.	  	  
	  
Recall,	  the	  precise	  reconstruction	  of	  the	  SNP	  set	  used	  by	  Hindorff	  et	  al.	  was	  not	  
entirely	   possible.	   Hindorff	   et	   al.	   corrected	   for	   the	   number	   of	   trait-­‐associated	  
SNPs	   in	   LD	   blocks,	   which	   is	   something	  we	   did	   not	   do.	   Overrepresentation	   of	  
SNPs	  in	  LD	  blocks	  would	  occur	  if	  more	  than	  one	  SNP	  in	  a	  similar	  genomic	  region	  
were	   found	   to	   be	   significantly	   associated	   to	   at	   least	   one	   trait.	   This	  
overrepresentation	   of	   particular	   genomic	   regions	   could	   highlight	   important	  
biological	   areas.	   We	   therefore	   did	   not	   reduce	   the	   number	   of	   trait-­‐associated	  
SNPs	   based	   on	   their	   location,	   other	   than	   removing	   the	   SNPs	   on	   non-­‐assigned	  
chromosomes	  or	  on	  the	  Y-­‐chromosome.	  
3.4.2 Expansion	   of	   analysis	   to	   more	   annotations	   and	   trait-­‐associated	  
variants	  
Significant	   SNPs	   (2011),	   a	   dataset	   containing	   1,909	   SNPs,	   was	   analysed	  
presenting	  a	  more	  recent	  set	  of	  GWAS	  hits	  than	  the	  set	  of	  SNPs	  from	  2009.	  The	  
results	   of	   the	   sampling	  method	   for	   Significant	   SNPs	   (2011)	   agreed	  with	  what	  
may	   have	   been	   expected.	   The	   study	   gained	   statistical	   power	   by	   investigating	  
more	   trait-­‐associated	   SNPs,	   as	   measured	   by	  more	   results	   that	   are	   significant	  
and	  a	  decreased	  confidence	  interval	  width	  in	  all	  genomic	  annotations,	  where	  an	  
odds	   ratio	   was	   observed	   in	   the	   smaller	   dataset.	   Moreover,	   odds	   ratios	   were	  
obtained	   in	  more	  annotations.	  For	   instance,	  we	  obtained	  odds	  ratios	   in	   the	  TS	  
miRNA	   annotation,	   which	   did	   not	   obtain	   an	   odds	   ratio	   in	   the	   Reconstructed	  
Hindorff	   SNPs.	   However,	   in	   this	   case,	   the	   corresponding	   confidence	   interval	  
width	  was	  very	  large	  with	  a	  value	  of	  158.53,	  as	  only	  four	  of	  the	  trait-­‐associated	  
SNPs	  overlapped	  with	  the	  annotation	  (see	  Table	  3-­‐2).	  On	  the	  other	  hand,	  all	  the	  
significant	   results	   obtained	   in	   the	   smaller	   dataset	   were	   also	   observed	   in	   the	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larger	  set.	  Significant	  SNPs	  (2011)	  obtained	  significant	  enrichment	  results	  in	  12	  
of	   14	   annotations	   analysed	   by	   Hindorff	   et	   al.	   Significant	   SNPs	   (2011)	   were	  
additionally	   significantly	   different	   to	   the	   published	   results	   in	   the	   intergenic	  
SNPs.	  	  
3.4.3 Reconstructed	  Hindorff	  SNPs	  vs.	  Significant	  SNPs	  (2011)	  
The	   odds	   ratios	   obtained	   for	   Significant	   SNPs	   (2011)	   were	   compared	   to	   the	  
odds	  ratios	  obtained	  for	  Reconstructed	  Hindorff	  SNPs.	  Significant	  SNPs	  (2011)	  
contained	   1,909	   SNPs,	   which	   included	   the	   478	   SNPs	   from	   the	   Reconstructed	  
Hindorff	  SNPs.	  It	  was	  therefore	  expected	  that	  Significant	  SNPs	  (2011)	  obtained	  
more	  significant	  odds	  ratios,	  as	  this	  dataset	  had	  more	  statistical	  power	  as	  more	  
SNPs	  were	  analysed.	  This	  was	  observed	  in	  10	  genomic	  annotations,	  where	  the	  
odds	  ratios	  for	  Significant	  SNPs	  (2011)	  were	  significant,	  but	  the	  odds	  ratios	  for	  
the	  Reconstructed	  Hindorff	  SNPs	  were	  not.	  The	  Bonferroni	  corrected	  threshold	  
changed	   from	   3.57	   ×	   10-­‐3	   to	   8.62	   ×	   10-­‐5	   with	   the	   inclusion	   of	   more	   genomic	  
annotations.	   The	   odds	   ratios	   for	   seven	   of	   these	   10	   annotations	   were	   more	  
moderate	   for	   the	   larger	   dataset,	   but	   significant	   due	   to	   a	   decrease	   of	   the	   95%	  
confidence	   interval	   width.	   Synonymous	   SNPs,	   transcriptional	   transition,	   and	  
strong	   enhancers	   (distal)	   obtained	   higher	   odds	   ratios	   for	   Significant	   SNPs	  
(2011).	   It	   is	   difficult	   to	   distinguish	   the	   effects	   of	   transcriptional	   elongation	   or	  
synonymous	  SNPs	   from	  effects	  caused	  by	  genic	   regions	  of	   the	  genome,	  as	  one	  
would	  define	  the	  other.	  
	  
The	  sampling	  strategy	  has	  been	  reproduced	  to	  an	  extent	  that	  we	  are	  confident	  
to	   use	   the	   results	   in	   comparison	   with	   a	   different	   method.	   We	   therefore	  
continued	   our	   investigation	   into	   the	   genomic	   features	   underlying	   the	   trait-­‐
associated	  SNPs	  with	  a	  method	  developed	  by	  us	  for	  this	  purpose:	  chromosome-­‐
wide	  circular	  permutations.	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4 CIRCULAR	  PERMUTATIONS	  
4.1 	  Introduction	  
The	   genomic	   features,	   such	   as	   the	   mentioned	   annotations,	   are	   not	   spread	  
uniformly	  throughout	  the	  chromosomes	  of	  the	  human	  genome,	  but	  rather	  occur	  
in	   clusters.	   This	   trend	   holds	   for	   the	   smallest	   changes	   in	   DNA	   to	   large	   genic	  
sequences.	   For	   instance,	   entire	   chromosomes	   are	   packaged	   into	   different	  
chromatin	   territories	   affecting	   gene	   transcription,	   DNA	   repair	   and	   replication	  
[134,	   135].	   The	   same	   trend	   is	   reflected	   in	   the	   clustering	   of	   genes	   [134],	  
functional	   elements	   [74]	   and	   transcription	   factor	   binding	   sites,	   which	   cluster	  
around	   the	   transcription	  start	  sites	   (TSS)	  of	  genes	   [136].	  The	  distribution	  and	  
number	   of	   SNPs	   also	   vary	   between	   chromosomes	   and	   chromatin	   states.	   For	  
example,	   heterochromatin	   contains	   a	   higher	   density	   of	   SNPs	   relative	   to	  more	  
open	  regions	  [137],	  while	  conversely,	  causal	  SNPs	  are	  expected	  to	  appear	  more	  
frequently	  in	  the	  latter.	  The	  uneven	  distribution	  of	  trait-­‐associated	  SNPs	  [18]	  is	  
an	  expected	  consequence	  of	  the	  non-­‐random	  distribution	  of	  the	  other	  functional	  
elements,	   and	   comprises	   additional	   information	  which	   can	   be	   used	   in	   further	  
analyses.	  	  
	  
The	  sampling	  method,	  introduced	  earlier,	  was	  designed	  to	  take	  certain	  types	  of	  
known	  biases	  into	  account.	  The	  sampled	  data	  presented	  in	  the	  previous	  chapter	  
were	   the	   variants	   present	   on	   genotyping	   arrays.	   As	   discussed	   in	   the	  
introduction	  of	  the	  thesis,	  the	  variants	  included	  on	  the	  genotyping	  arrays	  were	  
chosen	   according	   to	   different	   criteria.	   These	   criteria	   included	   the	   coverage	   of	  
the	   genome	   through	   the	   selection	   of	   variants	   that	   gave	   information	   on	  many	  
other	   SNPs	   (‘tagging	   SNPs’)	   or	   the	   overlap	   of	   variants	  with	   genes,	   and	  would	  
therefore	  be	  biased	  in	  their	  representation	  of	  chromosomes	  and	  genic	  material.	  
These	   biases	   were	   considered	   when	   the	   contributions	   of	   the	   different	  
genotyping	  arrays	  were	  recreated	  in	  the	  drawn	  samples.	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However,	  while	  the	  sampling	  method	  attempts	  to	  take	  the	  genotyping	  array	  bias	  
into	   account,	   it	   also	   assumes	   that	   the	   SNPs	   are	  uniformly	  distributed	   through	  
the	   genome.	   The	   subsets	   were	   chosen	   regardless	   of	   their	   genomic	   locations,	  
which	  resulted	  in	  biased	  samples	  with	  regards	  to	  chromosomal	  representation.	  
Some	  samples	  do	  not	  necessarily	  cover	  the	  entire	  genome,	  as	  chromosomes	  are	  
over-­‐/under-­‐represented	  and	  could	  in	  extreme	  cases	  be	  completely	  missed	  out.	  
We	  developed	  a	  method	  based	  on	  permutations	  that	  takes	  this	  representational	  
bias	  and	  the	  non-­‐uniform	  distribution	  of	   functional	  elements	  overlapping	  with	  
SNPs	   into	   account.	   Each	   chromosome	   is	   analysed	   on	   its	   own	   returning	   the	  
number	  of	  overlaps	  of	  SNPs	  and	  annotations	   for	  each	  chromosome,	  which	  are	  
then	   added	   to	   obtain	   a	   genome	  wide	   result.	   This	  method	   therefore	   takes	   the	  
chromosomal	   bias	   into	   account	   and	   preserves	   the	   local	   clustering	   of	   the	   real	  
data.	   The	   chosen	   number	   of	   performed	  permutations	   (n	   =	  20,000)	   allows	   the	  
calculation	  of	  empirical	  P-­values	  and	  confidence	  intervals.	  A	  fuller	  description	  of	  
the	  method	  can	  be	  found	  on	  page	  68	  of	  this	  thesis.	  	  
4.2 	  Materials	  and	  method	  
4.2.1 Data	  structure	  
The	   permutations	   were	   restricted	   to	   chromosomes,	   which	   were	   analysed	  
separately.	   Files	   representing	   all	   autosomes	   and	   the	   X	   chromosome	   were	  
compiled,	   each	   listing	   the	   available	   SNPs	   according	   to	   their	   position	   on	   the	  
chromosome.	   Each	   SNP	   row	   also	   contained	   information	   on	   any	   overlaps	   of	   a	  
genomic	  annotation	  with	  either	  the	  SNP	  or	  its	  LD	  partners	  (see	  Chapter	  section	  
2.1.10	   for	   definition).	   The	   lists	   contained	   a	   total	   of	   3,840,944	   variants	  
incorporating	  all	  SNPs	  represented	  on	  11	  genotyping	  arrays	  and	  were	  HapMap	  
CEU	   II	   SNPs.	   These	   lists	   were	   analysed	   individually	   and	   the	   results	   of	   the	  
chromosomes	  per	  permutation	  were	  summed	  giving	  a	  genome	  wide	  result.	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4.2.2 Circular	  permutation	  strategy	  
The	  structure	  of	  the	  data	  frames	  we	  had	  established	  attempted	  to	  recreate	  and	  
preserve	   the	   internal	   structure	   of	   the	   genome.	   Our	   goal	   in	   particular	   was	   to	  
maintain	  the	  number	  of	  SNPs	  between	  a	  SNP	  pair	  as	  a	  proxy	  of	  the	  non-­‐random	  
and	  non-­‐uniform	  clustered	  distribution	  of	  SNPs	  in	  the	  genome.	  The	  permutation	  
approach	   was	   designed	   to	   preserve	   this	   internal	   structure	   of	   the	   genome	   as	  
each	   permutation	   maintained	   the	   clustered	   distribution	   of	   SNPs	   as	   trait-­‐
association	   status	   was	   shifted	   or	   permuted	   along	   the	   chromosome,	   while	  
keeping	   the	   number	   of	   SNPs	   between	   trait-­‐associated	   variants	   constant.	   The	  
information	   for	   trait-­‐associated	   GWAS	   hits	   was	   downloaded	   from	   the	   NHGRI	  
webpage	  as	  previously	  stated	  (see	  Chapter	  section	  2.1.3).	  	  
	  
The	  permutations	  were	  performed	  per	  chromosome	  by	  shifting,	  or	  permuting,	  
the	  trait-­‐associated	  status	  along	  the	  chromosome,	  while	  the	  structure	  according	  
to	  the	  SNPs	  on	  the	  chromosomes	  remained	  the	  same	  throughout	  the	  analyses.	  
For	   each	   permutation	   a	   randomly	   generated	   number,	   drawn	   from	   a	   uniform	  
distribution	  between	  one	  and	   the	  number	  of	   SNPs	  per	   analysed	   chromosome,	  
was	  used	  to	  shift	  the	  status	  of	  trait-­‐association	  along	  the	  chromosome.	  The	  shift	  
was	  performed	  circularly,	  so	  that	  any	  variables	  exceeding	  the	  number	  of	  SNPs	  
on	   the	   chromosome	   were	   pushed	   to	   the	   beginning	   of	   the	   chromosome.	   The	  
trait-­‐association	   status	  was	   therefore	   re-­‐assigned	   to	   different	   variants,	  whose	  
previous	  trait-­‐association	  status	  was	  no	  longer	  relevant.	  The	  LD	  partners	  were	  
then	   re-­‐defined	   and	   overlaps	   of	   the	   newly	   labelled	   trait-­‐association	   variants	  
with	   annotations	   were	   counted	   as	   in	   the	   original	   trait-­‐associated	   variant	   set.	  
The	  permutations	   therefore	   sampled	   the	   chromosome	   in	   a	   controlled	  manner	  
by	  maintaining	   the	   distance	   of	   SNPs	   as	  measured	   by	   number	   of	   SNPs,	   rather	  
than	  nucleotides.	  This	  created	  a	  background	  distribution	  of	  SNPs	  and	  their	  LD	  
partners	  that	  were	  as	  biased	  in	  the	  number	  of	  SNPs	  on	  a	  given	  chromosome	  and	  
their	   distribution	   on	   that	   chromosome.	   Regions	   that	   are	   difficult	   to	   genotype	  
would	  be	   less	  represented	   in	  both	  the	  real	   trait-­‐associated	  variant	  set	  and	  the	  
background	  set.	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  Figure	  4-­‐1	  shows	  a	  cartoon-­‐like	  illustration	  of	  the	  circularised	  chromosome	  in	  
four	   scenarios:	   The	   observed	   data	   and	   three	   sequential	   permutations.	   This	  
produced	  a	  population	  of	  20,000	  chromosomes,	  circularly	  permuted	  relative	  to	  
the	  original	  chromosome,	  containing	  the	  same	  number	  of	  trait-­‐associated	  SNPs	  
and	   preserved	   the	   degree	   of	   genomic	   clustering	   observed	   in	   the	   original	   SNP	  
datasets.	  The	  chromosome	  results	  were	  summed	  to	  give	  a	  genome-­‐wide	  result.	  	  
	  
Figure	  4-­1	  –	  Diagram	  of	  permutations	  on	  virtually	  circularised	  chromosome	  
The	   permutations	  were	   performed	  on	   a	   virtually	   circularised	   chromosome	   (black	   circle).	   The	   start	  
and	  end	  of	   the	  chromosome	  are	  equivalent	  and	  are	  depicted	  by	   the	  vertical	   line	  at	   the	   top	  of	   the	  
circle.	   The	   coloured	   symbols	   (orange	   cones,	   light-­‐blue	   triangles,	   dark-­‐blue	   arches	   and	   grey	  
rectangles)	  represent	  different	  genomic	  features	  adopting	  a	  non-­‐uniform	  distribution	  and	  showing	  a	  
distinct	  clustering	  of	  the	  genomic	  annotations.	  The	  red	  stars	  depict	  the	  trait-­‐associated	  SNPs.	  Non-­‐
associated	   SNPs	   are	   left	   off	   the	   diagram	   for	   clarity.	   The	   black	   arrow	   highlights	   the	   same	   trait-­‐
associated	  SNP	  in	  each	  chromosome.	  A)	  Observed	  data	  and	  starting	  position.	  B)	  First	  permutation	  of	  
trait-­‐associated	  SNPs	  by	  90˚	  in	  clockwise	  direction	  from	  the	  starting	  position.	  C)	  Second	  permutation	  
of	   trait-­‐associated	   SNPs	   by	   180˚	   in	   clockwise	   direction	   from	   the	   starting	   position.	   D)	   Third	  
permutation	   of	   trait-­‐associated	   SNPs	   by	   270˚	   in	   clockwise	   direction	   from	   the	   starting	   position.	   In	  
practise	  the	  degree	  of	  rotation	  of	  SNPs	  versus	  annotation	  is	  randomly	  chosen.	  
	  
4.2.3 Odds	  ratios	  and	  confidence	  intervals	  
The	  number	  of	  overlaps	   for	   the	  real	   trait-­‐associated	  SNPs	  (observed)	   for	  each	  
annotation	   and	   the	   mean	   number	   of	   overlaps	   of	   permuted	   SNPs	   (expected)	  
were	   used	   to	   calculate	   odds	   ratios	   of	   enrichment	   or	   depletion	   (see	   equation	  
!" #"
$" %"
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below).	   The	   permuted	   overlaps	   were	   ranked	   according	   to	   the	   number	   of	  
overlaps	   creating	   a	   discrete	   uniform	   distribution	   used	   to	   calculate	   the	   95%	  
confidence	   intervals.	   This	   ranking	   of	   the	   permutation	   overlaps	   allowed	   the	  
calculation	  of	   the	  2.5th	  and	  97.5th	  percentile	  values,	  which	  were	  used	  to	  define	  
the	   95%	   confidence	   intervals	   of	   the	   data	   were	   observed.	   Since	   a	   two-­‐sided	  
hypothesis	  test	  was	  applied,	  i.e.,	  were	  there	  more	  or	  fewer	  trait-­‐associated	  SNPs	  
than	  expected	  by	  chance,	  the	  2.5th	  (500th	  ranked	  position)	  and	  97.5th	  (19,500th	  
ranked	   position)	   percentile	   values	   represent	   the	   95%	   boundaries.	   The	  
calculation	  for	  the	  confidence	  intervals	  was	  the	  same	  as	  for	  the	  odds	  ratios	  (see	  
paragraph	  2.1.11),	  except	  that	   the	  500th	  and	  19,500th	  value	  replaced	  the	  mean	  
number	   of	   overlaps	   of	   the	   expected	   data.	   The	  mean	   number	   of	   non-­‐overlaps	  
was	  defined	  as	  the	  difference	  of	  the	  total	  and	  the	  mean	  number	  of	  the	  overlaps.	  
This	   gives	   a	   thorough	   representation	   of	   the	   underlying	   distribution	   of	   the	  
overlaps	  between	  SNPs	  and	  genomic	  features,	  which	  can	  be	  easily	  displayed	  on	  
the	  graphs.	  These	  empirically	  derived	  confidence	  intervals	  were	  not	  symmetric	  
relative	   to	   the	   odds	   ratios	   on	   the	   log	   scale,	   in	   contrast	   to	   the	   confidence	  
intervals	   of	   the	   sampling	   method.	   The	   latter	   were	   calculated	   as	   theoretical	  
values	   using	   the	   standard	   errors	   of	   the	   odds	   ratios,	   which	   meant	   that	   they	  
would	  always	  be	  symmetric	  relative	  to	  the	  odds	  ratios	  on	  a	  log	  scale.	  	  
If	  the	  divisor	  of	  the	  odds	  ratios	  was	  zero,	  the	  values	  for	  the	  confidence	  intervals	  
or	   the	   odds	   ratios	   are	   undefined.	   In	   our	   case,	   this	   occurred	   if	   either	   the	   real	  
number	   of	   non-­‐overlaps	   was	   zero	   or	   the	   permuted	   number	   of	   overlaps	   was	  
zero.	  As	  it	  was	  more	  unlikely	  that	  a	  mean	  of	  permuted	  hits	  was	  zero,	  the	  odds	  
ratios	   were	   defined	   more	   often	   than	   confidence	   interval	   values,	   which	   were	  
based	  on	  only	  one	  permutation	  value.	  	  
Confidence	  intervals,	  which	  were	  set	  to	  infinity	  by	  R,	  were	  artificially	  delimited	  
to	   30,	   a	   value	   beyond	   the	   range	   of	   the	   graphs	   to	   enable	   the	   plotting	   of	   these	  
confidence	   intervals.	   The	   eight	   annotations,	   for	   which	   this	   occurred,	   are	  
sparsely	  distributed	  (see	  Table	  2-­‐1)	  in	  the	  genome	  and	  were	  removed	  from	  any	  
confidence	  interval	  width	  calculations	  (within	  miRNA,	  TS	  miRNA,	  evofold,	  splice	  
sites,	  gained	  stops,	  lost	  stops,	  microsatellites	  and	  repetitive/CNV	  (distal)).	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4.2.4 Calculating	  P-­‐values	  	  
The	  P-­value	  of	  the	  odds	  ratios	  for	  the	  permutations	  was	  the	  ratio	  of	  the	  number	  
of	  permuted	  datasets	  that	  were	  equal	  to	  or	  more	  extreme	  than	  the	  observations	  
in	  the	  observed	  trait-­‐associated	  SNP	  set,	  and	  the	  total	  number	  of	  permutations.	  
The	   lower	   bound	   of	   this	   empirically	   defined	   P-­value	   was	   therefore	   5	   ×	   10-­‐5	  
when	  only	  one	  in	  20,000	  permutations	  was	  equal	  to	  or	  more	  extreme	  than	  the	  
number	   of	   overlaps	   in	   the	   observed	   data.	   If	   none	   of	   the	   permutations	   were	  
equal	  to	  or	  more	  extreme	  than	  the	  observed	  data	  the	  P-­value	  was	  <	  5	  ×	  10-­‐5.	  The	  
P-­values	   are	   significant	   if	   they	   passed	   the	   Bonferroni	   corrected	   significance	  
threshold	  corrected	   for	   testing	  58	  genomic	  annotations	  (8.60	  ×	  10-­‐4),	  which	   is	  
equivalent	   to	   17	   permutations	   being	  more	   extreme	   or	   equal	   to	   the	   observed	  
data.	  Since	   the	   tested	  annotations	  were	  not	   independent	   from	  each	  other,	   this	  
threshold	  is	  likely	  to	  be	  very	  stringent.	  	  
4.3 	  Results	  
4.3.1 Comparison	   of	   permutations	   and	   sampling	   in	   Significant	   SNPs	  
(2011)	  
Figure	   4-­‐2	   shows	   the	   results	   obtained	   by	   both	   the	   permutation	   and	   the	  
sampling	   method	   for	   Significant	   SNPs	   (2011)	   with	   1,909	   significantly	   trait-­‐
associated	  SNPs.	  The	  three	  subcategories	  of	  the	  genomic	  features	  are	  shown	  in	  
the	  three	  panels	  of	  the	  figure.	  The	  genic	  and	  regulatory	  features	  are	  presented	  
in	   the	   top	   panel,	   the	   conserved	   and	   evolutionary	   figures	   are	   shown	   in	   the	  
middle	  panel	  and	  the	  histone	  modifications	  and	  chromatin	  states	  are	  shown	  in	  
the	   bottom	  panel.	   The	  majority	   of	   the	   genomic	   annotations	  were	   significantly	  
enriched	   for	   trait-­‐associated	   SNPs,	   while	   two	   annotations	   showed	   significant	  
depletion	   (closed	   chromatin	   and	   heterochrom/lo).	   The	   large	   number	   of	  
enrichment	  signals	  was	  also	  observed	  by	  the	  sampling	  method.	  Few	  differences	  
existed	  between	  the	  results	  from	  the	  permutation	  and	  the	  sampling	  approaches,	  
which	  we	  comment	  shortly.	  The	  obtained	  odds	  ratios	  correlated	  strongly	  with	  a	  
correlation	   of	   0.98	   and	   a	   significant	  P-­value	   (P	   =	   8.89	   ×	   10-­‐51).	   The	   observed	  
differences	  between	  the	  methods	  were	  significant	  at	  P-­value	  ≤	  0.05.	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There	  were	   three	   genomic	   annotations,	  where	   the	   odds	   ratio	   obtained	  by	   the	  
permutation	  method	  was	   not	   significant,	   but	  was	   significant	   for	   the	   sampling	  
method.	   The	   insulators	   (bottom	   panel)	   were	   significantly	   enriched	   for	  
permutations	   but	   not	   the	   sampling	   method.	   The	   methods	   agreed	   on	   the	  
remaining	  genomic	  annotations,	  10	  of	  which	  were	  not	  significantly	  enriched	  for	  
or	   depleted	   of	   trait-­‐associated	   SNPs.	   The	   two	  methods	   had	   very	   similar	   odds	  
ratio	   in	   the	   OMIM	  morbid	   regions.	   These	   regions	   were	   considered	   a	   positive	  
control,	   since	   they	  were	  defined	  as	  disease-­‐associated	  regions	  by	  a	  number	  of	  
different	   studies	   [99].	   The	   annotation	   serving	   as	   a	   negative	   control,	   named	  
negative	   (sequence),	   originated	   from	   the	   intergenic	   SNPs	   from	   which	   any	  
overlapping	  conserved	  or	  genic	  regions	  were	  excluded.	  For	  this	  annotation,	  only	  
the	   sampling	   method	   showed	   significant	   depletion,	   while	   the	   odds	   ratio	   of	  
depletion	  obtained	  by	  the	  permutation	  method	  was	  not	  significant.	  	  
The	   lack	   of	   significant	   depletion	   in	   the	   negative	   annotation	   could	   be	   due	   to	   a	  
number	  of	   reasons.	  One	  of	   these	   reasons	  was	   the	  difference	   in	   calculation	   for	  
the	   odds	   ratios	   and	   P-­values	   between	   the	   two	   methods.	   The	   odds	   ratios	   are	  
almost	   identical	   between	   the	   methods	   (sampling	   =	   0.79	   [0.69-­‐0.89];	  
permutations	  =	  0.81	  [0.71-­‐0.94])	  resulting	  from	  the	  number	  of	  overlaps	   in	  the	  
expected	  dataset	  (1051	  in	  sampling	  vs.	  1029	  in	  permutations).	  When	  the	  odds	  
ratio	   and	   confidence	   intervals	   and	   P-­value	   were	   calculated	   using	   the	   same	  
formula	  as	  used	  for	  the	  sampling	  method	  the	  result	  was	  0.82	  [0.72-­‐0.93]	  with	  a	  
P-­value	   of	   1.69	   ×	   10-­‐3.	   This	   P-­value	   is	   not	   significant	   after	   accounting	   for	  
multiple	   testing.	   Since	   the	   number	   of	   samples	   drawn	   and	   permutations	  
performed	   differs	   substantially	   it	   is	   possible	   that	   the	   permutations	   capture	  
more	   of	   the	   real	   distribution.	   It	   is	   also	   possible	   that	   the	   negative	   set	  was	   not	  
defined	   properly	   or	   that	   an	   informative	   and	   as	   of	   yet	   unidentified	   annotation	  
still	  overlaps	  with	  the	  negative	  annotation,	  but	  that	  would	  have	  impacted	  both	  
methods	  equally.	  	  
The	  largest	  difference	  between	  the	  two	  methods	  is	  in	  confidence	  interval	  width,	  
as	  shown	  above.	  The	  eight	  genomic	  annotations	  excluded	  from	  calculations	  for	  
the	   mean	   odds	   ratio	   and	   confidence	   interval	   widths	   were	   within	   miRNA,	   TS	  
miRNA,	   evofold,	   splice	   sites,	   gained	   stops,	   lost	   stops,	   microsatellites	   and	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repetitive/CNV	  (distal).	  The	  permutations	  obtained	  larger	  confidence	  intervals	  
with	  an	  average	  of	  2.06	   in	   those	  annotations,	  where	  both	  methods	  obtained	  a	  
defined	  confidence	  interval	   i.e.,	  one	  that	  was	  not	  set	  to	  infinity.	  The	  confidence	  
interval	  width	  of	  the	  sampling	  method	  in	  the	  same	  annotations	  was	  1.63.	  This	  
was	   an	   indication	   that	   the	   permutation	   approach	   was	   generally	   more	  
conservative,	  as	  expected,	  since	  the	  permutation	  approach	  was	  designed	  to	  take	  
an	   appropriate	   account	   of	   non-­‐random	   distributions	   of	   annotations	   and	   SNP	  
locations.	  The	  eight	  genomic	  annotations,	  which	  obtained	  confidence	   intervals	  
with	  values	  of	  infinity	  (denoted	  infinity	  in	  the	  tables),	  were	  sparsely	  distributed	  
throughout	  the	  genome.	  A	  value	  of	   infinity	  was	  returned	  when	  the	  dividend	  of	  
the	   odds	   ratio	   equation	   was	   too	   large	   when	   compared	   with	   the	   divisor	   (see	  
paragraph	   “Scoring	   LD	   blocks	   and	   definition	   of	   odds	   ratios”).	   Among	   these	  
genomic	   annotations	   were	   the	   four	   rare	   annotations	   mentioned	   previously	  
(microsatellites,	  within	  microRNA,	  splice	  sites	  and	  lost	  stop	  codons).	  The	  other	  
four	   genomic	   annotations	   were	   TS	   miRNA	   binding	   sites,	   gained	   stop	   codons,	  
evofold,	   and	   distal	   repetitive/CNV	   elements.	   The	   coverage	   of	   these	   eight	  
genomic	  features	  ranged	  between	  0.00-­‐0.21%	  annotated	  SNPs.	  The	  confidence	  
intervals	  were	  very	  wide,	  illustrating	  the	  uncertainty	  of	  the	  results,	  which	  were	  
based	   on	   a	   small	   number	   of	   coinciding	   SNPs.	   The	   number	   of	   overlaps	   for	   the	  
Significant	  SNPs	  (2011)	  set	  and	  its	  permutations,	  the	  resulting	  odds	  ratios	  with	  
confidence	  intervals	  and	  the	  P-­value	  of	  significance	  are	  shown	  in	  Table	  4-­‐1.	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Figure	  4-­2	  –	  Comparison	  of	  sampling	  vs.	  permutation	  results	  of	  Significant	  SNPs	  (2011)	  
There	   are	   few	   differences	   between	   the	   results	   for	   Significant	   SNPs	   (2011)	   (n	   =	   1,909)	   with	   the	  
permutation	  method	  ()	  when	  compared	  with	  the	  sampling	  method	  ().	  All	  P-­‐values	  are	  corrected	  
for	  multiple	  testing	  for	  the	  analysed	  genomic	  annotations.	  Solid	  symbols	  indicate	  significance	  at	  the	  
multiple-­‐testing	  corrected	  threshold.	  Top:	  Genic	  and	  regulatory	  regions.	  Middle:	  Conserved	  regions	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Table	  4-­1	  –	  Permutation	  results	  for	  Significant	  SNPs	  (2011)	  at	  r2	  >	  0.9	  threshold	  
This	  table	  summarises	  the	  results	  for	  Significant	  SNPs	  (2011)	  (n	  =	  1,909).	  The	  number	  of	  overlaps	  in	  
the	   observed	   set	   (Real),	   the	  mean	  of	   the	   permuted	  hits	   (Permutation	  Mean),	   the	   calculated	  odds	  
ratio	   and	   confidence	   interval	   (OR	   [LCI-­‐HCI])	   and	   the	   obtained	   P-­‐value	   for	   each	   of	   the	   genomic	  
annotations	  are	  shown	  below.	  Significant	  P-­‐values	  in	  bold.	  	  
Annotation	   Real	  	   Permutation	  Mean	   OR	  [LCI	  -­‐	  HCI]	   P-­‐value	  
1	  Kb	  TSS	   191	   71.53	   2.86	  [2.10-­‐3.97]	   <	  5.00	  ×	  10-­‐05	  
5	  Kb	  TSS	   461	   182.70	   3.01	  [2.41-­‐3.76]	   <	  5.00	  ×	  10-­‐05	  
CpG	  Islands	   112	   38.42	   3.03	  [2.10-­‐4.70]	   <	  5.00	  ×	  10-­‐05	  
ORegAnno	   100	   40.01	   2.58	  [1.86-­‐3.85]	   <	  5.00	  ×	  10-­‐05	  
vega	  Genes	   1053	   731.82	   1.98	  [1.70-­‐2.31]	   <	  5.00	  ×	  10-­‐05	  
OMIM	  genes	   1067	   640.94	   2.51	  [2.13-­‐2.97]	   <	  5.00	  ×	  10-­‐05	  
OMIM	  morbid	  regions	   514	   152.78	   4.24	  [3.20-­‐5.75]	   <	  5.00	  ×	  10-­‐05	  
Exons	   452	   148.72	   3.67	  [2.94-­‐4.62]	   <	  5.00	  ×	  10-­‐05	  
Intronic	  SNPs	   1161	   854.46	   1.92	  [1.63-­‐2.25]	   <	  5.00	  ×	  10-­‐05	  
Non.Syn.	  SNPs	  (UCSC)	   266	   78.45	   3.78	  [2.90-­‐5.17]	   <	  5.00	  ×	  10-­‐05	  
Coding	  SNPs	  (UCSC)	   364	   119.72	   3.52	  [2.78-­‐4.55]	   <	  5.00	  ×	  10-­‐05	  
Syn.	  SNPs	  (UCSC)	   166	   62.54	   2.81	  [2.10-­‐3.94]	   <	  5.00	  ×	  10-­‐05	  
Gained	  Stops	   9	   1.11	   8.17	  [2.26-­‐Infinity]	   9.50	  ×	  10-­‐04	  
3’UTR	   212	   78.20	   2.92	  [2.26-­‐3.92]	   <	  5.00	  ×	  10-­‐05	  
5’UTR	   48	   19.92	   2.45	  [1.56-­‐4.90]	   5.00	  ×	  10-­‐05	  
RNA	  Genes	   7	   4.80	   1.46	  [0.64-­‐7.02]	   2.25	  ×	  10-­‐01	  
ncRNA	   25	   16.81	   1.49	  [0.80-­‐3.61]	   1.08	  ×	  10-­‐01	  
TS	  miRNA	   4	   0.56	   7.13	  [1.33-­‐Infinity]	   9.95	  ×	  10-­‐03	  
eQTLs	   378	   95.90	   4.67	  [3.35-­‐6.39]	   <	  5.00	  ×	  10-­‐05	  
vega	  PseudoGenes	   63	   36.22	   1.76	  [1.11-­‐3.07]	   1.16	  ×	  10-­‐02	  
Intergenic	  SNPs	   1114	   1196.85	   0.83	  [0.71-­‐0.98]	   1.11	  ×	  10-­‐02	  
DNase	  Clusters	   1057	   609.66	   2.64	  [2.36-­‐2.97]	   <	  5.00	  ×	  10-­‐05	  
Insulators	  (sequence)	   163	   87.60	   1.94	  [1.50-­‐2.61]	   <	  5.00	  ×	  10-­‐05	  
Within	  miRNA	   0	   0.03	   0.00	  [0.00-­‐NA]	   <	  5.00	  ×	  10-­‐05	  
Splice	  Sites	   0	   0.90	   0.00	  [0.00-­‐NA]	   <	  5.00	  ×	  10-­‐05	  
Lost	  Stops	   0	   0.37	   0.00	  [0.00-­‐NA]	   <	  5.00	  ×	  10-­‐05	  
Microsatellites	   0	   1.51	   0.00	  [0.00-­‐NA]	   <	  5.00	  ×	  10-­‐05	  
EvoFold	   8	   4.03	   1.99	  [0.89-­‐Infinity]	   7.47	  ×	  10-­‐02	  
Pos.	  Sel.	  Genes	   831	   555.76	   1.88	  [1.60-­‐2.23]	   <	  5.00	  ×	  10-­‐05	  
Enhancers	  (sequence)	   12	   6.10	   1.97	  [0.92-­‐12.07]	   5.17	  ×	  10-­‐02	  
Exapted	  Repeats	   9	   5.39	   1.67	  [0.82-­‐9.04]	   1.23	  ×	  10-­‐01	  
PREMOD	   303	   197.22	   1.64	  [1.38-­‐1.97]	   <	  5.00	  ×	  10-­‐05	  
tfbs	  Conserved	   258	   161.38	   1.69	  [1.41-­‐2.05]	   <	  5.00	  ×	  10-­‐05	  
Indels	  Pure	  regions	   905	   624.32	   1.85	  [1.66-­‐2.08]	   <	  5.00	  ×	  10-­‐05	  
17	  spec.	  algmt	   614	   413.11	   1.72	  [1.51-­‐1.97]	   <	  5.00	  ×	  10-­‐05	  
28	  spec.	  algmt	  plc.mmls	   545	   328.96	   1.92	  [1.67-­‐2.22]	   <	  5.00	  ×	  10-­‐05	  
28	  spec.	  algmt	   618	   388.80	   1.87	  [1.65-­‐2.15]	   <	  5.00	  ×	  10-­‐05	  
44	  spec.	  algmt	   641	   392.17	   1.96	  [1.72-­‐2.24]	   <	  5.00	  ×	  10-­‐05	  
44	  spec.	  algmt	  plc.mmls	   578	   357.09	   1.89	  [1.65-­‐2.17]	   <	  5.00	  ×	  10-­‐05	  
44	  spec.	  algmt	  prim.	   573	   339.39	   1.98	  [1.73-­‐2.30]	   <	  5.00	  ×	  10-­‐05	  
Negative	  (sequence)	   932	   1029.98	   0.81	  [0.71-­‐0.94]	   1.95	  ×	  10-­‐03	  
Open	  Chromatin	   1458	   915.13	   3.51	  [2.84-­‐4.30]	   <	  5.00	  ×	  10-­‐05	  
Closed	  Chromatin	   502	   1030.96	   0.30	  [0.25-­‐0.38]	   <	  5.00	  ×	  10-­‐05	  
Active	  Promoter	   155	   59.18	   2.76	  [1.99-­‐4.03]	   <	  5.00	  ×	  10-­‐05	  
Weak	  Promoter	   164	   61.53	   2.82	  [2.09-­‐3.98]	   <	  5.00	  ×	  10-­‐05	  
Poised	  Promoter	   28	   7.74	   3.65	  [1.76-­‐14.19]	   9.50	  ×	  10-­‐04	  
Strong	  Enhancer	  (proximal)	   231	   64.59	   3.93	  [2.88-­‐5.58]	   <	  5.00	  ×	  10-­‐05	  
Strong	  Enhancer	  (distal)	   176	   69.03	   2.71	  [2.03-­‐3.78]	   <	  5.00	  ×	  10-­‐05	  
Weak	  Enhancer	  (proximal)	   201	   86.97	   2.47	  [1.92-­‐3.29]	   <	  5.00	  ×	  10-­‐05	  
Weak	  Enhancer	  (distal)	   367	   161.86	   2.57	  [2.09-­‐3.20]	   <	  5.00	  ×	  10-­‐05	  
Insulator	   108	   65.59	   1.69	  [1.29-­‐2.32]	   1.50	  ×	  10-­‐04	  
Txn	  Transition	   144	   52.56	   2.88	  [2.08-­‐4.24]	   <	  5.00	  ×	  10-­‐05	  
Txn	  Elongation	   360	   187.49	   2.13	  [1.71-­‐2.69]	   <	  5.00	  ×	  10-­‐05	  
Weak	  Txn	   631	   333.95	   2.33	  [1.96-­‐2.80]	   <	  5.00	  ×	  10-­‐05	  
Repressed	   289	   147.11	   2.14	  [1.66-­‐2.78]	   <	  5.00	  ×	  10-­‐05	  
Heterochrom/lo	   1314	   1533.73	   0.54	  [0.45-­‐0.64]	   <	  5.00	  ×	  10-­‐05	  
Repetitive/CNV	  (proximal)	   6	   4.73	   1.27	  [0.54-­‐6.02]	   6.65	  ×	  10-­‐01	  
Repetitive/CNV	  (distal)	   1	   3.96	   0.25	  [0.11-­‐Infinity]	   3.02	  ×	  10-­‐02	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4.3.2 Comparison	  of	  different	  significant	  thresholds	  
There	   has	   been	   substantial	   interest	   in	   the	   nature	   of	   GWAS	   variants	   which	  
showed	  ‘suggestive’	  levels	  of	  significance	  (i.e.,	  SNPs	  with	  P-­values	  =	  5	  ×	  10-­‐5	  -­‐	  5	  ×	  
10-­‐8),	  as	  they	  are	  believed	  to	  contain	  many	  true	  positives	  with	  modest	  effect	  size	  
[138].	   If	   that	   were	   correct,	   we	   would	   expect	   similarities	   in	   the	   functional	  
enrichment	  patterns	  of	  these	  variants	  and	  the	  significantly	  associated	  variants.	  
Our	  method	  can	  be	  used	  to	   test	   this	  hypothesis	  and	  the	  analysis	  of	  Suggestive	  
SNPs	   (2011)	   was	   in	   agreement	   with	   this	   hypothesis.	   The	   majority	   of	   the	  
genomic	   annotations	   are	   not	   significantly	   enriched	   or	   depleted	   of	   Suggestive	  
SNPs	   (2011),	   which	   is	   unlike	   the	   Significant	   SNPs	   (2011).	   Moreover,	   those	  
genomic	  annotations,	  which	  were	   significant	   for	   suggestively	  associated	  SNPs,	  
obtained	   odds	   ratios	   that	   were	   less	   extreme	   than	   the	   odds	   ratios	   for	   the	  
Significant	  SNPs	  (2011)	  in	  the	  same	  annotations.	  	  
	  
Figure	   4-­‐3	   shows	   the	   14	   enrichment	   and	   depletion	   results,	   where	   the	  
suggestively	  associated	  SNPs	  obtained	  a	  significant	  odds	  ratio.	  The	  trends	  were	  
similar	   to	   those	   observed	   for	   genome-­‐wide	   significant	   SNPs,	   but	   with	   more	  
moderate	   odds	   ratios.	   Of	   these	   14	   annotations,	   nine	   were	   from	   the	   genic	  
annotation	   category,	   and	   five	   from	   the	   chromatin	   states.	   None	   of	   the	  
annotations	   from	  the	  conserved	  annotation	  category	  obtained	  significant	  odds	  
ratios	  for	  Suggestive	  SNPs	  (2011).	  	  
	  
This	   lack	  of	   significant	   signal	   can	  also	  be	  observed	  Figure	  4-­‐4,	  which	   shows	  a	  
comparison	   of	   all	   annotations.	   This	   figure	   shows	   a	   comparison	   of	   all	   of	   the	  
genomic	   annotations	   and	   suggested	   that	   the	   general	   trend	   of	   all	   genomic	  
annotations	  was	   similar	   to	   those	   observed	   for	   genome-­‐wide	   significant	   SNPs.	  
There	  were	  a	   few	  annotations,	  which	  were	  exceptions	   to	   the	   trend,	  where	   the	  
suggestive	  SNPs	  had	  more	  extreme	  odds	  ratios.	  However,	   in	  those	  annotations	  
the	  enrichment	  was	  not	  statistically	  significant	   for	  either	  the	  significant	  or	  the	  
suggestive	   SNPs.	   The	   number	   of	   overlaps	   for	   Suggestive	   SNPs	   (2011),	   its	  
permutation	  overlaps,	  the	  resulting	  odds	  ratio	  with	  confidence	  intervals	  and	  the	  
P-­value	   of	   significance	   for	   the	   odds	   ratio	   are	   shown	   in	   Table	   4-­‐2.	   A	   graph	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showing	   the	   correlation	   of	   the	   odds	   ratios	   obtained	   in	   the	   Suggestive	   SNPs	  
(2011)	   and	   Significant	   SNPs	   (2011)	   was	   published	   in	   Kindt	   et	   al.	   [139].	   The	  
square	  of	  the	  correlation	  coefficient,	  r2,	  of	  the	  regression	  line	  of	  the	  odds	  ratio	  
obtained	  for	  the	  Suggestive	  SNPs	  (2011)	  onto	  the	  odds	  ratios	  obtained	  for	  the	  
Significant	  SNPs	  (2011)	  was	  0.81	  with	  a	  P-­‐value	  of	  4.42	  ×	  10-­‐20.	  
	  
Figure	  4-­3	  –	  Comparison	  of	  significant	  and	  suggestive	  variants	  in	  a	  subset	  of	  genomic	  annotations	  
The	   significantly	   trait-­‐associated	   variants	   (Significant	   SNPs	   (2011);	   n	   =	   1,909;	  )	   and	   the	   variants	  
with	  a	   suggestive	  P-­‐value	  of	  association	   (5	  ×	  10-­‐5	  >	  P-­‐value	  >	  5	  ×	  10-­‐8;	  Suggestive	  SNPs	   (2011);	  n	  =	  
2,410);	   )	   in	   the	   significant	   annotations	   for	   the	   Suggestive	   SNPs	   (2011)	   show	   similar	   trends.	  
Suggestive	  SNPs	  (2011)	  show	  the	  same	  trend	  in	  enrichment/depletion	  but	  with	  more	  moderate	  odds	  
ratios	  than	  Significant	  SNPs	  (2011).	  	  
	  
The	  mean	  of	   the	  odds	  ratios	   for	  Significant	  SNPs	  (2011)	   in	  50	  of	   the	  analysed	  
genomic	  annotations	  was	  2.33.	  The	  mean	  of	  the	  odds	  ratios	  of	  the	  same	  genomic	  
annotations	   in	   Suggestive	   SNPs	   (2011)	   was	   reduced	   to	   1.13.	   The	   confidence	  
intervals	  were	  also	  much	  narrower	  for	  Suggestive	  SNPs	  (2011)	  with	  a	  width	  of	  
0.56,	  while	  the	  confidence	  intervals	  were	  2.06	  for	  all	  50	  genomic	  annotations	  in	  
Significant	   SNPs	   (2011),	   presumably	   because	   there	   it	   consisted	   of	   a	   larger	  
number	   of	   SNPs.	   The	   confidence	   intervals	   were	   calculated	   without	   the	   eight	  
genomic	  annotations	  previously	  mentioned	   (microsatellites,	  within	  microRNA,	  
splice	  sites	  and	   lost	   stop	  codons,	  TS	  miRNA	  binding	  sites,	  gained	  stop	  codons,	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Figure	  4-­4	  –	  All	  annotations	  compared	  for	  Significant	  SNPs	  (2011)	  and	  Suggestive	  SNPs	  (2011)	  
The	   significantly	   trait-­‐associated	   variants	   (Significant	   SNPs	   (2011);	   n	   =	   1,909;	  )	   and	   the	   variants	  
with	  a	   suggestive	  P-­‐value	  of	  association	   (5	  ×	  10-­‐5	  >	  P-­‐value	  >	  5	  ×	  10-­‐8;	  Suggestive	  SNPs	   (2011);	  n	  =	  
2,410;	  )	  in	  all	  genomic	  annotations	  show	  similar	  trends	  of	  enrichment	  and	  depletion.	  Solid	  symbols	  
indicate	  significance	  at	  the	  multiple-­‐testing	  corrected	  threshold.	  Top:	  Genic	  and	  regulatory	  regions.	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Table	  4-­2	  –	  Permutation	  results	  for	  Suggestive	  SNPs	  (2011)	  
This	   table	   summarises	   the	   results	   for	   Suggestive	   SNPs	   (2011),	   which	   contained	   2,410	   SNPs.	   the	  
number	  of	  overlaps	  in	  the	  observed	  set	  (Real),	  the	  mean	  of	  the	  permuted	  hits	  (Permutation	  Mean),	  
the	  calculated	  odds	  ratio	  and	  confidence	  interval	  (OR	  [LCI-­‐HCI])	  and	  the	  obtained	  P-­‐value	  for	  each	  of	  
the	  genomic	  annotations	  are	  shown	  below.	  Significant	  P-­‐values	  in	  bold.	  	  
Annotation	   Real	   Permutation	  Mean	   OR	  [LCI	  -­‐	  HCI]]	   P-­‐value	  
1	  Kb	  TSS	   104	   84.05	   1.25	  [1.01-­‐1.60]	   1.94	  ×	  10-­‐02	  
5	  Kb	  TSS	   264	   217.43	   1.24	  [1.08-­‐1.44]	   9.00	  ×	  10-­‐04	  
CpG	  Islands	   46	   44.04	   1.05	  [0.79-­‐1.49]	   4.05	  ×	  10-­‐01	  
ORegAnno	   66	   48.40	   1.37	  [1.05-­‐1.91]	   8.40	  ×	  10-­‐03	  
vega	  Genes	   1017	   924.50	   1.17	  [1.08-­‐1.28]	   5.00	  ×	  10-­‐05	  
OMIM	  genes	   913	   796.53	   1.24	  [1.13-­‐1.35]	   <	  5.00	  ×	  10-­‐05	  
OMIM	  morbid	  regions	   251	   187.65	   1.38	  [1.18-­‐1.62]	   <	  5.00	  ×	  10-­‐05	  
Exons	   239	   176.32	   1.39	  [1.20-­‐1.65]	   <	  5.00	  ×	  10-­‐05	  
Intronic	  SNPs	   1146	   1059.80	   1.15	  [1.06-­‐1.26]	   3.00	  ×	  10-­‐04	  
Non.Syn.	  SNPs	  (UCSC)	   125	   92.71	   1.37	  [1.12-­‐1.70]	   7.00	  ×	  10-­‐04	  
Coding	  SNPs	  (UCSC)	   190	   142.10	   1.37	  [1.16-­‐1.63]	   5.00	  ×	  10-­‐05	  
Syn.	  SNPs	  (UCSC)	   91	   74.17	   1.24	  [1.00-­‐1.59]	   3.09	  ×	  10-­‐02	  
Gained	  Stops	   6	   1.27	   4.74	  [1.50-­‐Infinity]	   2.10	  ×	  10-­‐03	  
3’UTR	   120	   93.83	   1.29	  [1.07-­‐1.61]	   4.75	  ×	  10-­‐03	  
5’UTR	   32	   23.45	   1.37	  [0.97-­‐2.30]	   5.71	  ×	  10-­‐02	  
RNA	  Genes	   3	   6.00	   0.50	  [0.27-­‐1.50]	   6.21	  ×	  10-­‐02	  
ncRNA	   28	   20.28	   1.38	  [0.93-­‐2.35]	   6.73	  ×	  10-­‐02	  
TS	  miRNA	   0	   0.72	   0.00	  [0.00-­‐NA]	   <	  5.00	  ×	  10-­‐05	  
eQTLs	   210	   112.84	   1.94	  [1.61-­‐2.40]	   <	  5.00	  ×	  10-­‐05	  
vega	  PseudoGenes	   47	   42.87	   1.10	  [0.82-­‐1.58]	   2.85	  ×	  10-­‐01	  
Intergenic	  SNPs	   1494	   1527.22	   0.94	  [0.86-­‐1.03]	   8.68	  ×	  10-­‐02	  
DNase	  Clusters	   835	   758.58	   1.15	  [1.06-­‐1.26]	   3.00	  ×	  10-­‐04	  
Insulators	  (sequence)	   105	   105.58	   0.99	  [0.83-­‐1.23]	   4.61	  ×	  10-­‐01	  
Within	  miRNA	   0	   0.04	   0.00	  [0.00-­‐NA]	   <	  5.00	  ×	  10-­‐05	  
Splice	  Sites	   3	   1.05	   2.85	  [1.00-­‐Infinity]	   9.18	  ×	  10-­‐02	  
Lost	  Stops	   0	   0.42	   0.00	  [0.00-­‐NA]	   <	  5.00	  ×	  10-­‐05	  
Microsatellites	   5	   1.85	   2.70	  [1.00-­‐Infinity]	   4.13	  ×	  10-­‐02	  
EvoFold	   4	   5.04	   0.79	  [0.40-­‐4.00]	   2.60	  ×	  10-­‐01	  
Pos.	  Sel.	  Genes	   750	   691.65	   1.12	  [1.03-­‐1.23]	   6.65	  ×	  10-­‐03	  
Enhancers	  (sequence)	   8	   7.87	   1.02	  [0.57-­‐2.67]	   4.72	  ×	  10-­‐01	  
Exapted	  Repeats	   6	   6.83	   0.88	  [0.46-­‐3.00]	   3.25	  ×	  10-­‐01	  
PREMOD	   266	   251.41	   1.07	  [0.94-­‐1.22]	   1.78	  ×	  10-­‐01	  
tfbs	  Conserved	   208	   204.86	   1.02	  [0.89-­‐1.18]	   4.23	  ×	  10-­‐01	  
Indel	  Pure	  regions	   845	   788.00	   1.11	  [1.02-­‐1.21]	   7.15	  ×	  10-­‐03	  
17	  spec.	  algmt	   526	   523.52	   1.01	  [0.91-­‐1.11]	   4.62	  ×	  10-­‐01	  
28	  spec.	  algmt	  plc.mmls	   426	   415.98	   1.03	  [0.93-­‐1.15]	   3.05	  ×	  10-­‐01	  
28	  spec.	  algmt	   490	   489.72	   1.00	  [0.91-­‐1.11]	   4.99	  ×	  10-­‐01	  
44	  spec.	  algmt	   504	   494.81	   1.02	  [0.93-­‐1.13]	   3.33	  ×	  10-­‐01	  
44	  spec.	  algmt	  plc.mmls	   457	   452.02	   1.01	  [0.92-­‐1.13]	   4.10	  ×	  10-­‐01	  
44	  spec.	  algmt	  prim.	   433	   431.29	   1.00	  [0.91-­‐1.12]	   4.69	  ×	  10-­‐01	  
Negative	  (sequence)	   1252	   1306.89	   0.91	  [0.84-­‐0.99]	   1.53	  ×	  10-­‐02	  
Open	  Chromatin	   1308	   1144.60	   1.31	  [1.19-­‐1.44]	   <	  5.00	  ×	  10-­‐05	  
Closed	  Chromatin	   1128	   1286.75	   0.77	  [0.70-­‐0.84]	   <	  5.00	  ×	  10-­‐05	  
Active	  Promoter	   80	   69.96	   1.15	  [0.92-­‐1.50]	   1.28	  ×	  10-­‐01	  
Weak	  Promoter	   89	   73.76	   1.21	  [0.98-­‐1.58]	   4.64	  ×	  10-­‐02	  
Poised	  Promoter	   6	   8.78	   0.68	  [0.40-­‐2.00]	   1.35	  ×	  10-­‐01	  
Strong	  Enhancer	  (proximal)	   113	   77.75	   1.48	  [1.19-­‐1.89]	   1.50	  ×	  10-­‐04	  
Strong	  Enhancer	  (distal)	   109	   85.19	   1.29	  [1.05-­‐1.66]	   6.35	  ×	  10-­‐03	  
Weak	  Enhancer	  (proximal)	   115	   107.07	   1.08	  [0.89-­‐1.32]	   2.32	  ×	  10-­‐01	  
Weak	  Enhancer	  (distal)	   239	   199.47	   1.22	  [1.06-­‐1.42]	   3.25	  ×	  10-­‐03	  
Insulator	   86	   81.21	   1.06	  [0.86-­‐1.36]	   3.05	  ×	  10-­‐01	  
Txn	  Transition	   78	   62.47	   1.26	  [1.00-­‐1.65]	   3.25	  ×	  10-­‐02	  
Txn	  Elongation	   255	   226.96	   1.14	  [1.00-­‐1.31]	   3.25	  ×	  10-­‐02	  
Weak	  Txn	   466	   405.59	   1.18	  [1.06-­‐1.33]	   8.50	  ×	  10-­‐04	  
Repressed	   228	   177.83	   1.31	  [1.13-­‐1.54]	   1.00	  ×	  10-­‐04	  
Heterochrom/lo	   1939	   1960.31	   0.94	  [0.85-­‐1.05]	   1.39	  ×	  10-­‐01	  
Repetitive/CNV	  (proximal)	   2	   6.01	   0.33	  [0.18-­‐1.00]	   1.86	  ×	  10-­‐02	  
Repetitive/CNV	  (distal)	   3	   4.79	   0.63	  [0.33-­‐3.00]	   1.46	  ×	  10-­‐01	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4.3.3 Results	  of	  Significant	  SNPs	  (2011)	  vs.	  Significant	  SNPs	  (2013)	  
An	   increased	   number	   of	   analysed	   SNPs	   resulted	   in	   an	   increased	   number	   of	  
significant	   genomic	   annotations	   (see	   Figure	   4-­‐5),	   with	   three	  more	   significant	  
annotations	   in	   the	   Significant	   SNPs	   (2013).	   The	  most	   notable	   results	   are	   the	  
significant	   depletions	   in	   the	   negative	   set	   (middle	   panel)	   and	   the	   significant	  
enrichment	   in	   the	  poised	  promoters	   and	  gained	   stop	   codons	   (bottom	  and	   top	  
panel).	   The	   negative	   set	   consisted	   of	   only	   those	   intergenic	   SNPs	   that	   did	   not	  
overlap	   with	   any	   of	   the	   analysed	   genic	   or	   conserved	   regions.	   These	   findings	  
highlighted	  that	  results	  with	  narrower	  empirical	  confidence	   intervals	  could	  be	  
obtained	   with	   a	   larger	   dataset.	   The	   poised	   promoters	   also	   passed	   the	  
significance	  threshold	  after	  correcting	  for	  multiple	  testing.	  Since	  the	  difference	  
of	  the	  odds	  ratios	  was	  not	  significantly	  different	  (see	  all	  panels	  of	  Figure	  4-­‐5	  and	  
bottom	  panel	  of	  Figure	  4-­‐6),	  the	  change	  must	  be	  due	  to	  a	  decrease	  of	  confidence	  
interval	   width.	   The	   mean	   for	   the	   confidence	   interval	   width	   has	   decreased	   to	  
1.36	  in	  Significant	  SNPs	  (2013)	  from	  2.06	  in	  Significant	  SNPs	  (2011),	  while	  the	  
odds	  ratio	  decreased	  only	  marginally	  from	  2.33	  to	  2.25.	  This	  was	  representative	  
of	   the	   increase	   in	   statistical	   power	   caused	   by	   the	   larger	   number	   of	   analysed	  
trait-­‐associated	  SNPs.	  A	   linear	  model	  of	  Significant	  SNPs	   (2013)	  vs.	   Significant	  
SNPs	  (2011)	  had	  an	  r2	  value	  of	  0.91	  and	  a	  significant	  P-­value	  of	  2.34	  ×	  10-­‐31.	  This	  
implies	  that	  the	  results	  from	  the	  same	  dataset	  but	  different	  methods	  (sampling	  
and	  permutation)	  were	  more	  similar,	  than	  when	  two	  overlapping	  datasets	  were	  
analysed	  with	  the	  same	  method	  (0.98	  vs.	  0.91,	  respectively).	  Figure	  4-­‐6	  includes	  
two	  graphs,	  the	  first	  of	  which	  plots	  the	  odds	  ratios	  for	  Significant	  SNPs	  (2011)	  
obtained	  by	  sampling	  against	   those	  obtained	  by	  the	  permutations.	  The	  second	  
plot	   in	   Figure	   4-­‐6	   shows	   the	   odds	   ratios	   for	   Significant	   SNPs	   (2011)	   and	  
Significant	  SNPs	  (2013)	  obtained	  by	  the	  permutation	  methods.	  The	  number	  of	  
overlaps	   for	   Significant	   SNPs	   (2013)	   and	   the	   results	   obtained	   by	   the	  
permutations,	  the	  resulting	  odds	  ratio	  with	  confidence	  intervals	  and	  the	  P-­value	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Figure	  4-­5	  –	  Comparison	  of	  Significant	  SNPs	  (2011)	  and	  Significant	  SNPs	  (2013)	  in	  all	  annotations	  
The	  results	  of	  Significant	  SNPs	  (2011;	  n	  =	  1,909;	  /)	  and	  Significant	  SNPs	  (2013;	  n	  =	  3,283;	  (/)	  
are	   very	   similar.	   The	   newer	   dataset	   obtains	   more	   significant	   results,	   probably	   due	   to	   the	   larger	  
number	  of	  analysed	  SNPs.	  All	  P-­‐values	  are	  corrected	   for	  multiple	   testing	   for	   the	  analysed	  genomic	  
annotations	  and	  solid	  symbols	  indicate	  significance	  at	  that	  level.	  Top:	  Genic	  and	  regulatory	  regions.	  






















































































































































































































































































































































































Figure	  4-­6	  –	  Correlations	  between	  datasets	  and	  methods	  
Top:	   The	   correlation	   of	   odds	   ratios	   obtained	   by	   permutations	   and	   sampling	   in	   Significant	   SNPs	  
(2011).	  A	  strong	  and	  significant	  correlation	  is	  observed	  between	  the	  two	  methods	  with	  a	  r2	  value	  of	  
0.98	   and	   a	   P-­‐value	   of	   1.25	   ×	   10-­‐49.	   Bottom:	   The	   correlation	   between	   two	   datasets	   analysed	   by	  
permutations.	  Significant	  SNPs	  (2011)	  is	  a	  subset	  of	  Significant	  SNPs	  (2013).	  The	  correlation	  between	  
the	  two	  datasets	  is	  strong	  and	  significant	  with	  an	  r2	  of	  0.91	  and	  a	  P-­‐value	  of	  2.17	  ×	  10-­‐31.	  Correlations	  
were	  determined	  by	  a	  linear	  regression	  of	  the	  x-­‐axes	  values	  onto	  the	  y-­‐axes	  values.	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Table	  4-­3	  –	  Permutation	  results	  for	  Significant	  SNPs	  (2013).	  	  
This	   table	   summarises	   the	   results	   for	   Significant	   SNPs	   (2013),	   which	   contained	   3,283	   SNPs.	   The	  
number	  of	  overlaps	  in	  the	  observed	  set	  (Real),	  the	  mean	  of	  the	  permuted	  hits	  (Permutation	  Mean),	  
the	  calculated	  odds	  ratio	  and	  confidence	  interval	  (OR	  [LCI-­‐HCI])	  and	  the	  obtained	  P-­‐value	  for	  each	  of	  
the	  genomic	  annotations	  are	  shown	  below.	  Significant	  P-­‐values	  in	  bold.	  	  
Annotation	   Real	   Permutation	  Mean	   OR	  [LCI	  -­‐	  HCI]]	   P-­‐value	  
1	  Kb	  TSS	   345	   128.07	   2.89	  [2.16-­‐3.78]	   <	  5.00	  ×	  10-­‐05	  
5	  Kb	  TSS	   841	   327.68	   3.11	  [2.50-­‐3.74]	   <	  5.00	  ×	  10-­‐05	  
CpG	  Islands	   196	   68.62	   2.97	  [2.11-­‐4.28]	   <	  5.00	  ×	  10-­‐05	  
ORegAnno	   156	   72.12	   2.22	  [1.69-­‐3.04]	   <	  5.00	  ×	  10-­‐05	  
vega	  Genes	   1874	   1340.71	   1.93	  [1.69-­‐2.21]	   <	  5.00	  ×	  10-­‐05	  
OMIM	  genes	   1873	   1157.37	   2.44	  [2.12-­‐2.81]	   <	  5.00	  ×	  10-­‐05	  
OMIM	  morbid	  regions	   837	   275.12	   3.74	  [2.96-­‐4.79]	   <	  5.00	  ×	  10-­‐05	  
Exons	   793	   267.00	   3.60	  [2.95-­‐4.35]	   <	  5.00	  ×	  10-­‐05	  
Intronic	  SNPs	   2070	   1545.21	   1.92	  [1.68-­‐2.20]	   <	  5.00	  ×	  10-­‐05	  
Non.Syn.	  SNPs	  (UCSC)	   446	   140.62	   3.51	  [2.79-­‐4.49]	   <	  5.00	  ×	  10-­‐05	  
Coding	  SNPs	  (UCSC)	   618	   214.50	   3.32	  [2.71-­‐4.07]	   <	  5.00	  ×	  10-­‐05	  
Syn.	  SNPs	  (UCSC)	   288	   112.37	   2.71	  [2.13-­‐3.53]	   <	  5.00	  ×	  10-­‐05	  
Gained	  Stops	   15	   1.93	   7.81	  [2.51-­‐Infinity]	   <	  5.00	  ×	  10-­‐05	  
3’UTR	   369	   140.92	   2.82	  [2.26-­‐3.59]	   <	  5.00	  ×	  10-­‐05	  
5’UTR	   92	   35.79	   2.62	  [1.76-­‐4.27]	   <	  5.00	  ×	  10-­‐05	  
RNA	  Genes	   8	   8.50	   0.94	  [0.05-­‐2.67]	   4.26	  ×	  10-­‐01	  
ncRNA	   46	   30.48	   1.52	  [0.88-­‐2.90]	   6.18	  ×	  10-­‐02	  
TS	  miRNA	   4	   1.00	   4.00	  [1.00-­‐Infinity]	   3.80	  ×	  10-­‐02	  
eQTLs	   684	   170.89	   4.79	  [3.37-­‐6.23]	   <	  5.00	  ×	  10-­‐05	  
vega	  PseudoGenes	   113	   66.48	   1.72	  [1.09-­‐2.62]	   1.38	  ×	  10-­‐02	  
Intergenic	  SNPs	   2005	   2158.69	   0.82	  [0.71-­‐0.94]	   1.95	  ×	  10-­‐03	  
DNase	  Clusters	   1841	   1100.58	   2.53	  [2.31-­‐2.78]	   <	  5.00	  ×	  10-­‐05	  
Insulators	  (sequence)	   290	   157.94	   1.92	  [1.53-­‐2.43]	   <	  5.00	  ×	  10-­‐05	  
Within	  miRNA	   0	   0.07	   0.00	  [0.00-­‐NA]	   <	  5.00	  ×	  10-­‐05	  
Splice	  Sites	   0	   1.75	   0.00	  [0.00-­‐NA]	   <	  5.00	  ×	  10-­‐05	  
Lost	  Stops	   0	   0.68	   0.00	  [0.00-­‐NA]	   <	  5.00	  ×	  10-­‐05	  
Microsatellites	   1	   2.86	   0.35	  [0.12-­‐Infinity]	   1.05	  ×	  10-­‐01	  
EvoFold	   16	   7.19	   2.23	  [1.14-­‐8.03]	   1.43	  ×	  10-­‐02	  
Pos.	  Sel.	  Genes	   1450	   1005.77	   1.79	  [1.56-­‐2.06]	   <	  5.00	  ×	  10-­‐05	  
Enhancers	  (sequence)	   21	   10.94	   1.93	  [1.05-­‐5.28]	   2.40	  ×	  10-­‐02	  
Exapted	  Repeats	   14	   9.68	   1.45	  [0.78-­‐4.68]	   1.52	  ×	  10-­‐01	  
PREMOD	   543	   356.76	   1.63	  [1.41-­‐1.89]	   <	  5.00	  ×	  10-­‐05	  
tfbs	  Conserved	   445	   291.83	   1.61	  [1.39-­‐1.88]	   <	  5.00	  ×	  10-­‐05	  
Indel	  Pure	  regions	   1584	   1126.87	   1.78	  [1.63-­‐1.96]	   <	  5.00	  ×	  10-­‐05	  
17	  spec.	  algmt	   1075	   744.36	   1.66	  [1.49-­‐1.86]	   <	  5.00	  ×	  10-­‐05	  
28	  spec.	  algmt	  plc.mmls	   963	   592.74	   1.88	  [1.68-­‐2.12]	   <	  5.00	  ×	  10-­‐05	  
28	  spec.	  algmt	   1078	   701.19	   1.80	  [1.62-­‐2.01]	   <	  5.00	  ×	  10-­‐05	  
44	  spec.	  algmt	   1119	   706.72	   1.89	  [1.70-­‐2.11]	   <	  5.00	  ×	  10-­‐05	  
44	  spec.	  algmt	  plc.mmls	   1024	   643.72	   1.86	  [1.66-­‐2.09]	   <	  5.00	  ×	  10-­‐05	  
44	  spec.	  algmt	  prim.	   1000	   612.32	   1.91	  [1.71-­‐2.16]	   <	  5.00	  ×	  10-­‐05	  
Negative	  (sequence)	   1685	   1856.23	   0.81	  [0.71-­‐0.92]	   4.00	  ×	  10-­‐04	  
Open	  Chromatin	   2594	   1646.46	   3.74	  [3.05-­‐4.56]	   <	  5.00	  ×	  10-­‐05	  
Closed	  Chromatin	   931	   1861.83	   0.30	  [0.25-­‐0.37]	   <	  5.00	  ×	  10-­‐05	  
Active	  Promoter	   277	   105.89	   2.76	  [2.02-­‐3.69]	   <	  5.00	  ×	  10-­‐05	  
Weak	  Promoter	   282	   110.46	   2.70	  [2.06-­‐3.54]	   <	  5.00	  ×	  10-­‐05	  
Poised	  Promoter	   59	   14.01	   4.27	  [2.21-­‐9.99]	   <	  5.00	  ×	  10-­‐05	  
Strong	  Enhancer	  (proximal)	   358	   116.78	   3.32	  [2.56-­‐4.39]	   <	  5.00	  ×	  10-­‐05	  
Strong	  Enhancer	  (distal)	   300	   125.00	   2.54	  [2.02-­‐3.30]	   <	  5.00	  ×	  10-­‐05	  
Weak	  Enhancer	  (proximal)	   321	   156.95	   2.16	  [1.75-­‐2.69]	   <	  5.00	  ×	  10-­‐05	  
Weak	  Enhancer	  (distal)	   619	   292.71	   2.37	  [2.00-­‐2.84]	   <	  5.00	  ×	  10-­‐05	  
Insulator	   177	   118.69	   1.52	  [1.22-­‐1.95]	   3.00	  ×	  10-­‐04	  
Txn	  Transition	   239	   94.02	   2.66	  [2.02-­‐3.60]	   <	  5.00	  ×	  10-­‐05	  
Txn	  Elongation	   648	   335.99	   2.16	  [1.81-­‐2.61]	   <	  5.00	  ×	  10-­‐05	  
Weak	  Txn	   1084	   600.92	   2.20	  [1.89-­‐2.56]	   <	  5.00	  ×	  10-­‐05	  
Repressed	   532	   265.97	   2.19	  [1.76-­‐2.72]	   <	  5.00	  ×	  10-­‐05	  
Heterochrom/lo	   2409	   2772.18	   0.51	  [0.42-­‐0.61]	   <	  5.00	  ×	  10-­‐05	  
Repetitive/CNV	  (proximal)	   11	   8.46	   1.30	  [0.65-­‐3.68]	   7.36	  ×	  10-­‐01	  
Repetitive/CNV	  (distal)	   4	   7.22	   0.55	  [0.27-­‐2.00]	   1.15	  ×	  10-­‐01	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4.3.4 Results	  of	  Significant	  SNPs	  (2011)	  vs.	  Significant	  SNPs	  (Difference)	  
The	  regression	  of	   the	  permutation	   results	  onto	   the	   sampling	   results	  using	   the	  
Significant	  SNPs	  (2011)	  in	  both	  analyses	  gave	  an	  r2	  value	  of	  0.98.	  The	  results	  of	  
the	   permutation	   method	   using	   Significant	   SNPs	   (2011)	   and	   Significant	   SNPs	  
(2013)	  had	  a	  regression	  r2	  of	  0.91.	  While	  both	  values	  are	  very	  high,	  an	  analysis	  
of	  the	  difference	  between	  the	  sets	  was	  performed.	  This	  analysis	  focused	  on	  the	  
trait-­‐associated	  SNPs	  that	  appear	  in	  Significant	  SNPs	  (2013)	  only,	  i.e.,	  the	  most	  
recent	   trait-­‐associated	   variants.	   This	   set	   was	   termed	   Significant	   SNPs	  
(Difference),	  contained	  1,477	  SNPs	  and	  was	  analysed	  the	  permutation	  method.	  
The	   odds	   ratios	   of	   Significant	   SNPs	   (2011)	   and	   Significant	   SNPs	   (Difference)	  
(see	   Figure	   4-­‐7)	   are	   no	   longer	   as	   similar	   as	   in	   the	   comparison	   between	  
Significant	  SNPs	  (2011)	  and	  Significant	  SNPs	  (2013)	  (see	  Figure	  4-­‐5).	  There	  are	  
three	  genomic	  annotations	  where	  the	  odds	  ratio	  is	  no	  longer	  significant	  for	  the	  
recently	   identified	   trait-­‐associated	   variants:	   open	   regulatory	   annotations	  
(ORegAnno),	  regions	  associated	  with	  insulator	  activity	  and	  regions	  annotated	  as	  
target	   sites	   for	   microRNAs	   (TSmiRNA)	   have	   an	   odds	   ratio	   of	   zero	   (i.e.,	  
undefined).	  The	  mean	  of	  the	  odds	  ratios	  for	  Significant	  SNPs	  (Difference)	  in	  the	  
50	  annotations	  previously	  outlined	  is	  2.08	  and	  lower	  than	  in	  either	  Significant	  
SNPs	   (2013)	   (2.25)	   or	   Significant	   SNPs	   (2011)	   (2.33).	   Two	   additional	  
annotations	   (RNA	   genes	   and	   repetitive/CNV	   (proximal)	   regions)	   obtain	   an	  
undefined	   95%	   confidence	   interval	   of	   (denoted	   “Infinity”).	   When	   these	   are	  
removed,	   the	   mean	   of	   odds	   ratios	   increases	   to	   2.14	   and	   the	   mean	   of	   the	  
confidence	   interval	  width	   is	   1.94.	   There	   are	   two	  most	   plausible	   causes	  which	  
could	  contribute	  to	  the	  drop	  in	  the	  value	  of	  the	  odds	  ratios:	  the	  lower	  number	  of	  
trait-­‐associated	  variants	  reduced	  the	  amount	  of	  signal,	  or	  the	  drop	  was	  caused	  
by	  a	  slightly	  different	  distribution	  of	  the	  recent	  GWAS	  hits,	  or	  both.	  The	  results	  
for	  the	  permutations	  of	  Significant	  SNPs	  (Difference)	  are	  presented	  in	  Table	  4-­‐4,	  
which	  shows	  the	  number	  of	  overlaps	  in	  the	  real	  data	  and	  the	  mean	  number	  of	  
permuted	   overlaps,	   the	   calculated	   odds	   ratios	   and	   their	   confidence	   intervals	  
and	  their	  P-­value.	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Figure	  4-­7	  –	  Comparing	  Significant	  SNPs	  (2011)	  with	  Significant	  SNPs	  (Difference)	  
The	  results	  of	  Significant	  SNPs	  (2011;	  n	  =	  1,909)	  and	  Significant	  SNPs	  (Difference;	  n	  =	  1,477)	  (,;	  
respectively)	  show	  a	  number	  of	  differences.	  Significant	  SNPs	  (2013)	  have	  insignificant	  odds	  ratios	  in	  
ORegAnno	   and	   Insulators	   and	   an	   unavailable	   odds	   ratio	   for	   TS	   miRNA	   in	   Significant	   SNPs	  
(Difference).	  All	  P-­‐values	  are	  corrected	  for	  multiple	  testing	  for	  the	  analysed	  genomic	  annotations	  and	  
solid	   symbols	   indicate	   significance	   at	   that	   level.	   Top:	   Genic	   and	   regulatory	   regions.	   Middle:	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The	   odds	   ratios	   of	   Significant	   SNPs	   (Difference)	   and	   Significant	   SNPs	   (2011)	  
correlated	   weakly	   with	   each	   other	   (Figure	   4-­‐8).	   The	   r2	   of	   the	   regression	   of	  
Significant	   SNPs	   (Difference)	   on	   Significant	   SNPs	   (2011)	  was	  0.54,	  which	  was	  
considerably	  less	  than	  all	  other	  comparisons,	  but	  still	  significant	  with	  a	  P-­value	  
of	   2.94	   ×	   10-­‐11.	   However,	   the	   information	   from	   this	   correlation	   was	   strongly	  
influenced	   by	   the	   one	   change	   due	   to	   a	   genomic	   annotation,	   which	   was	   not	  
significant	  in	  either	  dataset	  (TS	  miRNA).	  This	  annotation	  obtained	  an	  odds	  ratio	  
of	  zero	  in	  the	  Significant	  SNPs	  (Difference),	  but	  reached	  a	  non-­‐significant	  odds	  
ratio	  of	  7.13	  in	  the	  Significant	  SNPs	  (2011).	  This	  could	  be	  due	  to	  a	  sampling	  bias,	  






Figure	  4-­8	  –	  Correlation	  of	  Significant	  SNPs	  (2011)	  with	  Significant	  SNPs	  (Difference)	  
The	  correlation	  of	  the	  odds	  ratios	  for	  Significant	  SNPs	  (2011)	  and	  Significant	  SNPs	  (Difference)	  is	  less	  
significant	  and	  almost	  halved	  (r2	  =	  0.54,	  P-­‐value	  =	  2.94	  ×	  10-­‐11),	  when	  compared	  to	  the	  correlation	  of	  
Significant	   SNPs	   (2011)	   with	   Significant	   SNPs	   (2013)	   (r2	   =	   0.91,	   P-­‐value	   =	   2.17	   ×	   10-­‐31).	   The	   most	  
striking	  difference	  is	  in	  the	  TS	  miRNA	  annotation,	  which	  is	  zero	  in	  Significant	  SNPs	  (Difference),	  but	  in	  
Significant	  SNPs	  (2011)	  it	  is	  7.13,	  albeit	  not	  significantly	  enriched.	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Table	  4-­4	  –	  Permutation	  results	  for	  Significant	  SNPs	  (Difference)	  
This	  table	  summarises	  the	  results	  for	  Significant	  SNPs	  (Difference),	  which	  contained	  1,477	  SNPs.	  The	  
number	  of	  overlaps	  in	  the	  observed	  set	  (Real),	  the	  mean	  of	  the	  permuted	  hits	  (Permutation	  Mean),	  
the	  calculated	  odds	  ratio	  and	  confidence	  interval	  (OR	  [LCI-­‐HCI])	  and	  the	  obtained	  P-­‐value	  for	  each	  of	  
the	  genomic	  annotations	  are	  shown	  below.	  Significant	  P-­‐values	  in	  bold.	  	  
Annotation	   Real	   Permutation	  Mean	   OR	  [LCI-­‐HCI]	   P-­‐value	  
1	  Kb	  TSS	   139	   54.97	   2.69	  [1.89-­‐3.83]	   <	  5.00	  ×	  10-­‐05	  
5	  Kb	  TSS	   362	   140.52	   3.09	  [2.39-­‐3.89]	   <	  5.00	  ×	  10-­‐05	  
CpG	  Islands	   81	   29.06	   2.89	  [1.89-­‐4.70]	   <	  5.00	  ×	  10-­‐05	  
ORegAnno	   50	   30.67	   1.65	  [1.17-­‐2.55]	   1.50	  ×	  10-­‐03	  
vega	  Genes	   766	   557.94	   1.78	  [1.55-­‐2.06]	   <	  5.00	  ×	  10-­‐05	  
OMIM	  genes	   784	   491.47	   2.28	  [1.96-­‐2.65]	   <	  5.00	  ×	  10-­‐05	  
OMIM	  morbid	  regions	   315	   116.44	   3.17	  [2.46-­‐4.18]	   <	  5.00	  ×	  10-­‐05	  
Exons	   327	   114.17	   3.40	  [2.66-­‐4.34]	   <	  5.00	  ×	  10-­‐05	  
Intronic	  SNPs	   875	   654.15	   1.84	  [1.59-­‐2.13]	   <	  5.00	  ×	  10-­‐05	  
Non.Syn.	  SNPs	  (UCSC)	   171	   60.20	   3.08	  [2.32-­‐4.27]	   <	  5.00	  ×	  10-­‐05	  
Coding	  SNPs	  (UCSC)	   244	   91.91	   2.99	  [2.32-­‐3.92]	   <	  5.00	  ×	  10-­‐05	  
Syn.	  SNPs	  (UCSC)	   119	   48.18	   2.60	  [1.90-­‐3.72]	   <	  5.00	  ×	  10-­‐05	  
Gained	  Stops	   6	   0.85	   7.12	  [2.00-­‐Infinity]	   1.10	  ×	  10-­‐03	  
3'UTR	   159	   60.29	   2.84	  [2.14-­‐3.93]	   <	  5.00	  ×	  10-­‐05	  
5'UTR	   43	   15.30	   2.86	  [1.74-­‐5.51]	   <	  5.00	  ×	  10-­‐05	  
RNA	  Genes	   1	   3.66	   0.27	  [0.12-­‐Infinity]	   2.87	  ×	  10-­‐02	  
ncRNA	   17	   13.28	   1.28	  [0.68-­‐3.43]	   2.20	  ×	  10-­‐01	  
TS	  miRNA	   0	   0.45	   0.00	  [0.00-­‐NA]	   <	  5.00	  ×	  10-­‐05	  
eQTLs	   293	   73.55	   4.73	  [3.11-­‐6.53]	   <	  5.00	  ×	  10-­‐05	  
vega	  PseudoGenes	   49	   27.86	   1.79	  [1.02-­‐3.13]	   2.34	  ×	  10-­‐02	  
Intergenic	  SNPs	   845	   921.66	   0.80	  [0.69-­‐0.93]	   1.40	  ×	  10-­‐03	  
DNase	  Clusters	   735	   467.92	   2.14	  [1.90-­‐2.43]	   <	  5.00	  ×	  10-­‐05	  
Insulators	  (sequence)	   124	   67.81	   1.91	  [1.43-­‐2.62]	   <	  5.00	  ×	  10-­‐05	  
Within	  miRNA	   0	   0.03	   0.00	  [NA-­‐NA]	   <	  5.00	  ×	  10-­‐05	  
Splice	  Sites	   0	   0.69	   0.00	  [0.00-­‐NA]	   <	  5.00	  ×	  10-­‐05	  
Lost	  Stops	   0	   0.29	   0.00	  [0.00-­‐NA]	   <	  5.00	  ×	  10-­‐05	  
Microsatellites	   1	   1.17	   0.85	  [0.25-­‐Infinity]	   3.28	  ×	  10-­‐01	  
EvoFold	   7	   3.09	   2.27	  [1.00-­‐Infinity]	   4.87	  ×	  10-­‐02	  
Pos.	  Sel.	  Genes	   601	   426.94	   1.69	  [1.45-­‐1.99]	   <	  5.00	  ×	  10-­‐05	  
Enhancers	  (sequence)	   8	   4.59	   1.75	  [0.80-­‐8.04]	   1.10	  ×	  10-­‐01	  
Exapted	  Repeats	   5	   4.09	   1.22	  [0.55-­‐5.01]	   3.85	  ×	  10-­‐01	  
PREMOD	   223	   152.14	   1.55	  [1.30-­‐1.89]	   <	  5.00	  ×	  10-­‐05	  
tfbs	  Conserved	   179	   124.53	   1.50	  [1.25-­‐1.84]	   5.00	  ×	  10-­‐05	  
Indel	  Pure	  regions	   649	   479.55	   1.63	  [1.45-­‐1.85]	   <	  5.00	  ×	  10-­‐05	  
17	  spec.	  algmt	   435	   318.28	   1.52	  [1.33-­‐1.76]	   <	  5.00	  ×	  10-­‐05	  
28	  spec.	  algmt	  plc.mmls	   392	   253.14	   1.75	  [1.51-­‐2.05]	   <	  5.00	  ×	  10-­‐05	  
28	  spec.	  algmt	   433	   298.87	   1.64	  [1.43-­‐1.90]	   <	  5.00	  ×	  10-­‐05	  
44	  spec.	  algmt	   445	   301.62	   1.68	  [1.47-­‐1.95]	   <	  5.00	  ×	  10-­‐05	  
44	  spec.	  algmt	  plc.mmls	   415	   275.01	   1.71	  [1.48-­‐2.00]	   <	  5.00	  ×	  10-­‐05	  
44	  spec.	  algmt	  prim.	   400	   261.50	   1.73	  [1.50-­‐2.01]	   <	  5.00	  ×	  10-­‐05	  
Negative	  (sequence)	   707	   793.37	   0.79	  [0.69-­‐0.90]	   2.50	  ×	  10-­‐04	  
Open	  Chromatin	   1074	   702.76	   2.98	  [2.40-­‐3.69]	   <	  5.00	  ×	  10-­‐05	  
Closed	  Chromatin	   416	   785.57	   0.34	  [0.28-­‐0.43]	   <	  5.00	  ×	  10-­‐05	  
Active	  Promoter	   120	   45.45	   2.79	  [1.92-­‐4.13]	   <	  5.00	  ×	  10-­‐05	  
Weak	  Promoter	   112	   47.25	   2.48	  [1.78-­‐3.59]	   <	  5.00	  ×	  10-­‐05	  
Poised	  Promoter	   27	   6.09	   4.50	  [2.10-­‐27.49]	   5.00	  ×	  10-­‐05	  
Strong	  Enhancer	  (proximal)	   116	   49.91	   2.44	  [1.77-­‐3.51]	   <	  5.00	  ×	  10-­‐05	  
Strong	  Enhancer	  (distal)	   108	   53.19	   2.11	  [1.59-­‐2.99]	   <	  5.00	  ×	  10-­‐05	  
Weak	  Enhancer	  (proximal)	   115	   66.92	   1.78	  [1.37-­‐2.41]	   <	  5.00	  ×	  10-­‐05	  
Weak	  Enhancer	  (distal)	   242	   124.69	   2.13	  [1.72-­‐2.67]	   <	  5.00	  ×	  10-­‐05	  
Insulator	   68	   50.61	   1.36	  [1.02-­‐1.93]	   2.03	  ×	  10-­‐02	  
Txn	  Transition	   104	   40.42	   2.69	  [1.92-­‐4.07]	   <	  5.00	  ×	  10-­‐05	  
Txn	  Elongation	   280	   143.44	   2.18	  [1.78-­‐2.72]	   <	  5.00	  ×	  10-­‐05	  
Weak	  Txn	   430	   256.67	   1.96	  [1.65-­‐2.35]	   <	  5.00	  ×	  10-­‐05	  
Repressed	   227	   113.34	   2.19	  [1.68-­‐2.83]	   <	  5.00	  ×	  10-­‐05	  
Heterochrom/lo	   1041	   1178.48	   0.60	  [0.50-­‐0.71]	   <	  5.00	  ×	  10-­‐05	  
Repetitive/CNV	  (proximal)	   4	   3.57	   1.12	  [0.50-­‐Infinity]	   4.65	  ×	  10-­‐01	  
Repetitive/CNV	  (distal)	   3	   2.93	   1.02	  [0.43-­‐Infinity]	   4.48	  ×	  10-­‐01	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4.3.5 Comparison	  of	  different	  LD	  thresholds	  in	  Significant	  SNPs	  (2011)	  
Recall,	  we	  had	  used	  r2	  abiding	  with	  standard	  notation	  to	  denote	  a	  measure	  of	  LD	  
and	  the	  correlation	  computed	  by	  linear	  threshold	  models.	  In	  this	  thesis	  we	  will	  
be	  using	  both	  concepts	   frequently,	  so	  to	  avoid	  confusion,	  we	  will	  be	  using	  r2LD	  
and	   r2c	   to	   denote	   the	   LD	   threshold	   and	   correlation	   computed	   using	   linear	  
regression	   models,	   respectively,	   in	   this	   section	   only.	   To	   continue	   the	   studies	  
presented	   so	   far,	   an	   investigation	   into	   the	   influence	   of	   using	   different	   LD	  
thresholds	  for	  the	  Significant	  SNPs	  (2011)	  was	  also	  performed,	  as	  an	  LD	  cut-­‐off	  
point	   of	   r2LD	   >	   0.9	   is	   considered	   rather	   stringent	   [50].	   An	   additional	   LD	  
threshold	   of	   r2LD	   >	   0.7	   was	   investigated	   to	   identify	   the	   effect	   of	   a	   lower	  
threshold	   resulting	   in	   a	   larger	   number	   of	   LD	   partners.	   Since	   LD	   decays	   with	  
increasing	   distance,	   the	   lower	   threshold	   would	   have	   a	   larger	   mean	   distance	  
between	  trait-­‐associated	  variants	  and	  their	  LD	  partners	  than	  the	  more	  stringent	  
cut-­‐off.	   Figure	   4-­‐9	   shows	   the	   resulting	   odds	   ratios	   of	   permutations	   using	   the	  
two	   thresholds	   for	   Significant	   SNPs	   (2011).	   There	   were	   seven	   genomic	  
annotations,	   where	   the	   results	   of	   the	   analyses	   using	   different	   LD	   thresholds	  
vary	   in	   significance,	   measured	   by	   the	   multiple	   testing	   corrected	   P-­value	  
obtained	   by	   the	   permutations.	   The	   lower	   threshold	   (r2LD	   >	   0.7)	   obtained	  
significance	   in	   four	   of	   these	   annotations	   (gained	   stop	   codons,	   TSmiRNA,	  
intergenic	  SNPs,	  and	  negative)	  where	  the	  higher	  threshold	  (r2LD	  >	  0.9)	  did	  not.	  
The	   higher	   threshold	  was	   significant	   in	   three	   annotations	   (5’UTRs,	   insulators	  
from	  the	  chromatin	  states,	  and	  weak	   transcription),	  where	   the	   lower	  was	  not.	  
There	  was	  a	  strong	  and	  positive	  correlation	  (r2c	  =	  0.82)	  of	  the	  odds	  ratios	  of	  the	  
two	  LD	  thresholds	  with	  a	  significant	  P-­value	  of	  5.61	  ×	  10-­‐23	  (Figure	  4-­‐10).	  The	  
number	  of	  overlaps	  for	  the	  observed	  data,	  the	  mean	  number	  of	  overlaps	  for	  the	  
permutations,	   the	   calculated	   odds	   ratios,	   their	   confidence	   intervals	   and	   the	  
observed	  P-­value	  of	   the	  analysis	  with	  the	   less	  stringent	  LD	  cut-­‐of	  point	  (r2LD	  >	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Figure	  4-­9	  –	  Comparison	  of	  r2>0.9	  with	  r2>0.7	  in	  Significant	  SNPs	  (2011)	  
The	  results	  of	  the	  two	  LD	  thresholds	  (r2>0.9	  ()	  and	  r2>0.7	  ())	  for	  Significant	  SNPs	  (2011)	  show	  no	  
significant	   differences.	   All	   P-­‐values	   are	   corrected	   for	   multiple	   testing	   for	   the	   analysed	   genomic	  
annotations	  and	  solid	  symbols	  indicate	  significance	  at	  that	  level.	  Top:	  Genic	  and	  regulatory	  regions.	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Figure	   4-­10	   –	   Correlation	   of	   the	   odds	   ratios	   in	   the	   analyses	   of	   the	   LD	   partners	   of	   r2LD>0.9	   and	  
r2LD>0.7	  in	  Significant	  SNPs	  (2011)	  
A	   strong	   positive	   correlation	   is	   observed	   for	   the	   odds	   ratios	   of	   the	   two	   different	   LD	   thresholds	  
analysed	   in	   Significant	   SNPs	   (2011)	   (r2c	   =	   0.82).	   The	  P-­‐value	   of	   the	   correlation	   is	   highly	   significant	  
with	  a	  value	  of	  5.61	  ×	  10-­‐23.	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Table	  4-­5	  –	  Permutations	  for	  Significant	  SNPs	  (2011)	  at	  r2LD	  >	  0.7	  LD	  threshold	  
This	  table	  summarises	  the	  results	  for	  Significant	  SNPs	  (2011)	  at	  a	  lower	  LD	  threshold	  (r2LD	  >	  0.7).	  The	  
number	  of	  overlaps	  in	  the	  observed	  set	  (Real),	  the	  mean	  of	  the	  permuted	  hits	  (Permutation	  Mean),	  
the	  calculated	  odds	  ratio	  and	  confidence	  interval	  (OR	  [LCI-­‐HCI])	  and	  the	  obtained	  P-­‐value	  for	  each	  of	  
the	  genomic	  annotations	  are	  shown	  below.	  Significant	  P-­‐values	  in	  bold.	  	  
Annotation	   Real	   Permutation	  Mean	   OR	  [LCI-­‐HCI]	   P-­‐value	  
1	  Kb	  TSS	   45	   19.80	   2.30	  [1.46-­‐4.17]	   4.50	  ×	  10-­‐04	  
5	  Kb	  TSS	   203	   77.33	   2.82	  [2.04-­‐3.94]	   5.00	  ×	  10-­‐05	  
CpG	  Islands	   31	   11.57	   2.71	  [1.64-­‐6.29]	   1.00	  ×	  10-­‐04	  
ORegAnno	   34	   13.11	   2.62	  [1.63-­‐5.75]	   5.00	  ×	  10-­‐05	  
vega	  Genes	   905	   667.80	   1.68	  [1.41-­‐1.98]	   <	  5.00	  ×	  10-­‐05	  
OMIM	  genes	   903	   573.34	   2.09	  [1.74-­‐2.50]	   <	  5.00	  ×	  10-­‐05	  
OMIM	  morbid	  regions	   423	   130.43	   3.88	  [2.82-­‐5.50]	   <	  5.00	  ×	  10-­‐05	  
Exons	   223	   51.81	   4.74	  [3.42-­‐6.88]	   <	  5.00	  ×	  10-­‐05	  
Intronic	  SNPs	   931	   770.03	   1.41	  [1.20-­‐1.65]	   1.50	  ×	  10-­‐04	  
Non.Syn.	  SNPs	  (UCSC)	   140	   25.92	   5.75	  [3.90-­‐9.36]	   <	  5.00	  ×	  10-­‐05	  
Coding	  SNPs	  (UCSC)	   183	   40.02	   4.95	  [3.51-­‐7.39]	   <	  5.00	  ×	  10-­‐05	  
Syn.	  SNPs	  (UCSC)	   53	   15.44	   3.50	  [2.24-­‐6.79]	   <	  5.00	  ×	  10-­‐05	  
Gained	  Stops	   3	   0.34	   8.97	  [1.50-­‐Infinity]	   4.50	  ×	  10-­‐04	  
3'UTR	   61	   24.06	   2.59	  [1.72-­‐4.47]	   <	  5.00	  ×	  10-­‐05	  
5'UTR	   12	   4.43	   2.72	  [1.34-­‐12.07]	   1.15	  ×	  10-­‐03	  
RNA	  Genes	   1	   0.87	   1.15	  [0.33-­‐Infinity]	   2.17	  ×	  10-­‐01	  
ncRNA	   15	   10.40	   1.45	  [0.65-­‐5.03]	   1.44	  ×	  10-­‐01	  
TS	  miRNA	   2	   0.15	   13.76	  [2.00-­‐Infinity]	   7.00	  ×	  10-­‐04	  
eQTLs	   222	   42.20	   5.82	  [3.92-­‐9.17]	   <	  5.00	  ×	  10-­‐05	  
vega	  PseudoGenes	   21	   13.69	   1.54	  [0.87-­‐3.53]	   6.20	  ×	  10-­‐02	  
Intergenic	  SNPs	   823	   1089.91	   0.57	  [0.49-­‐0.67]	   5.00	  ×	  10-­‐05	  
DNase	  Clusters	   472	   241.34	   2.27	  [1.93-­‐2.69]	   <	  5.00	  ×	  10-­‐05	  
Insulators	  (sequence)	   53	   24.95	   2.16	  [1.49-­‐3.61]	   1.50	  ×	  10-­‐04	  
Within	  miRNA	   0	   0.01	   0.00	  [NA-­‐NA]	   8.90	  ×	  10-­‐03	  
Splice	  Sites	   0	   0.25	   0.00	  [0.00-­‐NA]	   2.20	  ×	  10-­‐01	  
Lost	  Stops	   0	   0.05	   0.00	  [0.00-­‐NA]	   5.22	  ×	  10-­‐02	  
Microsatellites	   0	   0.31	   0.00	  [0.00-­‐NA]	   2.70	  ×	  10-­‐01	  
EvoFold	   2	   1.06	   1.89	  [0.67-­‐Infinity]	   9.40	  ×	  10-­‐02	  
Pos.	  Sel.	  Genes	   643	   461.62	   1.59	  [1.34-­‐1.90]	   <	  5.00	  ×	  10-­‐05	  
Enhancers	  (sequence)	   5	   1.84	   2.73	  [1.00-­‐Infinity]	   1.64	  ×	  10-­‐02	  
Exapted	  Repeats	   1	   1.13	   0.89	  [0.25-­‐Infinity]	   3.09	  ×	  10-­‐01	  
PREMOD	   100	   58.53	   1.75	  [1.35-­‐2.40]	   <	  5.00	  ×	  10-­‐05	  
tfbs	  Conserved	   74	   38.71	   1.95	  [1.47-­‐2.81]	   <	  5.00	  ×	  10-­‐05	  
Indel	  Pure	  regions	   407	   231.63	   1.96	  [1.70-­‐2.29]	   <	  5.00	  ×	  10-­‐05	  
17	  spec.	  algmt	   237	   125.79	   2.01	  [1.69-­‐2.46]	   <	  5.00	  ×	  10-­‐05	  
28	  spec.	  algmt	  plc.mmls	   223	   97.27	   2.46	  [2.01-­‐3.10]	   <	  5.00	  ×	  10-­‐05	  
28	  spec.	  algmt	   246	   116.97	   2.27	  [1.88-­‐2.79]	   <	  5.00	  ×	  10-­‐05	  
44	  spec.	  algmt	   257	   118.45	   2.35	  [1.95-­‐2.91]	   <	  5.00	  ×	  10-­‐05	  
44	  spec.	  algmt	  plc.mmls	   238	   106.74	   2.40	  [1.98-­‐3.02]	   <	  5.00	  ×	  10-­‐05	  
44	  spec.	  algmt	  prim.	   233	   104.25	   2.41	  [1.98-­‐3.02]	   <	  5.00	  ×	  10-­‐05	  
Negative	  (sequence)	   572	   850.14	   0.53	  [0.46-­‐0.63]	   <	  5.00	  ×	  10-­‐05	  
Open	  Chromatin	   1429	   894.69	   3.38	  [2.31-­‐4.54]	   <	  5.00	  ×	  10-­‐05	  
Closed	  Chromatin	   477	   1010.41	   0.30	  [0.22-­‐0.43]	   <	  5.00	  ×	  10-­‐05	  
Active	  Promoter	   46	   16.13	   2.90	  [1.79-­‐5.87]	   <	  5.00	  ×	  10-­‐05	  
Weak	  Promoter	   37	   15.70	   2.38	  [1.49-­‐4.70]	   1.00	  ×	  10-­‐04	  
Poised	  Promoter	   6	   2.58	   2.33	  [1.00-­‐Infinity]	   2.26	  ×	  10-­‐02	  
Strong	  Enhancer	  (proximal)	   90	   23.83	   3.91	  [2.57-­‐6.70]	   <	  5.00	  ×	  10-­‐05	  
Strong	  Enhancer	  (distal)	   51	   21.75	   2.38	  [1.56-­‐4.34]	   4.00	  ×	  10-­‐04	  
Weak	  Enhancer	  (proximal)	   57	   23.52	   2.47	  [1.65-­‐4.17]	   <	  5.00	  ×	  10-­‐05	  
Weak	  Enhancer	  (distal)	   112	   55.21	   2.09	  [1.57-­‐2.99]	   5.00	  ×	  10-­‐05	  
Insulator	   29	   17.16	   1.70	  [1.12-­‐3.26]	   4.95	  ×	  10-­‐03	  
Txn	  Transition	   44	   16.81	   2.66	  [1.64-­‐5.61]	   5.00	  ×	  10-­‐05	  
Txn	  Elongation	   190	   112.05	   1.77	  [1.34-­‐2.40]	   7.50	  ×	  10-­‐04	  
Weak	  Txn	   306	   200.10	   1.63	  [1.31-­‐2.04]	   1.00	  ×	  10-­‐03	  
Repressed	   156	   81.35	   2.00	  [1.43-­‐2.79]	   <	  5.00	  ×	  10-­‐05	  
Heterochrom/lo	   1067	   1423.58	   0.43	  [0.35-­‐0.54]	   2.50	  ×	  10-­‐04	  
Repetitive/CNV	  (proximal)	   2	   1.82	   1.10	  [0.33-­‐Infinity]	   2.72	  ×	  10-­‐01	  
Repetitive/CNV	  (distal)	   1	   1.16	   0.86	  [0.25-­‐Infinity]	   3.17	  ×	  10-­‐01	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4.4 Discussion	  
In	  this	  chapter,	  we	  presented	  the	  enrichment	  and	  depletion	  results	  of	  different	  
datasets	  of	  trait-­‐associated	  SNPs	  in	  genomic	  regions	  annotated	  for	  58	  different	  
functional	   genomic	   features	   using	   two	   different	   methods.	   Here,	   we	   discuss	  
obtained	  results.	  	  
4.4.1 Permutations	  vs.	  sampling	  
4.4.1.1 Computational	  requirements	  	  
We	   have	   developed	   and	   used	   a	   novel	   permutation	   method,	   which	   took	   the	  
internal	   genomic	   structure	   into	   account	   by	   preserving	   the	   distance	   between	  
trait-­‐associated	   SNPs	   in	   each	   permutation.	   The	   results	   obtained	   by	   the	  
permutations	  were	  compared	  to	  the	  results	  obtained	  by	  the	  sampling	  approach,	  
which	  does	  not	  depend	  on	   the	   internal	   structure,	   discussed	   in	  Chapter	  3.	  The	  
permutation	  method	   kept	   not	   only	   the	   number	   of	   SNPs	   per	   chromosome	   but	  
also	   the	   relative	   distance	   of	   these	   SNPs	   fixed	   in	   every	   permutation.	  However,	  
the	   process	   of	   performing	   the	   permutation	   analyses	   is	   quite	   time-­‐consuming.	  
The	  permutations	  were	  performed	  20,000	  times,	  which	  took	  almost	  three	  days	  
to	  complete	  for	  the	  entire	  genome.	  The	  20,000	  permutations	  meant	  that	  the	  P-­
value	  of	  significance	  was	  delimited	  at	  5	  ×	  10-­‐5.	  To	   increase	   the	  significance	  by	  
one	   order	   of	   magnitude	   to	   5	   ×	   10-­‐6	   would	   have	   meant	   increasing	   the	  
permutation	   number,	   and	   therefore	   the	   computational	   time,	   by	   an	   order	   of	  
magnitude,	  which	  would	   have	   been	   30	   days.	   In	   our	   analyses,	   this	   increase	   in	  
time	   was	   not	   justifiable	   for	   a	   change	   in	   significance	   of	   only	   one	   order	   of	  
magnitude.	  	  
	  
The	  sampling	  method	   is	  comparatively	   faster	   than	  the	  permutation	  method.	   It	  
was	   divided	   into	   two	   steps:	   the	   preparation	   of	   the	   samples	   and	   the	   analysis	  
itself.	  The	  analysis	  itself	  took	  less	  than	  an	  hour,	  but	  the	  establishing	  of	  mutually	  
exclusive	   samples	   and	   the	   establishing	   of	   their	   LD	   partners	   required	   a	   day.	  
However,	   it	   was	   only	   100	   samples	   that	   were	   analysed,	   as	   the	   study	   we	  
attempted	  to	  replicate	  also	  used	  100	  samples	  [50].	  These	  100	  samples	  were	  not	  
enough	   to	   establish	   defined	   confidence	   intervals	   that	   were	   based	   on	   the	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distribution	  of	   the	  expected	   results,	   as	  was	  done	   for	   the	  permutation	  method.	  
The	   empirical	   confidence	   intervals	   of	   the	   permutation	   method	   gave	   a	   more	  
conservative	  measure	   of	   enrichment	   or	   depletion	   as	   their	   average	  width	  was	  
generally	  wider	  than	  the	  average	  of	  the	  theoretical	  confidence	  interval	  width	  for	  
the	  sampling	  method.	  	  
4.4.1.2 Genomic	  annotations	  enriched	  for	  trait-­‐associated	  SNPs	  	  
Overall,	   we	   observed	   significant	   enrichment	   significant	   GWAS	   hits	   in	   genic	  
annotations	   and	   several	   features	   associated	   with	   particular	   chromatin	   states	  
with	   both	   methods.	   The	   enrichment	   in	   genic	   annotations	   had	   been	   well	  
documented	   in	   previous	   studies	   [50,	   65],	   while	   there	   had	   been	   evidence	   for	  
enrichment	   of	   trait-­‐associated	   SNPs	   in	   regions	   with	   distinct	   chromatin	  
structures	  [82].	  	  
 
There	  were	   some	  differences	   between	   the	   significant	   odds	   ratios	   obtained	   by	  
the	   two	  methods.	  Among	   these	  was	   the	  negative	  set,	  which	  was	  created	  as	  an	  
approximation	   to	  a	  negative	   control	   (Figure	  4-­‐2,	  middle	  panel).	  As	  mentioned	  
before,	  the	  Bonferroni	  corrected	  P-­value	  threshold	  was	  8.62	  ×	  10-­‐4.	  The	  P-­values	  
of	   the	   results	   had	   to	   be	   less	   than	   that	   threshold	   to	   be	   significant.	   The	  
permutation	  method	  obtained	  an	  odds	  ratio	  of	  0.81	  [0.71-­‐0.94]	  (P-­value	  =	  1.95	  
×	  10-­‐3),	  while	   the	   sampling	  method	  obtained	  an	  odds	   ratio	  of	  0.79	   [0.69-­‐0.89]	  
with	  a	  P-­value	  of	  1.73	  ×	  10-­‐4.	  The	  difference	  was	  marginal,	  but	   the	  P-­value	   for	  
the	  permutations	  was	  not	  significant	  after	  correcting	  for	  multiple	  testing	  using	  
the	   Bonferroni	   correction,	   but	   the	   odds	   ratio	   obtained	   by	   sampling	   was.	   The	  
poised	   promoters	   annotations	   were	   also	   not	   significantly	   enriched	   in	   the	  
permutation	  results	  of	  Significant	  SNPs	  (2011).	  The	  chromatin	  states	  associated	  
with	  insulating	  activity,	  however,	  were	  significant	  for	  the	  permutations,	  but	  not	  
for	   the	   sampling	  method.	   Several	   of	   the	   sparsely	   annotated	   genomic	   features	  
resulted	   in	   large	   confidence	   intervals	   on	   the	   estimated	   odds	   ratio	   by	   either	  
method,	  confirming	  the	  difficulties	  in	  obtaining	  results.	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The	  observed	  differences	  in	  significance	  were	  due	  to	  the	  different	  methods	  used	  
to	   calculate	   the	   P-­values	   and	   the	   confidence	   intervals.	   The	   theoretically	  
determined	  P-­values,	  which	  were	  a	  widely	  used	  asymptotic	  approximation	  (see	  
page	  50	  of	  this	  thesis)	  used	  in	  the	  sampling	  method,	  were	  compared	  with	  those	  
determined	  empirically	  in	  the	  circular	  permutations	  method	  (see	  page	  71	  of	  this	  
thesis).	  Theoretical	  values	  were	  used	  for	  the	  sampling	  method	  since	  they	  were	  
necessarily	  based	  on	  a	  limited	  number	  of	  random	  samples,	  and	  such	  limitations	  
did	  not	  apply	  to	  the	  permutation	  approach.	  The	  confidence	  intervals	  derived	  by	  
permutation	  were	  generally	  more	   conservative	   (i.e.,	   larger)	   than	   those	   for	   the	  
sampling	  approach	  were.	  This	  is	  because	  the	  permutation	  confidence	  intervals	  
were	   based	   on	   the	   empirically	   derived	   confidence	   intervals	   rather	   than	   the	  
calculated	   ones.	   The	   empirical	   confidence	   intervals	  were	   chosen	   to	   represent	  
the	  distribution	  of	  the	  overlaps	  obtained	  from	  the	  permutations	  not	  only	  in	  the	  
tables,	  but	  also	  on	  the	  graphs.	  They	  clearly	  show	  where	  the	  95%	  of	  the	  obtained	  
permutation	  overlaps	  were.	  	  
4.4.2 Modest	  functional	  enrichment	  in	  Suggestive	  SNPs	  (2011)	  
There	   has	   been	   substantial	   interest	   in	   trait-­‐associated	   variants	   with	   modest	  
associations	   of	   P-­values,	   as	   they	   are	   suspected	   to	   contain	   real	   positive	  
associations.	  We	  therefore	  analysed	  SNPs	  with	  more	  moderate	  P-­values	  that	  did	  
not	  pass	  the	  genome-­‐wide	  significance	  threshold	  (5	  ×	  10-­‐5	  >	  P-­value	  >	  5	  ×	  10-­‐8)	  
to	   determine	   if	   their	   distribution	  was	   similar	   to	   the	  distribution	  of	   significant	  
GWAS	  hits.	  Suggestive	  SNPs	  (2011)	  showed	  similar	  results	   to	  Significant	  SNPs	  
(2011)	   but	   with	   odds	   ratios	   that	   were	   less	   extreme	   than	   the	   odds	   ratios	   for	  
Significant	   SNPs	   (2011).	   This	   result	   was	   consistent	   with	   the	   suggestively	  
associated	  SNPs	  being	  a	  mixture	  of	   false	  positives	   (which	  we	  would	  expect	   to	  
have	   no	   bias	   towards	   particular	   annotations)	   and	   true	   associations,	   whose	  
effects	   were	   not	   of	   sufficient	   magnitude	   to	   show	   genome-­‐wide	   significance.	  
These	   true	   positives	   would	   be	   expected	   to	   have	   the	   same	   bias	   towards	  
particular	   genomic	   features	   as	   trait-­‐associated	   SNPs	   attaining	   genome-­‐wide	  
significance	  [65].	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The	   observed	   modest	   enrichment	   of	   functional	   elements	   in	   SNPs	   with	   not	  
significant	   P-­values	   of	   association	   is	   most	   likely	   due	   to	   reporting	   bias	   of	  
associated	   SNPs	   in	   the	   literature.	  While	   significantly	   trait-­‐associated	   SNPs	   are	  
documented	   consistently,	   suggestive	   associations	   often	   remained	   unreported	  
since	  they	  are	  generally	  assumed	  to	  contribute	  less	  to	  our	  understanding	  of	  the	  
underlying	  biology.	  Additionally,	  the	  NHGRI	  GWAS	  catalogue	  only	  incorporated	  
result	   variants	   with	   association	   levels	   starting	   at	   5	   ×	   10-­‐5,	   where	   the	   more	  
commonly	  accepted	   level	   for	  suggestively	  associated	  SNPs	   is	  5	  ×	  10-­‐4	   [36,	  50].	  
This	   meant	   that	   the	   significantly	   associated	   SNP	   set	   was	   likely	   to	   be	   a	   more	  
comprehensive	  and	  complete	  SNP	  set	  of	  true	  associations,	  despite	  containing	  a	  
smaller	   number	   of	   SNPs.	   The	   similarity	   of	   enrichment	   trends	   between	  
Significant	   SNPs	   (2011)	   and	   Suggestive	   SNPs	   (2011)	   were	   encouraging.	   The	  
results	  might	  be	  of	  use	   in	   follow-­‐up	  studies	   identifying	   true	  associations	   from	  
suggestively	   trait-­‐associated	   variants	   by	   focusing	   the	   search	   on	   areas,	   which	  
were	   enriched	   for	   significantly	   trait-­‐associated	   SNPs.	   The	   prediction	   of	  
functional	  suggestive	  variants	  may	  be	   improved	  by	  possibly	   investigating	  only	  
those	   SNPs	   that	   were	   overlapping	   with	   multiple	   annotations.	   However,	   care	  
should	   be	   taken	   in	   choosing	   the	   multiple	   overlapping	   annotations	   given	   that	  
some	   annotations	   are	   overlapping	   by	   definition,	   e.g.,	   exons	   and	   genes.	   An	  
analysis	   to	   estimate	   the	   proportion	   of	   true	   positives	   in	   the	   set	   of	   suggestive	  
variants	  could	  be	  undertaken	  by	  investigating	  which	  of	  the	  suggestive	  variants	  
were	  replicated	  in	  the	  SNP	  set	  of	  2013.	  However,	  this	  estimate	  would	  probably	  
be	  biased	  as,	  as	  mentioned	  above,	  the	  suggestive	  SNPs	  set	  is	  likely	  incomplete.	  	  
	  
4.4.3 Analysis	  of	  trait-­‐associated	  variants	  identified	  since	  2011	  
The	   Significant	   SNPs	   (2011)	   and	   Significant	   SNPs	   (2013)	   did	   not	   show	  
significant	   differences	   in	   the	   analyses,	   despite	   the	  more	   recent	   set	   containing	  
almost	  twice	  as	  many	  variants.	  This	  was	  likely	  due	  to	  the	  large	  overlap	  between	  
the	   two	   sets.	   The	   Significant	   SNPs	   (Difference)	   showed	   three	   significant	  
differences	  with	  an	  apparent	  shift	  of	  trait-­‐associated	  SNPs	  from	  transcriptional	  
elongation	   regions	   to	   regions	   5	   Kb	   upstream	   of	   transcription	   start	   sites.	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Significant	   SNPs	   (2013)	   resulted	   in	   a	   larger	  number	  of	   genomic	   features	  with	  
significant	   enrichment	   for	   trait-­‐associated	   variants	   arising	   from	   the	   larger	  
number	   of	   analysed	   variants.	   The	   most	   prominent	   difference	   between	   the	  
datasets	  was	   the	   smaller	   confidence	   interval	   for	   the	   newer	   set.	  However,	   this	  
was	   also	   expected,	   as	   a	   larger	  number	  of	   variants	  would	  have	  provided	  more	  
statistical	   power	   for	   the	   analysis,	   which	   was	   reflected	   in	   the	   reduced	   95%	  
confidence	  interval	  widths.	  	  
We	  wanted	  to	  investigate	  the	  new	  additions	  to	  the	  NHGRI	  catalogue	  to	  compare	  
them	  with	  the	  set	  of	  SNPs	  from	  2011.	  The	  analysis	  showed	  that	  the	  results	  for	  
Significant	   SNPs	   (2011)	   influenced	   the	   Significant	   SNPs	   (2013)	   results.	   We	  
observed	   three	   genomic	   annotations,	  which	   changed	   significance.	   These	  were	  
the	   ORegAnno	   annotation,	   gained	   stop	   codons,	   and	   the	   chromatin	   states	  
associated	  with	  insulators.	  The	  odds	  ratios	  of	  predicted	  binding	  sites	  of	  miRNA	  
(TS	   miRNA)	   and	   RNA	   genes	   dropped	   to	   odds	   ratios	   indicating	   depletion,	  
although	  these	  odds	  ratios	  did	  not	  reach	  significance.	  A	  quick	  investigation	  into	  
the	  effect	  sizes	  in	  the	  data	  showed	  that	  Significant	  SNPs	  (Difference)	  contained	  
11	  SNPs	  with	  an	  odds	  ratio	  higher	  than	  50,	  while	  Significant	  SNPs	  (2011)	  only	  
had	   three.	   These	   11	   variants	   were	   unlikely	   to	   significantly	   change	   the	  
distribution	  of	  the	  data,	  but	  they	  indicated	  that	  variants	  with	  possibly	  different	  
mechanisms	   were	   identified.	   The	   mean	   risk	   allele	   frequencies	   of	   the	   trait-­‐
associated	   variants	   in	   Significant	   SNPs	   (2011),	   Significant	   SNPs	   (2013),	   and	  
Significant	   SNPs	   (Difference)	   remained	   constant	   (0.39-­‐0.40).	   It	   can	   therefore	  
not	  be	  said,	   that	  the	  newer	  GWAS	  identified	  rare	  variants	  with	   large	  effects	  or	  
more	  eQTLs.	  As	  mentioned	  in	  the	  Methods	  section,	  odds	  ratios	  were	  undefined	  
when	  zero	  overlaps	  were	  observed	   in	  the	  trait-­‐associated	  SNP	  sets.	  This	  could	  
have	  been	  a	   sign	  of	   severe	  depletion	   in	   those	   genomic	   annotations	  where	   the	  
odds	   ratio	  was	   not	   available.	   However,	   it	  was	   not	   possible	   to	   accurately	   gain	  
insight	  into	  this,	  as	  the	  overlap	  of	  these	  genomic	  annotations	  with	  all	  SNPs	  was	  
relatively	   low	   (see	   Table	   2-­‐1).	   The	   calculations	   of	   odds	   ratios,	   as	   done	   here,	  
were	  known	  to	  perform	  poorly	  when	  small	  sample	  sizes	  were	  analysed	  [140],	  
so	   a	   greater	   accuracy	   would	   only	   be	   gained	   once	   more	   information	   became	  
available.	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4.4.4 Comparison	  of	  different	  LD	  thresholds	  	  
The	   LD	   threshold	   for	   SNPs	   segregating	   with	   the	   associated	   variant	   in	   all	  
datasets	   was	   set	   to	   r2LD	   >	   0.9.	   However,	   for	   completeness	   we	   analysed	   an	  
additional,	   lower	   LD	   threshold	   for	   Significant	   SNPs	   (2011)	   to	   r2LD	   >	   0.7.	   The	  
results	   for	   the	   lower	   LD	   threshold	   originated	   from	  more	   variants,	   as	   a	   larger	  
number	   of	   SNPs	   segregated	   with	   the	   trait-­‐associated	   variant	   at	   the	   lower	  
threshold.	  Additionally,	  these	  variants	  were	  located	  at	  a	  greater	  distance	  away	  
from	  the	  trait-­‐associated	  variant,	  as	  LD	  decays	  with	  distance:	  LD	  between	  two	  
variants	   decreases	   as	   the	   distance	   between	   them	   increases	   [141].	   The	   results	  
for	  the	  threshold	  of	  0.7	  were	  compared	  with	  the	  threshold	  of	  0.9.	  The	  increased	  
number	  of	  LD	  partners	  did	  result	  in	  more	  odds	  ratios	  with	  significant	  P-­values	  
in	  the	  genic	  regions.	  However,	  there	  were	  less	  odds	  ratios	  reaching	  significance	  
in	  the	  chromatin	  states	  associated	  with	  different	  regulatory	  states.	  The	  number	  
of	  genomic	  annotations	  for	  which	  the	  higher	  confidence	  interval	  bound	  was	  not	  
available	  increased	  to	  13	  in	  the	  0.7	  set	  with	  an	  additional	  five	  annotations	  (RNA	  
genes,	   enhancers	   (sequence),	   exapted	   repeats,	   poised	   promoters	   and	  
repetitive/CNV	  (proximal)).	  The	  confidence	  interval	  widths	  were	  calculated	  for	  
the	  remaining	  45	  genomic	  annotations.	  This	   increase	   in	  annotations	   for	  which	  
the	   higher	   confidence	   interval	   was	   not	   available	   suggested	   that	   the	   higher	  
number	  of	  analysed	  variants	  introduced	  more	  noise.	  	  
	  
We	   argued	   that	   the	   larger	   confidence	   intervals	   observed	   in	   the	   comparison	  
between	   the	  permutations	  vs.	   the	   sampling	  method	  were	  a	  more	  conservative	  
measure.	   This	   is	   because	   the	   confidence	   intervals	   are	   directly	   related	   to	   the	  
overlaps	   seen	   in	   the	   permutations	   rather	   than	   a	   theoretically	   calculated	  
interval.	   Furthermore,	   they	   are	   not	   defined	   to	   be	   symmetrically	   distributed	  
around	   the	   odds	   ratio	   unlike	   the	   theoretical	   values,	   so	   that	   the	   underlying	  
distribution	  of	  the	  permutation	  overlaps	  is	  immediately	  evident	  from	  the	  result	  
graphs.	   In	   the	   lower	   r2	   LD	   threshold	   analysis	   more	   annotations	   had	   infinite	  
confidence	   interval	   limits	   resulting	   from	   very	   large	   differences	   between	   the	  
overlaps	   in	   the	   permutations	   and	   real	   dataset.	   This	   is	   likely	   due	   to	   the	   extra	  
noise	  added	  by	  the	  additionally	  analysed	  variants	  that	  were	  included	  in	  the	  data	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when	  the	  lower	  r2	  LD	  threshold	  was	  analysed.	  The	  confidence	  intervals	  used	  for	  
the	  permutations	  therefore	  give	  a	  good	  idea	  of	  the	  underlying	  distribution	  of	  the	  
expected	  data.	  	  
4.4.5 Conclusion	  
The	   majority	   of	   the	   functional	   annotations	   showed	   enrichment	   for	   trait-­‐
associated	  SNPs	  of	  all	  analysed	  datasets.	  Some	  of	  the	  genomic	  annotations	  were	  
defined	  as	  overlapping	  with	  at	  least	  one	  other	  genomic	  annotation	  due	  to	  their	  
location.	  For	  example,	  non-­‐synonymous	  SNPs	  are	  defined	  as	  SNPs	  within	  coding	  
regions,	   which	   can	   change	   the	   resulting	   protein	   sequence.	   These	   SNPs	   will	  
overlap	  with	   regions	   defined	   as	   genes	   in	   the	   gene	   datasets	   and	   possibly	  with	  
functional	  elements	  associated	  with	  different	  chromatin	  states.	  These	  genomic	  
annotations	   are	   therefore	   not	   mutually	   exclusive,	   though	   examining	   them	   all	  
may	   provide	   extra	   information.	   Such	   dependencies	   among	   annotations	   make	  
drawing	   conclusions	   from	   these	   results	   difficult.	   Additional	   analyses	   in	   later	  
chapters	  examine	  solutions	  to	  this	  problem,	  and	  investigate	  the	  relative	  effect	  of	  
the	  individual	  genomic	  annotation	  using	  a	  stepwise	  regression	  approach.	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5 LOGISTIC	  REGRESSION	  
5.1 Introduction	  
As	  we	  have	  shown	  in	  the	  previous	  chapter,	  the	  methods	  discussed	  so	  far	  used	  to	  
analyse	  enrichment	  or	  depletion	  in	  individual	  genomic	  annotations	  discussed	  so	  
far	   gave	   encouraging	   results.	   However,	   the	   analysis	   of	   individual	   genomic	  
annotations	   could	   give	   rise	   to	   false	   positive	   enrichment	   signals	   when	   two	   or	  
more	   annotations	   are	   overlapping.	   In	   this	   case	   it	   is	   impossible	   to	   distinguish,	  
which	  of	  the	  overlapping	  genomic	  annotations	  are	  causing	  the	  observed	  signal.	  
A	  different	  method,	   logistic	  regression,	  was	  therefore	  applied	  to	   identify	  those	  
genomic	  annotations	  with	  the	  most	  influence	  on	  trait	  association	  status.	  Logistic	  
regression	   produces	   results	   based	   on	   an	   information	   criterion	   calculated	   for	  
each	   genomic	   annotation	   and	   determines	   the	   impact	   of	   single	   or	   multiple	  
independent	   variables.	   These	   variables	   are	   presented	   simultaneously	   and	   the	  
analysis	  predicts	  if	  the	  variables	  are	  associated	  with	  one	  of	  the	  two	  states	  of	  the	  
independent	  variable	  (0	  or	  1)	  more	  often	  than	  expected	  by	  chance	  [142,	  143].	  	  
	  
Logistic	  regression	  has	  previously	  been	  used	  to	   identify	  effects	  contributing	  to	  
certain	   traits	   additionally	   to	   the	   analysed	   SNPs.	   Such	   effects	   could	   be	   gender,	  
age	  or	  diet,	  which	  can	  affect	  a	  trait	  differently	  [144,	  145].	  Logistic	  regression	  has	  
also	  been	  used	  to	  investigate	  different	  models	  which	  could	  be	  more	  appropriate	  
to	  analyse	  GWAS	  [146].	  All	  of	   the	  mentioned	   logistic	  regression	  analyses	  were	  
performed	  using	  genotypes	  of	  individuals	  to	  analyse	  the	  effect	  of	  SNPs	  on	  a	  trait.	  
In	  contrast	  to	  more	  traditional	  regression	  analyses	  investigating	  the	  association	  
of	  SNP	  alleles	  with	  certain	  traits,	  we	  used	  the	  information	  on	  whether	  or	  not	  a	  
SNP	  overlapped	  with	  a	  particular	  annotation.	  The	  aim	  of	  our	  research	  was,	  as	  in	  
the	   sampling	   and	   permutation	   chapter,	   to	   identify	   genomic	   annotations	   that	  
showed	   any	   evidence	   for	   enrichment	   or	   depletion	   of	   trait-­‐associated	   SNPs.	   A	  
conceptually	  similar	  approach	  was	  applied	  in	  a	  study	  investigating	  the	  location	  
of	  eQTLs	  within	   the	  genome	  to	  see	   if	  eQTLs	  were	  most	   likely	   to	  coincide	  with	  
transcription	  factor	  binding	  sites	  [147].	  We	  further	  decided	  to	  explore	  distance	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to	   TSS	   in	   greater	   detail	   following	   [72],	   so	   we	   analysed	   the	   number	   of	  
nucleotides	  as	  a	  quantitative	  variable.	  This	  means	  that	  the	  distance	  to	  TSS	  was	  
not	  binary,	  but	  a	  continuous	  measure.	  
	  
This	   chapter	   focuses	   on	   how	   the	   logistic	   regression	  method	   is	   applied	   to	   our	  
available	  datasets.	  In	  all	  logistic	  regression	  models,	  we	  use	  genomic	  annotations	  
as	   variables	   in	   the	   model,	   where	   the	   total	   information	   carried	   by	   a	   genomic	  
annotation	  is	  the	  number	  of	  linkage	  disequilibrium	  (LD)	  blocks	  it	  overlaps	  with.	  
First,	  we	  performed	  a	  univariate	  logistic	  regression	  to	  compare	  the	  results	  with	  
the	   permutation	   results.	   The	   univariate	   approach	   is	   comparable	   to	   the	  
permutation	  and	  sampling	  analyses,	  as	  only	  one	  genomic	  annotation	  is	  analysed	  
at	   one	   time	   without	   information	   on	   other	   annotations.	   The	   results	   of	   the	  
individual	   annotation	   analysis	   are	   compared	   with	   the	   results	   from	   the	  
permutation	  analysis	  to	  identify	  possible	  biases	  in	  either	  approach.	  	  
	  
We	  used	  a	  stepwise	  approach	  to	  identify	  multivariate	  logistic	  regression	  models	  
where	   the	  smallest	  set	  of	  genomic	  annotations	  explains	   the	  maximum	  amount	  
of	   information.	  The	  variables	  modelled	  are	   the	  genomic	  annotations,	   as	   in	   the	  
univariate	  model.	  The	  identification	  of	  a	  smaller	  set	  of	  the	  entire	  set	  of	  analysed	  
annotations	  was	  achieved	  by	  a	  stepwise	  approach	  explained	  later	  in	  the	  method	  
section,	  which	  calculated	  the	  amount	  of	  information	  carried	  by	  a	  set	  of	  genomic	  
annotations	   at	   each	   step.	   A	   decision	  was	  made	   to	   either	   include	   or	   remove	   a	  
genomic	   annotation	   based	   on	   the	   amount	   of	   information	   each	   annotation	  
carried.	   The	   information	   criterion	   used	   for	   this	   analysis	   was	   the	   Akaike’s	  
Information	  Criterion	  (AIC)	  [148],	  which	  calculates	  the	  information	  carried	  by	  a	  
multiple	   variable	   model.	   All	   genomic	   annotations,	   which	   coincided	   with	   each	  
other	  and	  therefore	  did	  not	  provide	  additional	  information,	  were	  removed	  from	  
the	   model.	   This	   method	   identified	   the	   influence	   of	   the	   genomic	   annotations	  
relative	   to	   and	   in	   combination	  with	   each	   other.	   The	   results	   of	   these	   analyses	  
could	   be	   used	   further	   to	   calculate	   a	   prioritization	   score	   for	   newly	   discovered	  
GWAS	   variants,	   which	   could	   help	   choose	   trait-­‐associated	   SNPs	   for	   follow-­‐up	  
studies.	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The	   result	   of	   the	   analysis	   was	   a	   defined	   set	   of	   genomic	   annotations	   deemed	  
most	   important	   and	   informative,	   as	   judged	   by	   the	   decrease	   in	   the	   AIC	   value	  
during	  the	  analysis	  and	  the	  P-­value	  of	  the	  annotation	  in	  the	  final	  model.	  This	  set	  
of	  genomic	  annotations	  was	  influential	  in	  explaining	  trait-­‐association	  status	  of	  a	  
broad	  range	  of	  phenotypes	  allowing	  drawing	  of	  general	  conclusions.	  However,	  
this	   did	   not	   allow	   trait-­‐specific	   conclusions.	   We	   therefore	   additionally	  
investigated	   a	   number	   of	   trait-­‐specific	   subsets.	   The	   traits	   were	   divided	   using	  
data	  from	  the	  GaD	  database,	  into	  disease	  traits	  (e.g.,	  schizophrenia	  or	  diabetes)	  
or	   normal	   variation	   traits	   (e.g.,	   height	   or	   eye	   colour),	   and	   immune	   traits	   or	  
cancer	   traits.	  The	  association	  of	   the	  SNPs	   to	   these	   traits	  defined	   the	   following	  
subsets:	  Disease	  SNPs,	  Normal	  Variation	  SNPs,	  Immune	  SNPs	  and	  Cancer	  SNPs,	  
respectively.	   The	   stepwise	   logistic	   regression	   approach	   was	   applied	   to	   these	  
datasets,	   resulting	   in	   models	   containing	   different	   genomic	   annotations	   with	  
different	   effects.	   The	   effects	  were	   calculated	   as	   the	  weight	   or	   estimate	   of	   the	  
annotation	   in	   the	   model	   and	   were	   used	   to	   calculate	   their	   odds	   ratios	   and	  
confidence	   intervals.	   We	   identified	   a	   common	   set	   of	   genomic	   annotations	  
influential	  to	  both	  Normal	  Variation	  SNPs	  and	  Disease	  SNPs.	  The	  Immune	  SNPs	  
and	  Non-­‐immune	  SNPs	  showed	  the	  most	  significant	  differences	  in	  the	  obtained	  
odds	   of	   the	   same	   genomic	   annotations,	   while	   the	   Cancer	   SNPs	   had	   the	   least	  
number	  of	   influential	  annotations.	  We	  discuss	   these	   findings	   in	   the	  discussion	  
section	  of	  this	  chapter.	  	  
5.2 Method	  
Logistic	  regression	  was	  applied	  to	  model	  genomic	  annotations	  as	  variables	  that	  
influenced	  the	  trait-­‐association	  status	  of	  SNPs,	  where	  the	  models	  could	  include	  
either	  a	  single	  variable	  or	  multiple	  variables.	  The	  single	  variable	  or	  univariate	  
analysis	   only	   included	   the	   individual	   genomic	   annotation	   under	   investigation,	  
onto	  which	  trait-­‐association	  status	  was	  regressed.	  All	  regression	  analyses	  were	  
performed	   using	   the	   function	   glm	   available	   in	   R	   with	   the	   option	  
family=binomial(“logit”).	   The	   stepwise	   analysis	   determining	   the	  most	   influential	  
genomic	  annotations	  was	  performed	  using	  the	  stepAIC	  function	  available	  in	  the 
R package	  ‘MASS’	  [149].	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The	   trait-­‐association	   status,	   or	  dependent	   variable,	  was	  binary	   (one	   and	   zero,	  
where	  trait-­‐association	  was	  coded	  as	  one).	  The	  genomic	  annotations	  were	  used	  
as	   independent	   explanatory	   variables	   onto	   which	   the	   trait-­‐association	   status	  
was	   regressed.	   The	   independent	   variables	   contained	   information	   on	   the	  
presence	  or	  absence	  of	  the	  annotated	  feature	  at	  a	  given	  location	  (coded	  as	  one	  
and	   zero,	   respectively),	   taking	   into	   account	   the	   analysed	   SNPs	   and	   their	   LD	  
partners.	  All	  analyses	  used	  the	  SNPs	  and	  genomic	  annotations	  described	  in	  the	  
permutation	  chapter	  (Chapter	  4)	  combined	  into	  one	  list	  of	  3,840,944	  SNPs.	  The	  
summary	  of	  each	  final	  model	  included	  the	  estimated	  coefficients,	  their	  standard	  
errors,	  the	  β-­‐coefficients	  and	  the	  P-­‐values	  of	  each	  variable	  (genotyping	  array	  –	  
see	   section	   5.2	   –	   or	   genomic	   annotation)	   in	   the	   model.	   The	   β-­‐coefficient	   is	  
defined	   as	   the	   ratio	   of	   the	   estimate	   and	   its	   standard	   error	   and	   is	   used	   to	  
calculate	  the	  significance	  as	  a	  P-­value.	  The	  P-­values	  in	  the	  multivariate	  models	  
were	  not	  corrected	   for	  multiple	   testing.	  The	  values	   for	   the	   intercepts	  are	  only	  
shown	  in	  the	  tables	  to	  show	  the	  complete	  model.	  The	  calculations	  for	  the	  odds	  
ratio	   and	   confidence	   intervals	   for	   the	   genomic	   annotations	  were	   the	   standard	  
calculations:	  the	  exponent	  of	  the	  estimate	  for	  the	  odds	  ratio	  and	  the	  exponents	  
of	  (Estimates	  ±	  1.96*	  Standard	  Error	  of	  Estimate)	  for	  the	  confidence	  intervals.	  	  
5.2.1 Stepwise	  multivariate	  logistic	  regression	  
All	   genotyping	   arrays	   were	   included	   as	   explanatory	   variables	   in	   the	   ‘Base	  
model’,	   because	   genotyping	   arrays	   influence	   trait-­‐association	   status,	   as	  
discussed	   later.	  A	  Base	  model	  was	  needed	  as	  a	  starting	  point	   for	   the	   stepwise	  
logistic	  regression	  and	  is	  shown	  below.	  This	  model	  was	  fixed	  and	  the	  variables	  
included	  in	  this	  model	  were	  not	  subject	  to	  the	  ex-­‐	  or	  inclusion	  of	  the	  step-­‐wise	  
approach.	  	  
	  
	   Base	   Model:	   Trait-association Status ~ Affymetrix_250k_Nsp + 
Affymetrix_250k_Sty + Affymetrix_5.0 + Affymetrix_6.0 + Affymetrix_10k + 
Affymetrix_50k.1 + Affymetrix_50k.2 + Illumina_300 + Illumina_550 + Illumina_650 + 
Perlegen 
	  
	   103	  
If	   a	   stepwise	   regression	   analysis	   only	   focused	   on	   the	   inclusion	   of	   informative	  
variables,	   the	   direction	   specification	   would	   be	   “forward”.	   The	   “backward”	  
direction	   focuses	   only	   on	   the	   exclusion	   of	   non-­‐informative	   variables,	   or	  
annotations.	   However,	   both	   of	   these	   directions	   have	   their	   drawbacks	   and	  
benefits	   and	   so	   the	   “both”	   direction	   was	   used,	   which	   analysed	   the	   possible	  
exclusion	  and	  inclusion	  of	  annotations	  at	  every	  step	  and	  combines	  the	  benefits	  
of	   the	   other	   two	   directions	   without	   including	   their	   drawbacks.	   This	   ex-­‐	   or	  
inclusion	  of	  annotations	  in	  the	  model	  was	  based	  on	  a	  reduction	  of	  the	  Akaike’s	  
Information	   Criterion	   (AIC),	   which	   we	   will	   define	   shortly.	   The	   additional	  
annotations	  that	  were	  considered	  for	  the	  ex-­‐	  or	  inclusion	  were	  specified	  in	  the	  
experimental	  model	  shown	  below.	  The	  genotyping	  arrays	  were	  not	  considered	  
for	   the	   process,	   as	   they	   were	   included	   in	   the	   Base	   model.	   The	   results	   were	  
robust	  to	  the	  annotation	  order	  that	  were	  presented	  in	  the	  experimental	  model,	  
as	   the	   “both”	   direction	   started	   with	   the	   Base	   model	   and	   only	   added	   the	  
informative	  annotations.	  	  
	  
	   Experimental	   model:	   Trait-association Status ~ Affymetrix_250k_Nsp + 
Affymetrix_250k_Sty + Affymetrix_5.0 + Affymetrix_6.0 + Affymetrix_10k + 
Affymetrix_50k.1 + Affymetrix_50k.2 + Illumina_300 + Illumina_550 + Illumina_650 + 
Perlegen + 1 Kb TSS + 5 Kb TSS + CpG Islands + ORegAnno + vega Genes + 
Exons + Intronic SNPs + Non.Syn. SNPs (UCSC) + Coding SNPs (UCSC) + Syn. 
SNPs UCSC) + Gained Stops + 3'UTR + 5'UTR + RNA Genes + ncRNA + TS 
miRNA + eQTLs + vega PseudoGenes + Intergenic SNPs + DNase Clusters + 
Insulators (sequence) + EvoFold + Pos. Sel. Genes + Enhancers (sequence) + 
Exapted Repeats + PREMOD + tfbs Conserved + Indel Pure regions + 17 spec. 
algmt + 28 spec. algmt plc.mmls + 28 spec. algmt + 44 spec. algmt + 44 spec. algmt 
plc.mmls + 44 spec. algmt prim. + Negative (sequence) + Open Chromatin + Closed 
Chromatin + Active Promoter + Weak Promoter + Poised Promoter + Strong 
Enhancer (proximal) + Strong Enhancer (distal) + Weak Enhancer (proximal) + 
Weak Enhancer (distal) + Insulator + Txn Transition + Txn Elongation + Weak Txn + 
Repressed + Heterochrom/lo + Repetitive/CNV (proximal) + Repetitive/CNV (distal) 
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All	   analyses	  were	   performed	   in R with	   the	   available R package	  MASS	   [149].	  
The	   full	  code	   for	   the	  stepAIC	   function	   is	  stepAIC( direction="both", scope = list ( 
upper = taspsfull, lower = empty), empty), where	   “taspsfull”	   is	   the	  Experimental	  
model	   containing	   all	   genomic	   annotations	   and	   “empty”	   is	   the	   Base	   model	  
containing	  only	  the	  genotyping	  arrays.	  The	  AIC	  was	  calculated	  to	  maximise	  the	  
amount	  of	  variance	  explained	  by	  a	  model	  with	  the	  minimal	  number	  of	  genomic	  
annotations	  by	  penalising	  any	  increase	  in	  the	  number	  of	  included	  variables.	  The	  
AIC	  is	  defined	  as
€ 
AIC =  2k − 2ln(L),	  where	  k	  is	  the	  number	  of	  parameters	  in	  the	  
model	  and	  L	  is	  the	  maximised	  value	  of	  the	  likelihood	  function	  for	  the	  estimated	  
model,	   if	   a	   parameter	   were	   to	   be	   included.	   The	   stepwise	   logistic	   regression	  
method	  is	  an	  iterative	  process.	  This	  meant	  that	  after	  each	  in-­‐	  or	  exclusion	  of	  a	  
genomic	   annotation,	   the	   AIC	   was	   recalculated	   for	   each	   of	   the	   genomic	  
annotations	   to	   evaluate	   the	   next	   step.	   This	   could	   be	   the	   inclusion	   of	   an	  
additional	   annotation,	   or	   the	   exclusion	  of	   an	   annotation	  already	   in	   the	  model.	  
The	  stepwise	  logistic	  regression	  process	  halted,	  when	  the	  AIC	  increased	  rather	  
than	   decreased	   with	   additional	   variables.	   The	   final	   model	   of	   the	   logistic	  
regression	   was	   the	   one	   with	   the	   smallest	   AIC	   value,	   resulting	   in	   a	   model	  
balancing	   the	   maximum	   amount	   of	   information	   explained	   by	   the	   minimum	  
number	  of	  variables.	  	  
	  
As	  mentioned	   in	   the	  previous	  chapters,	  we	  had	   included	  the	  annotation	  of	   the	  
OMIM	   morbid	   regions,	   which	   are	   defined	   as	   trait-­‐associated	   regions	   of	   the	  
genome	   as	   a	   positive	   control	   for	   GWAS	   hits.	  We	   did	   not	   include	   them	   in	   the	  
logistic	   regression	   analysis,	   as	   they	   would	   skew	   the	   final	   model.	   This	   would	  
occur	  because	  of	  the	  penalizing	  of	  any	  additional	  variables	  that	  might	  add	  extra	  
information.	   Another	   annotation	   excluded	   from	   the	   analysis	   was	   the	   OMIM	  
genes,	  as	  we	  had	  two	  annotations	  defining	  genes	  and	  kept	  only	  one	  dataset	   to	  
avoid	  knowingly	  using	  redundant	  information	  in	  the	  logistic	  regression	  analysis.	  	  
5.2.2 Pseudo-­‐r2	  values	  
In	   order	   to	   evaluate	   a	   regression	   model,	   a	   ‘goodness-­‐of-­‐fit’	   parameter	   is	  
assessed.	  In	  linear	  regression,	  this	  parameter	  is	  the	  r2	  value,	  which	  is	  defined	  as	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€ 
r2 =1−










.	   In	  this	  equation,	  N	   is	  the	  number	  of	  observations	  within	  
the	  model	  and	  y	  is	  its	  dependent	  variable,	  
€ 
y 	  is	  the	  mean	  of	  all	  the	  values	  in	  the	  
dependent	  variable	  and	  
€ 
ˆ y 	  is	  the	  value	  predicted	  by	  the	  model	  [150,	  151].	  The	  r2	  
value	  of	  linear	  regression	  can	  be	  interpreted	  in	  three	  different	  ways:	  First,	  it	  can	  
be	  seen	  as	  the	  amount	  of	  variation	  the	  model	  explains	  [150,	  151].	  Second,	  it	  can	  
be	   seen	   as	   an	   improvement	   of	   the	   full	   model	   over	   the	   null	   model.	   The	   third	  
interpretation	   gives	   this	   value	   its	   name,	   as	   it	   is	   the	   square	   of	   the	   correlation	  
between	  the	  model’s	  predicted	  values	  and	  the	  actual	  analysed	  values	  [150,	  151].	  
Logistic	   regression	   models	   do	   not	   have	   an	   r2	   value	   as	   such,	   and	   there	   is	   no	  
generally	  agreed	  upon	  analogous	  value	  [152].	  However,	  a	  value,	  which	  can	  have	  
a	  similar	  interpretation	  to	  the	  r2	  value	  of	  linear	  regression,	  can	  be	  estimated	  in	  a	  
variety	  of	  ways	  and	  is	  called	  a	  pseudo-­‐r2	  value.	  Here,	  we	  chose	  the	  McKelvey	  and	  
Zavoina’s	  pseudo-­‐r2.	  The	  McKelvey	  and	  Zavoina’s	  pseudo-­‐r2	  was	  defined	  as	  the	  
ratio	   of	   the	   variance	   of	   a	   predicted	   continuous	   latent	   variable,	   which	   is	  
underlying	   the	   binary	   dependent	   variable	   (here:	   trait-­‐association	   status),	   and	  
the	  sum	  of	  that	  variance	  and	  an	  estimated	  error.	  This	  error	  variance	  is	  assumed	  
to	   be	   π2/3	   in	   logistic	   models	   [150,	   151,	   153].	   The	   McKelvey	   and	   Zavoina’s	  
pseudo-­‐r2	  is	  to	  be	  interpreted	  as	  the	  amount	  of	  variation	  explained	  in	  a	  model.	  
The R package	   descr	   (function	   LogRegR2)	   [154]	   was	   used	   to	   calculate	   the	  
pseudo-­‐r2	  values.	  The	  code	  for	  this	  function	  can	  be	  found	  in	  the	  Appendix	  (see	  
page	  222).	  	  
5.3 Results	  
5.3.1 Significant	  SNPs	  (2011)	  
5.3.1.1 Univariate	  regression	  vs.	  permutations	  
The	  Significant	  SNPs	  (2011)	  dataset	  was	  described	  previously	  (see	  page	  32	  for	  
further	   information).	   Figure	   5-­‐1	   compares	   the	   results	   obtained	   by	   the	  
univariate	  logistic	  regression	  and	  the	  permutations	  for	  Significant	  SNPs	  (2011).	  
Overall,	  the	  two	  methods	  obtained	  very	  similar	  odds	  ratios.	  A	  standard	  paired	  t-­‐
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test	   showed	   that	   the	   odds	   ratios	  were	   not	   significantly	   different	   between	   the	  
methods	   (P-­value	   =	   0.31,	   mean	   of	   the	   differences	   =	   0.12,	   95%	   confidence	  
intervals	  =	   -­‐0.12	  –	  0.36).	  When	   testing	   the	   standard	  errors	  of	   the	  odds	   ratios,	  
the	   t-­‐test	  was	   also	  not	   significant	   (P-­value	  =	  0.08,	  mean	  of	   the	  differences	  =	   -­‐
5.25,	   95%	   confidence	   intervals	   =	   -­‐11.22	   –	   0.72).	   The	   t-­‐test	   was	   used	   on	   the	  
results	   from	  54	  of	  58	  annotations,	  as	   the	  standard	  errors	   for	   four	  annotations	  
(within	  miRNA,	  splice	  sites,	   lost	  stops,	  and	  microsatellites)	  were	  undefined.	  As	  
mentioned	  before,	  undefined	  confidence	   intervals	  arose	  when	  the	  value	  at	   the	  
500th	  rank	  of	  the	  permutation	  overlaps	  was	  zero.	  The	  correlation	  coefficient	  of	  
the	  odds	  ratios	  obtained	  by	  both	  methods	  was	  very	  high	  at	  0.93.	  The	  r2	  of	   the	  
linear	   regression	  of	   the	  odds	  ratios	   from	  the	   logistic	   regression	  onto	   the	  odds	  
ratios	  from	  the	  permutations	  was	  0.87	  and	  a	  significant	  P-­value	  of	  1.03	  ×	  10-­‐26.	  
The	   odds	   ratios	   are	   shown	   in	   Figure	   5-­‐1,	   where	   the	   highest,	   albeit	   not	  
significant,	  odds	  ratios	  in	  both	  analyses	  were	  obtained	  for	  TS	  miRNA	  and	  gained	  
stop	  codons.	  The	  permutations	  obtained	  significant	  odds	  ratios	  twice,	  when	  the	  
univariate	   logistic	   regression	   did	   not	   (5’UTRs	   (top	   panel	   in	   Figure	   5-­‐2)	   and	  
insulators	   (bottom	   panel	   in	   Figure	   5-­‐2)).	   The	   logistic	   regression	   had	   three	  
significant	   odds	   ratios,	   where	   the	   permutations	   did	   not	   reach	   significance	  
(gained	   stops,	   intergenic	   SNPs	   (top	   panel)	   and	   negative	   (middle	   panel)).	   The	  
results	   of	   the	  univariate	   logistic	   regression	   are	   shown	   in	  Table	  5-­‐1	   listing	   the	  
estimate,	   its	   standard	   error,	   the	   β-­coefficient	   (defined	   as	   the	   ratio	   of	   the	  
estimate	   and	   its	   standard	   error),	   the	   calculated	   odds	   ratio	   and	   its	   confidence	  
interval	  and	  the	  P-­value	  of	  each	  analysed	  annotation.	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Figure	  5-­1	  –	  Odds	  ratios	  of	  univariate	  logistic	  regression	  vs.	  permutations	  
The	  odds	   ratios	  obtained	   for	   the	  Significant	  SNPs	   (2011)	  by	  a	  univariate	   regression	  model	  and	   the	  
odds	   ratios	   of	   the	   permutations	   are	   plotted	   in	   this	   figure.	   The	   odds	   ratios	   obtained	   by	   these	   two	  
methods	  correlated	  well	  (correlation	  =	  0.93).	  The	  adjusted	  r2	  of	  the	  regression	  shown	  in	  this	  figure	  is	  
0.87	  with	  a	  significant	  P-­‐value	  of	  1.03	  ×	  10-­‐26.	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Figure	  5-­2	  –	  Permutations	  vs.	  univariate	  logistic	  regression	  
A	  comparison	  of	  the	  results	  obtained	  by	  permutations	  ()	  and	  univariate	  logistic	  regression	  ()	  in	  
Significant	   SNPs	   (2011).	   All	  P-­‐values	  were	   corrected	   for	  multiple	   testing	   for	   the	   analysed	   genomic	  
annotations	  and	  solid	  symbols	  indicated	  significance	  at	  that	  level.	  Top:	  Genic	  and	  regulatory	  regions.	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Table	  5-­1	  –	  Univariate	  logistic	  regression	  for	  Significant	  SNPs	  (2011)	  
The	  results	  for	  the	  univariate	  logistic	  regression	  for	  the	  Significant	  SNPs	  (2011)	  are	  shown	  below.	  The	  
table	  presents	   the	  estimate	  of	   the	  effect,	   its	   standard	  error,	   the	  β-­‐coefficient,	   the	  calculated	  odds	  
ratio	  with	  its	  confidence	  interval,	  and	  the	  P-­‐value	  of	  the	  estimate	  for	  each	  of	  the	  individual	  genomic	  
annotations.	  Significant	  P-­‐values	  in	  bold.	  	  
Annotation	   Estimate	   Std.	  Error	   β 	   OR	  [LCI-­‐HCI]	   P-­‐value	  
1	  Kb	  TSS	   0.99	   0.17	   5.88	   2.69	  [1.93-­‐3.74]	   4.13	  ×	  10-­‐09	  
5	  Kb	  TSS	   1.11	   0.08	   13.71	   3.04	  [2.59-­‐3.56]	   8.91	  ×	  10-­‐43	  
CpG	  Islands	   1.13	   0.21	   5.36	   3.08	  [2.04-­‐4.65]	   8.26	  ×	  10-­‐08	  
ORegAnno	   1.08	   0.19	   5.59	   2.96	  [2.02-­‐4.32]	   2.32	  ×	  10-­‐08	  
vega	  Genes	   0.49	   0.05	   10.70	   1.63	  [1.49-­‐1.79]	   1.06	  ×	  10-­‐26	  
OMIM	  genes	   0.71	   0.05	   15.33	   2.02	  [1.85-­‐2.22]	   5.19	  ×	  10-­‐53	  
OMIM	  morbid	  regions	   1.34	   0.06	   23.79	   3.81	  [3.41-­‐4.25]	   3.92	  ×	  10-­‐125	  
Exons	   1.68	   0.08	   21.77	   5.38	  [4.62-­‐6.26]	   4.27	  ×	  10-­‐105	  
Intronic	  SNPs	   0.29	   0.05	   6.37	   1.34	  [1.22-­‐1.47]	   1.87	  ×	  10-­‐10	  
Non.Syn.	  SNPs	  (UCSC)	   1.90	   0.09	   20.13	   6.69	  [5.56-­‐8.06]	   3.83	  ×	  10-­‐90	  
Coding	  SNPs	  (UCSC)	   1.74	   0.08	   20.72	   5.72	  [4.85-­‐6.74]	   2.49	  ×	  10-­‐95	  
Syn.	  SNPs	  (UCSC)	   1.24	   0.17	   7.26	   3.45	  [2.47-­‐4.83]	   3.94	  ×	  10-­‐13	  
Gained	  Stops	   2.45	   0.58	   4.22	   11.57	  [3.72-­‐36.01]	   2.39	  ×	  10-­‐05	  
3’UTR	   1.02	   0.15	   6.97	   2.77	  [2.08-­‐3.69]	   3.18	  ×	  10-­‐12	  
5’UTR	   1.00	   0.35	   2.83	   2.73	  [1.36-­‐5.46]	   4.69	  ×	  10-­‐03	  
RNA	  Genes	   0.48	   1.00	   0.48	   1.62	  [0.23-­‐11.51]	   6.30	  ×	  10-­‐01	  
ncRNA	   0.37	   0.28	   1.31	   1.44	  [0.84-­‐2.49]	   1.89	  ×	  10-­‐01	  
TS	  miRNA	   2.12	   1.00	   2.12	   8.34	  [1.17-­‐59.50]	   3.43	  ×	  10-­‐02	  
eQTLs	   1.93	   0.08	   25.62	   6.89	  [5.94-­‐7.99]	   9.26	  ×	  10-­‐145	  
vega	  PseudoGenes	   0.34	   0.25	   1.34	   1.40	  [0.86-­‐2.29]	   1.81	  ×	  10-­‐01	  
Intergenic	  SNPs	   -­‐0.67	   0.05	   -­‐14.40	   0.51	  [0.47-­‐0.56]	   5.05	  ×	  10-­‐47	  
DNase	  Clusters	   0.76	   0.06	   13.07	   2.15	  [1.91-­‐2.41]	   4.87	  ×	  10-­‐39	  
Insulators	  (sequence)	   0.74	   0.17	   4.43	   2.09	  [1.51-­‐2.89]	   9.54	  ×	  10-­‐06	  
Within	  miRNA	   -­‐4.96	   83.85	   -­‐0.06	   0.01	  [0.00-­‐1.66	  ×	  1069]	   9.53	  ×	  10-­‐01	  
Splice	  Sites	   -­‐7.96	   74.86	   -­‐0.11	   0.00	  [0.00-­‐1.83	  ×	  1060]	   9.15	  ×	  10-­‐01	  
Lost	  Stops	   -­‐6.96	   101.93	   -­‐0.07	   0.00	  [0.00-­‐5.52	  ×	  1083]	   9.46	  ×	  10-­‐01	  
Microsatellites	   -­‐7.96	   68.01	   -­‐0.12	   0.00	  [0.00-­‐2.70	  ×	  1054]	   9.07	  ×	  10-­‐01	  
EvoFold	   -­‐9.96	   98.69	   -­‐0.10	   0.00	  [0.00-­‐4.78	  ×	  1079]	   9.20	  ×	  10-­‐01	  
Pos.	  Sel.	  Genes	   0.44	   0.05	   8.84	   1.55	  [1.40-­‐1.70]	   9.27	  ×	  10-­‐19	  
Enhancers	  (sequence)	   1.04	   0.50	   2.08	   2.84	  [1.06-­‐7.57]	   3.73	  ×	  10-­‐02	  
Exapted	  Repeats	   -­‐9.96	   97.16	   -­‐0.10	   0.00	  [0.00-­‐2.39	  ×	  1078]	   9.18	  ×	  10-­‐01	  
PREMOD	   0.48	   0.12	   3.98	   1.61	  [1.27-­‐2.04]	   6.94	  ×	  10-­‐05	  
tfbs	  Conserved	   0.70	   0.13	   5.22	   2.02	  [1.55-­‐2.63]	   1.78	  ×	  10-­‐07	  
Indels	  Pure	  regions	   0.65	   0.06	   10.60	   1.91	  [1.70-­‐2.15]	   2.83	  ×	  10-­‐26	  
17	  specs.	  algmt.	   0.62	   0.08	   7.85	   1.86	  [1.59-­‐2.17]	   4.01	  ×	  10-­‐15	  
28	  specs.	  algmt.	  plac.	  mmls	   0.85	   0.08	   10.47	   2.34	  [1.99-­‐2.74]	   1.16	  ×	  10-­‐25	  
28	  specs.	  algmt.	   0.80	   0.08	   10.45	   2.22	  [1.91-­‐2.58]	   1.45	  ×	  10-­‐25	  
44	  specs.	  algmt.	   0.81	   0.08	   10.63	   2.24	  [1.93-­‐2.60]	   2.17	  ×	  10-­‐26	  
44	  specs.	  algmt.	  plac.	  mmls	   0.83	   0.08	   10.59	   2.29	  [1.97-­‐2.67]	   3.39	  ×	  10-­‐26	  
44	  specs.	  algmt.	  primates	   0.80	   0.08	   10.04	   2.23	  [1.91-­‐2.61]	   9.81	  ×	  10-­‐24	  
Negative	  (sequence)	   -­‐0.78	   0.05	   -­‐14.96	   0.46	  [0.41-­‐0.51]	   1.36	  ×	  10-­‐50	  
Open	  Chromatin	   1.26	   0.05	   23.95	   3.53	  [3.18-­‐3.91]	   1.01	  ×	  10-­‐126	  
Closed	  Chromatin	   -­‐1.18	   0.05	   -­‐22.20	   0.31	  [0.28-­‐0.34]	   3.62	  ×	  10-­‐109	  
Active	  Promoter	   1.21	   0.17	   7.28	   3.35	  [2.42-­‐4.64]	   3.42	  ×	  10-­‐13	  
Weak	  Promoter	   0.88	   0.20	   4.43	   2.40	  [1.63-­‐3.53]	   9.45	  ×	  10-­‐06	  
Poised	  Promoter	   1.02	   0.45	   2.28	   2.77	  [1.15-­‐6.67]	   2.28	  ×	  10-­‐02	  
Strong	  Enhancer	  (proximal)	   1.49	   0.12	   12.75	   4.46	  [3.54-­‐5.61]	   2.97	  ×	  10-­‐37	  
Strong	  Enhancer	  (distal)	   0.85	   0.16	   5.19	   2.34	  [1.70-­‐3.23]	   2.08	  ×	  10-­‐07	  
Weak	  Enhancer	  (proximal)	   0.71	   0.17	   4.09	   2.03	  [1.44-­‐2.85]	   4.39	  ×	  10-­‐05	  
Weak	  Enhancer	  (distal)	   0.73	   0.11	   6.53	   2.07	  [1.67-­‐2.58]	   6.41	  ×	  10-­‐11	  
Insulator	   0.55	   0.22	   2.49	   1.73	  [1.12-­‐2.66]	   1.26	  ×	  10-­‐02	  
Txn	  Transition	   1.05	   0.17	   6.18	   2.87	  [2.05-­‐4.01]	   6.48	  ×	  10-­‐10	  
Txn	  Elongation	   0.61	   0.08	   7.54	   1.84	  [1.57-­‐2.16]	   4.70	  ×	  10-­‐14	  
Weak	  Txn	   0.47	   0.07	   7.08	   1.61	  [1.41-­‐1.83]	   1.45	  ×	  10-­‐12	  
Repressed	   0.76	   0.09	   8.56	   2.14	  [1.80-­‐2.54]	   1.10	  ×	  10-­‐17	  
Heterochrom/low	   -­‐1.04	   0.05	   -­‐22.60	   0.36	  [0.32-­‐0.39]	   4.75	  ×	  10-­‐113	  
Repetitive/CNV	  (proximal)	   -­‐0.48	   1.00	   -­‐0.48	   0.62	  [0.09-­‐4.40]	   6.32	  ×	  10-­‐01	  
Repetitive/CNV	  (distal)	   -­‐9.96	   90.03	   -­‐0.11	   0.00	  [0.00-­‐2.04	  ×	  1072]	   9.12	  ×	  10-­‐01	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5.3.1.2 Multiple	  variables	  model	  
We	  hypothesized	  that	  the	  prior	  probability	  of	  a	  SNP	  found	  to	  be	  trait-­‐associated	  
would	   change,	   if	   it	   were	   included	   on	   one	   or	   more	   genotyping	   arrays.	   A	  
multivariate	  model	   showed	   that	   genotyping	   arrays	   explained	   a	   non-­‐negligible	  
amount	  of	  information	  (pseudo-­‐r2	  =	  0.14),	  which	  supported	  our	  hypothesis.	  The	  
genotyping	   arrays	   were	   therefore	   included	   in	   every	   following	   analysis.	   The	  
model	  including	  all	  genotyping	  arrays	  was	  used	  as	  a	  baseline	  (“Base	  model”)	  in	  
all	   analyses.	  Any	   additional	   genomic	   annotations	  were	   added	   to	   this	  model,	   if	  
they	  reduced	  the	  AIC	  (see	  page	  102).	  The	  genotyping	  arrays	  were	  not	  removed	  
from	  the	  model,	  as	  they	  were	  part	  of	  the	  Base	  model	  and	  therefore	  fixed.	  
	  
As	   mentioned	   in	   the	   Methods	   section	   of	   this	   chapter,	   the	   stepwise	   analysis	  
finished	   when	   no	   further	   variable	   could	   be	   added	   that	   explained	   extra	  
information	  without	   incurring	   a	  penalty	   effect	   for	   the	   additional	   variable	   (see	  
page	  102).	  The	  variables	  analysed	  here,	  were	  the	  different	  genomic	  annotations.	  
The	   final	   model	   contained	   all	   genotyping	   arrays,	   as	   outlined	   above,	   and	   all	  
genomic	  annotations	  that	  added	  non-­‐redundant	  information	  in	  explaining	  trait-­‐
associated	  variants,	  as	  defined	  by	  the	  stepwise	  procedure	  based	  on	  the	  change	  
in	  AIC.	  The	  model	   that	  was	   returned	  at	   the	  end	  of	   the	  analysis	  was	   called	   the	  
Final	   Model,	   and	   included	   the	   genotyping	   arrays	   and	   the	   subset	   of	   the	  
annotations	   returned	   by	   the	   stepwise	   procedure.	   Figure	   5-­‐3	   showed	   the	  
significant	   genomic	   annotations	   of	   the	   Final	   Model	   for	   the	   Significant	   SNPs	  
(2011).	  The	  odds	  ratio	  of	  a	  genomic	  annotation	  was	  calculated	  as	  the	  exponent	  
of	   the	   estimate	   of	   the	   genomic	   annotation	   in	   the	   model.	   Its	   95%	   confidence	  
intervals	  were	  calculated	  as	  the	  exponents	  of	  the	  sum/difference	  of	  the	  estimate	  
and	  the	  product	  of	  its	  standard	  error	  and	  1.96,	  which	  is	  the	  approximate	  value	  
of	   the	   97.5	   percentile	   point	   of	   the	   normal	   distribution	   (exp	   (Estimate	   +	  
1.96*Standard	  Error)).	  	  
	  
The	   genomic	   annotations	   shown	   in	   all	   figures	   in	   this	   chapter	   were	   ranked	  
according	   to	   decreasing	   significance	   in	   the	   model,	   with	   the	   most	   significant	  
annotations	   on	   the	   left.	   Four	   of	   the	   five	   significantly	   depleted	   genomic	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annotations	  were	  previously	  significantly	  enriched	  in	  all	  analyses	  investigating	  
genomic	   annotations	   individually.	   These	   annotations	   were	   transcriptional	  
elongation,	  synonymous	  SNPs,	  active	  promoters	  and	  5’UTRs.	  In	  a	  model,	  which	  
includes	  several	  annotations,	  the	  estimates	  are	  the	  effects	  of	  those	  annotations	  
accounting	  for	  the	  fact	  that	  other	  annotations	  are	  already	  included	  in	  the	  model.	  
These	   four	   annotations	   were	   therefore	   relatively	   depleted	   of	   trait-­‐associated	  
SNPs	   when	   compared	   to	   the	   other	   genomic	   annotations	   and	   once	   they	   were	  
included	  in	  the	  model.	  	  
	  
The	  most	   significant	   genomic	   annotations	   found	   to	   influence	   trait-­‐association	  
status	   in	   the	   dataset	   of	   Significant	   SNPs	   (2011)	  were	   open	   chromatin,	   eQTLs,	  
and	  DNase	  clusters.	  These	  findings	  will	  to	  some	  extent	  be	  discussed	  at	  the	  end	  
of	  this	  chapter,	  but	  to	  a	  greater	  detail	  in	  the	  Discussion	  chapter	  (Chapter	  7).	  The	  
results	   are	   also	   shown	   in	   Table	   5-­‐2.	   The	   McKelvey	   and	   Zavoina’s	   pseudo-­‐r2	  
value	  of	   the	  Base	  model	   for	   the	  Significant	  SNPs	  (2011)	  was	  0.14	  and	  0.23	  for	  
the	   final	  model.	  The	  genotyping	  arrays	  were	  not	   included	   in	   the	   figure	  below,	  
but	  were	  a	  part	  of	  the	  final	  model.	  	  
	  
Figure	  5-­3	  –	  Odds	  ratios	  of	  the	  final	  multivariate	  model	  for	  Significant	  SNPs	  (2011)	  
Odds	   ratios	   of	   the	   significant	   genomic	   annotations	   for	   the	   final	  multivariate	  model	   for	   Significant	  
SNPs	   (2011),	   sorted	   in	   decreasing	   significance	   in	   the	  model.	   The	   above	   figure	   demonstrated	   that	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Table	  5-­2	  –	  Stepwise	  logistic	  regression	  results	  for	  Significant	  SNPs	  (2011)	  without	  Distance	  to	  TSS	  
The	  results	  for	  the	  multivariate	  model	  using	  Significant	  SNPs	  (2011)	  without	  distance	  to	  TSS	  included	  
in	  the	  model	  are	  shown	  below.	  The	  table	  presents	  the	  estimate	  of	  the	  effect,	  its	  standard	  error,	  the	  
β-­‐coefficient,	  the	  calculated	  odds	  ratio	  with	  its	  confidence	  interval,	  and	  the	  P-­‐value	  of	  the	  estimate	  
in	   the	   final	  model	   for	   each	   of	   the	   included	   genomic	   annotations	   in	   the	   final	  model.	   Significant	  P-­‐
values	  in	  bold.	  
Annotation	   Estimate	   Std.	  Error	   β 	   OR	  [LCI-­‐HCI]	   P-­‐value	  
Intercept	   -­‐9.26	   0.08	   -­‐116.06	   0.00	  [0.00-­‐0.00]	   0.00	  ×	  1000	  
Affymetrix_250k_Nsp	   0.33	   0.16	   2.10	   1.40	  [1.02-­‐1.91]	   3.59	  ×	  10-­‐02	  
Affymetrix_250k_Sty	   0.49	   0.15	   3.25	   1.64	  [1.22-­‐2.21]	   1.16	  ×	  10-­‐03	  
Affymetrix_5.0	   0.12	   0.15	   0.79	   1.12	  [0.84-­‐1.51]	   4.31	  ×	  10-­‐01	  
Affymetrix_6.0	   0.25	   0.07	   3.55	   1.29	  [1.12-­‐1.49]	   3.80	  ×	  10-­‐04	  
Affymetrix_10k	   0.50	   0.30	   1.67	   1.66	  [0.92-­‐2.99]	   9.44	  ×	  10-­‐02	  
Affymetrix_50k.1	   -­‐0.06	   0.14	   -­‐0.43	   0.94	  [0.71-­‐1.25]	   6.64	  ×	  10-­‐01	  
Affymetrix_50k.2	   -­‐0.04	   0.14	   -­‐0.30	   0.96	  [0.72-­‐1.27]	   7.63	  ×	  10-­‐01	  
Illumina_300	   0.85	   0.07	   11.44	   2.34	  [2.02-­‐2.70]	   2.68	  ×	  10-­‐30	  
Illumina_550	   1.44	   0.20	   7.29	   4.22	  [2.87-­‐6.22]	   3.09	  ×	  10-­‐13	  
Illumina_650	   -­‐0.10	   0.19	   -­‐0.54	   0.90	  [0.62-­‐1.31]	   5.91	  ×	  10-­‐01	  
Perlegen	   0.21	   0.06	   3.72	   1.23	  [1.10-­‐1.38]	   1.99	  ×	  10-­‐04	  
Open	  Chromatin	   0.79	   0.06	   13.31	   2.21	  [1.97-­‐2.49]	  	   2.00	  ×	  10-­‐40	  
Exons	   0.58	   0.09	   6.52	   1.79	  [1.50-­‐2.14]	   6.94	  ×	  10-­‐11	  
DNase	  Clusters	   0.46	   0.05	   8.52	   1.58	  [1.42-­‐1.75]	   1.58	  ×	  10-­‐17	  
eQTLs	   0.72	   0.07	   10.70	   2.05	  [1.79-­‐2.33]	   1.01	  ×	  10-­‐26	  
Strong	  Enhancer	  (proximal)	   0.47	   0.08	   5.98	   1.60	  [1.37-­‐1.87]	   2.29	  ×	  10-­‐09	  
vega	  Genes	   0.27	   0.05	   5.51	   1.31	  [1.19-­‐1.44]	   3.59	  ×	  10-­‐08	  
Repressed	   0.24	   0.07	   3.60	   1.28	  [1.12-­‐1.46]	   3.19	  ×	  10-­‐04	  
Heterochrom/low	   -­‐0.37	   0.05	   -­‐6.69	   0.69	  [0.62-­‐0.77]	   2.26	  ×	  10-­‐11	  
Txn	  Elongation	   -­‐0.43	   0.07	   -­‐5.87	   0.65	  [0.56-­‐0.75]	   4.26	  ×	  10-­‐09	  
5	  Kb	  TSS	   0.36	   0.07	   5.53	   1.44	  [1.26-­‐1.64]	   3.26	  ×	  10-­‐08	  
Non.Syn.	  SNPs	  (UCSC)	   0.23	   0.09	   2.56	   1.26	  [1.05-­‐1.50]	   1.06	  ×	  10-­‐02	  
44	  specs.	  algmt.	  primates	   0.17	   0.07	   2.33	   1.18	  [1.03-­‐1.36]	   2.00	  ×	  10-­‐02	  
Active	  Promoter	   -­‐0.25	   0.10	   -­‐2.47	   0.78	  [0.64-­‐0.95]	   1.37	  ×	  10-­‐02	  
Gained	  Stops	   1.15	   0.35	   3.32	   3.16	  [1.60-­‐6.25]	   8.95	  ×	  10-­‐04	  
Syn.	  SNPs	  (UCSC)	   -­‐0.32	   0.10	   -­‐3.12	   0.73	  [0.60-­‐0.89]	   1.83	  ×	  10-­‐03	  
Indels	  Pure	  regions	   0.11	   0.06	   1.76	   1.11	  [0.99-­‐1.25]	   7.79	  ×	  10-­‐02	  
5’UTR	   -­‐0.31	   0.16	   -­‐2.01	   0.73	  [0.54-­‐0.99]	   4.50	  ×	  10-­‐02	  
Repetitive/CNV	  (distal)	   -­‐1.41	   1.00	   -­‐1.41	   0.24	  [0.03-­‐1.73]	   1.58	  ×	  10-­‐01	  
Poised	  Promoter	   0.37	   0.20	   1.87	   1.44	  [0.98-­‐2.12]	   6.14	  ×	  10-­‐02	  
Insulator	   -­‐0.18	   0.10	   -­‐1.80	   0.83	  [0.68-­‐1.02]	   7.24	  ×	  10-­‐02	  
Enhancers	  (sequence)	   0.53	   0.29	   1.80	   1.69	  [0.95-­‐3.00]	   7.22	  ×	  10-­‐02	  
Weak	  Enhancer	  (distal)	   0.10	   0.06	   1.52	   1.10	  [0.97-­‐1.25]	   1.28	  ×	  10-­‐01	  
44	  specs.	  algmt.	   0.24	   0.11	   2.31	   1.28	  [1.04-­‐1.57]	   2.07	  ×	  10-­‐02	  
44	  specs.	  algmt.	  plac.	  mmls	   -­‐0.20	   0.11	   -­‐1.80	   0.82	  [0.66-­‐1.02]	   7.14	  ×	  10-­‐02	  
TS	  miRNA	   0.83	   0.51	   1.61	   2.29	  [0.83-­‐6.28]	   1.08	  ×	  10-­‐01	  
	  
	  
As	  mentioned	  in	  the	  Introduction,	  we	  decided	  to	  explore	  distance	  from	  the	  trait-­‐
associated	   variant	   to	   the	   nearest	   transcription	   start	   site	   (TSS)	   to	   a	   greater	  
detail,	   so	  we	   added	   a	   quantitative	   variable	   to	   the	   analyses:	   “Distance	   to	   TSS”.	  
Previous	  analyses	  had	  suggested	  that	  the	  majority	  of	  eQTLs	  were	  within	  a	  20	  Kb	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window	   from	   the	   nearest	   TSS	   [72]	   and	   that	   the	   majority	   of	   trait-­‐associated	  
variants	   were	   eQTLs	   [110].	   An	   additional	   analysis	   was	   performed	   using	  
Significant	   SNPs	   (2011)	   to	   determine	   if	   the	   variable	   explained	   a	   significant	  
amount	  of	  variation	  in	  trait-­‐association	  status.	  Figure	  5-­‐4	  shows	  the	  odds	  ratios	  
obtained	  in	  the	  model	  for	  Significant	  SNPs	  (2011),	  which	  included	  the	  distance	  
to	   TSS	   annotation.	   The	   five	   annotations,	   which	   were	   depleted	   for	   Significant	  
SNPs	   (2011)	   in	   the	   model	   without	   distance	   to	   TSS,	   still	   have	   odds	   ratios	   of	  
depletion.	  The	  odds	  ratios	  did	  not	  change	  significantly	  between	  the	  models	  with	  
a	   correlation	   coefficient	   of	   0.99	   between	   the	   odds	   ratios	   of	   the	   common	  
annotations	   of	   the	   two	   models.	   The	   model	   with	   the	   distance	   to	   TSS	   further	  
included	   an	   additional	   five	   annotations	   (negative	   (sequence),	   splice	   sites,	  
PREMOD,	  microsatellites,	  and	   lost	  stop	  codons),	  which	  were	  now	  adding	  extra	  
information	  to	  the	  model.	  The	  annotation,	  which	  was	  not	  included	  in	  the	  model	  
with	  distance	  to	  TSS	  but	  was	  included	  in	  the	  model	  without	  distance	  to	  TSS	  was	  
the	  TS	  miRNA	  annotation.	  The	  biggest	  difference	  between	  the	  models	  was	   the	  
change	  in	  the	  pseudo-­‐r2	  value	  of	  the	  Final	  Model,	  which	  increased	  from	  0.23	  for	  
the	  model	  without	  distance	  to	  TSS	  to	  0.42	  for	  the	  model	  including	  distance.	  The	  
pseudo-­‐r2	   therefore	  almost	  doubled	  with	   inclusion	  of	   the	  distance	   to	  TSS.	  The	  
distance	   to	   TSS	   annotation	   obtained	   a	   very	   small	   estimate	   in	   the	   model,	  
indicating	  that	  as	  the	  distance	  between	  a	  TSS	  and	  a	  SNP	  increases,	  the	  odds	  that	  
this	  SNP	  is	  a	  trait-­‐associated	  SNP	  decreases.	  However,	  the	  distance	  is	  measured	  
in	   single	   bases	   rather	   than	   kilo	   bases,	   so	   the	   effect	   of	   increasing	   the	   distance	  
would	   be	   very	   small.	   Distance	   to	   TSS	   was,	   however,	   very	   significant,	   which	  
means	   that	   while	   the	   effect	   is	   small,	   it	   is	   very	   important	   in	   explaining	   trait-­‐
association	   status.	   Since	   the	   inclusion	   of	   the	   distance	   to	   TSS	   had	   such	   a	   large	  
impact	  on	  the	  pseudo-­‐r2	  value	  of	  the	  Significant	  SNPs	  (2011)	  model,	  the	  rest	  of	  
the	  regression	  models	  were	  all	  performed	  with	  the	  inclusion	  of	  this	  annotation	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Figure	   5-­4	   –	   Odds	   ratios	   of	   the	   final	   multivariate	   model	   for	   Significant	   SNPs	   (2011)	   including	  
Distance	  to	  TSS	  
Odds	   ratios	   of	   the	   significant	   genomic	   annotations	   for	   the	   final	  multivariate	  model	   for	   Significant	  
SNPs	   (2011),	   sorted	   in	   decreasing	   significance	   in	   the	   model	   including	   distance	   to	   TSS.	   Only	   the	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Table	  5-­3	  –	  Stepwise	  logistic	  regression	  results	  for	  Significant	  SNPs	  (2011)	  with	  Distance	  to	  TSS	  
The	  results	  for	  the	  multivariate	  model	  using	  Significant	  SNPs	  (SNPs)	  with	  distance	  to	  TSS	  are	  shown	  
below.	   The	   table	   presents	   the	   estimate	   of	   the	   effect,	   its	   standard	   error,	   the	   β-­‐coefficient,	   the	  
calculated	  odds	  ratio	  with	  its	  confidence	  interval,	  and	  the	  P-­‐value	  of	  the	  estimate	  in	  the	  final	  model	  
for	  each	  of	  the	  included	  genomic	  annotations	  in	  the	  final	  model.	  Significant	  P-­‐values	  in	  bold.	  
Annotation	   Estimate	  
Std.	  
Error	  
β 	   OR	  [LCI-­‐HCI]	   P-­‐value	  
Intercept	   -­‐8.79	   0.09	   -­‐100.04	   0.00	  [0.00-­‐0.00]	   0.00	  ×	  10+00	  
Affymetrix_250k_Nsp	   0.35	   0.16	   2.17	   1.41	  [1.03-­‐1.93]	   2.96	  ×	  10-­‐02	  
Affymetrix_250k_Sty	   0.48	   0.15	   3.17	   1.62	  [1.20-­‐2.18]	   1.53	  ×	  10-­‐03	  
Affymetrix_5.0	   0.12	   0.15	   0.82	   1.13	  [0.84-­‐1.51]	   4.11	  ×	  10-­‐01	  
Affymetrix_6.0	   0.25	   0.07	   3.48	   1.28	  [1.11-­‐1.48]	   5.10	  ×	  10-­‐04	  
Affymetrix_10k	   0.50	   0.30	   1.66	   1.65	  [0.91-­‐2.98]	   9.67	  ×	  10-­‐02	  
Affymetrix_50k.1	   -­‐0.04	   0.14	   -­‐0.25	   0.96	  [0.73-­‐1.28]	   8.02	  ×	  10-­‐01	  
Affymetrix_50k.2	   -­‐0.01	   0.14	   -­‐0.08	   0.99	  [0.74-­‐1.31]	   9.37	  ×	  10-­‐01	  
Illumina_300	   0.84	   0.07	   11.30	   2.31	  [2.00-­‐2.67]	   1.33	  ×	  10-­‐29	  
Illumina_550	   1.43	   0.20	   7.25	   4.18	  [2.84-­‐6.16]	   4.11	  ×	  10-­‐13	  
Illumina_650	   -­‐0.10	   0.19	   -­‐0.52	   0.91[0.63-­‐1.31]	   6.00	  ×	  10-­‐01	  
Perlegen	   0.20	   0.06	   3.57	   1.22	  [1.09-­‐1.37]	   3.63	  ×	  10-­‐04	  
Distance	  to	  TSS	   0.00	   0.00	   -­‐12.18	   1.00	  [1.00-­‐1.00]	   4.15	  ×	  10-­‐34	  
DNase	  Clusters	   0.43	   0.05	   8.14	   1.54	  [1.39-­‐1.71]	   4.04	  ×	  10-­‐16	  
eQTLs	   0.68	   0.07	   10.28	   1.97	  [1.73-­‐2.24]	   9.05	  ×	  10-­‐25	  
Open	  Chromatin	   0.53	   0.06	   8.72	   1.69	  [1.50-­‐1.91]	   2.68	  ×	  10-­‐18	  
Exons	   0.48	   0.09	   5.44	   1.62	  [1.36-­‐1.93]	   5.41	  ×	  10-­‐08	  
Strong	  Enhancer	  
(proximal)	  
0.47	   0.08	   5.97	   1.60	  [1.37-­‐1.87]	   2.44	  ×	  10-­‐09	  
Txn	  Elongation	   -­‐0.43	   0.07	   -­‐5.99	   0.65	  [0.56-­‐0.75]	   2.06	  ×	  10-­‐09	  
44	  specs.	  algmt.	  primates	   0.19	   0.07	   2.57	   1.20	  [1.05-­‐1.39]	   1.02	  ×	  10-­‐02	  
Heterochrom/lo	   -­‐0.30	   0.06	   -­‐5.27	   0.74	  [0.66-­‐0.83]	   1.34	  ×	  10-­‐07	  
vega	  Genes	   0.25	   0.05	   4.55	   1.28	  [1.15-­‐1.42]	   5.25	  ×	  10-­‐06	  
Indels	  Pure	  regions	   0.14	   0.06	   2.38	   1.16	  [1.03-­‐1.30]	   1.74	  ×	  10-­‐02	  
Syn.	  SNPs	  (UCSC)	   -­‐0.30	   0.10	   -­‐2.95	   0.74	  [0.61-­‐0.90]	   3.19	  ×	  10-­‐03	  
Repressed	   0.16	   0.07	   2.41	   1.18	  [1.03-­‐1.35]	   1.60	  ×	  10-­‐02	  
Gained	  Stops	   1.19	   0.34	   3.48	   3.29	  [1.68-­‐6.43]	   4.93	  ×	  10-­‐04	  
Negative	  (sequence)	   0.12	   0.06	   2.17	   1.13	  [1.01-­‐1.26]	   3.03	  ×	  10-­‐02	  
Non.Syn.	  SNPs	  (UCSC)	   0.21	   0.09	   2.40	   1.24	  [1.04-­‐1.48]	   1.63	  ×	  10-­‐02	  
Active	  Promoter	   -­‐0.25	   0.10	   -­‐2.47	   0.78	  [0.64-­‐0.95]	   1.35	  ×	  10-­‐02	  
5	  Kb	  TSS	   0.14	   0.07	   2.04	   1.15	  [1.01-­‐1.31]	   4.12	  ×	  10-­‐02	  
Splice	  Sites	   -­‐11.80	   151.99	   -­‐0.08	   0.00	  [0.00-­‐1.78	  ×	  10+124]	   9.38	  ×	  10-­‐01	  
PREMOD	   0.14	   0.07	   1.89	   1.15	  [0.99-­‐1.32]	   5.92	  ×	  10-­‐02	  
5’UTR	   -­‐0.31	   0.16	   -­‐2.01	   0.73	  [0.54-­‐0.99]	   4.42	  ×	  10-­‐02	  
Microsatellites	   -­‐10.99	   109.51	   -­‐0.10	   0.00	  [0.00-­‐2.79	  ×	  10+88]	   9.20	  ×	  10-­‐01	  
Insulator	   -­‐0.20	   0.10	   -­‐1.92	   0.82	  [0.67-­‐1.00]	   5.52	  ×	  10-­‐02	  
Repetitive/CNV	  (distal)	   -­‐1.38	   1.00	   -­‐1.37	   0.25	  [0.04-­‐1.80]	   1.69	  ×	  10-­‐01	  
Enhancers	  (sequence)	   0.55	   0.29	   1.86	   1.73	  [0.97-­‐3.07]	   6.31	  ×	  10-­‐02	  
44	  specs.	  algmt.	   0.25	   0.11	   2.35	   1.28	  [1.04-­‐1.57]	   1.86	  ×	  10-­‐02	  
44	  specs.	  algmt.	  plac.	  
mmls	  
-­‐0.19	   0.11	   -­‐1.70	   0.83	  [0.67-­‐1.03]	   8.91	  ×	  10-­‐02	  
Poised	  Promoter	   0.31	   0.20	   1.57	   1.36	  [0.93-­‐2.00]	   1.16	  ×	  10-­‐01	  
Weak	  Enhancer	  (distal)	   0.10	   0.06	   1.48	   1.10	  [0.97-­‐1.25]	   1.38	  ×	  10-­‐01	  
Lost	  Stops	   -­‐11.95	   235.66	   -­‐0.05	   0.00	  [0.00-­‐2.56	  ×	  10+195]	   9.60	  ×	  10-­‐01	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5.3.2 Suggestive	  SNPs	  (2011)	  
Additionally	  to	  significantly	  associated	  SNPs	  we	  investigated	  SNPs	  with	  P-­values	  
of	   association	   that	   did	   not	   pass	   the	   genome-­‐wide	   significance	   threshold.	   This	  
dataset	   presumably	   contains	   a	   mixture	   of	   spurious	   associations	   and	   true	  
signals,	  which	  did	  not	  pass	  the	  threshold	  due	  to	  insufficient	  sample	  size	  in	  their	  
GWA	  study.	  The	  stepwise	  logistic	  regression	  analysis	  resulted	  in	  not	  only	  fewer	  
genomic	  annotations	  included	  in	  the	  model	  for	  Suggestive	  SNPs	  (2011),	  but	  the	  
included	   genomic	   annotations	   also	   obtained	   odds	   ratios	   with	   less	   extreme	  
values	  when	  compared	  to	  the	  results	  obtained	  for	  Significant	  SNPs	  (2011).	  The	  
results	   for	   the	   Suggestive	   SNPs	   (2011)	   are	   included	   in	   Table	   5-­‐4.	   Figure	   5-­‐5	  
shows	  the	  eight	  genomic	  annotations,	  which	  were	  significant	  in	  the	  Suggestive	  
SNPs	  (2011)	  analysis.	  Four	  of	  these	  annotations	  obtained	  significantly	  different	  
odds	  ratios.	  These	  four	  were	  eQTLs,	  exons,	  open	  chromatin,	  and	  distance	  to	  TSS.	  
The	   McKelvey	   and	   Zavoina’s	   pseudo-­‐r2	   value	   of	   the	   Base	   model	   for	   the	  
Suggestive	  SNPs	  (2011)	  was	  0.16,	  and	  0.18	   for	   the	   final	  model.	  For	  suggestive	  
SNPs	   the	   amount	   of	   variance	   explained	   by	   the	   genomic	   annotations	   was	  
therefore	  very	  little	  in	  comparison	  with	  that	  added	  by	  the	  genotyping	  arrays.	  	  
	  
Figure	  5-­5	  –	  Genomic	  annotations	  for	  Significant	  SNPs	  vs.	  Suggestive	  SNPs	  (2011)	  
Odds	  ratios	   for	  all	   significant	  genomic	  annotations	   in	   the	  Suggestive	  SNPs	   (2011)	  model	  present	   in	  
the	  Significant	  SNPs	  (2011)	  sorted	  after	  significance	  for	  the	  suggestive	  SNPs.	  Suggestive	  SNPs	  (2011)	  
are	  shown	  as	  	  and	  Significant	  SNPs	  (2011)	  are	  shown	  as	  .	  Solid	  symbols	  indicate	  significance	  at	  P-­‐
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Two	  histograms	  of	  the	  frequency	  of	  the	  Significant	  SNPs	  (2011)	  and	  Suggestive	  
SNPs	  (2011)	  are	  shown	  in	  Figure	  5-­‐6	  and	  Figure	  5-­‐7,	  where	  the	  former	  shows	  
the	   region	   up	   to	   20	   Kb	   and	   the	   latter	   shows	   the	   frequencies	   of	   the	   variants	  
further	  away.	  Both	  of	  these	  figures	  were	  adapted	  from	  a	  supplementary	  figure	  
from	  Kindt	  et	  al.	  published	  in	  2013	  [139].	  These	  figures	  show	  the	  distribution	  of	  
trait-­‐associated	   variants	   and	   highlight	   what	   the	   Distance	   to	   TSS	   odds	   ratio	  
already	  indicated.	  The	  majority	  of	  the	  significantly	  trait-­‐associated	  variants	  was	  
close	   to	   a	   transcription	   start	   site	   and	   outnumber	   the	   suggestively	   trait-­‐
associated	  variants	  up	  until	  a	  distance	  of	  <	  11	  Kb.	  The	  suggestively	  associated	  
variants	  were	  most	  often	  located	  further	  away,	  as	  seen	  in	  Figure	  5-­‐7.	  	  
	  
	  
Figure	  5-­6	  –	  Histogram	  of	  distance	  to	  TSS	  of	  significant	  and	  suggestive	  variants	  (<	  20	  Kb)	  
Significant	  SNPs	  (2011)	  are	  more	  frequent	  in	  the	  areas	  closer	  to	  the	  TSS.	  This	  trend	  is	  most	  obvious	  in	  
the	   first	   10	   windows,	   but	   is	   prevalent	   throughout.	   Significant	   SNPs	   (2011)	   shown	   in	   filled	   bars,	  
Suggestive	  SNPs	  (2011)	  shown	  in	  open	  bars.	  
	  
	  
Figure	  5-­7	  -­	  Histogram	  of	  distance	  to	  TSS	  of	  significant	  and	  suggestive	  variants	  (≤	  420	  Kb)	  
Significant	  SNPs	  (2011)	  are	  much	  more	  frequent	  regions	  up	  to	  20	  Kb	  away	  from	  the	  TSS.	  However,	  
the	  Suggestive	  SNPs	  (2011)	  are	  more	  frequent	  in	  all	  other	  frequencies.	  Significant	  SNPs	  (2011)	  shown	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Table	  5-­4	  –	  Stepwise	  logistic	  regression	  results	  for	  Suggestive	  SNPs	  (2011)	  with	  Distance	  to	  TSS	  	  
This	   table	   lists	   the	   results	   for	   Suggestive	   SNPs	   (2011)	   for	   the	   multivariate	   model	   including	   the	  
distance	  to	  TSS.	  The	  estimate	  of	  the	  effect,	  its	  standard	  error,	  the	  β-­‐coefficient,	  the	  calculated	  odds	  
ratio	  with	  its	  confidence	  interval,	  and	  the	  P-­‐value	  of	  the	  estimate	  in	  the	  final	  model	  for	  each	  of	  the	  
included	  genomic	  annotations	  in	  the	  final	  model	  are	  shown	  below.	  Significant	  P-­‐values	  in	  bold.	  	  
Annotation	   Estimate	   Std.	  Error	   β 	   OR	  [LCI-­‐HCI]	   P-­‐value	  
Intercept	   -­‐8.58	   0.10	   -­‐85.31	   0.00	  [0.00-­‐0.00]	   0.00	  ×	  10+00	  
Affymetrix_250k_Nsp	   0.74	   0.12	   5.98	   2.09	  [1.64-­‐2.66]	   2.21	  ×	  10-­‐09	  
Affymetrix_250k_Sty	   0.92	   0.12	   7.80	   2.50	  [1.99-­‐3.15]	   6.12	  ×	  10-­‐15	  
Affymetrix_5.0	   -­‐0.11	   0.11	   -­‐0.99	   0.89	  [0.71-­‐1.12]	   3.21	  ×	  10-­‐01	  
Affymetrix_6.0	   0.15	   0.06	   2.43	   1.16	  [1.03-­‐1.32]	   1.51	  ×	  10-­‐02	  
Affymetrix_10k	   0.25	   0.22	   1.14	   1.28	  [0.84-­‐1.95]	   2.53	  ×	  10-­‐01	  
Affymetrix_50k.1	   0.96	   0.08	   11.99	   2.62	  [2.24-­‐3.06]	   3.82	  ×	  10-­‐33	  
Affymetrix_50k.2	   0.71	   0.09	   7.70	   2.02	  [1.69-­‐2.42]	   1.35	  ×	  10-­‐14	  
Illumina_300	   0.75	   0.06	   11.96	   2.12	  [1.87-­‐2.39]	   6.02	  ×	  10-­‐33	  
Illumina_550	   1.43	   0.17	   8.43	   4.19	  [3.00-­‐5.85]	   3.56	  ×	  10-­‐17	  
Illumina_650	   -­‐0.03	   0.16	   -­‐0.17	   0.97	  [0.71-­‐1.34]	   8.65	  ×	  10-­‐01	  
Perlegen	   0.48	   0.05	   10.65	   1.62	  [1.49-­‐1.78]	   1.83	  ×	  10-­‐26	  
eQTLs	   0.45	   0.07	   5.96	   1.56	  [1.35-­‐1.81]	   2.50	  ×	  10-­‐09	  
Open	  Chromatin	   0.26	   0.09	   2.75	   1.29	  [1.08-­‐1.56]	   5.91	  ×	  10-­‐03	  
Exons	   0.23	   0.07	   3.11	   1.25	  [1.09-­‐1.45]	   1.88	  ×	  10-­‐03	  
Gained	  Stops	   1.55	   0.39	   4.04	   4.73	  [2.23-­‐10.07]	   5.40	  ×	  10-­‐05	  
Strong	  Enhancer	  
(proximal)	  
0.31	   0.09	   3.23	   1.36	  [1.13-­‐1.64]	   1.24	  ×	  10-­‐03	  
Distance	  to	  TSS	   0.00	   0.00	   -­‐2.45	   1.00	  [1.00-­‐1.00]	   1.42	  ×	  10-­‐02	  
vega	  Genes	   0.12	   0.05	   2.63	   1.13	  [1.03-­‐1.23]	   8.64	  ×	  10-­‐03	  
Repressed	   0.15	   0.07	   2.20	   1.16	  [1.02-­‐1.33]	   2.75	  ×	  10-­‐02	  
Microsatellites	   1.05	   0.45	   2.33	   2.86	  [1.18-­‐6.89]	   1.96	  ×	  10-­‐02	  
Poised	  Promoter	   -­‐0.67	   0.41	   -­‐1.63	   0.51	  [0.23-­‐1.14]	   1.02	  ×	  10-­‐01	  
Closed	  Chromatin	   0.16	   0.09	   1.68	   1.17	  [0.97-­‐1.40]	   9.21	  ×	  10-­‐02	  
Pos.	  Sel.	  Genes	   -­‐0.08	   0.05	   -­‐1.53	   0.93	  [0.84-­‐1.02]	   1.25	  ×	  10-­‐01	  
TS	  miRNA	   -­‐9.52	   66.24	   -­‐0.14	   0.00	  [0.00-­‐1.77	  ×	  10+52]	   8.86	  ×	  10-­‐01	  
Insulators	  (sequence)	   -­‐0.15	   0.10	   -­‐1.47	   0.86	  [0.71-­‐1.05]	   1.43	  ×	  10-­‐01	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5.3.3 Significant	  SNPs	  (2013)	  	  
The	   more	   recent	   catalogue	   of	   trait-­‐associated	   SNPs,	   Significant	   SNPs	   (2013),	  
was	   analysed	   as	   five	  different	   sets.	   First,	   it	  was	   analysed	   as	   a	   complete	   set	   of	  
trait-­‐associated	   SNPs	   incorporating	   associations	   across	   a	   broad	   range	   of	  
phenotypes.	   The	   total	   set	   was	   then	   separated	   into	   subsets	   depending	   on	  
different	   trait-­‐categories	   to	   allow	   trait-­‐specific	   results	   and	   conclusions.	   The	  
traits	   in	   the	  subsets	  are	   listed	   in	   the	  Appendix	   (page	  203).	  The	  results	   for	   the	  
final	  model	  for	  Significant	  SNPs	  (2013)	  including	  Distance	  to	  TSS	  are	  shown	  in	  
Table	  5-­‐5.	  There	  were	  no	  significant	  differences	  between	  the	  odds	  ratios	  of	  the	  
Significant	   SNPs	   (2011)	   and	   Significant	   SNPs	   (2013).	   The	   odds	   ratios	   of	   the	  
annotations,	  which	  were	  present	  in	  both	  models,	  are	  shown	  in	  Figure	  5-­‐6.	  While	  
there	  were	  no	  differences	  in	  the	  odds	  ratios	  in	  the	  common	  annotations,	  the	  two	  
models	   varied	   in	   some	   of	   the	   included	   annotations.	   Therefore	   for	   Significant	  
SNPs	   (2011)	   further	   contained	  microsatellites,	   repetitive/CNV	   (distal),	   and	  44	  
species	   alignment	  with	   placental	  mammals,	  which	  were	   not	   significant	   in	   the	  
model.	  The	  Significant	  SNPs	  (2013)	  model	  also	  contained	  RNA	  genes,	  positively	  
selected	  genes,	  and	  conserved	  sites	  from	  the	  17	  species	  alignment,	  all	  of	  which	  
were	   significant.	   The	   weak	   enhancer	   (proximal)	   and	   the	   weak	   transcription	  
regions	  were	  not	   significant	   in	   the	  model.	  Those	   annotations,	  which	  were	  not	  
significant	   in	   the	  model,	  were	   included	  as	   they	  explained	  additional	   variation,	  
albeit	  not	  significantly	  when	  compared	  to	  all	  other	  annotations.	  	  
	  
For	   Significant	   SNPs	   (2013)	   there	   were	   32	   included	   annotations	   in	   the	   Final	  
Model,	  of	  which	  24	  had	  a	  standard	  error	  of	  less	  than	  two	  and	  were	  significant	  at	  
≥0.05	   (Figure	  5-­‐9).	  Distance	   to	  TSS	  has	  an	  odds	  ratio	  of	  one	  with	  a	  P-­value	  of	  
9.01	  ×	  10-­‐52,	  but	  is	  in	  fact	  depleted	  with	  an	  odds	  ratio	  of	  0.999.	  This	  annotation	  
is	   a	   quantitative	   annotation,	   as	   the	   distance	   to	   TSS	   was	   included	   as	   a	   linear	  
variable.	  As	  discussed	  above,	  a	  change	  in	  the	  distance	  to	  TSS	  by	  one	  unit	  would	  
be	   the	   change	   in	  one	  nucleotide,	   so	  would	  have	  a	  very	   small	   effect.	  The	  effect	  
returned	   by	   the	   model	   is	   negative	   for	   distance	   to	   TSS,	   so	   with	   increasing	  
distance	   the	   likelihood	   that	   a	   SNP	   is	   trait-­‐associated	   decreases.	   The	   most	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significant	  annotations	  in	  the	  model	  are	  eQTLs,	  distance	  to	  TSS,	  open	  chromatin,	  
DNase	  clusters	  and	  exons.	  The	  rest	  of	  the	  annotations	  have	  P-­values	  that	  are	  an	  
order	  of	  magnitude	  larger	  than	  these	  four	  very	  significant	  annotations.	  	  
	  
Figure	  5-­8	  –	  Correlation	  of	  odds	  ratios	  for	  Significant	  SNPs	  (2011)	  and	  Significant	  SNPs	  (2013)	  
The	  odds	  ratios	  of	  the	  common	  genomic	  annotations	  for	  Significant	  SNPs	  (2011)	  and	  Significant	  SNPs	  
(2013)	  agreed	  very	  well	  with	  each	  other.	  The	   r2	  of	   the	   regression	   line	  of	   the	   results	   for	  Significant	  
SNPs	  (2011)	  onto	  Significant	  SNPs	  (2013)	  was	  0.97	  with	  a	  P-­‐value	  of	  3.37	  ×	  10-­‐22.	  	  
	  
	  
Additionally	   to	   the	   annotation	   of	   “Distance	   to	   TSS”	   there	   were	   eight	   more	  
annotations	   showing	   depletion	   of	   significantly	   trait-­‐associated	   SNPs.	   The	  
genomic	   annotations	   depleted	   in	   the	   dataset	   of	   Significant	   SNPs	   (2013)	   are	  
regions	   with	   chromatin	   states	   associated	   with	   heterochromatin/low	  
transcription,	   transcriptional	   elongation,	   insulators,	   and	   active	   promoters	   and	  
genic	  regions	  annotated	  as	  synonymous	  SNPs,	  RNA	  genes,	  5’UTRs,	  and	  regions	  
conserved	   in	   a	   17	   species	   alignment.	   The	   McKelvey	   and	   Zavoina’s	   pseudo-­‐r2	  
values	   were	   0.12	   for	   the	   genotyping	   arrays	   only,	   and	   0.36	   for	   the	   model	  
including	  the	  Distance	  to	  TSS.	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Figure	  5-­9	  –	  Significant	  genomic	  annotations	  for	  Significant	  SNPs	  (2013)	  	  
Odds	  ratios	  for	  all	  significant	  genomic	  annotations	  in	  the	  Significant	  SNPs	  (2013)	  model	  sorted	  after	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Table	  5-­5	  –	  Stepwise	  logistic	  regression	  results	  for	  Significant	  SNPs	  (2013)	  	  
The	   results	   for	   the	  multivariate	   model	   using	   Significant	   SNPs	   (2013)	   are	   shown	   below.	   The	   table	  
presents	   the	  estimate	  of	   the	  effect,	   its	   standard	  error,	   the	  β-­‐coefficient,	   the	   calculated	  odds	   ratio	  
with	   its	   confidence	   interval,	   and	   the	   P-­‐value	   of	   the	   estimate	   in	   the	   final	   model	   for	   each	   of	   the	  
included	  genomic	  annotations	  in	  the	  final	  model.	  Significant	  P-­‐valus	  in	  bold.	  	  
Annotation	   Estimate	   Std.	  Error	   β 	   OR	  [LCI-­‐HCI]	   P-­‐value	  
Intercept	   -­‐8.08	   0.07	   -­‐121.06	   0.00	  [0.00-­‐0.00]	   0.00	  ×	  10+00	  
Affymetrix_250k_Nsp	   0.36	   0.12	   3.00	   1.43	  [1.13-­‐1.81]	   2.73	  ×	  10-­‐03	  
Affymetrix_250k_Sty	   0.38	   0.12	   3.25	   1.46	  [1.16-­‐1.82]	   1.14	  ×	  10-­‐03	  
Affymetrix_5.0	   0.04	   0.11	   0.34	   1.04	  [0.83-­‐1.30]	   7.31	  ×	  10-­‐01	  
Affymetrix_6.0	   0.37	   0.05	   6.95	   1.45	  [1.30-­‐1.61]	   3.71	  ×	  10-­‐12	  
Affymetrix_10k	   0.54	   0.25	   2.18	   1.72	  [1.06-­‐2.81]	   2.90	  ×	  10-­‐02	  
Affymetrix_50k.1	   -­‐0.08	   0.12	   -­‐0.67	   0.92	  [0.74-­‐1.16]	   5.00	  ×	  10-­‐01	  
Affymetrix_50k.2	   -­‐0.17	   0.12	   -­‐1.37	   0.84	  [0.66-­‐1.08]	   1.71	  ×	  10-­‐01	  
Illumina_300	   0.66	   0.06	   11.47	   1.94	  [1.73-­‐2.17]	   1.94	  ×	  10-­‐30	  
Illumina_550	   0.97	   0.13	   7.33	   2.65	  [2.04-­‐3.44]	   2.23	  ×	  10-­‐13	  
Illumina_650	   0.21	   0.13	   1.67	   1.23	  [0.96-­‐1.58]	   9.48	  ×	  10-­‐02	  
Perlegen	   0.26	   0.04	   6.11	   1.30	  [1.20-­‐1.42]	   1.03	  ×	  10-­‐09	  
Distance	  to	  TSS	   0.00	   0.00	   -­‐15.14	   1.00	  [1.00-­‐1.00]	   9.01	  ×	  10-­‐52	  
eQTLs	   0.79	   0.05	   15.48	   2.19	  [1.99-­‐2.42]	   4.81	  ×	  10-­‐54	  
DNase	  Clusters	   0.39	   0.04	   9.62	   1.48	  [1.37-­‐1.61]	   6.70	  ×	  10-­‐22	  
Open	  Chromatin	   0.53	   0.05	   11.62	   1.70	  [1.56-­‐1.86]	   3.17	  ×	  10-­‐31	  
Exons	   0.55	   0.07	   8.10	   1.74	  [1.52-­‐1.98]	   5.71	  ×	  10-­‐16	  
Repressed	   0.18	   0.05	   3.54	   1.20	  [1.09-­‐1.33]	   3.98	  ×	  10-­‐04	  
Indels	  Pure	  regions	   0.15	   0.05	   3.19	   1.16	  [1.06-­‐1.27]	   1.45	  ×	  10-­‐03	  
Strong	  Enhancer	  (proximal)	   0.30	   0.06	   4.71	   1.35	  [1.19-­‐1.54]	   2.44	  ×	  10-­‐06	  
Txn	  Elongation	   -­‐0.31	   0.06	   -­‐5.34	   0.74	  [0.66-­‐0.82]	   9.52	  ×	  10-­‐08	  
Heterochrom/lo	   -­‐0.27	   0.05	   -­‐5.92	   0.76	  [0.70-­‐0.83]	   3.28	  ×	  10-­‐09	  
5	  Kb	  TSS	   0.24	   0.05	   4.73	   1.27	  [1.15-­‐1.41]	   2.26	  ×	  10-­‐06	  
Syn.	  SNPs	  (UCSC)	   -­‐0.32	   0.08	   -­‐4.06	   0.73	  [0.62-­‐0.85]	   5.00	  ×	  10-­‐05	  
44	  specs.	  algmt.	  primates	   0.15	   0.06	   2.68	   1.16	  [1.04-­‐1.29]	   7.38	  ×	  10-­‐03	  
Gained	  Stops	   1.19	   0.27	   4.47	   3.28	  [1.95-­‐5.52]	   7.74	  ×	  10-­‐06	  
vega	  Genes	   0.20	   0.04	   4.67	   1.22	  [1.12-­‐1.33]	   2.96	  ×	  10-­‐06	  
Insulator	   -­‐0.26	   0.08	   -­‐3.16	   0.77	  [0.66-­‐0.91]	   1.59	  ×	  10-­‐03	  
Poised	  Promoter	   0.46	   0.14	   3.22	   1.58	  [1.20-­‐2.08]	   1.26	  ×	  10-­‐03	  
Active	  Promoter	   -­‐0.20	   0.08	   -­‐2.57	   0.82	  [0.71-­‐0.95]	   1.01	  ×	  10-­‐02	  
Splice	  Sites	   -­‐11.35	   93.25	   -­‐0.12	   0.00	  [0.00-­‐2.82	  ×	  10+74]	   9.03	  ×	  10-­‐01	  
PREMOD	   0.14	   0.06	   2.57	   1.15	  [1.03-­‐1.29]	   1.01	  ×	  10-­‐02	  
5’UTR	   -­‐0.25	   0.12	   -­‐2.15	   0.78	  [0.62-­‐0.98]	   3.17	  ×	  10-­‐02	  
RNA	  Genes	   -­‐0.82	   0.38	   -­‐2.17	   0.44	  [0.21-­‐0.92]	   3.03	  ×	  10-­‐02	  
Enhancers	  (sequence)	   0.55	   0.23	   2.43	   1.74	  [1.11-­‐2.72]	   1.52	  ×	  10-­‐02	  
Pos.	  Sel.	  Genes	   -­‐0.08	   0.04	   -­‐1.78	   0.93	  [0.85-­‐1.01]	   7.50	  ×	  10-­‐02	  
44	  specs.	  algmt.	   0.17	   0.06	   2.66	   1.18	  [1.04-­‐1.33]	   7.88	  ×	  10-­‐03	  
17	  specs.	  algmt.	   -­‐0.12	   0.06	   -­‐2.03	   0.88	  [0.78-­‐1.00]	   4.27	  ×	  10-­‐02	  
Non.Syn.	  SNPs	  (UCSC)	   0.13	   0.07	   1.91	   1.14	  [1.00-­‐1.31]	   5.64	  ×	  10-­‐02	  
Lost	  Stops	   -­‐11.51	   143.43	   -­‐0.08	   0.00	  [0.00-­‐1.23	  ×	  10+117]	   9.36	  ×	  10-­‐01	  
Weak	  Enhancer	  (proximal)	   -­‐0.12	   0.07	   -­‐1.83	   0.89	  [0.78-­‐1.01]	   6.76	  ×	  10-­‐02	  
Negative	  (sequence)	   0.07	   0.04	   1.71	   1.08	  [0.99-­‐1.17]	   8.75	  ×	  10-­‐02	  
Weak	  Enhancer	  (distal)	   0.09	   0.05	   1.71	   1.09	  [0.99-­‐1.21]	   8.70	  ×	  10-­‐02	  
Weak	  Txn	   -­‐0.08	   0.05	   -­‐1.63	   0.93	  [0.84-­‐1.02]	   1.03	  ×	  10-­‐01	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5.3.4 Subsets	  of	  Significant	  SNPs	  (2013)	  
The	   dataset	   of	   Significant	   SNPs	   (2013)	   consisted	   of	   3,283	   SNPs,	   which	   is	   a	  
sufficient	   number	   of	   SNPs	   that	   allowed	   splitting	   the	   set	   into	   several	   subsets	  
divided	   on	   the	   basis	   of	   phenotype	   groupings.	   This	   splitting	   of	   the	   dataset	  
allowed	  exploring	  if	  different	  phenotype	  classes	  were	  affected	  preferentially	  by	  
different	  annotations.	  The	  Significant	  SNPs	   (Difference)	  were	  analysed	  as	  well	  
as	   four	   SNP	   sets	   associated	   to	   four	   specific	   trait	   categories	   (disease	   traits,	  
normal	  variation	  traits,	  immunity	  traits,	  and	  cancer	  traits).	  The	  trait-­‐association	  
of	  the	  SNPs	  to	  four	  trait-­‐categories	  defined	  the	  SNP	  subsets	  and	  were	  analysed	  
to	   compare	   different	   trait	   classes.	   In	   particular,	   the	   comparison	   of	   Normal	  
Variation	  and	  Disease	   SNPs,	  which	  were	   two	  mutually	   exclusive	  datasets.	  The	  
Immune	  SNPs	  and	   the	  Cancer	  SNPs	  were	  compared	   to	  Non-­‐immune	  and	  Non-­‐
cancer	  SNPs.	  The	  traits	  in	  the	  subsets	  are	  listed	  in	  the	  Appendix	  (page	  203).	  
5.3.4.1 Significant	  SNPs	  (Difference)	  
In	  order	  to	  analyse	  only	  the	  newest	  SNPs,	  we	  investigated	  the	  Significant	  SNPs	  
(Difference)	   set,	   which	   contained	   only	   those	   SNPs	   that	   were	   present	   in	  
Significant	   SNPs	   (2013)	   but	   not	   in	   Significant	   SNPs	   (2011).	   These	   SNPs	  were	  
analysed	  in	  a	  multiple	  logistic	  regression	  model	  and	  the	  results	  were	  compared	  
with	  the	  results	  for	  the	  Significant	  SNPs	  (2011).	  The	  17	  annotations	  common	  to	  
both	   regression	   models	   showed	   only	   three	   significant	   differences.	   The	  
transcriptional	   elongation	   regions	   were	   less	   depleted	   of	   Significant	   SNPs	  
(Difference)	  than	  for	  Significant	  SNPs	  (2011)	  while	  the	  5	  Kb	  regions	  upstream	  
of	   transcription	   start	   sites	   were	   more	   enriched	   for	   the	   Significant	   SNPs	  
(Difference).	  The	  distance	   to	  TSS	  was	  also	   significantly	  different,	   as	   judged	  by	  
their	  P-­values	  obtained	  from	  a	  t-­‐test.	  Figure	  5-­‐8	  shows	  the	  genomic	  annotations	  
common	   to	   both	   final	   models	   and	   presents	   the	   numerical	   results	   of	   the	  
Significant	  SNPs	  (Difference).	  Table	  5-­‐6	   lists	   the	  estimates,	   standard	  errors,	  β-­‐
coefficients	  (ratio	  of	  estimate	  over	  standard	  errors),	  odds	  ratios	  and	  confidence	  
intervals	  and	  the	  P-­values	  of	  all	  the	  genomic	  annotations,	  genotyping	  arrays	  and	  
intercept	  of	  the	  final	  model	  for	  Significant	  SNPs	  (Difference).	  Table	  5-­‐3	  contains	  
the	  results	  for	  the	  Significant	  SNPs	  (2011).	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Figure	   5-­10	   –	   Common	   genomic	   annotations	   for	   Significant	   SNPs	   (2011)	   and	   Significant	   SNPs	  
(Difference)	  	  
Odds	  ratios	  for	  all	  common	  genomic	  annotations	  in	  the	  Significant	  SNPs	  (2011)	  and	  Significant	  SNPs	  
(Difference)	  model	  sorted	  after	  significance.	  Significant	  SNPs	  (2011)	  are	  shown	  as	  	  and	  Significant	  
SNPs	   (Difference)	  are	   shown	  as	  .	   Solid	   symbols	   indicate	   significance	  at	  P-­‐value	  ≤	  0.05.	  Red	  stars	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Table	  5-­6	  –	  Stepwise	  logistic	  regression	  results	  for	  Significant	  SNPs	  (Difference)	  	  
The	  results	  for	  the	  multivariate	  model	  using	  Significant	  SNPs	  (Difference)	  are	  shown	  below.	  The	  table	  
presents	   the	  estimate	  of	   the	  effect,	   its	   standard	  error,	   the	  β-­‐coefficient,	   the	   calculated	  odds	   ratio	  
with	   its	   confidence	   interval,	   and	   the	   P-­‐value	   of	   the	   estimate	   in	   the	   final	   model	   for	   each	   of	   the	  
included	  genomic	  annotations	  in	  the	  final	  model.	  Significant	  P-­‐values	  in	  bold.	  	  
Annotation	   Estimate	   Std.	  Error	   β 	   OR	  [LCI-­‐HCI]	   P-­‐value	  
Intercept	   -­‐8.69	   0.09	   -­‐92.44	   0.00	  [0.00-­‐0.00]	   0.00	  ×	  10+00	  
Affymetrix_250k_Nsp	   0.35	   0.18	   1.94	   1.41	  [1.00-­‐2.01]	   5.23	  ×	  10-­‐02	  
Affymetrix_250k_Sty	   0.22	   0.17	   1.25	   1.24	  [0.88-­‐1.75]	   2.12	  ×	  10-­‐01	  
Affymetrix_5.0	   -­‐0.06	   0.17	   -­‐0.34	   0.94	  [0.68-­‐1.32]	   7.35	  ×	  10-­‐01	  
Affymetrix_6.0	   0.48	   0.08	   6.19	   1.61	  [1.39-­‐1.87]	   6.01	  ×	  10-­‐10	  
Affymetrix_10k	   0.44	   0.44	   1.00	   1.55	  [0.66-­‐3.65]	   3.19	  ×	  10-­‐01	  
Affymetrix_50k.1	   -­‐0.12	   0.19	   -­‐0.64	   0.89	  [0.61-­‐1.28]	   5.24	  ×	  10-­‐01	  
Affymetrix_50k.2	   -­‐0.34	   0.21	   -­‐1.61	   0.71	  [0.47-­‐1.08]	   1.08	  ×	  10-­‐01	  
Illumina_300	   0.35	   0.09	   3.96	   1.41	  [1.19-­‐1.68]	   7.60	  ×	  10-­‐05	  
Illumina_550	   0.63	   0.17	   3.64	   1.88	  [1.34-­‐2.64]	   2.73	  ×	  10-­‐04	  
Illumina_650	   0.47	   0.16	   2.90	   1.60	  [1.16-­‐2.19]	   3.72	  ×	  10-­‐03	  
Perlegen	   0.33	   0.07	   5.10	   1.39	  [1.23-­‐1.58]	   3.37	  ×	  10-­‐07	  
Distance	  to	  TSS	   0.00	   0.00	   -­‐9.39	   1.00	  [1.00-­‐1.00]	   6.13	  ×	  10-­‐21	  
eQTLs	   0.87	   0.08	   11.43	   2.38	  [2.05-­‐2.76]	   2.94	  ×	  10-­‐30	  
Exons	   0.60	   0.09	   6.81	   1.83	  [1.54-­‐2.17]	   9.47	  ×	  10-­‐12	  
Open	  Chromatin	   0.50	   0.07	   7.42	   1.64	  [1.44-­‐1.87]	   1.14	  ×	  10-­‐13	  
DNase	  Clusters	   0.33	   0.06	   5.48	   1.39	  [1.24-­‐1.56]	   4.37	  ×	  10-­‐08	  
Repressed	   0.23	   0.08	   3.00	   1.26	  [1.08-­‐1.47]	   2.68	  ×	  10-­‐03	  
5	  Kb	  TSS	   0.42	   0.08	   5.13	   1.52	  [1.30-­‐1.78]	   2.84	  ×	  10-­‐07	  
Insulator	   -­‐0.28	   0.13	   -­‐2.14	   0.75	  [0.58-­‐0.98]	   3.22	  ×	  10-­‐02	  
Poised	  Promoter	   0.63	   0.20	   3.13	   1.88	  [1.26-­‐2.79]	   1.77	  ×	  10-­‐03	  
RNA	  Genes	   -­‐1.88	   1.00	   -­‐1.88	   0.15	  [0.02-­‐1.08]	   6.00	  ×	  10-­‐02	  
Weak	  Enhancer	  (proximal)	   -­‐0.23	   0.10	   -­‐2.23	   0.79	  [0.65-­‐0.97]	   2.58	  ×	  10-­‐02	  
Heterochrom/lo	   -­‐0.23	   0.07	   -­‐3.60	   0.79	  [0.70-­‐0.90]	   3.19	  ×	  10-­‐04	  
Indels	  Pure	  regions	   0.12	   0.07	   1.80	   1.13	  [0.99-­‐1.29]	   7.25	  ×	  10-­‐02	  
Syn.	  SNPs	  (UCSC)	   -­‐0.30	   0.12	   -­‐2.52	   0.74	  [0.59-­‐0.94]	   1.17	  ×	  10-­‐02	  
Txn	  Elongation	   -­‐0.17	   0.08	   -­‐2.05	   0.84	  [0.71-­‐0.99]	   4.08	  ×	  10-­‐02	  
Gained	  Stops	   1.19	   0.41	   2.88	   3.29	  [1.46-­‐7.42]	   4.02	  ×	  10-­‐03	  
28	  specs.	  algmt.	  plac.	  mmls	   0.14	   0.08	   1.81	   1.15	  [0.99-­‐1.34]	   7.10	  ×	  10-­‐02	  
vega	  Genes	   0.15	   0.06	   2.64	   1.17	  [1.04-­‐1.31]	   8.26	  ×	  10-­‐03	  
1	  Kb	  TSS	   -­‐0.21	   0.11	   -­‐1.86	   0.81	  [0.66-­‐1.01]	   6.27	  ×	  10-­‐02	  
Weak	  Txn	   -­‐0.11	   0.07	   -­‐1.58	   0.90	  [0.78-­‐1.03]	   1.15	  ×	  10-­‐01	  
PREMOD	   0.15	   0.08	   1.82	   1.16	  [0.99-­‐1.37]	   6.86	  ×	  10-­‐02	  
Splice	  Sites	   -­‐11.51	   155.31	   -­‐0.07	   0.00	  [0.00-­‐1.59	  ×	  10+127]	   9.41	  ×	  10-­‐01	  
TS	  miRNA	   -­‐11.85	   181.48	   -­‐0.07	   0.00	  [0.00-­‐2.14	  ×	  10+149]	   9.48	  ×	  10-­‐01	  
Pos.	  Sel.	  Genes	   -­‐0.09	   0.06	   -­‐1.48	   0.91	  [0.80-­‐1.03]	   1.40	  ×	  10-­‐01	  
ORegAnno	   -­‐0.22	   0.15	   -­‐1.42	   0.81	  [0.60-­‐1.09]	   1.55	  ×	  10-­‐01	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5.3.4.2 Immune	  SNPs	  	  
The	   final	   model	   for	   the	   Immune	   SNPs	   contained	   39	   genomic	   annotations,	   of	  
which	  20	  were	  significant	  at	  P	  ≤	  0.05	  (see	  Figure	  5-­‐8).	  The	  final	  model	  obtained	  
in	  the	  Immune	  SNPs	  was	  run	  on	  the	  complementary	  set	  of	  Non-­‐immune	  SNPs	  to	  
enable	   comparisons	   between	   the	   two	   sets.	   Table	   5-­‐7	   and	   Table	   5-­‐8	   list	   the	  
results	   of	   the	   final	   models	   for	   the	   Immune	   SNPs	   and	   the	   Non-­‐immune	   SNPs,	  
respectively,	  showing	  the	  estimates,	  standard	  errors,	  β-­‐coefficients,	  odds	  ratios	  
and	   confidence	   intervals	   and	   the	   P-­values	   of	   all	   the	   genomic	   annotations,	  
genotyping	   arrays	   and	   intercept.	   The	   nine	   genomic	   annotations	   that	   are	  
significantly	  depleted	  of	   immune-­‐associated	  SNPs	  are	  mainly	  chromatin	  states	  
or	  conserved	  regions	  with	  the	  exception	  of	  5’UTRs.	  The	  annotations	  are	  ranked	  
in	   order	   of	   decreasing	   significance	   distance	   to	   TSS,	   positively	   selected	   genes,	  
regions	   associated	   with	   chromatin	   states	   indicative	   of	   heterochromatin/low	  
transcription,	  transcriptional	  elongation,	  conserved	  transcription	  factor	  binding	  
sites,	  open	  regulatory	  annotations,	  closed	  chromatin,	  5’UTRs,	  and	  sites	  found	  to	  
be	  conserved	  in	  a	  28	  species	  alignment.	  	  
	  
The	  11	  annotations	  that	  are	  enriched	  for	  immune-­‐associated	  SNPs	  are	  in	  order	  
of	  decreasing	  significance	  eQTLs,	  open	  chromatin,	  strong	  enhancer	  (proximal),	  
exons,	  vega	  genes,	  DNase	  clusters,	  5	  Kb	  TSS,	  repressed	  chromatin	  states,	  weak	  
enhancers	  (distal),	  TS	  miRNA	  binding	  sites,	  and	  vega	  pseudo	  genes.	  The	  strong	  
enhancer	  (proximal),	  eQTLs,	  DNase	  clusters,	  and	  open	  chromatin	  regions	  were	  
the	  annotations	  that	  were	  enriched	  for	  trait-­‐associated	  SNPs	  in	  the	  majority	  of	  
the	  analyses.	  The	  strong	  enhancer	  (proximal)	  annotation	  was	  the	  most	  enriched	  
annotation	  in	  the	  analysis	  for	  Significant	  SNPs	  (2011).	  	  
	  
There	   are	   13	   genomic	   annotations,	   which	   have	   statistically	   significantly	  
different	  odds	  ratios	  for	  Immune	  and	  Non-­‐immune	  SNPs.	  The	  conserved	  regions	  
(positively	   selected	   genes,	   conserved	   transcription	   factor	   binding	   sites,	   and	  
conserved	   sites	   from	   a	   28	   species	   alignment)	   are	   significantly	   depleted	   of	  
Immune	  SNPs,	  while	  Non-­‐immune	  SNPs	  are	  either	  enriched	  in	  these	  regions	  or	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do	   not	   show	   significant	   enrichment/depletion.	   The	   ORegAnno	   annotation	  
contains,	   amongst	   other	   regulatory	   annotations,	   transcription	   factor	   binding	  
sites,	   so	   the	   Immune	   SNPs	   are	   consistently	   depleted	   in	   these	   sites.	   The	   other	  
significant	   differences	   are	   in	   eQTLs,	   strong	   enhancer	   (proximal)	   regions,	   vega	  
genes,	   distance	   to	   TSS,	   Heterochromatin/low	   transcription	   regions,	   5	   Kb	  
regions	  upstream	  the	  TSS,	  closed	  chromatin,	  open	  regulatory	  annotations,	  vega	  
pseudo	  genes,	  and	  strong	  enhancer	  (distal)	  regions.	  	  
The	  McKelvey	   and	   Zavoina’s	   pseudo-­‐r2	   value	   of	   the	   final	  model	   including	   the	  
distance	  to	  TSS	  was	  0.45	  for	  the	  Immune	  SNPs,	  and	  for	  the	  Base	  model	  was	  0.18.	  
The	  pseudo-­‐r2	  values	  for	  the	  empty	  Non-­‐immune	  SNP	  model	  was	  0.11,	  and	  for	  
the	  final	  model	  0.35.	  	  
	  
	  
Figure	  5-­11	  –	  Effect	  of	  genomic	  annotations	  in	  Immune	  vs.	  Non-­immune	  SNPs	  
Odds	   ratios	   for	   all	   genomic	   annotations	   in	   the	   Immune	   SNPs	   model	   sorted	   after	   significance.	  
Immune	   SNPs	   are	   shown	   as	  	   and	   Non-­‐immune	   SNPs	   are	   shown	   as	  .	   Solid	   symbols	   indicate	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Table	  5-­7	  –	  Stepwise	  logistic	  regression	  results	  for	  Immune	  SNPs	  	  
The	  results	  for	  the	  multivariate	  model	  using	  the	  Immune	  SNPs	  are	  shown	  below.	  The	  table	  presents	  
the	   estimate	   of	   the	   effect,	   its	   standard	   error,	   the	  β-­‐coefficient,	   the	   calculated	   odds	   ratio	  with	   its	  
confidence	   interval,	   and	   the	   P-­‐value	   of	   the	   estimate	   in	   the	   final	   model	   for	   each	   of	   the	   included	  
genomic	  annotations	  in	  the	  final	  model.	  Significant	  P-­‐values	  in	  bold.	  	  
Annotation	   Estimate	   Std.	  Error	   β 	   OR	  [LCI-­‐HCI]	   P-­‐value	  
Intercept	   -­‐9.82	   0.24	   -­‐41.21	   0.00	  [0.00-­‐0.00]	   0.00	  ×	  10+00	  
Affymetrix_250k_Nsp	   0.59	   0.26	   2.31	   1.81	  [1.09-­‐3.00]	   2.08	  ×	  10-­‐02	  
Affymetrix_250k_Sty	   0.58	   0.24	   2.36	   1.78	  [1.10-­‐2.87]	   1.83	  ×	  10-­‐02	  
Affymetrix_5.0	   -­‐0.17	   0.24	   -­‐0.70	   0.84	  [0.53-­‐1.35]	   4.81	  ×	  10-­‐01	  
Affymetrix_6.0	   0.23	   0.12	   1.91	   1.26	  [0.99-­‐1.59]	   5.58	  ×	  10-­‐02	  
Affymetrix_10k	   -­‐0.93	   1.02	   -­‐0.91	   0.39	  [0.05-­‐2.91]	   3.61	  ×	  10-­‐01	  
Affymetrix_50k.1	   -­‐0.12	   0.26	   -­‐0.44	   0.89	  [0.53-­‐1.49]	   6.61	  ×	  10-­‐01	  
Affymetrix_50k.2	   -­‐0.03	   0.26	   -­‐0.11	   0.97	  [0.58-­‐1.62]	   9.16	  ×	  10-­‐01	  
Illumina_300	   0.54	   0.11	   4.84	   1.72	  [1.38-­‐2.14]	   1.30	  ×	  10-­‐06	  
Illumina_550	   0.99	   0.26	   3.79	   2.69	  [1.61-­‐4.48]	   1.50	  ×	  10-­‐04	  
Illumina_650	   0.95	   0.25	   3.77	   2.58	  [1.57-­‐4.22]	   1.66	  ×	  10-­‐04	  
Perlegen	   0.09	   0.10	   0.97	   1.10	  [0.91-­‐1.33]	   3.31	  ×	  10-­‐01	  
eQTLs	   1.14	   0.10	   11.05	   3.13	  [2.55-­‐3.83]	   2.29	  ×	  10-­‐28	  
Open	  Chromatin	   0.46	   0.22	   2.13	   1.58	  [1.04-­‐2.41]	   3.29	  ×	  10-­‐02	  
Strong	  Enhancer	  (proximal)	   0.75	   0.12	   6.04	   2.11	  [1.66-­‐2.69]	   1.51	  ×	  10-­‐09	  
Distance	  to	  TSS	   0.00	   0.00	   -­‐4.32	   1.00	  [1.00-­‐1.00]	   1.56	  ×	  10-­‐05	  
Exons	   0.75	   0.14	   5.25	   2.11	  [1.60-­‐2.79]	   1.54	  ×	  10-­‐07	  
Pos.	  Sel.	  Genes	   -­‐0.44	   0.11	   -­‐4.11	   0.64	  [0.52-­‐0.79]	   4.02	  ×	  10-­‐05	  
vega	  Genes	   0.49	   0.10	   5.12	   1.63	  [1.35-­‐1.96]	   3.09	  ×	  10-­‐07	  
DNase	  Clusters	   0.39	   0.09	   4.27	   1.48	  [1.24-­‐1.77]	   1.95	  ×	  10-­‐05	  
Heterochrom/lo	   -­‐0.38	   0.09	   -­‐4.24	   0.68	  [0.57-­‐0.82]	   2.22	  ×	  10-­‐05	  
Txn	  Elongation	   -­‐0.39	   0.12	   -­‐3.16	   0.68	  [0.53-­‐0.86]	   1.56	  ×	  10-­‐03	  
5	  Kb	  TSS	   0.43	   0.10	   4.07	   1.53	  [1.25-­‐1.88]	   4.72	  ×	  10-­‐05	  
tfbs	  Conserved	   -­‐0.40	   0.16	   -­‐2.55	   0.67	  [0.49-­‐0.91]	   1.09	  ×	  10-­‐02	  
ORegAnno	   -­‐0.52	   0.24	   -­‐2.15	   0.59	  [0.37-­‐0.96]	   3.19	  ×	  10-­‐02	  
Repressed	   0.37	   0.11	   3.34	   1.45	  [1.16-­‐1.80]	   8.41	  ×	  10-­‐04	  
Closed	  Chromatin	   -­‐0.49	   0.21	   -­‐2.32	   0.62	  [0.41-­‐0.93]	   2.03	  ×	  10-­‐02	  
Weak	  Enhancer	  (distal)	   0.22	   0.11	   2.07	   1.25	  [1.01-­‐1.54]	   3.89	  ×	  10-­‐02	  
5’UTR	   -­‐0.53	   0.26	   -­‐2.00	   0.59	  [0.35-­‐0.99]	   4.51	  ×	  10-­‐02	  
Syn.	  SNPs	  (UCSC)	   -­‐0.29	   0.18	   -­‐1.61	   0.75	  [0.53-­‐1.07]	   1.08	  ×	  10-­‐01	  
Strong	  Enhancer	  (distal)	   0.26	   0.14	   1.92	   1.30	  [0.99-­‐1.69]	   5.52	  ×	  10-­‐02	  
TS	  miRNA	   1.55	   0.72	   2.16	   4.71	  [1.15-­‐19.29]	   3.10	  ×	  10-­‐02	  
Insulator	   -­‐0.35	   0.20	   -­‐1.69	   0.71	  [0.47-­‐1.06]	   9.02	  ×	  10-­‐02	  
Repetitive/CNV	  (distal)	   -­‐11.63	   173.69	   -­‐0.07	   0.00	  [0.00-­‐6.30	  ×	  10+142]	   9.47	  ×	  10-­‐01	  
Enhancers	  (sequence)	   -­‐11.19	   141.87	   -­‐0.08	   0.00	  [0.00-­‐7.94	  ×	  10+115]	   9.37	  ×	  10-­‐01	  
Intronic	  SNPs	   -­‐0.18	   0.11	   -­‐1.62	   0.84	  [0.68-­‐1.04]	   1.05	  ×	  10-­‐01	  
vega	  PseudoGenes	   0.40	   0.20	   2.01	   1.49	  [1.01-­‐2.18]	   4.43	  ×	  10-­‐02	  
28	  specs.	  algmt.	   -­‐0.28	   0.12	   -­‐2.42	   0.76	  [0.60-­‐0.95]	   1.55	  ×	  10-­‐02	  
Non.Syn.	  SNPs	  (UCSC)	   0.24	   0.15	   1.57	   1.27	  [0.94-­‐1.70]	   1.16	  ×	  10-­‐01	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Table	  5-­8	  –	  Stepwise	  logistic	  regression	  results	  for	  Non-­immune	  SNPs	  	  
The	   results	   for	   the	   multivariate	   model	   using	   the	   Non-­‐immune	   SNPs	   are	   shown	   below.	   The	   table	  
presents	   the	  estimate	  of	   the	  effect,	   its	   standard	  error,	   the	  β-­‐coefficient,	   the	   calculated	  odds	   ratio	  
with	   its	   confidence	   interval,	   and	   the	   P-­‐value	   of	   the	   estimate	   in	   the	   final	   model	   for	   each	   of	   the	  
included	  genomic	  annotations	  in	  the	  final	  model.	  
Annotation	   Estimate	   Std.	  Error	   β 	   OR	  [LCI-­‐HCI]	   P-­‐value	  
Intercept	   -­‐8.20	   0.10	   -­‐81.54	   0.00	  [0.00-­‐0.00]	   0.00	  ×	  10+00	  
Affymetrix_250k_Nsp	   0.30	   0.14	   2.24	   1.36	  [1.04-­‐1.77]	   2.49	  ×	  10-­‐02	  
Affymetrix_250k_Sty	   0.33	   0.13	   2.50	   1.39	  [1.07-­‐1.79]	   1.25	  ×	  10-­‐02	  
Affymetrix_5.0	   0.09	   0.13	   0.74	   1.10	  [0.86-­‐1.41]	   4.59	  ×	  10-­‐01	  
Affymetrix_6.0	   0.40	   0.06	   6.79	   1.50	  [1.33-­‐1.68]	   1.12	  ×	  10-­‐11	  
Affymetrix_10k	   0.75	   0.26	   2.87	   2.11	  [1.27-­‐3.51]	   4.12	  ×	  10-­‐03	  
Affymetrix_50k.1	   -­‐0.05	   0.13	   -­‐0.37	   0.95	  [0.74-­‐1.23]	   7.11	  ×	  10-­‐01	  
Affymetrix_50k.2	   -­‐0.19	   0.14	   -­‐1.38	   0.82	  [0.63-­‐1.08]	   1.68	  ×	  10-­‐01	  
Illumina_300	   0.70	   0.07	   10.36	   2.00	  [1.76-­‐2.29]	   3.77	  ×	  10-­‐25	  
Illumina_550	   0.97	   0.15	   6.26	   2.63	  [1.94-­‐3.56]	   3.97	  ×	  10-­‐10	  
Illumina_650	   0.03	   0.15	   0.20	   1.03	  [0.77-­‐1.37]	   8.41	  ×	  10-­‐01	  
Perlegen	   0.30	   0.05	   6.20	   1.35	  [1.23-­‐1.48]	   5.75	  ×	  10-­‐10	  
eQTLs	   0.63	   0.06	   10.96	   1.89	  [1.68-­‐2.11]	   5.76	  ×	  10-­‐28	  
Open	  Chromatin	   0.46	   0.09	   5.28	   1.59	  [1.34-­‐1.89]	   1.27	  ×	  10-­‐07	  
Strong	  Enhancer	  (proximal)	   0.11	   0.08	   1.44	   1.12	  [0.96-­‐1.31]	   1.49	  ×	  10-­‐01	  
Distance	  to	  TSS	   0.00	   0.00	   -­‐14.21	   1.00	  [1.00-­‐1.00]	   7.64	  ×	  10-­‐46	  
Exons	   0.53	   0.08	   6.99	   1.71	  [1.47-­‐1.98]	   2.69	  ×	  10-­‐12	  
Pos.	  Sel.	  Genes	   0.00	   0.05	   -­‐0.06	   1.00	  [0.90-­‐1.11]	   9.52	  ×	  10-­‐01	  
vega	  Genes	   0.09	   0.05	   2.04	   1.10	  [1.00-­‐1.20]	   4.18	  ×	  10-­‐02	  
DNase	  Clusters	   0.42	   0.04	   9.30	   1.52	  [1.39-­‐1.66]	   1.46	  ×	  10-­‐20	  
Heterochrom/lo	   -­‐0.16	   0.05	   -­‐3.39	   0.85	  [0.77-­‐0.93]	   6.94	  ×	  10-­‐04	  
Txn	  Elongation	   -­‐0.29	   0.06	   -­‐4.62	   0.75	  [0.66-­‐0.85]	   3.93	  ×	  10-­‐06	  
5	  Kb	  TSS	   0.18	   0.06	   3.23	   1.20	  [1.07-­‐1.33]	   1.24	  ×	  10-­‐03	  
tfbs	  Conserved	   0.10	   0.06	   1.52	   1.10	  [0.97-­‐1.24]	   1.30	  ×	  10-­‐01	  
ORegAnno	   0.12	   0.10	   1.24	   1.13	  [0.93-­‐1.37]	   2.14	  ×	  10-­‐01	  
Repressed	   0.23	   0.06	   4.06	   1.26	  [1.13-­‐1.41]	   4.80	  ×	  10-­‐05	  
Closed	  Chromatin	   0.03	   0.08	   0.32	   1.03	  [0.87-­‐1.21]	   7.48	  ×	  10-­‐01	  
Weak	  Enhancer	  (distal)	   0.05	   0.06	   0.87	   1.05	  [0.94-­‐1.18]	   3.86	  ×	  10-­‐01	  
5’UTR	   -­‐0.23	   0.13	   -­‐1.85	   0.79	  [0.62-­‐1.01]	   6.47	  ×	  10-­‐02	  
Syn.	  SNPs	  (UCSC)	   -­‐0.29	   0.09	   -­‐3.31	   0.75	  [0.63-­‐0.89]	   9.35	  ×	  10-­‐04	  
Strong	  Enhancer	  (distal)	   -­‐0.09	   0.08	   -­‐1.05	   0.92	  [0.78-­‐1.08]	   2.92	  ×	  10-­‐01	  
TS	  miRNA	   -­‐0.06	   0.71	   -­‐0.08	   0.94	  [0.23-­‐3.79]	   9.33	  ×	  10-­‐01	  
Insulator	   -­‐0.23	   0.09	   -­‐2.45	   0.80	  [0.66-­‐0.96]	   1.41	  ×	  10-­‐02	  
Repetitive/CNV	  (distal)	   -­‐0.33	   0.50	   -­‐0.66	   0.72	  [0.27-­‐1.92]	   5.12	  ×	  10-­‐01	  
Enhancers	  (sequence)	   0.77	   0.23	   3.37	   2.16	  [1.38-­‐3.37]	   7.41	  ×	  10-­‐04	  
Intronic	  SNPs	   0.04	   0.06	   0.76	   1.04	  [0.94-­‐1.16]	   4.45	  ×	  10-­‐01	  
vega	  PseudoGenes	   -­‐0.16	   0.12	   -­‐1.32	   0.86	  [0.68-­‐1.08]	   1.88	  ×	  10-­‐01	  
28	  specs.	  algmt.	   0.30	   0.05	   5.81	   1.35	  [1.22-­‐1.50]	   6.35	  ×	  10-­‐09	  
Non.Syn.	  SNPs	  (UCSC)	   0.16	   0.08	   2.03	   1.17	  [1.01-­‐1.36]	   4.23	  ×	  10-­‐02	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5.3.4.3 Cancer	  SNPs	  
The	   results	   for	   the	   stepwise	   logistic	   regression	   of	   Cancer	   SNPs	   are	   shown	   in	  
Figure	  5-­‐9	  and	  are	  also	  presented	   in	  Table	  5-­‐9.	  The	  Final	  Model	   in	   the	  Cancer	  
SNPs	   was	   used	   to	   analyse	   the	   Non-­‐cancer	   SNPs	   (see	   Table	   5-­‐10).	   A	  
heterogeneous	   disease	   would	   be	   unlikely	   to	   have	   similar	   pathways	   to	   a	  
phenotype.	  Since	  cancer	   is	  a	  very	  heterogeneous	  disease	  classification	  and	  the	  
Cancer	  SNP	  set	   contained	  a	   small	  number	  of	  associated	  SNPs	   (268	  SNPs),	   any	  
result	  would	  have	  been	  encouraging.	  Despite	  these	  problems,	  we	  have	  obtained	  
15	  annotations	   influencing	  cancer	  association,	   five	  of	  which	  were	  significantly	  
different	   between	   Cancer	   and	   Non-­‐cancer	   SNPs:	   Exons,	   conserved	   regions	   in	  
primates	   in	   a	   44	   species	   alignment,	   coding	   SNPs,	   weak	   enhancers	   (proximal)	  
regions,	   and	   intronic	   SNPs.	   The	   Cancer	   SNPs	   had	   a	   higher	   odds	   ratio	   in	   the	  
conserved	  regions	  and	  weak	  enhancers	  than	  the	  Non-­‐cancer	  SNPs	  suggesting	  a	  
more	  important	  role	  of	  conserved	  regions	  in	  cancer	  aetiology.	  While	  the	  exons	  
are	   significantly	   more	   enriched	   for	   Cancer	   SNPs	   than	   Non-­‐cancer	   SNPs,	   the	  
coding	   SNPs	   and	   the	   introns	   are	   significantly	   depleted	   for	   Cancer	   SNPs.	   This	  
seems	  contradictory,	  but	   it	   is	  not	  since	  the	  annotations	  were	  analysed	  relative	  
to	  each	  other.	  The	  McKelvey	  and	  Zavoina’s	  pseudo-­‐r2	  value	  for	  the	  Final	  Model	  
of	   the	   Cancer	   SNPs	   was	   0.41,	   which	   meant	   that	   the	   included	   genomic	  
annotations	   improved	   the	   Base	  model	   (base	  model:	   0.20).	   The	  McKelvey	   and	  
Zavoina’s	  pseudo-­‐r2	  value	  for	  the	  Base	  model	  of	  the	  Non-­‐cancer	  SNPs	  was	  0.11	  
and	  for	  the	  full	  model	  was	  0.37.	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Figure	  5-­12	  –	  Cancer	  SNPs	  vs.	  Non-­cancer	  SNPs	  
Odds	  ratios	  for	  all	  genomic	  annotations	   in	  the	  Cancer	  SNPs	  model	  sorted	  after	  significance.	  Cancer	  
SNPs	  are	  shown	  as	  	  and	  Non-­‐cancer	  SNPs	  are	  shown	  as	  .	  Solid	  symbols	  indicate	  significance	  at	  P-­‐
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Table	  5-­9	  –	  Stepwise	  logistic	  regression	  results	  for	  Cancer	  SNPs	  	  
The	  results	  for	  the	  multivariate	  model	  using	  the	  Cancer	  SNPs	  are	  shown	  below.	  The	  table	  presents	  
the	   estimate	   of	   the	   effect,	   its	   standard	   error,	   the	  β-­‐coefficient,	   the	   calculated	   odds	   ratio	  with	   its	  
confidence	   interval,	   and	   the	   P-­‐value	   of	   the	   estimate	   in	   the	   final	   model	   for	   each	   of	   the	   included	  
genomic	  annotations	  in	  the	  final	  model.	  Significant	  P-­‐values	  in	  bold.	  	  
Annotation	   Estimate	   Std.	  Error	   β 	   OR	  [LCI-­‐HCI]	   P-­‐value	  
Intercept	   -­‐10.44	   0.19	   -­‐55.11	   0.00	  [0.00-­‐0.00]	   0.00	  ×	  10+00	  
Affymetrix_250k_Nsp	   0.24	   0.41	   0.58	   1.27	  [0.57-­‐2.82]	   5.60	  ×	  10-­‐01	  
Affymetrix_250k_Sty	   0.57	   0.38	   1.51	   1.77	  [0.84-­‐3.74]	   1.32	  ×	  10-­‐01	  
Affymetrix_5.0	   -­‐0.07	   0.37	   -­‐0.19	   0.93	  [0.45-­‐1.94]	   8.52	  ×	  10-­‐01	  
Affymetrix_6.0	   0.50	   0.18	   2.85	   1.65	  [1.17-­‐2.32]	   4.41	  ×	  10-­‐03	  
Affymetrix_10k	   1.45	   0.79	   1.83	   4.25	  [0.90-­‐20.03]	   6.72	  ×	  10-­‐02	  
Affymetrix_50k.1	   0.04	   0.33	   0.11	   1.04	  [0.55-­‐1.96]	   9.13	  ×	  10-­‐01	  
Affymetrix_50k.2	   -­‐1.52	   0.65	   -­‐2.35	   0.22	  [0.06-­‐0.78]	   1.86	  ×	  10-­‐02	  
Illumina_300	   1.38	   0.20	   6.76	   3.99	  [2.67-­‐5.96]	   1.35	  ×	  10-­‐11	  
Illumina_550	   1.55	   0.57	   2.73	   4.69	  [1.55-­‐14.24]	   6.35	  ×	  10-­‐03	  
Illumina_650	   -­‐0.08	   0.54	   -­‐0.15	   0.92	  [0.32-­‐2.65]	   8.78	  ×	  10-­‐01	  
Perlegen	   0.26	   0.14	   1.78	   1.29	  [0.98-­‐1.71]	   7.43	  ×	  10-­‐02	  
Distance	  to	  TSS	   0.00	   0.00	   -­‐4.29	   1.00	  [1.00-­‐1.00]	   1.75	  ×	  10-­‐05	  
44	  specs.	  algmt.	  primates	   0.60	   0.16	   3.78	   1.82	  [1.33-­‐2.48]	   1.57	  ×	  10-­‐04	  
DNase	  Clusters	   0.48	   0.14	   3.54	   1.62	  [1.24-­‐2.11]	   3.97	  ×	  10-­‐04	  
Closed	  Chromatin	   -­‐0.41	   0.15	   -­‐2.76	   0.66	  [0.49-­‐0.89]	   5.74	  ×	  10-­‐03	  
Poised	  Promoter	   1.13	   0.39	   2.88	   3.08	  [1.43-­‐6.62]	   3.94	  ×	  10-­‐03	  
Weak	  Enhancer	  (proximal)	   0.54	   0.20	   2.77	   1.72	  [1.17-­‐2.53]	   5.54	  ×	  10-­‐03	  
eQTLs	   0.49	   0.19	   2.66	   1.64	  [1.14-­‐2.35]	   7.74	  ×	  10-­‐03	  
Intronic	  SNPs	   -­‐0.31	   0.13	   -­‐2.34	   0.73	  [0.56-­‐0.95]	   1.92	  ×	  10-­‐02	  
Gained	  Stops	   2.06	   0.73	   2.83	   7.82	  [1.88-­‐32.47]	   4.63	  ×	  10-­‐03	  
PREMOD	   0.39	   0.17	   2.24	   1.48	  [1.05-­‐2.08]	   2.50	  ×	  10-­‐02	  
Heterochrom/lo	   -­‐0.30	   0.14	   -­‐2.09	   0.74	  [0.56-­‐0.98]	   3.67	  ×	  10-­‐02	  
Exons	   1.08	   0.26	   4.20	   2.95	  [1.78-­‐4.89]	   2.64	  ×	  10-­‐05	  
Coding	  SNPs	  (UCSC)	   -­‐0.89	   0.28	   -­‐3.16	   0.41	  [0.24-­‐0.71]	   1.58	  ×	  10-­‐03	  
Weak	  Promoter	   -­‐0.55	   0.29	   -­‐1.87	   0.58	  [0.32-­‐1.03]	   6.17	  ×	  10-­‐02	  
3’UTR	   -­‐0.43	   0.26	   -­‐1.62	   0.65	  [0.39-­‐1.09]	   1.04	  ×	  10-­‐01	  
Exapted	  Repeats	   -­‐12.08	   245.23	   -­‐0.05	   0.00	  [0.00-­‐3.13	  ×	  10+203]	   9.61	  ×	  10-­‐01	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Table	  5-­10	  –	  Stepwise	  logistic	  regression	  results	  for	  Non-­cancer	  SNPs	  	  
The	   results	   for	   the	   multivariate	   model	   using	   the	   Non-­‐cancer	   SNPs	   are	   shown	   below.	   The	   table	  
presents	   the	  estimate	  of	   the	  effect,	   its	   standard	  error,	   the	  β-­‐coefficient,	   the	   calculated	  odds	   ratio	  
with	   its	   confidence	   interval,	   and	   the	   P-­‐value	   of	   the	   estimate	   in	   the	   final	   model	   for	   each	   of	   the	  
included	  genomic	  annotations	  in	  the	  final	  model.	  Significant	  P-­‐values	  in	  bold.	  
Annotation	   Estimate	   Std.	  Error	   β 	   OR	  [LCI-­‐HCI]	   P-­‐value	  
Intercept	   -­‐7.54	   0.05	   -­‐141.53	   0.00	  [0.00-­‐0.00]	   0.00	  ×	  10+00	  
Affymetrix_250k_Nsp	   0.38	   0.13	   3.06	   1.47	  [1.15-­‐1.88]	   2.21	  ×	  10-­‐03	  
Affymetrix_250k_Sty	   0.38	   0.12	   3.11	   1.46	  [1.15-­‐1.85]	   1.88	  ×	  10-­‐03	  
Affymetrix_5.0	   0.05	   0.12	   0.43	   1.05	  [0.83-­‐1.33]	   6.67	  ×	  10-­‐01	  
Affymetrix_6.0	   0.35	   0.06	   6.22	   1.41	  [1.27-­‐1.58]	   4.87	  ×	  10-­‐10	  
Affymetrix_10k	   0.48	   0.26	   1.81	   1.61	  [0.96-­‐2.69]	   7.06	  ×	  10-­‐02	  
Affymetrix_50k.1	   -­‐0.08	   0.12	   -­‐0.68	   0.92	  [0.72-­‐1.17]	   4.98	  ×	  10-­‐01	  
Affymetrix_50k.2	   -­‐0.06	   0.13	   -­‐0.51	   0.94	  [0.73-­‐1.20]	   6.08	  ×	  10-­‐01	  
Illumina_300	   0.59	   0.06	   9.83	   1.81	  [1.61-­‐2.03]	   8.01	  ×	  10-­‐23	  
Illumina_550	   0.93	   0.14	   6.82	   2.54	  [1.94-­‐3.31]	   9.34	  ×	  10-­‐12	  
Illumina_650	   0.23	   0.13	   1.81	   1.26	  [0.98-­‐1.63]	   6.97	  ×	  10-­‐02	  
Perlegen	   0.27	   0.05	   5.89	   1.31	  [1.20-­‐1.43]	   3.75	  ×	  10-­‐09	  
Distance	  to	  TSS	   0.00	   0.00	   -­‐15.98	   1.00	  [1.00-­‐1.00]	   1.69	  ×	  10-­‐57	  
44	  specs.	  algmt.	  primates	   0.14	   0.05	   2.84	   1.15	  [1.05-­‐1.27]	   4.47	  ×	  10-­‐03	  
DNase	  Clusters	   0.46	   0.04	   11.20	   1.58	  [1.46-­‐1.71]	   3.88	  ×	  10-­‐29	  
Closed	  Chromatin	   -­‐0.45	   0.05	   -­‐9.98	   0.64	  [0.58-­‐0.70]	   1.79	  ×	  10-­‐23	  
Poised	  Promoter	   0.59	   0.15	   3.96	   1.80	  [1.34-­‐2.40]	   7.57	  ×	  10-­‐05	  
Weak	  Enhancer	  (proximal)	   -­‐0.14	   0.07	   -­‐2.09	   0.87	  [0.76-­‐0.99]	   3.62	  ×	  10-­‐02	  
eQTLs	   0.79	   0.05	   15.45	   2.21	  [2.00-­‐2.45]	   8.12	  ×	  10-­‐54	  
Intronic	  SNPs	   0.03	   0.04	   0.77	   1.03	  [0.95-­‐1.12]	   4.43	  ×	  10-­‐01	  
Gained	  Stops	   1.14	   0.28	   4.02	   3.12	  [1.79-­‐5.43]	   5.92	  ×	  10-­‐05	  
PREMOD	   0.17	   0.06	   2.98	   1.18	  [1.06-­‐1.32]	   2.89	  ×	  10-­‐03	  
Heterochrom/lo	   -­‐0.18	   0.04	   -­‐4.17	   0.84	  [0.77-­‐0.91]	   3.03	  ×	  10-­‐05	  
Exons	   0.48	   0.08	   5.88	   1.62	  [1.38-­‐1.91]	   4.16	  ×	  10-­‐09	  
Coding	  SNPs	  (UCSC)	   0.07	   0.08	   0.89	   1.08	  [0.92-­‐1.26]	   3.73	  ×	  10-­‐01	  
Weak	  Promoter	   -­‐0.02	   0.07	   -­‐0.24	   0.98	  [0.85-­‐1.13]	   8.10	  ×	  10-­‐01	  
3’UTR	   -­‐0.03	   0.07	   -­‐0.43	   0.97	  [0.84-­‐1.11]	   6.70	  ×	  10-­‐01	  
Exapted	  Repeats	   0.48	   0.28	   1.70	   1.61	  [0.93-­‐2.79]	   8.98	  ×	  10-­‐02	  
	  
5.3.4.4 Normal	  Variation	  SNPs	  vs.	  Disease	  SNPs	  
Another	   partitioning	   of	   the	   Significant	   SNPs	   (2013)	  was	   undertaken	   to	   divide	  
the	  total	  number	  of	  significantly	  trait-­‐associated	  SNPs	  into	  SNPs	  associated	  with	  
Normal	  Variation	   traits	   (see	  page	  211)	  and	  Disease	   traits	   (see	  page	  218).	  The	  
comparison	   between	   SNPs	   associated	   with	   Normal	   Variation	   traits,	   such	   as	  
height,	  eye	  or	  hair	  colour,	  and	  SNPs	  associated	  with	  Diseases	  showed	  that	  there	  
was	   a	   common	   set	   of	   genomic	   annotations	   that	   influenced	   trait-­‐association	  
status.	  The	  results	  of	  the	  Final	  Model	  for	  the	  Normal	  Variation	  SNPs	  are	  shown	  
in	  Table	  5-­‐11	  and	  the	  results	  for	  the	  Disease	  SNPs	  are	  listed	  in	  Table	  5-­‐12.	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Figure	  5-­‐13	  shows	  these	  common	  genomic	  annotations.	  The	  Disease	  SNPs	  were	  
significantly	  different	  to	  the	  Normal	  Variation	  SNPs	  in	  exons	  and	  3’UTRs.	  	  
	  
Figure	  5-­13	  –	  Normal	  Variation	  SNPs	  vs.	  Disease	  SNPs	  
Odds	   ratios	   for	   all	   common	   genomic	   annotations	   in	   the	  Disease	   SNPs	   and	  Normal	   Variation	   SNPs	  
models	   sorted	   after	   significance	   in	   the	  Disease	  model.	   Disease	   SNPs	   are	   shown	   as	  	   and	  Normal	  
Variation	  SNPs	  are	  shown	  as	  .	  Solid	  symbols	  indicate	  significance	  at	  P-­‐value	  ≤	  0.05.	  The	  red	  stars	  
()	  indicate	  significant	  differences	  between	  the	  two	  datasets.	  	  
	  
The	  McKelvey	  and	  Zavoina’s	  pseudo-­‐r2	  value	  for	  the	  final	  model	  determined	  for	  
the	  Normal	  Variation	  SNPs	  was	  0.38,	  while	  for	  the	  Base	  model	  it	  was	  0.08.	  The	  
Base	  model	  for	  the	  Disease	  SNPs	  had	  a	  McKelvey	  and	  Zavoina’s	  pseudo-­‐r2	  value	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Table	  5-­11	  –	  Stepwise	  logistic	  regression	  results	  for	  Normal	  Variation	  SNPs	  	  
The	  results	  for	  the	  multivariate	  model	  using	  the	  Normal	  Variation	  SNPs	  are	  shown	  below.	  The	  table	  
presents	   the	  estimate	  of	   the	  effect,	   its	   standard	  error,	   the	  β-­‐coefficient,	   the	   calculated	  odds	   ratio	  
with	   its	   confidence	   interval,	   and	   the	   P-­‐value	   of	   the	   estimate	   in	   the	   final	   model	   for	   each	   of	   the	  
included	  genomic	  annotations	  in	  the	  final	  model.	  Significant	  P-­‐values	  in	  bold.	  	  
Annotation	   Estimate	   Std.	  Error	   β 	   OR	  [LCI-­‐HCI]	   P-­‐value	  
Intercept	   -­‐8.67	   0.10	   -­‐88.45	   0.00	  [0.00-­‐0.00]	   0.00	  ×	  10+00	  
Affymetrix_250k_Nsp	   0.34	   0.19	   1.78	   1.40	  [0.97-­‐2.03]	   7.52	  ×	  10-­‐02	  
Affymetrix_250k_Sty	   0.18	   0.19	   0.97	   1.20	  [0.83-­‐1.72]	   3.33	  ×	  10-­‐01	  
Affymetrix_5.0	   0.06	   0.18	   0.33	   1.06	  [0.75-­‐1.51]	   7.41	  ×	  10-­‐01	  
Affymetrix_6.0	   0.34	   0.08	   4.16	   1.40	  [1.20-­‐1.65]	   3.14	  ×	  10-­‐05	  
Affymetrix_10k	   0.92	   0.34	   2.71	   2.50	  [1.29-­‐4.85]	   6.63	  ×	  10-­‐03	  
Affymetrix_50k.1	   0.09	   0.18	   0.50	   1.09	  [0.77-­‐1.54]	   6.19	  ×	  10-­‐01	  
Affymetrix_50k.2	   -­‐0.13	   0.20	   -­‐0.65	   0.88	  [0.60-­‐1.29]	   5.16	  ×	  10-­‐01	  
Illumina_300	   0.45	   0.09	   4.83	   1.56	  [1.30-­‐1.88]	   1.34	  ×	  10-­‐06	  
Illumina_550	   0.68	   0.19	   3.60	   1.98	  [1.36-­‐2.87]	   3.21	  ×	  10-­‐04	  
Illumina_650	   0.26	   0.18	   1.46	   1.29	  [0.92-­‐1.83]	   1.45	  ×	  10-­‐01	  
Perlegen	   0.39	   0.07	   5.91	   1.48	  [1.30-­‐1.68]	   3.44	  ×	  10-­‐09	  
Distance	  to	  TSS	   0.00	   0.00	   -­‐10.19	   1.00	  [1.00-­‐1.00]	   2.09	  ×	  10-­‐24	  
Exons	   0.70	   0.10	   7.28	   2.02	  [1.67-­‐2.44]	   3.27	  ×	  10-­‐13	  
eQTLs	   0.69	   0.08	   8.57	   1.99	  [1.70-­‐2.33]	   1.02	  ×	  10-­‐17	  
Open	  Chromatin	   0.49	   0.07	   7.32	   1.63	  [1.43-­‐1.86]	   2.44	  ×	  10-­‐13	  
DNase	  Clusters	   0.36	   0.06	   5.85	   1.43	  [1.27-­‐1.61]	   4.79	  ×	  10-­‐09	  
44	  specs.	  algmt.	   0.47	   0.13	   3.68	   1.59	  [1.24-­‐2.04]	   2.35	  ×	  10-­‐04	  
RNA	  Genes	   -­‐12.19	   104.08	   -­‐0.12	   0.00	  [0.00-­‐2.00	  ×	  10+83]	   9.07	  ×	  10-­‐01	  
Syn.	  SNPs	  (UCSC)	   -­‐0.45	   0.12	   -­‐3.72	   0.64	  [0.50-­‐0.81]	   1.99	  ×	  10-­‐04	  
Intergenic	  SNPs	   -­‐0.16	   0.06	   -­‐2.59	   0.85	  [0.75-­‐0.96]	   9.74	  ×	  10-­‐03	  
Txn	  Elongation	   -­‐0.26	   0.09	   -­‐2.99	   0.77	  [0.65-­‐0.91]	   2.76	  ×	  10-­‐03	  
5	  Kb	  TSS	   0.40	   0.08	   4.77	   1.50	  [1.27-­‐1.76]	   1.82	  ×	  10-­‐06	  
1	  Kb	  TSS	   -­‐0.32	   0.12	   -­‐2.59	   0.73	  [0.57-­‐0.93]	   9.72	  ×	  10-­‐03	  
Indels	  Pure	  regions	   0.16	   0.07	   2.26	   1.18	  [1.02-­‐1.35]	   2.37	  ×	  10-­‐02	  
Weak	  Enhancer	  (proximal)	   -­‐0.24	   0.11	   -­‐2.27	   0.79	  [0.64-­‐0.97]	   2.34	  ×	  10-­‐02	  
Repressed	   0.16	   0.08	   1.98	   1.17	  [1.00-­‐1.37]	   4.77	  ×	  10-­‐02	  
3’UTR	   -­‐0.26	   0.11	   -­‐2.40	   0.77	  [0.62-­‐0.95]	   1.65	  ×	  10-­‐02	  
Insulator	   -­‐0.30	   0.13	   -­‐2.27	   0.74	  [0.57-­‐0.96]	   2.31	  ×	  10-­‐02	  
ORegAnno	   0.25	   0.13	   1.90	   1.29	  [0.99-­‐1.68]	   5.69	  ×	  10-­‐02	  
44	  specs.	  algmt.	  primates	   0.19	   0.09	   2.24	   1.21	  [1.02-­‐1.44	   2.54	  ×	  10-­‐02	  
44	  specs.	  algmt.	  plac.	  mmls	   -­‐0.22	   0.13	   -­‐1.70	   0.81	  [0.63-­‐1.03]	   8.91	  ×	  10-­‐02	  
5’UTR	   -­‐0.34	   0.19	   -­‐1.80	   0.71	  [0.49-­‐1.03]	   7.19	  ×	  10-­‐02	  
CpG	  Islands	   0.34	   0.14	   2.47	   1.40	  [1.07-­‐1.83]	   1.37	  ×	  10-­‐02	  
Active	  Promoter	   -­‐0.27	   0.13	   -­‐2.03	   0.76	  [0.59-­‐0.99	   4.27	  ×	  10-­‐02	  
Enhancers	  (sequence)	   0.57	   0.34	   1.67	   1.76	  [0.91-­‐3.42]	   9.47	  ×	  10-­‐02	  
Splice	  Sites	   -­‐12.41	   258.30	   -­‐0.05	   0.00	  [0.00-­‐3.02	  ×	  10+214]	   9.62	  ×	  10-­‐01	  
Heterochrom/lo	   -­‐0.11	   0.07	   -­‐1.65	   0.89	  [0.78-­‐1.02]	   9.98	  ×	  10-­‐02	  
17	  specs.	  algmt.	   -­‐0.15	   0.09	   -­‐1.65	   0.86	  [0.71-­‐1.03]	   9.87	  ×	  10-­‐02	  
PREMOD	   0.14	   0.09	   1.64	   1.15	  [0.97-­‐1.36]	   1.01	  ×	  10-­‐01	  
vega	  Genes	   0.09	   0.06	   1.44	   1.09	  [0.97-­‐1.23]	   1.50	  ×	  10-­‐01	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Table	  5-­12	  –	  Stepwise	  logistic	  regression	  results	  for	  Disease	  SNPs	  	  
The	  results	  for	  the	  multivariate	  model	  using	  the	  Disease	  SNPs	  are	  shown	  below.	  The	  table	  presents	  
the	   estimate	   of	   the	   effect,	   its	   standard	   error,	   the	  β-­‐coefficient,	   the	   calculated	   odds	   ratio	  with	   its	  
confidence	   interval,	   and	   the	   P-­‐value	   of	   the	   estimate	   in	   the	   final	   model	   for	   each	   of	   the	   included	  
genomic	  annotations	  in	  the	  final	  model.	  Significant	  P-­‐values	  in	  bold.	  	  
Annotation	   Estimate	   Std.	  Error	   β 	   OR	  [LCI-­‐HCI]	   P-­‐value	  
Intercept	   -­‐9.03	   0.10	   -­‐89.78	   0.00	  [0.00-­‐0.00]	   0.00	  ×	  10+00	  
Affymetrix_250k_Nsp	   0.36	   0.18	   2.01	   1.44	  [1.01-­‐2.05]	   4.49	  ×	  10-­‐02	  
Affymetrix_250k_Sty	   0.55	   0.17	   3.22	   1.74	  [1.24-­‐2.43]	   1.27	  ×	  10-­‐03	  
Affymetrix_5.0	   0.02	   0.17	   0.15	   1.03	  [0.74-­‐1.42]	   8.82	  ×	  10-­‐01	  
Affymetrix_6.0	   0.43	   0.08	   5.18	   1.53	  [1.30-­‐1.80]	   2.24	  ×	  10-­‐07	  
Affymetrix_10k	   0.44	   0.41	   1.09	   1.56	  [0.70-­‐3.46]	   2.75	  ×	  10-­‐01	  
Affymetrix_50k.1	   -­‐0.36	   0.20	   -­‐1.81	   0.70	  [0.47-­‐1.03]	   7.06	  ×	  10-­‐02	  
Affymetrix_50k.2	   -­‐0.25	   0.19	   -­‐1.31	   0.78	  [0.53-­‐1.13]	   1.90	  ×	  10-­‐01	  
Illumina_300	   0.77	   0.09	   8.69	   2.15	  [1.81-­‐2.55]	   3.59	  ×	  10-­‐18	  
Illumina_550	   1.18	   0.22	   5.38	   3.26	  [2.12-­‐5.01]	   7.52	  ×	  10-­‐08	  
Illumina_650	   0.12	   0.21	   0.59	   1.13	  [0.75-­‐1.71]	   5.53	  ×	  10-­‐01	  
Perlegen	   0.20	   0.07	   3.05	   1.23	  [1.08-­‐1.40]	   2.33	  ×	  10-­‐03	  
Distance	  to	  TSS	   0.00	   0.00	   -­‐9.51	   1.00	  [1.00-­‐1.00]	   1.88	  ×	  10-­‐21	  
eQTLs	   0.84	   0.08	   10.99	   2.33	  [2.00-­‐2.71]	   4.50	  ×	  10-­‐28	  
DNase	  Clusters	   0.41	   0.06	   6.40	   1.50	  [1.33-­‐1.70]	   1.55	  ×	  10-­‐10	  
Open	  Chromatin	   0.48	   0.07	   6.72	   1.62	  [1.41-­‐1.87]	   1.84	  ×	  10-­‐11	  
Exons	   0.37	   0.12	   3.06	   1.44	  [1.14-­‐1.82]	   2.22	  ×	  10-­‐03	  
Strong	  Enhancer	  (proximal)	   0.48	   0.09	   5.12	   1.61	  [1.34-­‐1.94]	   3.00	  ×	  10-­‐07	  
44	  specs.	  algmt.	  primates	   0.29	   0.09	   3.31	   1.33	  [1.12-­‐1.58]	   9.30	  ×	  10-­‐04	  
Syn.	  SNPs	  (UCSC)	   -­‐0.61	   0.13	   -­‐4.71	   0.54	  [0.42-­‐0.70]	   2.48	  ×	  10-­‐06	  
Gained	  Stops	   1.65	   0.33	   4.96	   5.23	  [2.72-­‐10.05]	   6.93	  ×	  10-­‐07	  
Repressed	   0.27	   0.08	   3.43	   1.31	  [1.12-­‐1.53]	   6.11	  ×	  10-­‐04	  
Heterochrom/lo	   -­‐0.29	   0.07	   -­‐4.39	   0.75	  [0.66-­‐0.85]	   1.15	  ×	  10-­‐05	  
Txn	  Elongation	   -­‐0.29	   0.09	   -­‐3.28	   0.75	  [0.63-­‐0.89]	   1.05	  ×	  10-­‐03	  
5	  Kb	  TSS	   0.28	   0.08	   3.55	   1.32	  [1.13-­‐1.53]	   3.85	  ×	  10-­‐04	  
Insulator	   -­‐0.40	   0.13	   -­‐2.99	   0.67	  [0.52-­‐0.87]	   2.76	  ×	  10-­‐03	  
vega	  Genes	   0.21	   0.06	   3.42	   1.23	  [1.09-­‐1.39]	   6.33	  ×	  10-­‐04	  
Pos.	  Sel.	  Genes	   -­‐0.22	   0.07	   -­‐3.24	   0.80	  [0.70-­‐0.92]	   1.18	  ×	  10-­‐03	  
Coding	  SNPs	  (UCSC)	   0.37	   0.13	   2.92	   1.45	  [1.13-­‐1.86]	   3.51	  ×	  10-­‐03	  
Weak	  Enhancer	  (distal)	   0.20	   0.08	   2.55	   1.22	  [1.05-­‐1.41]	   1.09	  ×	  10-­‐02	  
Insulators	  (sequence)	   -­‐0.22	   0.11	   -­‐2.04	   0.80	  [0.64-­‐0.99]	   4.10	  ×	  10-­‐02	  
3’UTR	   0.21	   0.10	   2.01	   1.23	  [1.01-­‐1.50]	   4.42	  ×	  10-­‐02	  
28	  specs.	  algmt.	  plac.	  mmls	   0.31	   0.13	   2.42	   1.36	  [1.06-­‐1.74]	   1.56	  ×	  10-­‐02	  
28	  specs.	  algmt.	   -­‐0.23	   0.12	   -­‐1.97	   0.79	  [0.63-­‐1.00]	   4.91	  ×	  10-­‐02	  
Active	  Promoter	   -­‐0.22	   0.11	   -­‐1.97	   0.80	  [0.64-­‐1.00]	   4.89	  ×	  10-­‐02	  
PREMOD	   0.15	   0.09	   1.79	   1.17	  [0.99-­‐1.38]	   7.28	  ×	  10-­‐02	  
Splice	  Sites	   -­‐11.53	   149.85	   -­‐0.08	   0.00	  [0.00-­‐3.55	  ×	  10+122]	   9.39	  ×	  10-­‐01	  
Exapted	  Repeats	   0.67	   0.36	   1.87	   1.95	  [0.97-­‐3.94]	   6.18	  ×	  10-­‐02	  
Enhancers	  (sequence)	   0.61	   0.34	   1.81	   1.85	  [0.95-­‐3.59]	   7.01	  ×	  10-­‐02	  
Weak	  Enhancer	  (proximal)	   -­‐0.17	   0.10	   -­‐1.67	   0.85	  [0.69-­‐1.03]	   9.55	  ×	  10-­‐02	  
Microsatellites	   -­‐10.65	   109.66	   -­‐0.10	   0.00	  [0.00-­‐5.27	  ×	  10+88]	   9.23	  ×	  10-­‐01	  
TS	  miRNA	   0.90	   0.52	   1.72	   2.47	  [0.88-­‐6.90]	   8.52	  ×	  10-­‐02	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5.3.5 Pseudo-­‐r2	  values	  
As	  mentioned	  in	  the	  methods	  section	  of	  this	  chapter,	  we	  used	  the	  McKelvey	  and	  
Zavoina’s	  pseudo-­‐r2	  value.	  The	  McKelvey	  and	  Zavoina’s	  pseudo-­‐r2	  value	  has	  two	  
interpretations:	  the	  first	  and	  third	  approach	  of	  the	  linear	  regression	  r2	  outlined	  
in	   the	   methods	   section	   of	   this	   chapter	   [150,	   151,	   153].	   First,	   it	   can	   be	  
understood	  as	   the	  proportion	  of	  variance	  explained	  by	  a	  model.	   It	   can	  also	  be	  
seen	  as	  a	  square	  of	  the	  correlation	  between	  the	  model’s	  predicted	  values	  for	  the	  
dependent	  variable	  and	  its	  actual	  values.	  The	  dataset	  with	  the	  highest	  pseudo-­‐r2	  
value	  was	   the	   Immune	  SNPs	  with	  a	  value	  of	  0.45.	  The	  base	  models	  containing	  
only	   the	   genotyping	   arrays	   ranged	   between	   0.08	   and	   0.20	   depending	   on	   the	  
dataset	  under	  investigation.	  	  
	  
	  
Table	  5-­13	  –	  McKelvey	  and	  Zavoina’s	  pseudo-­r2	  values	  for	  different	  SNP	  sets	  
This	  table	  presents	  the	  McKelvey	  and	  Zavoina’s	  pseudo-­‐r2	  values	  calculated	  for	  the	  different	  logistic	  
regression	  models	  calculated	  for	  the	  Base	  model	  containing	  only	  the	  genotyping	  arrays	  (Genotyping	  
arrays	  only)	  and	  the	  Final	  Model,	  which	  was	  returned	  as	  the	  final	  model	  (Final	  model).	  
Dataset	   Genotyping	  arrays	  only	   Final	  model	  
Significant	  SNPs	  (2011)	   0.14	   0.42	  
Suggestive	  SNPs	  (2011)	   0.16	   0.18	  
Significant	  SNPs	  (Difference)	   0.12	   0.31	  
Significant	  SNPs	  (2013)	   0.12	   0.36	  
Immune	  SNPs	  	   0.18	   0.45	  
Non-­‐immune	  SNPs	  	   0.11	   0.35	  
Cancer	  SNPs	  	   0.20	   0.41	  
Non-­‐cancer	  SNPs	   0.11	   0.37	  
Normal	  Variation	  SNPs	  	   0.08	   0.38	  
Disease	  SNPs	   0.14	   0.39	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5.4 Discussion	  
In	   this	   chapter	   we	   analysed	   univariate	   and	   multivariate	   logistic	   regression	  
models	   to	   analyse	   the	   distribution	   of	   trait-­‐associated	   variants.	   We	   analysed	  
eight	   different	   datasets,	   which	   consisted	   of	   two	   thresholds	   of	   significance,	   a	  
more	   recent	   set	   of	   trait-­‐associated	   variants	   and	   the	   analysis	   of	   trait-­‐specific	  
subsets.	   The	   multivariate	   analysis	   obtained	   different	   models	   for	   the	   trait-­‐
subsets,	  which	  allowed	  the	  trait-­‐specific	  conclusions.	  	  
	  
The	   univariate	   regression	   was	   performed	   to	   allow	   comparisons	   between	   the	  
sampling	  and	  permutation	  methods,	  which	  could	  be	  called	  univariate	  analyses	  
as	   they	   were	   analysing	   individual	   annotations.	   The	   analysis	   of	   the	   univariate	  
regression	   returned	   odds	   ratios	   and	   standard	   errors,	   which	   were	   not	  
significantly	   different	   to	   the	   results	   returned	   by	   the	   permutations.	   This	  
suggested	   that	   univariate	   logistic	   regression	   might	   be	   a	   useful	   method	   of	  
analysing	   individual	   annotations,	   as	   they	   were	   performed	   significantly	   faster	  
(one	  day	  for	  100	  samples	  vs.	  three	  days	  for	  20,000	  permutations	  vs.	  two	  hours	  
for	  the	  univariate	  regression).	  	  
	  
The	   iterative	   stepwise	   logistic	   regression	   approach	   in-­‐	   or	   excluded	   genomic	  
annotations	   according	   to	   the	   information	   they	   added	   to	   the	   model.	   This	   was	  
calculated	  as	  the	  Akaike’s	  Information	  Criterion	  (AIC),	  which	  was	  defined	  in	  the	  
Methods	  (see	  page	  102).	  Once	  a	  genomic	  annotation	  was	  included,	  it	  could	  have	  
a	  positive	  or	  negative	  influence	  on	  trait-­‐association	  status,	  which	  was	  indicative	  
of	   enrichment	   for	   or	   depletion	   of	   trait-­‐associated	   variants,	   respectively.	  
Genomic	   annotations	  with	   100%	  overlap	   or	   non-­‐overlap	  with	   trait-­‐associated	  
SNPs	  were	  deemed	  more	  influential	  or	  informative	  than	  those	  annotations	  that	  
occurred	  with	  trait-­‐associated	  variants	  only	  50%	  of	  the	  time.	  	  
	  
The	   stepwise	   logistic	   regression	   of	   the	   multivariate	   model	   was	   performed	   in	  
order	   to	   remove	   the	   redundant	   information	   and	   balanced	   the	   information	  
carried	   by	   each	   genomic	   annotation	   against	   the	   included	   number	   of	   genomic	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annotations.	  The	  model	  showed	  the	  relative	  influence	  of	  the	  annotations	  to	  each	  
other,	   once	   all	   other	   genomic	   annotations	   and	   genotyping	   arrays	   were	   taken	  
into	  account.	  This	   can	   clearly	  be	   seen	   in	  Figure	  5-­‐3	  and	  Table	  5-­‐2,	  where	   five	  
genomic	   annotations	  were	   significantly	   depleted,	   which	  were	   enriched	   in	   the	  
individual	   annotation	   analyses.	   Four	   of	   these	   (transcriptional	   elongation,	  
synonymous	   SNPs,	   active	   promoters,	   and	   5’UTRs)	  were	   enriched	   in	   all	   of	   the	  
methods	   analysing	   the	   genomic	   annotations	   individually.	   These	   four	  
annotations,	  which	  were	  depleted	   in	   the	  multivariate	  model,	  are	  all	  coinciding	  
with	  or	  are	  close	  to	  coding	  regions	  of	  the	  genome	  and	  could	  be	  overlapping	  with	  
the	   distance	   to	   TSS	   annotation.	   The	   coding	   regions	   are	   possibly	  
overrepresented	  in	  the	  analysis	  as	  the	  majority	  of	  the	  genomic	  annotations	  are	  
annotating	  genes	  or	  genic	  regions,	  while	  only	  1.5%	  of	  the	  genome	  is	  thought	  to	  
be	   coding.	  However,	   since	   there	   is	   a	  bias	   in	   the	  ascertainment	  of	   the	  genomic	  
annotation	   there	   is,	  as	  previously	  discussed,	  also	  a	  bias	   in	   the	   inclusion	  of	   the	  
SNPs	   on	   the	   genotyping	   arrays	   with	   clear	   preferences	   towards	   the	   coding	  
regions	  of	  the	  genome.	  It	  is	  also	  possible	  that	  the	  univariate	  methods	  overstated	  
the	   importance	   of	   the	   analysed	   genomic	   annotation,	   as	   the	   influences	   of	   the	  
other	   genomic	   annotations	   were	   not	   taken	   into	   account	   in	   the	   analysis.	   The	  
latter	   is	   a	   more	   plausible	   explanation	   since	   the	   majority	   of	   the	   genomic	  
annotations	   are	   not	   mutually	   exclusive	   and	   therefore	   share	   some	   of	   the	  
information.	   These	   results	   were	   therefore	   not	   contradictory	   to	   previous	  
findings	   but	   did	   highlight	   the	   necessity	   of	   analysing	   the	   genomic	   annotations	  
together	   to	   add	   extra	   information	   into	   the	  model.	   A	   possible	   improvement	   to	  
this	  model	  could	  be	  to	  analyse	  each	  individual	  annotation	  after	  the	  genotyping	  
arrays	  were	  included	  in	  the	  model	  as	  a	  single	  variate	  combining	  the	  information	  
carried	   by	   all	   genotyping	   arrays.	   Alternatively,	   an	   analysis	   of	   the	   genomic	  
annotations	  without	   the	  distance	   to	  TSS	   could	  be	  performed	   to	   investigate	   its	  
effect	   on	   these	   annotations.	  This	  was	  not	  done,	   as	  we	  wanted	   to	   compare	   the	  
univariate	  analyses	  to	  each	  other	  and	  neither	  the	  permutation	  nor	  the	  sampling	  
method	  allowed	  that	  particular	  step.	  However,	   it	  would	  add	  an	  additional	  step	  
into	   the	   comparison	   process	   of	   univariate	   and	   multiple	   variate	   analyses	   and	  
could	  be	  performed	  in	  future	  studies.	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The	   results	   for	   the	   trait-­‐associated	   SNPs	   with	   P-­values	   that	   did	   not	   pass	   the	  
genome-­‐wide	   significance	   threshold	   (Suggestive	   SNPs	   (2011))	   were	   very	  
comparable	  to	  the	  results	  for	  the	  significantly	  trait-­‐associated	  SNPs.	  The	  results	  
were	   therefore	  consistent	  with	   the	  hypothesis	   that	   the	  dataset	  of	   suggestively	  
trait-­‐associated	  SNPs	  was	  a	  mixture	  of	   false	  positives	  and	  real	   trait-­‐associated	  
SNPs.	  The	  real	  trait-­‐associations	  were,	  however,	  not	  of	  sufficient	  magnitude	  to	  
reach	  significance	  at	  the	  genome-­‐wide	  level.	  These	  real	  trait-­‐associated	  variants	  
would	  be	  expected	  to	  have	  the	  same	  bias	   towards	  particular	  genomic	   features	  
as	   the	   significantly	   trait-­‐associated	   variants	   [65].	   False	   positives,	   however,	  
would	   be	   expected	   to	   have	   a	   similar	   genomic	   annotation	   profile	   as	   non-­‐
associated	  variants.	  
	  
GWAS	   identify	  many	   trait-­‐associated	   variants	  with	   different	   P-­values	   of	   trait-­‐
association,	  many	  of	  which	  do	  not	  pass	  the	  genome-­‐wide	  significance	  threshold.	  
It	   is	   therefore	   expected,	   that	   for	   every	   reported	   suggestive	   SNP	   there	   were	  
many	   more	   that	   were	   not	   reported,	   since	   the	   general	   assumption	   is	   that	  
suggestive	  associations	  provided	  less	  information	  on	  the	  trait.	  Additionally,	  the	  
NHGRI	   catalogue	   reported	   genome-­‐wide	   studies	   associations	  with	   association	  
P-­values	  starting	  from	  5	  ×	  10-­‐5	  while	  the	  more	  commonly	  accepted	  P-­value	  for	  
suggestively	  associated	  SNPs	  started	  at	  5	  ×	  10-­‐4	   [36,	  85].	  The	  Significant	  SNPs	  
(2011)	  were	  therefore	  a	  more	  comprehensive	  dataset,	  despite	  it	  being	  smaller,	  
and	   the	   conclusions	   drawn	   from	   its	   results	   were	   thus	   expected	   to	   be	   more	  
informative.	   However,	   the	   similarity	   of	   enrichment	   and	   depletion	   trends	  
between	  Significant	  SNPs	  (2011)	  and	  Suggestive	  SNPs	  (2011)	  were	  encouraging	  
and	  may	  aid	   further	  research	  aimed	  at	   identifying	  true	  positives.	  The	  genomic	  
annotations,	   which	   were	   shown	   to	   be	   important	   for	   significant	   associations	  
could	  be	  used	   to	   calculate	   a	   prior	   probability	   of	   trait-­‐association.	  Operatively,	  
this	  in	  turn	  could	  be	  used	  to	  adjust	  the	  P-­value	  of	  suggestive	  SNPs,	  which	  could	  
lead	  to	  more	  SNPs	  that	  pass	  the	  chosen	  significance	  threshold.	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The	  newly	  included	  annotation	  of	  distance	  to	  TSS	  was	  quantitative,	  rather	  than	  
binary	  and	  including	  the	  annotation	  explained	  an	  additional	  20%,	  as	  judged	  by	  
the	  McKelvey	  and	  Zavoina’s	  pseudo-­‐r2,	  of	   the	  observed	  variation	   in	  Significant	  
SNPs	   (2011).	  While	   the	   new	   final	  model,	   obtained	   after	   including	   distance	   to	  
TSS,	   did	   include	   four	   additional	   annotations	   only	   one	   of	   them	  was	   significant	  
and	  they	  did	  not	  contribute	  greatly	  to	  the	  pseudo-­‐r2	  value.	   It	   is	   likely,	   that	   the	  
model	   included	   more	   annotations,	   as	   the	   distance	   to	   TSS	   annotation	   added	  
noise,	   as	   well	   as	   signal.	   This	   meant	   that	   including	   the	   additional	   genomic	  
annotations	  further	  aided	  in	  explaining	  the	  observed	  variation.	  	  
5.4.1 Immune	  SNPs	  vs.	  Non-­‐immune	  SNPs	  
The	  aim	  of	  the	  comparison	  of	  Immune	  vs.	  Non-­‐Immune	  SNPs	  was	  to	   identify	  a	  
set	   of	   genomic	   annotations	   that	   were	   significantly	   different	   between	   the	   two	  
datasets,	   thereby	   allowing	   the	   drawing	   of	   immune	   specific	   conclusions.	   We	  
compared	   the	   Final	  Model	   obtained	   for	   the	   Immune	   SNPs	  with	   the	   estimates	  
obtained	   for	   the	  Non-­‐immune	   SNPs	  using	   the	   same	  genomic	   annotations.	   The	  
odds	  ratios	  obtained	  for	  the	  two	  datasets	  differed	  in	  many	  genomic	  annotations,	  
but	  the	  most	  striking	  was	  for	  the	  positively	  selected	  genes.	  These	  genic	  regions	  
were	   high-­‐confidence	   orthologues	   in	   a	   multi-­‐species	   alignment	   [115],	   which	  
were	   then	   tested	   for	   positive	   selection	   [115].	   However,	   as	   mentioned	   in	   the	  
Methods	   section,	   these	   regions	  were	  not	   restricted	  according	   to	   their	  positive	  
selection	   score,	   so	   that	   the	   regions	   analysed	   here	   highlight	   highly	   conserved	  
regions.	   They	  were	   larger	   than	   the	   other	   conserved	   elements	   included	   in	   the	  
analyses	   and	   also	   included	   pseudo	   genes	   and	   were	   significantly	   depleted	   for	  
Immune	  SNPs.	  Depletion	  in	  conserved	  sites	  was	  shown	  by	  the	  significant	  odds	  
ratios	  observed	   in	   the	   conserved	   regions	   identified	   in	   a	  28	   species	   alignment.	  
The	  conserved	  transcription	  factor	  binding	  sites	  were	  significantly	  depleted	  for	  
Immune	   SNPs	   and	   significantly	   different	   from	   the	   Non-­‐immune	   SNPs.	   The	  
depletion	   in	   these	   conserved	   sites	   corroborated	   the	   observed	   significant	  
depletion	   in	   the	   positively	   selected	   genes.	   It	   is	   assumed	   that	   they	   have	   an	  
important	   function	   in	   the	   cell	   so	   they	  were	   conserved	   over	   time	   [64],	   so	   that	  
their	  disruption	  would	  likely	  be	  deleterious.	  The	  eQTLs	  were	  significantly	  more	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enriched	   for	   Immune	   SNPs	   than	   Non-­‐immune	   SNPs,	   which	   could	   highlight	  
potential	   involvement	   of	   eQTLs	   in	   the	   immune	   response.	   A	   recent	   study	  
discovered	  that	  both	  cis-­	  and	  trans-­eQTLs	  were	  involved	  in	  newly	  identified	  cell-­‐
type	   specific	   networks	   in	   the	   pathogenesis	   of	   autoimmune	   diseases	   [155].	  
However,	   it	   has	   generally	   been	   accepted	   that	   all	   trait-­‐associated	   SNPs	   were	  
more	   likely	   to	   be	   eQTLs,	   and	   the	   enrichment	   in	   the	   Non-­‐immune	   SNPs	   was	  
therefore	   not	   surprising	   [110].	   The	   significant	   difference	   in	   depletion	   in	   the	  
closed	   chromatin	   annotations	   was	   also	   reasonable,	   if	   not	   expected,	   as	   the	  
annotation	  was	  obtained	  from	  a	  lymphoblastoid	  cell	  line	  [126].	  It	  was	  therefore	  
encouraging	   to	   see	   that	   Immune	   SNPs	   were	   depleted	   in	   chromatin	   states	  
associated	   with	   closed	   and	   not	   transcribed	   genes	   in	   a	   cell	   line	   co-­‐ordinating	  
immune	   response.	   The	   same	   reasoning	   is	   true	   for	   the	   Heterochromatin/low	  
transcription	   regions,	  which	  were	  obtained	   from	  a	   lymphoblastoid	   cell	   after	   a	  
comparison	  of	  nine	  different	  cell	  lines.	  	  
5.4.2 Cancer	  SNPs	  vs.	  Non-­‐cancer	  SNPs	  	  
Since	  only	  268	  SNPs	  were	  associated	  to	  cancers,	  a	  very	  heterogeneous	  disease	  
classification	   in	   itself,	   the	   identification	   of	   any	   genomic	   annotations	   that	  
significantly	  influence	  association	  status	  would	  be	  surprising	  and	  encouraging.	  
When	  the	  results	  of	  the	  regression	  model	  for	  the	  Cancer	  associated	  SNPs	  were	  
compared	   to	   the	   results	   for	   the	   Non-­‐cancer	   SNPs,	   five	   genomic	   annotations	  
were	   significantly	   different	   between	   the	   two	   sets.	   Exons,	   conserved	   sites	   in	  
primates,	   weak	   enhancers	   (proximal)	   were	   significantly	   more	   enriched	   in	  
Cancer	   SNPs	   than	  Non-­‐cancer	   SNPs	  while	   coding	   SNPs	   and	   intronic	   SNPs	  had	  
lower	   odds	   ratios	   for	   Cancer	   SNPs.	   As	   mentioned	   before,	   a	   disruption	   in	  
conserved	  sites	  is	  likely	  to	  be	  deleterious.	  	  
	  
The	  results	  for	  the	  Cancer	  SNPs	  showed	  significant	  enrichment	  in	  the	  exons,	  but	  
significant	  depletion	  in	  the	  coding	  and	  intronic	  SNPs.	  As	  mentioned	  before,	  the	  
stepwise	   logistic	   regression	   approach	   analysed	   the	   genomic	   annotations	   in	  
relation	  with	  each	  other,	  which	  explains	  results,	  which	  may	  seem	  contradictory	  
at	  first	  glance.	  While	  exons	  are	  enriched	  in	  comparison	  with	  the	  other	  genomic	  
	   143	  
annotations,	   coding	   SNPs	  were	   significantly	   depleted	   in	   comparison	  when	   all	  
other	   genomic	   annotations	   were	   taken	   into	   account.	   The	   weak	   enhancer	  
annotation	   was	   significantly	   enriched	   for	   Cancer	   SNPs	   and	   significantly	  
depleted	   for	   Non-­‐cancer	   SNPs.	   This	   genomic	   annotation	   was	   identified	   as	  
regions	   with	   a	   distinct	   combination	   of	   histone	   modifications	   that	   were	  
repeatedly	   associated	  with	   enhancer	   regions	   across	   nine	   different	   human	   cell	  
lines	   [82].	   The	  method	   identified	   four	   different	   states	   of	   enhancers	   that	  were	  
divided	   according	   to	   the	   strength	   of	   their	   gene	   regulation	   and	   the	   observed	  
distance	   between	   enhancers	   and	   the	   expressed	   genes.	   While	   the	   distance	  
between	   the	   enhancers	   and	   the	   genes	   did	   not	   change	   between	   cell	   lines,	   the	  
strength	   of	   the	   regulations	   did	   [82].	   The	   enhancers	   analysed	   here	  were	  weak	  
enhancers	   in	   the	   GM12878	   lymphoblastoid	   cell	   line,	   but	   could	   be	   strong	  
enhancers	   in	   a	   different	   cell	   line.	   The	   analysis	   therefore	   indicates	   that	   Cancer	  
SNPs	  could	  lie	  within	  strong	  enhancers.	  
5.4.3 Normal	  Variation	  SNPs	  vs.	  Disease	  SNPs	  	  
We	   identified	   the	   genomic	   annotations	   influential	   on	   the	   association	   status	   of	  
SNPs	   associated	   with	   normal	   variation	   traits	   and	   compared	   them	   with	   the	  
genomic	   annotations	   that	  were	   identified	   as	   important	   for	   disease-­‐associated	  
SNPs.	  The	  comparison	  highlighted	  that	  there	  were	  19	  genomic	  annotations	  that	  
were	  influential	  for	  both	  datasets,	  but	  two	  had	  significantly	  different	  impact	  on	  
trait-­‐association	  status.	  The	  exons	  had	  a	  significantly	  higher	  impact	  on	  the	  SNPs	  
associated	   with	   normal	   variation	   than	   with	   diseases.	   The	   3’UTRs	   were	  
significantly	   depleted	   for	   the	   Normal	   Variation	   SNPs,	   while	   they	   were	  
significantly	  enriched	  for	  the	  Disease	  SNPs.	  The	  other	  17	  annotations	  had	  odds	  
ratios	   that	   were	   very	   similar	   between	   the	   two	   SNP	   categories.	   The	   common	  
annotations	  significant	  for	  both	  categories	  showed	  that	  there	  are	  some	  common	  
underlying	   biological	   mechanisms	   for	   the	   disease-­‐	   and	   the	   normal	   variation-­‐
associated	  SNPs.	  
5.4.4 Pseudo-­‐r2	  values	  
The	  McKelvey	  and	  Zavoina’s	  pseudo-­‐r2	   value	  was	  designed	   to	  be	  analogous	  of	  
two	  interpretations	  of	  the	  traditional	  r2	  value	  obtained	  by	  linear	  regression.	  The	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full	   models	   varied	   between	   18-­‐42%	   of	   explained	   variability,	   while	   the	   base	  
models	   containing	   only	   the	   genotyping	   arrays	   varied	   between	  11-­‐20%.	  These	  
values	  may	  have	  been	  higher	  if	  validated	  trait-­‐causing	  mutations	  were	  analysed.	  
Although	   the	   false	   positive	   rate	   has	   decreased	   since	   multiple	   stage	   testing	  
approaches	  have	  been	  implemented	  [156]	  and	  meta-­‐analyses	  are	  continuously	  
being	  performed	  to	  analyse	  trait-­‐association	  across	  different	  arrays	  and	  studies	  
[57,	  63,	  144,	  157,	  158],	  false	  positives	  may	  still	  exist	  in	  the	  trait-­‐associated	  SNP	  
datasets.	   Additionally,	   false	   negatives	   will	   undoubtedly	   be	   included	   in	   the	  
background	   data.	   False	   negatives	   occur	   when	   a	   study	   does	   not	   have	   the	  
required	  sample	  size	   to	  detect	  variants	  with	  modest	  effects	   that	  did	  not	  reach	  
the	  genome-­‐wide	  significance	  threshold	  [32,	  58].	  As	  in	  any	  analysis,	  this	  lack	  of	  
information	   about	   true	   associations	   will	   have	   impacted	   the	   results,	   although	  
there	  is	  no	  way	  of	  knowing	  how	  much	  and	  how	  the	  results	  would	  have	  differed	  
if	   there	   was	   a	   clear	   separation	   between	   true	   and	   false	   positives.	   There	   is	  
additionally	   an	   imbalance	   of	   non-­‐associated	   SNPs	   vs.	   trait-­‐associated	   SNPs	  
(~3.5	  million	  vs.	  a	   few	  hundreds	  or	   thousands).	  This	  disproportionate	  amount	  
of	  non-­‐associated	  variants	  will	  have	  skewed	  the	  results	  of	  logistic	  regression	  to	  
be	  better	  at	  explaining	  non-­‐associated	  than	  associated	  data.	  	  
5.4.5 Method	  discussion	  and	  future	  work	  
The	   logistic	   regression	   method	   is	   highly	   affected	   by	   co-­‐linearity	   of	   the	  
independent	   variables,	   as	   it	   is	   assumed	   that	   the	   included	   variables	   are	  
independent	  from	  each	  other.	  If	  complete	  co-­‐linearity	  of	  variables/annotations	  
occurred	  in	  the	  analyses,	  an	  error	  was	  printed	  and	  the	  analysis	  stopped.	  While	  
co-­‐linearity	  could	  have	  occurred	  at	  certain	  instances,	  only	  some	  of	  the	  genomic	  
annotations	   would	   be	   perfectly	   correlated	   with	   each	   other.	   An	   example	   of	  
almost	   perfect	   co-­‐linearity	   would	   be	   the	   position	   of	   genes	   downloaded	   from	  
more	  than	  one	  database.	  While	  the	  databases	  would	  have	  some	  differences,	  the	  
majority	  of	  the	  covered	  bases	  by	  the	  annotated	  genes	  would	  overlap	  with	  each	  
other.	  It	  was	  therefore	  prudent	  to	  remove	  one	  set	  of	  genes	  from	  the	  multivariate	  
analyses,	   which	   we	   did	   by	   excluding	   all	   genes	   from	   the	   OMIM	   database.	   For	  
future	   studies	   it	   could	   be	  worthwhile	   to	   assess	   the	   partial	   co-­‐linearity	   of	   the	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annotations	  by	  possibly	  by	   looking	  at	  a	  similarity	  matrix	  between	  annotations	  
or	   analysing	   the	   correlation	   between	   annotations	   using	   a	   Spearman’s	   rho	  
correlation.	  The	  gained	  values	  could	  be	  used	  as	  a	  threshold	  for	  the	  inclusion	  of	  
genomic	   annotations	   in	   the	   experimental	   model,	   i.e.,	   into	   the	   analysis	   itself.	  
Alternatively,	  the	  stability	  of	  the	  final	  multivariate	  models	  could	  be	  assessed	  by	  
cross-­‐validation.	  With	  respect	  to	  univariate	  models	  it	  must	  be	  remembered	  that	  
the	  variance	  explained	  in	  univariate	  analyses	  will	  not	  be	  additive	  in	  multivariate	  
analyses.	  
The	   genotyping	   arrays	  were	   included	   as	   independent	   factors	   rather	   than	   one	  
single	  co-­‐variate.	  If	  there	  has	  been	  an	  annotation	  bias	  in	  the	  selection	  of	  variants	  
on	  an	  array	  i.e.	  non-­‐synonymous	  SNPs,	  this	  could	  have	  given	  certain	  genotyping	  
arrays	   an	   erroneously	   inflated	   weight	   thereby	   decreasing	   the	   effect	   of	   any	  
included	   genomic	   annotation.	   A	   genotyping	   array	   that	   could	   have	   potentially	  
have	  been	  affected	  by	  this	  is	  the	  Ilumina	  300	  array	  given	  the	  biased	  selection	  of	  
variants.	  Fitting	   the	  number	  of	  genotyping	  arrays	  containing	  a	  particular	  SNP,	  
rather	   than	   each	   array	   individually,	  may	   allow	   for	   the	   correction	   for	  multiple	  
testing	  without	  biasing	  the	  annotation.	  This	  is	  also	  a	  possible	  step	  that	  could	  be	  
taken	  in	  future	  analyses.	  	  
The	  results	  from	  the	  trait-­‐subset	  analyses	  could	  possibly	  be	  used	  to	  guide	  study	  
designs	  on	  a	  trait	  class	  basis,	  where	  the	  results	  of	  GWAS	  analysing	  certain	  trait-­‐
categories	  would	  be	  analysed	  differently	  or	   the	  SNPs	  selection	  biased	  towards	  
those	   annotations	   types	   of	   annotation	   enrich	   in	   immune	   versus	   non-­‐immune	  
traits	  for	  example.	  The	  follow	  up	  of	  GWAS	  results	  could	  be	  guided	  according	  to	  
the	  importance	  of	  the	  genomic	  annotations	  from	  the	  different	  subsets,	  as	  it	  was	  
shown	   that	   Immune-­‐associated	   SNPs	   have	   a	   completely	   different	   genomic	  
signature	  than,	  e.g.,	  Cancer	  SNPs.	  While	  these	  analyses	  are	  great	  for	  the	  analysis	  
of	   future	   GWAS,	   it	   is	   unclear	   if	   they	   could	   guide	   next	   generation	   sequencing	  
studies.	  It	  is	  potentially	  possible	  to	  guide	  whole	  genome	  sequencing	  studies,	  but	  
it	  is	  less	  likely	  that	  this	  could	  guide	  exome	  studies.	  The	  results	  presented	  in	  this	  
thesis	  do	  include	  genomic	  areas	  outside	  of	  coding	  regions,	  so	  for	  the	  results	  to	  
be	   valid	   in	   exome	   sequencing	   studies	   it	   would	   be	   recommended	   to	   perform	  
additional	  logistic	  regression	  analyses	  with	  only	  coding	  areas.	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6 APPLICATION	  OF	  METHODS	  TO	  OTHER	  DATA	  
6.1 Introduction	  	  
As	  the	  permutation	  and	  stepwise	  regression	  methods	  have	  produced	  promising	  
results,	   which	   confirmed	   previous	   study	   results	   and	   were	   intuitive	   with	  
enrichment	   and	   depletion	   in	   expected	   genomic	   regions,	   we	   investigated	   the	  
applicability	  of	  our	  methods	  to	  two	  different	  datasets.	  The	  dataset	  used	  for	  the	  
permutation	  analysis	  was	  a	  set	  of	  SNPs	  associated	  to	  gene	  expression	  levels	  in	  
the	   Stockholm	   atherosclerosis	   gene	   expression	   study	   (STAGE)	   [83],	   which	  
investigated	   gene	   expression	   levels	   in	   seven	   tissues	   of	   a	   cohort	   of	  
cardiovascular	   disease	   patients.	   RNA	   was	   extracted	   from	   tissue	   biopsies	   of	  
skeletal	   muscle,	   atherosclerotic	   arterial	   wall,	   internal	   mammary	   artery,	   liver,	  
subcutaneous	  and	  visceral	  fat,	  and	  whole	  blood	  in	  147	  patients.	  The	  result	  of	  the	  
study	  was	  the	  identification	  of	  several	  thousand	  SNPs	  associated	  with	  changing	  
levels	   of	   gene	   expression	   in	   the	   different	   tissues.	   We	   analysed	   significant	  
associations,	   i.e.,	   SNPs	   with	   a	   P-­value	   that	   were	   below	   the	   genome-­‐wide	  
significance	   threshold.	   Experiments	   validating	   the	   effect	   on	   gene	   expression	  
were	  not	  performed,	  so	  they	  are	  only	  suspected	  to	  be	  eQTLs	  and	  were	  therefore	  
termed	   eSNPs.	   The	   investigation	   of	   the	   distribution	   of	   these	   eSNPs	   was	   an	  
opportunity	   to	   use	   different	   datasets	   for	   the	   permutation	   analysis,	   as	  well	   as	  
providing	   a	   thorough	   examination	   of	   the	   genomic	   distribution	   of	   potential	  
eQTLs.	  The	  analysis	  of	  a	  SNP	  set	  originating	  from	  a	  single	  study	  meant	  that	  the	  
background	   distribution	   was	   not	   as	   heterogeneous	   and	   taking	   account	   of	  
different	  genotyping	  platforms	  was	  no	  longer	  needed.	  In	  previous	  permutation	  
analyses	  (see	  Chapter	  4)	  we	  strived	  to	  analyse	  the	  entire	  background	  of	  SNPs,	  
which	   were	   analysed	   for	   trait-­‐association.	   Using	   just	   one	   study	   allowed	   the	  
creation	   of	   a	   background	   consisting	   of	   all	   SNPs	   tested	   for	   association	   to	   gene	  
expression	   levels.	   The	   background	   distribution	   for	   the	   eSNPs	   was	   therefore	  
changed	   accordingly	   for	   the	   analysis.	   The	   aim	   of	   the	   investigation	   was	   to	  
identify	   differences	   between	   the	   distributions	   of	   GWAS	   hits	   and	   eSNPs.	  
Furthermore,	   differences	   between	   tissue-­‐specific	   eSNPs	   and	   eSNPs	   shared	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across	   different	   tissues	  were	   also	   investigated.	   If	   the	   results	   show	   significant	  
differences	  in	  enrichment/depletion	  patterns	  between	  GWAS	  hits	  and	  eSNPs,	  it	  
could	   imply	   that	   GWAS	   hits	   and	   eSNPs	   affect	   different	   pathways	   leading	   to	  
phenotypes.	  	  
	  
We	  additionally	  wanted	  to	  apply	  a	  regression	  model	  to	  test	  the	  effect	  of	  using	  a	  
continuous	   distribution	   of	   P-­values	   rather	   than	   an	   artificially	   created	   binary	  
variable	   for	   trait-­‐association	   status.	   The	   use	   of	   a	   continuous	   distribution	  
allowed	  the	  analysis	  of	  all	  association	  P-­values.	  This	  included	  more	  information	  
than	  the	  analysis	  of	  a	  binary	  variable,	  as	  all	  SNPs	  had	  a	  value	  associated	  with	  it,	  
informing	  on	  more	  SNPs.	  For	  this	  analysis	  we	  used	  the	  P-­values	  obtained	  by	  a	  
meta-­‐analysis	   investigating	  the	  genetic	  components	  of	  height	  published	  by	  the	  
Genetic	  Investigation	  of	  Anthropometric	  Traits	  (GIANT)	  consortium	  [57].	  The	  P-­‐
values	   were	   used	   rather	   than	   the	   effect	   sizes,	   which	   might	   have	   been	   more	  
informative,	  as	  these	  were	  not	  available	  at	  the	  time	  when	  the	  GIANT	  data	  was	  
downloaded.	   This	   meta-­‐analysis	   combined	   a	   total	   of	   61	   studies	   investigating	  
height	  in	  different	  populations	  providing	  an	  in-­‐depth	  analysis	  of	  the	  underlying	  
genetic	   factors	   of	   height.	   Since	   a	   continuous	   variable	   was	   used,	   we	   applied	  
linear	  rather	  than	  logistic	  regression.	  	  
6.2 Methods	  
6.2.1 STAGE	  eSNPs	  
A	  total	  of	  109	  patients	  rather	  than	  147	  patients	  had	  sufficient	  DNA,	  so	  the	  final	  
set	   of	   analysed	   individuals	   was	   109.	   For	   the	   analyses	   of	   the	   eSNPs	   data	   the	  
background	  distribution	  was	  the	  intersection	  of	  the	  SNPs	  present	  in	  the	  dataset	  
used	  for	  the	  permutations	  and	  logistic	  regression	  in	  the	  previous	  chapters,	  and	  
the	  SNPs	  genotyped	  with	   the	  GenomeWideSNP_6	  Affymetrix	  array	  used	   in	   the	  
STAGE	  study	  that	  passed	  quality	  control.	  The	  intersection	  of	  these	  two	  datasets	  
was	   used	   to	   ensure	   that	   an	   appropriate	   background	   distribution	   was	   used,	  
against	  which	   the	   observed	   data	  was	   compared.	   The	   background	   distribution	  
had	  to	  consider	  all	   the	  SNPs,	  which	  were	  tested	  for	  an	  association	  to	  changing	  
gene	   expression	   levels.	   This	   meant	   that	   only	   the	   SNPs	   that	   passed	   quality	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control	  represented	  the	  background	  distribution.	  This	  set	  of	  background	  SNPs	  
was	  termed	  eSNP	  background	  and	  was	  used	  for	  all	  analyses	  and	  comparisons	  
that	  were	  performed	  for	  this	  dataset.	  	  
	  
In	  all	  analyses	  outlined	  below,	  the	  eSNPs	  with	  P-­values	  of	  association	  below	  the	  
genome-­‐wide	  significance	  threshold	  (P-­value	  ≤	  5	  ×	  10-­‐8)	  were	  coded	  as	  one,	  and	  
the	  non-­‐significant	  SNPs	  were	  coded	  as	  zero.	  All	  eSNPs	  were	  analysed	  with	  their	  
LD	  partners,	  i.e.,	  SNPs	  that	  were	  in	  linkage	  disequilibrium	  (LD;	  r2	  >	  0.9)	  with	  the	  
significantly	  associated	  eSNP.	  This	  was	  similar	  to	  the	  analysis	  of	  trait-­‐associated	  
SNPs	  in	  the	  previous	  chapters.	  The	  permutations,	  which	  were	  run	  to	  analyse	  the	  
distribution	  of	  eSNPs	   in	  58	  genomic	  annotations,	  were	  also	  performed	  20,000	  
times,	  like	  in	  the	  previous	  permutation	  analyses.	  The	  eSNPs	  were	  only	  analysed	  
on	   the	   autosomes,	   therefore	   disregarding	   the	   sex	   chromosomes.	   Table	   6-­‐1	  
shows	   a	   summary	   of	   the	   total	   number	   of	   analysed	   SNPs	   and	   the	   number	   of	  
significant	  eSNPs	  per	  chromosome.	  A	  two-­‐sample	  two-­‐sided	  t-­‐test	  (see	  page	  37	  
of	  this	  thesis),	  assuming	  unequal	  variances,	  was	  employed	  to	  test	  for	  significant	  
differences	   between	   the	   obtained	   odds	   ratios	   in	   the	   enrichment/depletion	  
permutation	  analysis.	  The	  P-­value	  was	  only	  judged	  as	  significant	  if	  it	  passed	  the	  
Bonferroni	   corrected	   significance	   threshold,	   which	   took	   the	   58	   analysed	  
annotations	  into	  account.	  
	  
Two	  comparisons	  of	  different	  SNP	  sets	  were	  carried	  out	  for	  the	  eSNPs	  dataset.	  
The	   first	   comparison	   analysed	   differences	   between	   the	   distributions	   in	   the	  
genome	  of	  significant	  eSNPs	  and	  GWAS	  hits.	  The	  GWAS	  hits	  used	  in	  this	  analysis	  
were	   downloaded	   from	   the	  NHGRI	  GWAS	   catalogue	   on	   4th	  October	   2012.	   The	  
data	   contained	   969	   GWAS	   hits	   which	   were	   analysed	   like	   the	   trait-­‐associated	  
GWAS	   hits	   in	   Chapter	   4	   with	   the	   exception	   of	   a	   different	   background	  
distribution.	   The	   number	   of	   significant	   eSNPs	   was	   29,530,	   but	   26,546	   eSNPs	  
were	  available	  in	  the	  previously	  compiled	  background	  of	  SNPs,	  due	  to	  changes	  
in	  rs	  numbers.	  The	  26,546	  eSNPs	  were	  compared	  to	  969	  GWAS	  hits.	  GWAS	  hits	  
and	  eSNPs	  were	  analysed	  with	  LD	  partners	  (r2	  >	  0.9).	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Table	  6-­1	  –	  Distribution	  of	  SNPs	  and	  eSNPs	  across	  chromosomes	  
The	  number	  of	   SNPs	  and	  different	  eSNP	  datasets	  were	   summarised	  across	   chromosomes.	   The	   sex	  
chromosomes	  were	  not	  analysed	  in	  this	  study.	  	  
Chromosome	  
Total	  Number	  of	  
SNPs	  
Number	  of	  eSNPs	  




Chr1	   36875	   2553	   588	   1965	  
Chr2	   29481	   2234	   478	   1756	  
Chr3	   33959	   1471	   379	   1092	  
Chr4	   28865	   1275	   210	   1065	  
Chr5	   31715	   1586	   384	   1202	  
Chr6	   31819	   2377	   820	   1557	  
Chr7	   26617	   1153	   217	   936	  
Chr8	   27845	   1138	   232	   906	  
Chr9	   22608	   1038	   238	   800	  
Chr10	   26671	   1392	   426	   966	  
Chr11	   24446	   1663	   498	   1165	  
Chr12	   23956	   1456	   367	   1089	  
Chr13	   18000	   652	   156	   496	  
Chr14	   15402	   851	   147	   704	  
Chr15	   14780	   884	   230	   654	  
Chr16	   15008	   855	   213	   642	  
Chr17	   11064	   999	   303	   696	  
Chr18	   14504	   450	   88	   362	  
Chr19	   6349	   944	   296	   648	  
Chr20	   12902	   576	   143	   433	  
Chr21	   6575	   470	   124	   346	  
Chr22	   6135	   529	   163	   366	  
	  
The	   second	   set	   of	   comparisons	   was	   performed	   to	   investigate	   differences	  
between	   shared	   and	   tissue-­‐specific	   eSNPs,	   in	   terms	   of	   distribution	   across	  
annotations.	  The	   tissue-­‐specific	   eSNPs	  were	   significantly	   associated	  with	  gene	  
expression	   in	   only	   one	   tissue,	   while	   the	   shared	   eSNPs	   were	   significantly	  
affecting	  gene	  expression	   in	  at	   least	   two	   tissues.	  Of	   the	   total	  of	  26,546	  eSNPs,	  
6,700	  were	   identified	  as	   shared	  eSNPs	  and	  19,846	  were	   tissue-­‐specific	  eSNPs.	  
All	   analyses	  were	   performed,	   as	  mentioned	   above,	   with	   20,000	   permutations	  
and	  the	  eSNP	  background.	  	  
6.2.2 GIANT	  SNPs	  	  
The	   Genetic	   Investigation	   of	   Anthropometric	   Traits	   (GIANT)	   consortium	  
performed	  a	  meta-­‐analysis	  on	   three	  different	  human	  traits	   (height,	  body	  mass	  
index,	  and	  body	  mass	  index	  adjusted	  for	  hip	  to	  waist	  ratio.	  Here,	  we	  have	  only	  
investigated	   the	   data	   analysed	   for	   association	   to	   height.	   The	   height	   meta-­‐
analysis	   applied	   two	   stages	   of	   testing	   and	   an	   additional	   family-­‐based	   analysis	  
investigating	  SNPs	   for	  an	  association	  with	  height.	  The	   first	   stage	  combined	  46	  
	   150	  
studies,	   which	   in	   total	   consisted	   of	   133,653	   individuals	   of	   recent	   European	  
ancestry.	  The	  meta-­‐analysis	  was	  performed	  by	  imputing	  2,834,208	  SNPs	  using	  
the	   HapMap	   CEU	   II	   reference	   population.	   The	   second	   stage	   analysed	   an	  
additional	   50,074	   individuals	   from	   15	   further	   studies,	   which	   allowed	   the	  
replication	   of	   180	   of	   207	   previously	   significantly	   associated	   genetic	   loci	   [57].	  
The	   association	   data	   are	   publicly	   available	   and	   contained	   information	   on	   the	  
SNP	  name,	  the	  alleles	  of	  the	  SNP,	  and	  the	  frequency	  of	  the	  trait-­‐increasing	  allele	  
in	   the	   HapMap	   CEU	   II	   population	   (Link	   at	   which	   the	   data	   is	   available:	  
http://www.broadinstitute.org/collaboration/giant/index.php/GIANT_consorti
um_data_files).	   Additionally,	   it	   listed	   the	  P-­value	   of	   association	   obtained	   after	  
the	   performed	   meta-­‐analysis	   and	   after	   the	   results	   were	   corrected	   for	   an	  
inflation	   of	   test	   statistics	   using	   genomic	   control.	   It	   also	   listed	   the	   number	   of	  
times	  a	  SNP	  was	  observed	  within	  the	  population	  sample.	  	  
The	   previously	   established	   dataset	   used	   in	   the	   permutations	   and	   the	   logistic	  
regression	   analyses	   contained	   2,469,014	   SNPs	   of	   the	   total	   number	   of	   SNPs	  
tested	   for	   height-­‐association	   (2,834,208	   SNPs).	   A	   stepwise	   regression	   model	  
was	  employed	  to	  establish	  the	  most	  influential	  genomic	  annotations	  for	  height,	  
as	  measured	  by	  a	  reduction	  in	  the	  AIC	  value	  (see	  Methods	  chapter	  of	  this	  thesis	  
and	  Chapter	  5).	  However,	  the	  difference	  to	  the	  logistic	  regression	  employed	  in	  
Chapter	   5,	   is	   that	   here	   a	   linear	   regression	   was	   used,	   since	   the	   dependent	  
variable	   was	   the	   negative	   logarithm	   of	   the	   association	   P-­value	   instead	   of	   a	  
binary	   trait-­‐association	   status	   (trait-­‐associated	   or	   not).	   The	   analysed	   variable	  
was	   therefore	   continuous	   rather	   than	   binary,	   which	   meant	   that	   linear	  
regression	   rather	   than	   logistic	   regression	  was	   the	  appropriate	  method	   for	   the	  
analysis.	   As	   the	   dependent	   variable	  was	   continuous,	   the	   returned	   estimate	   of	  
any	   analysed	   annotation	   in	   the	  model	   is	   to	   be	   interpreted	   as	   explaining	   unit	  
changes	  in	  the	  negative	  logarithm	  of	  the	  P-­value,	  rather	  than	  determining	  trait-­‐
association	  status.	  Since	  linear	  regression	  was	  employed,	  pseudo-­‐r2	  values	  were	  
not	  calculated,	  but	  an	  r2	  value	  was	  extracted	  from	  the	  summary	  of	  the	  analyses.	  
The	  total	  number	  of	  analysed	  SNPs	  was	  2,469,014,	  as	  SNPs	  that	  were	  not	  in	  our	  
background	  data	  were	  excluded	  from	  the	  analyses.	  This	  ensured	  the	  selection	  of	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the	   appropriate	   background	   distribution,	   and	   that	   a	   SNP	  was	   compared	  with	  
only	  those	  SNPs	  that	  were	  tested	  for	  height-­‐association.	  	  
6.3 Results	  
6.3.1 STAGE	  eSNPs	  
The	  STAGE	  eSNPs	  were	  analysed	  in	  two	  different	  comparisons.	  The	  dataset	  was	  
analysed	   as	   a	   total	   set	   (All	   eSNPs)	   and	   compared	   to	   GWAS	   hits.	   The	   second	  
analysis	  was	  the	  partition	  of	  All	  eSNPs	  into	  two	  subsets	  according	  to	  the	  number	  
of	   tissues,	   in	  which	   the	   eSNPs	  were	   associated	   to	   changes	   in	   gene	   expression	  
levels;	  Shared	  eSNPs	  and	  Tissue-­‐specific	  eSNPs.	  	  
6.3.1.1 GWAS	  hits	  vs.	  All	  eSNPs	  
The	  results	  of	  the	  permutation	  analyses	  using	  the	  STAGE	  eSNPs	  were	  compared	  
to	   GWAS	   hits	   that	   were	   present	   on	   the	   same	   genotyping	   array	   as	   the	   SNPs	  
tested	  for	  gene	  expression.	  The	  results	  are	  shown	  in	  Figure	  6-­‐1,	  where	  a	  red	  star	  
indicates	  eight	  significant	  differences	  between	  GWAS	  hits	  and	  eSNPs.	  Table	  6-­‐2	  
and	  Table	  6-­‐3	  present	   the	  numerical	  results	   for	   the	  GWAS	  hits	  and	  the	  eSNPs,	  
respectively.	   The	   tables	   show	   the	   number	   of	   overlaps	   for	   each	   genomic	  
annotation	  with	  the	  observed	  data	  and	  the	  mean	  number	  of	  overlaps	  obtained	  
for	   the	   permuted	   data.	   They	   also	   show	   the	   calculated	   odds	   ratio	   and	   its	  
confidence	   interval	  as	  well	   as	   the	  obtained	  P-­value,	  which	  was	  determined	  by	  
the	   number	   of	   permutations	   that	   had	   the	   same	   or	   more	   extreme	   number	   of	  
overlaps	  as	  the	  observed	  data.	  	  
	  
The	  most	  important	  results	  of	  this	  comparison	  are	  the	  significant	  differences	  in	  
the	   eQTL	   annotation	   and	   the	   OMIM	   morbid	   regions,	   as	   these	   were	   the	   two	  
positive	   controls	   for	   the	   different	   datasets.	   The	   results	   in	   these	   annotations,	  
therefore,	  added	  confidence	  to	  the	  remaining	  results.	  The	  GWAS	  hits	  (OR	  =	  3.68	  
[2.71-­‐5.08])	   obtained	   an	   odds	   ratio	   that	   was	   twice	   as	   high	   as	   the	   odds	   ratio	  
obtained	   by	   the	   eSNPs	   (OR	   =	   1.99	   [1.70-­‐2.33])	   in	   the	   OMIM	  morbid	   regions.	  
While	  the	  enrichment	  pattern	  was	  the	  opposite	  in	  the	  eQTL	  annotation	  (OR	  for	  
GWAS	   hits	   =	   3.28	   [2.36-­‐4.50];	   OR	   for	   eSNPs	   =	   8.91	   [6.68-­‐10.36]).	   The	   overall	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results	   were	   that	   eSNPs	   showed	  more	   extreme	   and	   significant	   odds	   ratios	   of	  
enrichment	   than	   the	   GWAS	   hits.	   The	   only	   annotation,	  which	   had	   a	   significant	  
result	  for	  the	  GWAS	  hits,	  but	  not	  the	  eSNPs,	  was	  the	  heterochromatin/low	  state.	  
However,	  there	  were	  many	  examples	  of	  annotations,	  which	  were	  significant	  for	  
the	  eSNPs	  but	  not	  the	  GWAS	  hits.	  The	  mean	  of	  the	  odds	  ratios	  of	  All	  eSNPs	  was	  
2.64,	  while	  for	  GWAS	  hits	  it	  was	  2.01.	  The	  eight	  significant	  differences	  between	  
the	  eSNPs	  and	  the	  GWAS	  hits	  are	  in	  the	  1	  Kb	  and	  5	  Kb	  regions	  upstream	  of	  TSS,	  
the	   OMIM	  morbid	   regions,	   the	   intronic	   SNPs,	   the	   eQTL	   annotation,	   positively	  
selected	  genes,	  and	  regions	  associated	  with	  transcriptional	  elongation	  and	  weak	  
transcription.	   The	   three	   annotations,	   which	   had	   obtained	   the	   highest	   odds	  
ratios	   for	   All	   eSNPs	   besides	   eQTLs,	   1	   Kb	   upstream	   of	   TSS	   (OR	   =	   4.28	   [3.34-­‐
4.99]),	   5	   Kb	   upstream	   of	   TSS	   (OR	   =	   4.22	   [3.39-­‐4.75])	   and	   regions	   associated	  
with	   transcriptional	   elongation	   (OR	   =	   4.16	   [3.46-­‐4.71]).	   Splice	   sites	   and	  
microsatellites	  also	  obtained	  odds	  ratios	  with	  realistic	  confidence	  intervals	  (OR	  
for	   splice	   sites	   =	   2.94	   [1.41-­‐9.01];	   OR	   for	   microsatellites	   =	   0.94	   [0.51-­‐2.22]),	  
which	  was	  the	  first	  time	  for	  both	  of	  the	  annotations	  in	  any	  of	  the	  permutation	  
analyses.	  However,	  neither	  of	  the	  annotations	  passed	  the	  Bonferroni	  corrected	  
significance	  threshold	  and	  were	  not	  included	  on	  the	  graphs.	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Figure	  6-­1	  –	  Comparison	  of	  odds	  ratios	  obtained	  for	  GWAS	  hits	  and	  All	  eSNPs	  	  
A	   comparison	   of	   GWAS	   hits	   (n	   =	   969,	  )	   and	   All	   eSNPs	   (n	   =	   26,546,	  ).	   Solid	   symbols	   indicate	  
significance	  at	  multiple-­‐test	   corrected	  P-­‐value.	   Eight	   annotations	   are	   significantly	  different	   in	   their	  
enrichment	   patterns.	   Red	   stars	   ()	   indicate	   significant	   differences.	   All	   P-­‐values	   are	   corrected	   for	  
multiple	   testing	   for	   the	  analysed	  genomic	  annotations.	  Top:	  Genic	  and	   regulatory	   regions.	  Middle:	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Table	  6-­2	  –	  Permutation	  results	  for	  the	  GWAS	  hits	  for	  the	  comparison	  with	  All	  STAGE	  eSNPs	  
This	  table	  summarises	  results	  for	  the	  GWAS	  hits	  showing	  the	  number	  of	  overlaps	  in	  the	  observed	  set	  
(Real),	  the	  mean	  of	  the	  permuted	  hits	  (Permutation	  Mean),	  the	  calculated	  odds	  ratio	  and	  confidence	  
interval	  (OR	  [LCI-­‐HCI])	  and	  the	  P-­‐value	  for	  each	  of	  the	  annotations.	  Significant	  P-­‐values	  in	  bold.	  
Annotation	   Real	   Permutation	  Mean	   OR	  [LCI-­‐HCI]	   P-­‐value	  
1	  Kb	  TSS	   87	   42.55	   2.15	  [1.49-­‐3.20]	   1.00	  ×	  10-­‐04	  
5	  Kb	  TSS	   223	   108.82	   2.36	  [1.83-­‐3.07]	   <	  5.00	  ×	  10-­‐05	  
CpG	  Islands	   57	   20.17	   2.94	  [1.89-­‐5.44]	   5.00	  ×	  10-­‐05	  
ORegAnno	   43	   26.15	   1.67	  [1.14-­‐2.77]	   5.60	  ×	  10-­‐03	  
vega	  Genes	   515	   381.57	   1.75	  [1.49-­‐2.04]	   <	  5.00	  ×	  10-­‐05	  
OMIM	  genes	   533	   335.31	   2.31	  [1.93-­‐2.77]	   <	  5.00	  ×	  10-­‐05	  
OMIM	  morbid	  regions	   240	   79.56	   3.68	  [2.71-­‐5.08]	   <	  5.00	  ×	  10-­‐05	  
Exons	   219	   85.86	   3.00	  [2.30-­‐4.00]	   <	  5.00	  ×	  10-­‐05	  
Intronic	  SNPs	   599	   452.83	   1.85	  [1.56-­‐2.19]	   5.00	  ×	  10-­‐05	  
Non.Syn.	  SNPs	  (UCSC)	   121	   43.79	   3.01	  [2.20-­‐4.47]	   <	  5.00	  ×	  10-­‐05	  
Coding	  SNPs	  (UCSC)	   164	   69.11	   2.65	  [2.01-­‐3.59]	   <	  5.00	  ×	  10-­‐05	  
Syn.	  SNPs	  (UCSC)	   73	   37.98	   2.00	  [1.41-­‐3.08]	   1.50	  ×	  10-­‐04	  
Gained	  Stops	   3	   0.59	   5.14	  [1.00-­‐Infinity]	   3.37	  ×	  10-­‐02	  
3'UTR	   123	   47.59	   2.82	  [2.06-­‐4.12]	   <	  5.00	  ×	  10-­‐05	  
5'UTR	   24	   11.21	   2.17	  [1.27-­‐4.90]	   3.75	  ×	  10-­‐03	  
RNA	  Genes	   3	   2.94	   1.02	  [0.43-­‐Infinity]	   4.53	  ×	  10-­‐01	  
ncRNA	   15	   9.62	   1.57	  [0.79-­‐5.06]	   1.05	  ×	  10-­‐01	  
TS	  miRNA	   2	   0.29	   6.94	  [1.00-­‐Infinity]	   4.12	  ×	  10-­‐02	  
eQTLs	   234	   85.85	   3.28	  [2.36-­‐4.50]	   <	  5.00	  ×	  10-­‐05	  
vega	  PseudoGenes	   30	   20.38	   1.49	  [0.91-­‐2.78]	   5.93	  ×	  10-­‐02	  
Intergenic	  SNPs	   560	   628.32	   0.74	  [0.63-­‐0.88]	   3.00	  ×	  10-­‐04	  
DNase	  Clusters	   534	   396.42	   1.77	  [1.53-­‐2.05]	   <	  5.00	  ×	  10-­‐05	  
Insulators	  (sequence)	   83	   55.54	   1.54	  [1.15-­‐2.18]	   2.25	  ×	  10-­‐03	  
Within	  miRNA	   0	   0.01	   0.00	  [NA-­‐NA]	   <	  5.00	  ×	  10-­‐05	  
Splice	  Sites	   0	   0.56	   0.00	  [0.00-­‐NA]	   <	  5.00	  ×	  10-­‐05	  
Lost	  Stops	   0	   0.18	   0.00	  [0.00-­‐NA]	   <	  5.00	  ×	  10-­‐05	  
Microsatellites	   0	   0.81	   0.00	  [0.00-­‐NA]	   <	  5.00	  ×	  10-­‐05	  
EvoFold	   3	   2.51	   1.20	  [0.50-­‐Infinity]	   4.51	  ×	  10-­‐01	  
Pos.	  Sel.	  Genes	   424	   298.20	   1.75	  [1.47-­‐2.09]	   <	  5.00	  ×	  10-­‐05	  
Enhancers	  (sequence)	   8	   4.18	   1.92	  [0.89-­‐8.06]	   8.14	  ×	  10-­‐02	  
Exapted	  Repeats	   4	   3.67	   1.09	  [0.50-­‐Infinity]	   4.90	  ×	  10-­‐01	  
PREMOD	   168	   126.65	   1.39	  [1.15-­‐1.73]	   5.00	  ×	  10-­‐04	  
tfbs	  Conserved	   148	   102.91	   1.52	  [1.23-­‐1.92]	   <	  5.00	  ×	  10-­‐05	  
Indel	  Pure	  regions	   464	   401.07	   1.30	  [1.13-­‐1.49]	   1.00	  ×	  10-­‐04	  
17	  spec.	  algmt	   313	   254.92	   1.34	  [1.15-­‐1.57]	   <	  5.00	  ×	  10-­‐05	  
28	  spec.	  algmt	  plc.mmls	   285	   205.07	   1.55	  [1.32-­‐1.85]	   <	  5.00	  ×	  10-­‐05	  
28	  spec.	  algmt	   310	   239.39	   1.43	  [1.22-­‐1.69]	   <	  5.00	  ×	  10-­‐05	  
44	  spec.	  algmt	   321	   242.99	   1.48	  [1.26-­‐1.76]	   <	  5.00	  ×	  10-­‐05	  
44	  spec.	  algmt	  plc.mmls	   297	   222.86	   1.48	  [1.26-­‐1.75]	   <	  5.00	  ×	  10-­‐05	  
44	  spec.	  algmt	  prim.	   308	   212.56	   1.66	  [1.41-­‐1.97]	   <	  5.00	  ×	  10-­‐05	  
Negative	  (sequence)	   456	   554.32	   0.66	  [0.57-­‐0.78]	   <	  5.00	  ×	  10-­‐05	  
Open	  Chromatin	   701	   483.75	   2.62	  [2.01-­‐3.31]	   <	  5.00	  ×	  10-­‐05	  
Closed	  Chromatin	   297	   514.06	   0.39	  [0.31-­‐0.51]	   <	  5.00	  ×	  10-­‐05	  
Active	  Promoter	   84	   33.95	   2.61	  [1.78-­‐4.09]	   5.00	  ×	  10-­‐05	  
Weak	  Promoter	   92	   37.20	   2.63	  [1.85-­‐3.96]	   <	  5.00	  ×	  10-­‐05	  
Poised	  Promoter	   11	   4.44	   2.50	  [1.10-­‐11.11]	   1.79	  ×	  10-­‐02	  
Strong	  Enhancer	  (proximal)	   113	   40.84	   3.00	  [2.11-­‐4.44]	   5.00	  ×	  10-­‐05	  
Strong	  Enhancer	  (distal)	   92	   44.44	   2.18	  [1.59-­‐3.17]	   3.50	  ×	  10-­‐04	  
Weak	  Enhancer	  (proximal)	   88	   56.31	   1.62	  [1.21-­‐2.26]	   1.05	  ×	  10-­‐03	  
Weak	  Enhancer	  (distal)	   174	   106.68	   1.77	  [1.40-­‐2.31]	   5.50	  ×	  10-­‐04	  
Insulator	   50	   42.19	   1.20	  [0.87-­‐1.76]	   1.49	  ×	  10-­‐01	  
Txn	  Transition	   77	   32.82	   2.46	  [1.69-­‐3.90]	   <	  5.00	  ×	  10-­‐05	  
Txn	  Elongation	   199	   100.98	   2.22	  [1.71-­‐2.91]	   <	  5.00	  ×	  10-­‐05	  
Weak	  Txn	   302	   193.53	   1.81	  [1.47-­‐2.24]	   6.50	  ×	  10-­‐04	  
Repressed	   148	   98.16	   1.60	  [1.23-­‐2.12]	   8.50	  ×	  10-­‐04	  
Heterochrom/low	   667	   809.90	   0.43	  [0.35-­‐0.54]	   <	  5.00	  ×	  10-­‐05	  
Repetitive/CNV	  (proximal)	   2	   2.15	   0.93	  [0.33-­‐Infinity]	   3.87	  ×	  10-­‐01	  
Repetitive/CNV	  (distal)	   2	   1.92	   1.04	  [0.40-­‐Infinity]	   4.45	  ×	  10-­‐01	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Table	  6-­3	  –	  Permutation	  results	  for	  All	  STAGE	  eSNPs	  	  
This	  table	  summarises	  the	  results	  for	  All	  eSNPs	  showing	  the	  number	  of	  overlaps	  in	  the	  observed	  set	  
(Real),	  the	  mean	  of	  the	  permuted	  hits	  (Permutation	  Mean),	  the	  calculated	  odds	  ratio	  and	  confidence	  
interval	  (OR	  [LCI-­‐HCI])	  and	  the	  obtained	  P-­‐value	  for	  each	  annotation.	  Significant	  P-­‐values	  in	  bold.	  
Annotation	   Real	   Permutation	  Mean	   OR	  [LCI-­‐HCI]	   P-­‐value	  
1	  Kb	  TSS	   4346	   1161.25	   4.28	  [3.34-­‐4.99]	   <	  5.00	  ×	  10-­‐05	  
5	  Kb	  TSS	   9273	   2996.71	   4.22	  [3.39-­‐4.75]	   <	  5.00	  ×	  10-­‐05	  
CpG	  Islands	   2327	   554.79	   4.50	  [3.42-­‐5.46]	   <	  5.00	  ×	  10-­‐05	  
ORegAnno	   1649	   723.23	   2.36	  [1.97-­‐2.74]	   <	  5.00	  ×	  10-­‐05	  
vega	  Genes	   15164	   10300.26	   2.10	  [1.88-­‐2.29]	   <	  5.00	  ×	  10-­‐05	  
OMIM	  genes	   14813	   9179.15	   2.39	  [2.12-­‐2.62]	   <	  5.00	  ×	  10-­‐05	  
OMIM	  morbid	  regions	   3950	   2144.92	   1.99	  [1.70-­‐2.33]	   <	  5.00	  ×	  10-­‐05	  
Exons	   7756	   2357.28	   4.24	  [3.46-­‐4.76]	   <	  5.00	  ×	  10-­‐05	  
Intronic	  SNPs	   18804	   12356.07	   2.79	  [2.48-­‐3.06]	   <	  5.00	  ×	  10-­‐05	  
Non.Syn.	  SNPs	  (UCSC)	   4094	   1207.13	   3.83	  [3.09-­‐4.42]	   <	  5.00	  ×	  10-­‐05	  
Coding	  SNPs	  (UCSC)	   6171	   1902.31	   3.92	  [3.21-­‐4.45]	   <	  5.00	  ×	  10-­‐05	  
Syn.	  SNPs	  (UCSC)	   3610	   1043.26	   3.85	  [3.15-­‐4.44]	   <	  5.00	  ×	  10-­‐05	  
Gained	  Stops	   28	   15.38	   1.82	  [0.90-­‐5.60]	   5.64	  ×	  10-­‐02	  
3'UTR	   4854	   1307.14	   4.32	  [3.50-­‐4.94]	   <	  5.00	  ×	  10-­‐05	  
5'UTR	   1387	   309.87	   4.67	  [3.50-­‐5.92]	   <	  5.00	  ×	  10-­‐05	  
RNA	  Genes	   211	   80.10	   2.65	  [1.91-­‐3.93]	   <	  5.00	  ×	  10-­‐05	  
ncRNA	   663	   259.54	   2.59	  [1.90-­‐3.69]	   <	  5.00	  ×	  10-­‐05	  
TS	  miRNA	   31	   8.13	   3.82	  [1.72-­‐15.52]	   1.00	  ×	  10-­‐04	  
eQTLs	   12324	   2352.39	   8.91	  [6.68-­‐10.36]	   <	  5.00	  ×	  10-­‐05	  
vega	  PseudoGenes	   1266	   528.07	   2.47	  [1.80-­‐3.09]	   <	  5.00	  ×	  10-­‐05	  
Intergenic	  SNPs	   16877	   17246.25	   0.94	  [0.86-­‐1.03]	   8.88	  ×	  10-­‐02	  
DNase	  Clusters	   15833	   10809.54	   2.15	  [1.99-­‐2.27]	   <	  5.00	  ×	  10-­‐05	  
Insulators	  (sequence)	   3218	   1517.03	   2.28	  [1.93-­‐2.58]	   <	  5.00	  ×	  10-­‐05	  
Within	  miRNA	   2	   0.24	   8.50	  [1.00-­‐Infinity]	   6.07	  ×	  10-­‐02	  
Splice	  Sites	   45	   15.31	   2.94	  [1.41-­‐9.01]	   1.45	  ×	  10-­‐03	  
Lost	  Stops	   46	   5.18	   8.89	  [3.29-­‐Infinity]	   <	  5.00	  ×	  10-­‐05	  
Microsatellites	   20	   21.24	   0.94	  [0.51-­‐2.22]	   4.58	  ×	  10-­‐01	  
EvoFold	   87	   68.86	   1.26	  [0.90-­‐1.89]	   9.64	  ×	  10-­‐02	  
Pos.	  Sel.	  Genes	   14598	   8176.41	   2.74	  [2.44-­‐3.01]	   <	  5.00	  ×	  10-­‐05	  
Enhancers	  (sequence)	   91	   110.84	   0.82	  [0.60-­‐1.21]	   1.53	  ×	  10-­‐01	  
Exapted	  Repeats	   91	   99.72	   0.91	  [0.69-­‐1.28]	   2.81	  ×	  10-­‐01	  
PREMOD	   4173	   3470.07	   1.24	  [1.15-­‐1.34]	   <	  5.00	  ×	  10-­‐05	  
tfbs	  Conserved	   4295	   2807.51	   1.63	  [1.52-­‐1.75]	   <	  5.00	  ×	  10-­‐05	  
Indel	  Pure	  regions	   13566	   10939.49	   1.49	  [1.42-­‐1.57]	   <	  5.00	  ×	  10-­‐05	  
17	  spec.	  algmt	   9874	   6943.60	   1.67	  [1.58-­‐1.78]	   <	  5.00	  ×	  10-­‐05	  
28	  spec.	  algmt	  plc.mmls	   8235	   5585.88	   1.69	  [1.58-­‐1.81]	   <	  5.00	  ×	  10-­‐05	  
28	  spec.	  algmt	   9492	   6526.30	   1.71	  [1.60-­‐1.82]	   <	  5.00	  ×	  10-­‐05	  
44	  spec.	  algmt	   10014	   6630.26	   1.82	  [1.71-­‐1.94]	   <	  5.00	  ×	  10-­‐05	  
44	  spec.	  algmt	  plc.mmls	   9088	   6071.62	   1.76	  [1.65-­‐1.88]	   <	  5.00	  ×	  10-­‐05	  
44	  spec.	  algmt	  prim.	   8373	   5786.80	   1.65	  [1.54-­‐1.77]	   <	  5.00	  ×	  10-­‐05	  
Negative	  (sequence)	   13791	   15165.28	   0.81	  [0.75-­‐0.89]	   1.50	  ×	  10-­‐04	  
Open	  Chromatin	   20526	   13300.19	   3.40	  [2.54-­‐4.00]	   <	  5.00	  ×	  10-­‐05	  
Closed	  Chromatin	   7202	   14028.49	   0.33	  [0.28-­‐0.44]	   <	  5.00	  ×	  10-­‐05	  
Active	  Promoter	   4013	   931.43	   4.90	  [3.81-­‐5.76]	   <	  5.00	  ×	  10-­‐05	  
Weak	  Promoter	   3670	   1009.57	   4.06	  [3.23-­‐4.69]	   <	  5.00	  ×	  10-­‐05	  
Poised	  Promoter	   286	   115.62	   2.49	  [1.60-­‐3.56]	   2.50	  ×	  10-­‐04	  
Strong	  Enhancer	  (proximal)	   2992	   1115.53	   2.90	  [2.32-­‐3.36]	   <	  5.00	  ×	  10-­‐05	  
Strong	  Enhancer	  (distal)	   3069	   1216.51	   2.72	  [2.26-­‐3.12]	   <	  5.00	  ×	  10-­‐05	  
Weak	  Enhancer	  (proximal)	   3969	   1526.03	   2.88	  [2.48-­‐3.21]	   <	  5.00	  ×	  10-­‐05	  
Weak	  Enhancer	  (distal)	   6079	   2897.83	   2.42	  [2.11-­‐2.67]	   <	  5.00	  ×	  10-­‐05	  
Insulator	   2390	   1146.15	   2.19	  [1.89-­‐2.46]	   <	  5.00	  ×	  10-­‐05	  
Txn	  Transition	   3064	   892.80	   3.75	  [2.97-­‐4.43]	   <	  5.00	  ×	  10-­‐05	  
Txn	  Elongation	   8715	   2788.14	   4.16	  [3.46-­‐4.71]	   <	  5.00	  ×	  10-­‐05	  
Weak	  Txn	   12020	   5301.61	   3.32	  [2.84-­‐3.66]	   <	  5.00	  ×	  10-­‐05	  
Repressed	   3779	   2639.21	   1.50	  [1.27-­‐1.71]	   1.30	  ×	  10-­‐03	  
Heterochrom/low	   19686	   22180.76	   0.56	  [0.51-­‐0.65]	   2.50	  ×	  10-­‐04	  
Repetitive/CNV	  (proximal)	   121	   59.07	   2.05	  [1.41-­‐3.28]	   1.00	  ×	  10-­‐04	  
Repetitive/CNV	  (distal)	   38	   51.70	   0.73	  [0.51-­‐1.19]	   8.49	  ×	  10-­‐02	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6.3.1.2 Shared	  eSNPs	  vs.	  Tissue-­‐specific	  eSNPs	  
The	  odds	  ratios	  of	  the	  Shared	  eSNPs	  and	  the	  Tissue-­‐specific	  eSNPs	  obtained	  by	  
permutations	  are	  shown	  in	  Table	  6-­‐4	  and	  Table	  6-­‐5,	  which	  list	  the	  overlaps	  for	  
each	  annotation,	   the	  mean	  number	  of	  overlaps	   in	  permutations,	   the	  calculated	  
odds	  ratios	  and	  their	  confidence	  intervals	  and	  the	  obtained	  P-­value.	  The	  results	  
for	  the	  Shared	  eSNPs	  vs.	  Tissue-­‐specific	  eSNPs	  are	  compared	  with	  each	  other	  in	  
Figure	  6-­‐2,	  where	  a	   red	   star	   indicates	   significant	  differences	  between	   the	   two	  
sets.	  The	  majority	  of	  the	  annotations	  show	  significantly	  different	  odds	  ratios	  for	  
the	   two	   datasets.	   The	   Shared	   eSNPs	   have	   more	   extreme	   odds	   ratios	   in	   all	  
annotations,	  where	  the	  odds	  ratios	  were	  significant	  at	  the	  Bonferroni	  corrected	  
threshold.	  However,	  the	  trend	  between	  the	  two	  datasets	   is	  the	  same.	  Only	  one	  
genomic	   annotation,	   the	   repetitive/CNV	   (distal)	   sites,	   has	   an	   odds	   ratio	   of	  
enrichment	   for	   the	   Tissue-­‐specific	   eSNPs	  when	   it	  was	   depleted	   in	   the	   Shared	  
SNPs.	   The	   mean	   of	   the	   odds	   ratios	   for	   the	   Shared	   eSNPs	   is	   4.49	   and	   for	   the	  
Tissue-­‐specific	   eSNPs	   is	   2.15.	   The	   Shared	   eSNPs	   therefore	   have	   on	   average	   a	  
much	  higher	  odds	  ratios	  than	  the	  Tissue-­‐specific	  eSNPs,	  All	  eSNPs	  or	  GWAS	  hits.	  
The	   highest	   odds	   ratio	   was	   obtained	   for	   the	   eQTL	   annotation	   for	   the	   Shared	  
eSNPs	   (OR	   =	   27.99	   [17.11-­‐37.29]),	   which	   suggests	   that	   they	   contain	   a	   larger	  
proportion	  of	   ‘true’	  eQTLs.	  The	   likelihood	  of	  detecting	   tissue	  specific	  eQTLs	   is	  
much	   lower	   than	   detecting	   eQTLs	   that	   are	   affecting	   several	   tissues	   (i.e.,	   the	  
shared	   eSNPs),	   as	   tissue	   specific	   studies	   will	   have	   less	   power.	   It	   is	   therefore	  
possible	  that	  the	  Shared	  eSNPs	  are	  more	  represented	  in	  the	  eQTL	  annotation	  as	  
there	   was	   more	   power	   to	   detect	   them,	   rather	   than	   representing	   a	   greater	  
proportion	   of	   true	   eQTLs.	   This	   will	   be	   discussed	   further	   in	   the	   Discussion	  
section	  of	  this	  chapter.	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Figure	  6-­2	  –	  Shared	  eSNPs	  vs.	  Tissue-­specific	  eSNPs	  
A	  comparison	  of	  Shared	  eSNPs	  (n	  =	  6,700,	  )	  and	  Tissue-­‐specific	  eSNPs	  (n	  =	  19,846,	  ).	  Red	  stars	  
()	   indicate	   significant	  differences	  between	   the	  odds	   ratios.	   Solid	   symbols	   indicate	   significance	  at	  
multiple	  corrected	  P-­‐value.	  A	  black	  star	  ()	   indicates	  the	  odds	  ratio	  for	  eQTLs	  in	  the	  Shared	  eSNPs	  
(27.99	  [17.11-­‐37.29])	  data	  that	  is	  greater	  than	  the	  maximum	  of	  the	  graph.	  Top:	  Genic	  and	  regulatory	  




















































































































































































































































































































































































	   158	  
Table	  6-­4	  –	  Permutation	  results	  for	  Shared	  STAGE	  eSNPs	  	  
This	   table	   summarises	   the	   results	   for	   the	   Shared	   eSNPs	   showing	   the	   number	   of	   overlaps	   in	   the	  
observed	   set	   (Real),	   the	   mean	   of	   the	   permuted	   hits	   (Permutation	   Mean),	   the	   odds	   ratio	   and	  
confidence	  interval	  (OR	  [LCI-­‐HCI])	  and	  the	  P-­‐value	  for	  each	  annotation.	  Significant	  P-­‐values	  in	  bold.	  	  
Annotation	   Real	   Permutation	  Mean	   OR	  [LCI-­‐HCI]	   P-­‐value	  
1	  Kb	  TSS	   1787	   303.63	   7.66	  [5.03-­‐10.23]	   <	  5.00	  ×	  10-­‐05	  
5	  Kb	  TSS	   3372	   779.75	   7.69	  [5.47-­‐9.53]	   <	  5.00	  ×	  10-­‐05	  
CpG	  Islands	   1021	   148.04	   7.96	  [4.92-­‐11.63]	   <	  5.00	  ×	  10-­‐05	  
ORegAnno	   662	   187.60	   3.81	  [2.83-­‐5.18]	   <	  5.00	  ×	  10-­‐05	  
vega	  Genes	   4324	   2605.72	   2.86	  [2.33-­‐3.41]	   <	  5.00	  ×	  10-­‐05	  
OMIM	  genes	   4355	   2333.71	   3.47	  [2.81-­‐4.18]	   <	  5.00	  ×	  10-­‐05	  
OMIM	  morbid	  regions	   1249	   546.68	   2.58	  [1.90-­‐3.56]	   <	  5.00	  ×	  10-­‐05	  
Exons	   3040	   614.27	   8.23	  [6.01-­‐10.23]	   <	  5.00	  ×	  10-­‐05	  
Intronic	  SNPs	   5346	   3138.10	   4.48	  [3.65-­‐5.37]	   <	  5.00	  ×	  10-­‐05	  
Non.Syn.	  SNPs	  (UCSC)	   1637	   314.88	   6.56	  [4.68-­‐8.67]	   <	  5.00	  ×	  10-­‐05	  
Coding	  SNPs	  (UCSC)	   2438	   495.91	   7.16	  [5.19-­‐9.08]	   <	  5.00	  ×	  10-­‐05	  
Syn.	  SNPs	  (UCSC)	   1498	   272.45	   6.79	  [4.90-­‐8.99]	   <	  5.00	  ×	  10-­‐05	  
Gained	  Stops	   13	   4.23	   3.08	  [0.93-­‐Infinity]	   3.98	  ×	  10-­‐02	  
3'UTR	   1964	   338.34	   7.80	  [5.56-­‐10.15]	   <	  5.00	  ×	  10-­‐05	  
5'UTR	   625	   81.92	   8.31	  [5.04-­‐13.68]	   <	  5.00	  ×	  10-­‐05	  
RNA	  Genes	   103	   19.97	   5.22	  [2.81-­‐14.93]	   <	  5.00	  ×	  10-­‐05	  
ncRNA	   283	   67.59	   4.33	  [2.38-­‐9.81]	   <	  5.00	  ×	  10-­‐05	  
TS	  miRNA	   10	   2.16	   4.64	  [1.11-­‐Infinity]	   1.83	  ×	  10-­‐02	  
eQTLs	   4946	   613.22	   27.99	  [17.11-­‐37.29]	   <	  5.00	  ×	  10-­‐05	  
vega	  PseudoGenes	   526	   141.69	   3.94	  [2.20-­‐6.19]	   <	  5.00	  ×	  10-­‐05	  
Intergenic	  SNPs	   4667	   4341.70	   1.25	  [1.04-­‐1.49]	   7.95	  ×	  10-­‐03	  
DNase	  Clusters	   4614	   2739.51	   3.20	  [2.80-­‐3.55]	   <	  5.00	  ×	  10-­‐05	  
Insulators	  (sequence)	   1196	   390.87	   3.51	  [2.64-­‐4.48]	   <	  5.00	  ×	  10-­‐05	  
Within	  miRNA	   0	   0.07	   0.00	  [0.00-­‐NA]	   <	  5.00	  ×	  10-­‐05	  
Splice	  Sites	   28	   4.16	   6.76	  [1.87-­‐Infinity]	   1.10	  ×	  10-­‐03	  
Lost	  Stops	   21	   1.39	   15.21	  [3.01-­‐Infinity]	   <	  5.00	  ×	  10-­‐05	  
Microsatellites	   7	   5.63	   1.24	  [0.41-­‐Infinity]	   3.28	  ×	  10-­‐01	  
EvoFold	   21	   17.44	   1.20	  [0.62-­‐3.51]	   2.93	  ×	  10-­‐01	  
Pos.	  Sel.	  Genes	   4465	   2076.46	   4.45	  [3.65-­‐5.34]	   <	  5.00	  ×	  10-­‐05	  
Enhancers	  (sequence)	   28	   27.51	   1.02	  [0.55-­‐2.55]	   4.54	  ×	  10-­‐01	  
Exapted	  Repeats	   17	   24.75	   0.69	  [0.39-­‐1.55]	   1.53	  ×	  10-­‐01	  
PREMOD	   1341	   871.68	   1.67	  [1.44-­‐1.95]	   <	  5.00	  ×	  10-­‐05	  
tfbs	  Conserved	   1398	   707.01	   2.24	  [1.94-­‐2.60]	   <	  5.00	  ×	  10-­‐05	  
Indel	  Pure	  regions	   3971	   2755.27	   2.08	  [1.89-­‐2.33]	   <	  5.00	  ×	  10-­‐05	  
17	  spec.	  algmt	   3122	   1746.02	   2.48	  [2.19-­‐2.83]	   <	  5.00	  ×	  10-­‐05	  
28	  spec.	  algmt	  plc.mmls	   2648	   1405.10	   2.46	  [2.16-­‐2.83]	   <	  5.00	  ×	  10-­‐05	  
28	  spec.	  algmt	   3091	   1646.63	   2.63	  [2.32-­‐2.99]	   <	  5.00	  ×	  10-­‐05	  
44	  spec.	  algmt	   3197	   1670.35	   2.75	  [2.43-­‐3.15]	   <	  5.00	  ×	  10-­‐05	  
44	  spec.	  algmt	  plc.mmls	   2823	   1527.32	   2.47	  [2.17-­‐2.84]	   <	  5.00	  ×	  10-­‐05	  
44	  spec.	  algmt	  prim.	   2678	   1455.98	   2.40	  [2.10-­‐2.76]	   <	  5.00	  ×	  10-­‐05	  
Negative	  (sequence)	   3347	   3816.17	   0.75	  [0.64-­‐0.89]	   2.50	  ×	  10-­‐04	  
Open	  Chromatin	   5574	   3347.33	   4.96	  [3.28-­‐6.62]	   <	  5.00	  ×	  10-­‐05	  
Closed	  Chromatin	   1421	   3544.92	   0.24	  [0.18-­‐0.37]	   <	  5.00	  ×	  10-­‐05	  
Active	  Promoter	   1699	   242.57	   9.04	  [5.86-­‐12.52]	   <	  5.00	  ×	  10-­‐05	  
Weak	  Promoter	   1518	   261.29	   7.22	  [4.90-­‐9.67]	   <	  5.00	  ×	  10-­‐05	  
Poised	  Promoter	   134	   30.91	   4.40	  [1.96-­‐9.75]	   5.00	  ×	  10-­‐05	  
Strong	  Enhancer	  (proximal)	   1077	   288.35	   4.26	  [2.93-­‐5.75]	   <	  5.00	  ×	  10-­‐05	  
Strong	  Enhancer	  (distal)	   1064	   311.40	   3.87	  [2.84-­‐5.13]	   <	  5.00	  ×	  10-­‐05	  
Weak	  Enhancer	  (proximal)	   1450	   391.03	   4.46	  [3.42-­‐5.54]	   <	  5.00	  ×	  10-­‐05	  
Weak	  Enhancer	  (distal)	   1954	   741.28	   3.31	  [2.65-­‐4.02]	   <	  5.00	  ×	  10-­‐05	  
Insulator	   871	   292.02	   3.28	  [2.56-­‐4.13]	   <	  5.00	  ×	  10-­‐05	  
Txn	  Transition	   1163	   231.98	   5.86	  [4.05-­‐8.22]	   <	  5.00	  ×	  10-­‐05	  
Txn	  Elongation	   3180	   718.51	   7.52	  [5.63-­‐9.55]	   <	  5.00	  ×	  10-­‐05	  
Weak	  Txn	   3984	   1364.94	   5.73	  [4.49-­‐6.93]	   <	  5.00	  ×	  10-­‐05	  
Repressed	   1026	   676.50	   1.61	  [1.23-­‐2.07]	   2.50	  ×	  10-­‐03	  
Heterochrom/low	   4897	   5567.66	   0.55	  [0.45-­‐0.69]	   6.50	  ×	  10-­‐04	  
Repetitive/CNV	  (proximal)	   43	   15.15	   2.85	  [1.39-­‐8.65]	   1.15	  ×	  10-­‐03	  
Repetitive/CNV	  (distal)	   21	   13.06	   1.61	  [0.81-­‐5.26]	   1.04	  ×	  10-­‐01	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Table	  6-­5	  –	  Permutation	  results	  for	  Tissue-­specific	  STAGE	  eSNPs	  
This	  table	  summarises	  the	  results	  for	  the	  Tissue-­‐specific	  eSNPs,	  including	  the	  number	  of	  overlaps	  in	  
the	   observed	   set	   (Real),	   the	  mean	  of	   the	   permuted	  hits	   (Permutation	  Mean),	   the	   calculated	  odds	  
ratio	   and	   confidence	   interval	   (OR	   [LCI-­‐HCI])	   and	   the	   obtained	   P-­‐value	   for	   each	   of	   the	   genomic	  
annotations.	  Significant	  P-­‐values	  in	  bold.	  	  
Annotation	   Real	   Permutation	  Mean	   OR	  [LCI-­‐HCI]	   P-­‐value	  
1	  Kb	  TSS	   2559	   857.62	   3.28	  [2.69-­‐3.80]	   <	  5.00	  ×	  10-­‐05	  
5	  Kb	  TSS	   5901	   2216.96	   3.36	  [2.81-­‐3.75]	   <	  5.00	  ×	  10-­‐05	  
CpG	  Islands	   1306	   406.75	   3.37	  [2.68-­‐4.05]	   <	  5.00	  ×	  10-­‐05	  
ORegAnno	   987	   535.62	   1.89	  [1.59-­‐2.19]	   <	  5.00	  ×	  10-­‐05	  
vega	  Genes	   10840	   7694.54	   1.90	  [1.73-­‐2.05]	   <	  5.00	  ×	  10-­‐05	  
OMIM	  genes	   10458	   6845.43	   2.12	  [1.90-­‐2.30]	   <	  5.00	  ×	  10-­‐05	  
OMIM	  morbid	  regions	   2701	   1598.24	   1.80	  [1.56-­‐2.09]	   <	  5.00	  ×	  10-­‐05	  
Exons	   4716	   1743.01	   3.24	  [2.73-­‐3.61]	   <	  5.00	  ×	  10-­‐05	  
Intronic	  SNPs	   13458	   9217.97	   2.43	  [2.19-­‐2.64]	   <	  5.00	  ×	  10-­‐05	  
Non.Syn.	  SNPs	  (UCSC)	   2457	   892.25	   3.00	  [2.50-­‐3.44]	   <	  5.00	  ×	  10-­‐05	  
Coding	  SNPs	  (UCSC)	   3733	   1406.40	   3.04	  [2.57-­‐3.42]	   <	  5.00	  ×	  10-­‐05	  
Syn.	  SNPs	  (UCSC)	   2112	   770.81	   2.95	  [2.49-­‐3.38]	   <	  5.00	  ×	  10-­‐05	  
Gained	  Stops	   15	   11.16	   1.34	  [0.65-­‐5.00]	   2.27	  ×	  10-­‐01	  
3'UTR	   2890	   968.80	   3.32	  [2.78-­‐3.78]	   <	  5.00	  ×	  10-­‐05	  
5'UTR	   762	   227.96	   3.44	  [2.69-­‐4.34]	   <	  5.00	  ×	  10-­‐05	  
RNA	  Genes	   108	   60.13	   1.80	  [1.29-­‐2.78]	   4.00	  ×	  10-­‐04	  
ncRNA	   380	   191.95	   2.00	  [1.49-­‐2.79]	   5.00	  ×	  10-­‐05	  
TS	  miRNA	   21	   5.97	   3.52	  [1.50-­‐21.02]	   1.50	  ×	  10-­‐03	  
eQTLs	   7378	   1739.17	   6.16	  [4.95-­‐7.07]	   <	  5.00	  ×	  10-­‐05	  
vega	  PseudoGenes	   740	   386.37	   1.95	  [1.54-­‐2.42]	   1.50	  ×	  10-­‐04	  
Intergenic	  SNPs	   12210	   12904.55	   0.86	  [0.79-­‐0.93]	   8.50	  ×	  10-­‐04	  
DNase	  Clusters	   11219	   8070.03	   1.90	  [1.78-­‐2.00]	   <	  5.00	  ×	  10-­‐05	  
Insulators	  (sequence)	   2022	   1126.16	   1.89	  [1.64-­‐2.13]	   <	  5.00	  ×	  10-­‐05	  
Within	  miRNA	   2	   0.17	   11.96	  [1.00-­‐Infinity]	   3.42	  ×	  10-­‐02	  
Splice	  Sites	   17	   11.15	   1.52	  [0.74-­‐5.67]	   1.40	  ×	  10-­‐01	  
Lost	  Stops	   25	   3.80	   6.59	  [2.50-­‐Infinity]	   <	  5.00	  ×	  10-­‐05	  
Microsatellites	   13	   15.62	   0.83	  [0.45-­‐2.17]	   3.21	  ×	  10-­‐01	  
EvoFold	   66	   51.42	   1.28	  [0.90-­‐2.00]	   8.69	  ×	  10-­‐02	  
Pos.	  Sel.	  Genes	   10133	   6099.94	   2.35	  [2.12-­‐2.56]	   <	  5.00	  ×	  10-­‐05	  
Enhancers	  (sequence)	   63	   83.33	   0.76	  [0.55-­‐1.13]	   7.30	  ×	  10-­‐02	  
Exapted	  Repeats	   74	   74.97	   0.99	  [0.74-­‐1.42]	   4.67	  ×	  10-­‐01	  
PREMOD	   2832	   2598.39	   1.10	  [1.03-­‐1.19]	   2.55	  ×	  10-­‐03	  
tfbs	  Conserved	   2897	   2100.50	   1.44	  [1.35-­‐1.55]	   <	  5.00	  ×	  10-­‐05	  
Indel	  Pure	  regions	   9595	   8184.22	   1.33	  [1.27-­‐1.40]	   <	  5.00	  ×	  10-­‐05	  
17	  spec.	  algmt	   6752	   5197.59	   1.45	  [1.38-­‐1.54]	   <	  5.00	  ×	  10-­‐05	  
28	  spec.	  algmt	  plc.mmls	   5587	   4180.78	   1.47	  [1.38-­‐1.56]	   <	  5.00	  ×	  10-­‐05	  
28	  spec.	  algmt	   6401	   4879.67	   1.46	  [1.38-­‐1.55]	   <	  5.00	  ×	  10-­‐05	  
44	  spec.	  algmt	   6817	   4959.90	   1.57	  [1.48-­‐1.66]	   <	  5.00	  ×	  10-­‐05	  
44	  spec.	  algmt	  plc.mmls	   6265	   4544.29	   1.55	  [1.46-­‐1.65]	   <	  5.00	  ×	  10-­‐05	  
44	  spec.	  algmt	  prim.	   5695	   4330.83	   1.44	  [1.35-­‐1.53]	   <	  5.00	  ×	  10-­‐05	  
Negative	  (sequence)	   10444	   11349.11	   0.83	  [0.77-­‐0.90]	   4.00	  ×	  10-­‐04	  
Open	  Chromatin	   14952	   9952.86	   3.04	  [2.35-­‐3.50]	   <	  5.00	  ×	  10-­‐05	  
Closed	  Chromatin	   5781	   10483.57	   0.37	  [0.32-­‐0.47]	   5.00	  ×	  10-­‐05	  
Active	  Promoter	   2314	   688.86	   3.67	  [3.00-­‐4.29]	   <	  5.00	  ×	  10-­‐05	  
Weak	  Promoter	   2152	   748.29	   3.10	  [2.57-­‐3.57]	   <	  5.00	  ×	  10-­‐05	  
Poised	  Promoter	   152	   84.70	   1.80	  [1.28-­‐2.59]	   2.50	  ×	  10-­‐03	  
Strong	  Enhancer	  (proximal)	   1915	   827.18	   2.46	  [2.05-­‐2.83]	   <	  5.00	  ×	  10-­‐05	  
Strong	  Enhancer	  (distal)	   2005	   905.11	   2.35	  [2.02-­‐2.69]	   <	  5.00	  ×	  10-­‐05	  
Weak	  Enhancer	  (proximal)	   2519	   1135.00	   2.40	  [2.11-­‐2.67]	   <	  5.00	  ×	  10-­‐05	  
Weak	  Enhancer	  (distal)	   4125	   2156.55	   2.15	  [1.91-­‐2.36]	   <	  5.00	  ×	  10-­‐05	  
Insulator	   1519	   854.13	   1.84	  [1.62-­‐2.07]	   <	  5.00	  ×	  10-­‐05	  
Txn	  Transition	   1901	   660.82	   3.08	  [2.52-­‐3.62]	   <	  5.00	  ×	  10-­‐05	  
Txn	  Elongation	   5535	   2069.63	   3.32	  [2.83-­‐3.74]	   <	  5.00	  ×	  10-­‐05	  
Weak	  Txn	   8036	   3936.66	   2.75	  [2.42-­‐3.02]	   <	  5.00	  ×	  10-­‐05	  
Repressed	   2753	   1962.71	   1.47	  [1.26-­‐1.65]	   1.30	  ×	  10-­‐03	  
Heterochrom/low	   14789	   16613.10	   0.57	  [0.52-­‐0.64]	   2.50	  ×	  10-­‐04	  
Repetitive/CNV	  (proximal)	   78	   43.92	   1.78	  [1.20-­‐2.90]	   2.35	  ×	  10-­‐03	  
Repetitive/CNV	  (distal)	   17	   38.64	   0.44	  [0.30-­‐0.74]	   1.35	  ×	  10-­‐03	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6.3.2 GIANT	  consortium	  data	  
The	  results	  of	   the	   linear	  regression	  performed	  using	  the	  negative	   logarithm	  of	  
the	  P-­value	  of	  association	  in	  the	  meta-­‐analysis	  investigating	  height	  are	  shown	  in	  
Figure	  6-­‐3.	  The	  final	  model	  contained	  51	  genomic	  annotations,	  which	  explained	  
some	  of	  the	  variability	  towards	  the	  observed	  P-­values	  of	  association	  for	  height.	  
This	   is	   a	   very	   large	   number	   of	   annotations	   included	   in	   the	   model.	   Roughly	  
speaking,	   the	   stepwise	   regression	   process	   eliminates	   those	   genomic	  
annotations,	   which	   carry	   redundant	   information	   as	   explained	   in	   more	   detail	  
earlier.	  The	  analysis	  for	  the	  GIANT	  dataset	  removed	  only	  three	  annotations	  (TS	  
miRNA,	   CpG	   islands	   and	   exapted	   repeats)	   from	   the	   full	   model	   that	   were	   not	  
informative,	  when	  other	  annotations	  were	   included	  in	  the	  model,	  while	  all	   the	  
others	   carried	   additional	   information.	   The	   r2	   value	   of	   the	   final	   model	   was	  
extracted	  from	  the	  summary	  with	  a	  value	  of	  0.03	  (0.027),	  meaning	  that	  most	  of	  
the	   variation	   in	  –log(P-value of association)	   remained	  unexplained.	   The	  model,	  
which	  contained	  only	  the	  genotyping	  arrays,	  had	  an	  r2	  value	  of	  0.00	  (0.0004).	  Of	  
the	  51	  annotations	  included	  in	  the	  final	  model,	  49	  were	  significant	  at	  P	  ≤	  0.05.	  
The	   majority	   of	   these	   annotations	   had	   odds	   ratios	   with	   values	   indicative	   of	  
enrichment,	   while	   13	   of	   the	   annotations	   had	   odds	   ratios	   that	   indicated	  
depletion	  of	  height-­‐associated	  SNPs.	  These	  13	  annotations	  were	  distance	  to	  TSS,	  
closed	  chromatin,	  RNA	  genes,	  gained	  stops,	  coding	  SNPs,	  1	  Kb	  upstream	  of	  TSS,	  
splice	   sites,	   ncRNA,	   exons,	   within	   miRNA,	   evofold	   regions,	   lost	   stops,	   and	  
insulators.	   These	   regions	  were	   depleted	   of	   height-­‐associated	   SNPs	   relative	   to	  
the	   other	   36	   annotations	   that	   were	   enriched	   for	   height-­‐associated	   SNPs	   and	  
when	   these	  were	   included	   in	   the	  model.	   All	   the	   annotations	   had	   a	   very	   small	  
effect	  on	  the	  negative	  logarithm	  of	  the	  P-­value	  of	  association,	  as	  judged	  by	  their	  
odds	  ratios.	  The	  highest	  odds	  ratio	  observed	  was	  for	  eQTLs	  (ORs	  =	  1.24	  [1.23-­‐
1.24])	  and	  the	  lowest	  for	  within	  miRNA	  binding	  sites	  (ORs	  =	  0.66	  [0.54-­‐0.81]).	  
While	   the	   values	   of	   the	   odds	   ratios	   may	   be	   modest,	   the	   P-­values	   of	   the	  
annotations	  in	  the	  model	  are	  very	  significant	  (see	  Table	  6-­‐6).	  Height-­‐associated	  
SNPs	   overlapped	   preferentially	   with	   the	   region	   between	   the	   1	   Kb	   and	   5	   Kb	  
region	  upstream	  of	  TSS,	  which	  could	  indicate	  a	  preference	  to	  a	  specific	  type	  of	  
promoters.	  This	  was	  suggested	  by	  a	  combination	  of	  the	  negativeβ-­‐coefficients	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(indicating	  relative	  depletion)	  of	  1	  Kb	  upstream	  of	  the	  TSS	  and	  the	  positiveβ-­‐
coefficients	   (indicating	   relative	   enrichment)	   of	   the	   5	   Kb	   upstream	   of	   the	   TSS.	  
Additionally,	   the	   distance	   to	   TSS	   annotation	   obtained	   a	   very	   high	   negativeβ-­‐
coefficient,	  which	  indicated	  that	  SNPs	  closer	  to	  the	  TSS	  were	  more	  likely	  to	  be	  
height-­‐associated.	   The	   distance	   was	   calculated	   as	   the	   absolute	   value	   of	   the	  
minimum	   distance	   between	   a	   SNP	   and	   its	   nearest	   TSS,	   which	   did	   not	  
discriminate	   between	   SNPs	   up-­‐	   or	   downstream	   of	   the	   nearest	   TSS.	   This	  
separation	   could	   have	   been	   performed	   with	   the	   inclusion	   of	   an	   additional	  
annotation	   and	   could	   be	   performed	   in	   future	   experiments.	   The	   genomic	  
annotation	   with	   the	   highest	   impact	   on	   the	   P-­value	   of	   height-­‐associated	   SNPs	  
was	   the	  eQTL	  annotation.	  Theβ-­‐coefficient	   for	   that	  annotation	  was	  82.58	  and	  
an	  odds	  ratio	  of	  1.32	  [1.32-­‐1.33],	  the	  highest	  odds	  ratio	  in	  that	  analysis.	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Figure	  6-­3	  –	  Odds	  ratios	  for	  GIANT	  height	  data	  
This	   figure	   shows	   the	   significant	   odds	   ratios	   (P	   ≤	   0.05)	   for	   linear	   regression	   in	   the	  data	   for	   height	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Table	  6-­6	  –	  GIANT	  height	  linear	  regression	  results	  
This	  table	  presents	  the	  results	  for	  the	  height-­‐associated	  SNPs	  including	  the	  estimate	  of	  the	  effect,	  its	  
standard	  error,	   the	  β-­‐coefficient,	   the	   calculated	  odds	   ratio	  with	   its	   confidence	   interval,	   and	   the	  P-­‐
value	  of	   the	  estimate	   in	   the	   final	  model	   for	  each	  of	   the	   included	  genomic	  annotations	   in	   the	   final	  
model.	  Significant	  P-­‐values	  in	  bold.	  	  
Annotation	   Estimate	   Std.	  Error	   β 	   OR	  [LCI-­‐HCI]	   P-­‐value	  
Intercept	   0.44	   0.00	   127.14	   1.55	  [1.54-­‐1.57]	   0.00	  ×	  10+00	  
Affymetrix_250k_Nsp	   0.00	   0.00	   0.43	   1.00	  [0.99-­‐1.01]	   6.71	  ×	  10-­‐01	  
Affymetrix_250k_Sty	   0.00	   0.00	   0.46	   1.00	  [0.99-­‐1.01]	   6.45	  ×	  10-­‐01	  
Affymetrix_5.0	   0.01	   0.00	   1.60	   1.01	  [1.00-­‐1.01]	   1.09	  ×	  10-­‐01	  
Affymetrix_6.0	   -­‐0.01	   0.00	   -­‐6.89	   0.99	  [0.99-­‐0.99]	   5.46	  ×	  10-­‐12	  
Affymetrix_10k	   0.00	   0.01	   0.45	   1.00	  [0.99-­‐1.02]	   6.56	  ×	  10-­‐01	  
Affymetrix_50k.1	   -­‐0.01	   0.00	   -­‐1.58	   0.99	  [0.99-­‐1.00]	   1.14	  ×	  10-­‐01	  
Affymetrix_50k.2	   0.01	   0.00	   2.07	   1.01	  [1.00-­‐1.02]	   3.87	  ×	  10-­‐02	  
Illumina_300	   0.02	   0.00	   7.05	   1.02	  [1.01-­‐1.02]	   1.82	  ×	  10-­‐12	  
Illumina_550	   0.01	   0.00	   3.85	   1.01	  [1.01-­‐1.02]	   1.18	  ×	  10-­‐04	  
Illumina_650	   -­‐0.02	   0.00	   -­‐4.69	   0.98	  [0.98-­‐0.99]	   2.67	  ×	  10-­‐06	  
Perlegen	   0.01	   0.00	   4.23	   1.01	  [1.00-­‐1.01]	   2.35	  ×	  10-­‐05	  
eQTLs	   0.21	   0.00	   95.08	   1.24	  [1.23-­‐1.24]	   0.00	  ×	  10+00	  
Weak	  Txn	   0.05	   0.00	   29.24	   1.05	  [1.05-­‐1.05]	   7.47	  ×	  10-­‐188	  
Open	  Chromatin	   0.01	   0.00	   4.31	   1.01	  [1.01-­‐1.02]	   1.60	  ×	  10-­‐05	  
44	  specs.	  algmt.	  plac.	  mmls	   0.01	   0.00	   5.23	   1.01	  [1.01-­‐1.02]	   1.72	  ×	  10-­‐07	  
Weak	  Promoter	   0.07	   0.00	   23.04	   1.07	  [1.06-­‐1.08]	   2.05	  ×	  10-­‐117	  
Distance	  to	  TSS	   0.00	   0.00	   -­‐33.66	   1.00	  [1.00-­‐1.00]	   2.62	  ×	  10-­‐248	  
DNase	  Clusters	   0.02	   0.00	   21.05	   1.03	  [1.02-­‐1.03]	   2.28	  ×	  10-­‐98	  
Txn	  Elongation	   0.04	   0.00	   19.49	   1.05	  [1.04-­‐1.05]	   1.27	  ×	  10-­‐84	  
Strong	  Enhancer	  (proximal)	   0.06	   0.00	   19.23	   1.06	  [1.05-­‐1.06]	   2.06	  ×	  10-­‐82	  
Insulators	  (sequence)	   0.04	   0.00	   17.59	   1.04	  [1.04-­‐1.04]	   2.95	  ×	  10-­‐69	  
PREMOD	   0.02	   0.00	   13.23	   1.02	  [1.02-­‐1.03]	   5.93	  ×	  10-­‐40	  
ORegAnno	   0.04	   0.00	   13.28	   1.05	  [1.04-­‐1.05]	   3.22	  ×	  10-­‐40	  
44	  specs.	  algmt.	  primates	   0.02	   0.00	   12.40	   1.02	  [1.02-­‐1.02]	   2.74	  ×	  10-­‐35	  
Repetitive/CNV	  (distal)	   0.15	   0.01	   14.86	   1.16	  [1.14-­‐1.19]	   6.32	  ×	  10-­‐50	  
Non.Syn.	  SNPs	  (UCSC)	   0.10	   0.01	   18.03	   1.10	  [1.09-­‐1.11]	   1.20	  ×	  10-­‐72	  
Enhancers	  (sequence)	   0.12	   0.01	   14.83	   1.12	  [1.11-­‐1.14]	   9.44	  ×	  10-­‐50	  
Active	  Promoter	   0.04	   0.00	   12.38	   1.04	  [1.03-­‐1.05]	   3.26	  ×	  10-­‐35	  
Closed	  Chromatin	   -­‐0.05	   0.00	   -­‐16.52	   0.95	  [0.95-­‐0.96]	   2.65	  ×	  10-­‐61	  
Weak	  Enhancer	  (distal)	   0.02	   0.00	   9.85	   1.02	  [1.01-­‐1.02]	   7.04	  ×	  10-­‐23	  
RNA	  Genes	   -­‐0.12	   0.01	   -­‐13.36	   0.89	  [0.87-­‐0.91]	   9.91	  ×	  10-­‐41	  
Gained	  Stops	   -­‐0.27	   0.02	   -­‐13.09	   0.76	  [0.73-­‐0.80]	   3.61	  ×	  10-­‐39	  
Syn.	  SNPs	  (UCSC)	   0.09	   0.01	   17.52	   1.09	  [1.08-­‐1.10]	   1.03	  ×	  10-­‐68	  
Coding	  SNPs	  (UCSC)	   -­‐0.08	   0.01	   -­‐12.88	   0.92	  [0.91-­‐0.93]	   5.98	  ×	  10-­‐38	  
Pos.	  Sel.	  Genes	   0.01	   0.00	   8.02	   1.01	  [1.01-­‐1.02]	   1.06	  ×	  10-­‐15	  
Negative	  (sequence)	   0.01	   0.00	   7.16	   1.01	  [1.01-­‐1.02]	   8.24	  ×	  10-­‐13	  
Splice	  Sites	   -­‐0.21	   0.02	   -­‐9.38	   0.81	  [0.78-­‐0.85]	   6.73	  ×	  10-­‐21	  
44	  specs.	  algmt.	   0.02	   0.00	   6.46	   1.02	  [1.01-­‐1.02]	   1.08	  ×	  10-­‐10	  
Repetitive/CNV	  (proximal)	   0.08	   0.01	   7.77	   1.08	  [1.06-­‐1.10]	   8.10	  ×	  10-­‐15	  
Heterochrom/lo	   0.01	   0.00	   6.83	   1.01	  [1.01-­‐1.02]	   8.31	  ×	  10-­‐12	  
Repressed	   0.01	   0.00	   6.17	   1.01	  [1.01-­‐1.02]	   6.67	  ×	  10-­‐10	  
Microsatellites	   0.11	   0.02	   7.13	   1.12	  [1.08-­‐1.15]	   1.01	  ×	  10-­‐12	  
Intronic	  SNPs	   0.01	   0.00	   5.33	   1.01	  [1.01-­‐1.02]	   9.73	  ×	  10-­‐08	  
1	  Kb	  TSS	   -­‐0.04	   0.00	   -­‐11.16	   0.96	  [0.96-­‐0.97]	   6.37	  ×	  10-­‐29	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Annotation	   Estimate	   Std.	  Error	   β 	   OR	  [LCI-­‐HCI]	   P-­‐value	  
5	  Kb	  TSS	   0.02	   0.00	   7.94	   1.02	  [1.01-­‐1.02]	   2.08	  ×	  10-­‐15	  
Weak	  Enhancer	  (proximal)	   0.01	   0.00	   5.93	   1.01	  [1.01-­‐1.02]	   2.95	  ×	  10-­‐09	  
3’UTR	   0.02	   0.00	   6.99	   1.02	  [1.01-­‐1.03]	   2.75	  ×	  10-­‐12	  
Poised	  Promoter	   0.04	   0.01	   5.43	   1.04	  [1.03-­‐1.06]	   5.71	  ×	  10-­‐08	  
ncRNA	   -­‐0.03	   0.01	   -­‐5.54	   0.97	  [0.96-­‐0.98]	   3.09	  ×	  10-­‐08	  
tfbs	  Conserved	   0.01	   0.00	   4.86	   1.01	  [1.01-­‐1.01]	   1.17	  ×	  10-­‐06	  
Indels	  Pure	  regions	   0.00	   0.00	   3.79	   1.00	  [1.00-­‐1.01]	   1.52	  ×	  10-­‐04	  
Within	  miRNA	   -­‐0.41	   0.11	   -­‐3.87	   0.66	  [0.54-­‐0.81]	   1.08	  ×	  10-­‐04	  
EvoFold	   -­‐0.03	   0.01	   -­‐3.41	   0.97	  [0.95-­‐0.99]	   6.40	  ×	  10-­‐04	  
Strong	  Enhancer	  (distal)	   0.01	   0.00	   3.15	   1.01	  [1.00-­‐1.01]	   1.65	  ×	  10-­‐03	  
vega	  PseudoGenes	   0.01	   0.00	   3.34	   1.01	  [1.00-­‐1.02]	   8.51	  ×	  10-­‐04	  
Exons	   -­‐0.01	   0.00	   -­‐3.94	   0.99	  [0.98-­‐0.99]	   8.08	  ×	  10-­‐05	  
5’UTR	   0.02	   0.00	   3.79	   1.02	  [1.01-­‐1.03]	   1.50	  ×	  10-­‐04	  
Lost	  Stops	   -­‐0.09	   0.03	   -­‐2.92	   0.91	  [0.86-­‐0.97]	   3.53	  ×	  10-­‐03	  
Txn	  Transition	   0.01	   0.00	   2.69	   1.01	  [1.00-­‐1.02]	   7.18	  ×	  10-­‐03	  
Insulator	   -­‐0.01	   0.00	   -­‐2.58	   0.99	  [0.99-­‐1.00]	   9.90	  ×	  10-­‐03	  
Intergenic	  SNPs	   0.00	   0.00	   1.79	   1.00	  [1.00-­‐1.01]	   7.28	  ×	  10-­‐02	  
vega	  Genes	   0.00	   0.00	   1.79	   1.00	  [1.00-­‐1.01]	   7.29	  ×	  10-­‐02	  
	  
6.4 Discussion	  
6.4.1 STAGE	  eSNPs	  	  
The	   results	   of	   the	   four	   analysed	   datasets	   for	   the	   STAGE	   eSNPs	   differed	  
substantially	  from	  each	  other.	  The	  means	  of	  the	  odds	  ratios	  for	  the	  different	  sets	  
were	  2.64	  for	  All	  eSNPs,	  2.01	  for	  GWAS	  hits,	  4.49	  for	  the	  Shared	  eSNPs,	  and	  2.15	  
for	  Tissue-­‐specific	  SNPs.	  The	  odds	  ratios	  for	  All	  eSNPs	  are	  therefore	  much	  closer	  
to	   the	  odds	   ratios	   for	  Tissue-­‐specific	   eSNPs	   than	  Shared	  eSNPs.	  This	   could	  be	  
expected,	   since	   there	   are	   more	   Tissue-­‐specific	   eSNPs	   than	   Shared	   eSNPs	   the	  
combined	   set	   would	   be	   more	   influenced	   by	   the	   larger	   subset.	   However,	   the	  
results	  were	  even	  less	  similar	  to	  the	  GWAS	  hits	  than	  to	  each	  other.	  The	  Shared	  
eSNPs	  had	  a	  very	  high	  mean	  of	  odds	  ratios	  in	  comparison	  with	  the	  others,	  while	  
the	  GWAS	  hits	  had	  the	  lowest	  mean	  of	  odds	  ratios.	  The	  correlations	  of	  the	  odds	  
ratios	   for	   the	   annotations	   between	   the	   SNP	   datasets	  were	   0.90	   for	   Shared	   vs.	  
Tissue-­‐specific	  eSNPs,	  0.94	  for	  Shared	  eSNPs	  vs.	  All	  eSNPs,	  and	  0.99	  for	  Tissue-­‐
specific	  eSNPs	  vs.	  All	  eSNPs.	  These	  correlations	  are	  very	  high	  and	  stand	  in	  quite	  
a	  large	  contrast	  with	  the	  correlations	  of	  the	  odds	  ratios	  of	  the	  GWAS	  hits	  and	  the	  
eSNPs	   sets:	  The	  correlation	  of	  GWAS	  vs.	  All	   eSNPs	  was	  0.52,	  GWAS	  vs.	   Shared	  
eSNPs	  was	   0.39,	   and	   GWAS	   vs.	   Tissue-­‐specific	   eSNPs	  was	   0.57.	   This	   suggests	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that	   the	  eSNPs	  were	  more	  similar	   to	  each	  other	   than	  to	  GWAS	  hits,	  but	  GWAS	  
hits	  were	  more	   like	   the	  Tissue-­‐specific	  eSNPs	   than	  either	  Shared	  eSNPs	  or	  All	  
eSNPs.	  	  
	  
The	  poor	  correlations	  between	  the	  GWAS	  hits	  and	  the	  eSNPs	  may	  be	  due	  to	  the	  
number	  of	   analysed	  SNPs.	  The	   total	  number	  of	  GWAS	  hits	  was	  969,	  while	   the	  
different	  eSNPs	  sets	  were	  6,700,	  19,846	  and	  26,546	  SNPs.	  This	  may	  not	  be	  a	  fair	  
comparison	  due	  to	  the	  large	  difference	  in	  numbers,	  which	  may	  have	  influenced	  
the	  results,	  especially	  in	  the	  sparser	  genomic	  annotations	  like	  the	  splice	  sites.	  It	  
could	  be	  speculated	  that	  the	  Shared	  eSNPs	  are	  a	  set	  of	  “truer”	  eQTLs.	  There	  has	  
been	  more	  experimental	  evidence	  for	  them,	  as	  Shared	  eSNPs	  have	  been	  shown	  
to	  influence	  gene	  expression	  in	  at	  least	  two	  different	  tissues.	  The	  association	  to	  
gene	  expression	  has	  therefore	  been	  replicated	  in	  at	   least	  one	  other	  tissue.	  The	  
set	   of	   Tissue-­‐specific	   eSNPs	   is	   quite	   likely	   to	   consist	   of	   true	   positives	   and	  
spurious	  associations,	  similar	  to	  the	  set	  of	  trait-­‐associated	  SNPs	  with	  suggestive	  
levels	   of	   trait-­‐association.	   The	   trend	   of	   enrichments	   for	   the	   Shared	   eSNPs	   is	  
followed	   by	   the	   Tissue-­‐specific	   eSNPs.	   The	   copying	   of	   the	   trend	   of	   the	   odds	  
ratios	  for	  the	  Tissue-­‐specific	  eSNPs	  without	  reaching	  the	  same	  observed	  levels	  
as	  the	  odds	  ratios	  in	  the	  Shared	  eSNP	  set,	  was	  very	  comparable	  to	  the	  trend	  of	  
the	  results	  of	  the	  Suggestive	  SNPs	  (2011)	  following	  the	  results	  of	  the	  Significant	  
SNPs	   (2011).	   However,	   here	   the	   majority	   of	   genomic	   annotations	   reached	  
significance,	   which	   is	   likely	   due	   to	   the	   number	   of	   analysed	   SNPs,	   where	   the	  
Tissue-­‐specific	   eSNPs	   had	   almost	   three	   times	  more	   SNPs	   than	   the	   Suggestive	  
SNPs	  (2011).	  	  
	  
All	   eSNP	  datasets	  had	  more	  significantly	  enriched	  annotations	   than	   the	  GWAS	  
hits	   dataset.	   The	   analysed	   eSNPs	   are	   only	   suspected	   to	   be	   eQTLs	   influencing	  
gene	   expression	   levels,	   as	   no	   validating	   experiments	  were	   performed.	   If	   they	  
were	  true	  eQTLs,	  they	  would	  be	  enriched	  in	  those	  regions	  where	  experimental	  
evidence	  already	  exists	  for	  eQTLs,	  i.e.,	  regions	  shown	  to	  influence	  levels	  of	  gene	  
expression.	   The	   genomic	   annotations	   that	   showed	   significantly	   different	   odds	  
ratios	  of	  enrichment	  between	  GWAS	  and	  All	  eSNPs,	  where	  eSNPs	  had	  a	  higher	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odds	   ratio	  were:	   1	   Kb	   and	   5	   Kb	   regions	   upstream	   of	   transcription	   start	   sites	  
(TSS),	   intronic	   SNPs,	   previously	   identified	   eQTLs,	   positively	   selected	   genes,	  
transcriptional	  elongation	  and	  weak	  transcription.	  The	  regions	  upstream	  of	  the	  
transcription	   start	   sites	   (TSS)	   are	   regions	   associated	  with	   putative	   promoters	  
[50],	  and	  there	  has	  been	  a	  substantial	  amount	  of	  evidence	  for	  eQTLs	  clustering	  
in	  those	  regions	  [72,	  108,	  147,	  159,	  160].	  	  
	  
Further	  literature	  findings	  supporting	  the	  existence	  of	  real	  eQTLs	  in	  the	  eSNPs	  
showed	  that	  exons	  were	  enriched	  over	   introns	  and	  that	  the	  preferred	  location	  
of	  eQTLs	  was	  in	  or	  near	  target	  genes	  and	  transcribed	  regions	  [72].	  We	  observed	  
similar	   odds	   ratios	   in	   exons	   and	   exonic	   SNPs	   obtaining	   higher	   than	   intronic	  
SNPs	   and	   significant	   differences	   in	   the	   regions	   associated	   with	   weak	  
transcription	  and	  transcriptional	  elongation	  (see	  Table	  6-­‐3).	  Additionally,	  it	  has	  
previously	   been	   observed	   that	   non-­‐synonymous	   SNPs	   are	   preferentially	   not	  
eQTLs,	   so	   the	   relative	   depletion	   in	   comparison	   with	   synonymous	   SNPs	   is	   an	  
encouraging	  result	  [161,	  162].	  There	  was	  a	  strong	  and	  significant	  correlation	  in	  
gene	  expression	   levels	  of	  positively	   selected	   regions	   in	   the	  Yoruba	  population	  
and	   the	   number	   of	   eQTLs	   coinciding	   with	   these	   regions	   [163],	   which	   could	  
explain	  the	  significant	  odds	  ratio	  of	  enrichment	  in	  the	  positively	  selected	  genes	  
(All	   eSNPs	   OR	   =	   2.74	   [2.44-­‐3.01],	   Shared	   eSNPs	   =	   4.45	   [3.65-­‐5.34],	   Tissue-­‐
specific	   eSNPs	   =	   2.35	   [2.12-­‐2.56]).	   Enrichment	   of	   eSNPs	   in	   these	   areas	   is	  
therefore	   an	   indication	   that	   the	   eSNPs	   datasets	   contain	   real	   eQTLs,	  while	   the	  
other	  enriched	  regions	  could	  have	  regulatory	  functions	  that	  were	  previously	  not	  
shown.	  	  
	  
Most	   of	   these	   regions	   either	   coincided	   with	   or	   were	   regulatory	   regions;	   so	  
higher	   enrichment	   signals	   for	   eQTLs	   in	   comparison	   with	   GWAS	   were	   highly	  
encouraging.	   The	   only	   genomic	   annotation,	   which	   had	   a	   higher	   odds	   ratio	   of	  
enrichment	   for	   GWAS	   hits	   than	   for	   eSNPs,	   was	   OMIM	   morbid	   regions.	   As	  
pointed	  out	   in	  previous	  chapters,	   these	  regions	  were	   the	  genomic	   locations	  of	  
the	  underlying	  biology	  for	  a	  large	  variety	  of	  traits	  and	  were	  used	  as	  a	  proxy	  for	  a	  
positive	  control	  for	  GWAS	  hits.	  The	  enrichment	  result	  of	  GWAS	  hits	  in	  the	  OMIM	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morbid	   regions	   and	   high	   enrichment	   signal	   of	   All	   eSNPs	   in	   the	   previously	  
identified	  eQTL	  dataset	  were	  very	  intuitive	  and	  encouraging.	  We	  have	  therefore	  
shown	  that	  there	  is	  not	  only	  significant	  enrichment	  of	  eSNPs	  in	  areas	  prone	  to	  
harbour	  eQTLs,	  but	  also	  show	  that	  the	  distribution	  of	  the	  eSNPs	  is	  different	  to	  
GWAS	  hits.	  
The	   enrichment	   of	   eSNPs	   in	   a	   number	   of	   genomic	   annotations	   previously	  
associated	   with	   eQTLs	   suggests	   that	   the	   analysed	   datasets	   did	   contain	   real	  
eQTLs.	   The	   investigation	   of	   gene	   expression	   levels	   was	   performed	   on	   a	   very	  
small	   number	   of	   patients	   (n	   =	   109),	   which	   could	   have	   introduced	   a	   large	  
number	   of	   false	   (positive	   and	   negative)	   signals	   due	   to	   multiple	   testing	   and	  
stochastic	   associations.	   The	   false	   discovery	   rate	   applied	   to	   identify	   the	   real	  
associations	  may	   not	   have	   been	   stringent	   enough	   to	   distinguish	   between	   the	  
real	   and	   false	   positive	   signal.	   However,	   the	   analysis	   of	   gene	   expression	   in	  
different	  tissues	  did	  lend	  extra	  confidence	  to	  the	  accuracy	  of	  the	  results	  as	  more	  
evidence	   of	   the	   association	   to	   gene	   expression	   levels	  was	   found.	   It	  may	   have	  
benefitted	   the	   results	   and	   conclusions	   of	   the	   study	   to	   restrict	   the	   analysis	   to	  
only	   those	   eSNPs,	   for	   which	   there	   was	   evidence	   of	   associations	   to	   gene	  
expression	  in	  at	  least	  two	  tissues	  (i.e.,	  Shared	  eSNPs),	  as	  it	  would	  have	  reduced	  
the	  number	  of	   false	  positives.	  Additionally,	   increasing	   the	  number	  of	  analysed	  
patients	  or	  the	   inclusion	  of	  a	  control	  group	  of	  healthy	  people	  may	  also	  aid	  the	  
discovery	  of	  real	  eQTLs.	  	  
6.4.2 GIANT	  height	  consortium	  
The	  SNPs	  from	  the	  GIANT	  consortium	  were	  the	  first	  analysed	  dataset	  for	  which	  
the	   inclusion	   of	   the	   genotyping	   arrays	   did	   not	   contribute	   any	   additional	  
information.	  The	  model,	  which	  contained	  only	  the	  genotyping	  arrays,	  had	  an	  r2	  
value	  of	  0.00	  (0.0004),	  so	  the	  information	  added	  by	  the	  genotyping	  arrays	  to	  the	  
final	   model	   was	   minimal.	   This	   was	   a	   surprising	   result,	   as	   the	   meta-­‐analysis	  
combined	  the	  results	  of	  61	   individual	  cohort	  or	  case-­‐control	  studies,	  which	  all	  
used	   different	   genotyping	   arrays	   [57].	   It	   would	   have	   been	   expected	   that	   the	  
genotyping	  arrays	  added	  more	  than	  0.0004	  to	  the	  model.	  However,	  it	  is	  possible	  
that	   the	   effect	   was	   reduced	   to	   insignificant	   amounts,	   as	   all	   of	   the	   61	   studies	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performed	   imputations	   to	   ease	   comparison	   across	   the	   different	   studies.	   The	  
results	   of	   the	   meta-­‐analysis	   were	   all	   based	   on	   the	   imputed	   genotypes	   of	   the	  
SNPs.	  The	  r2	  value	  of	   the	   final	  model	  was	  extracted	   from	  the	  summary	  with	  a	  
value	  of	  0.03	  (0.027),	  meaning	  that	  most	  of	  the	  variation	  remained	  unexplained.	  
The	  modest	  r2	  value	  of	  the	  final	  model	  suggests	  that	  the	  majority	  of	  the	  height-­‐
associated	   variation	   is	   either	   still	   not	   captured	   or	   is	   explained	   by	   a	   different	  
genomic	  annotation	  not	  yet	  analysed.	  Half	  of	  the	  final	  genomic	  annotations	  with	  
significant	  P-­values	  had	  a	  negative	  estimated	  effect	  in	  the	  model.	  The	  dependent	  
variable	  was	   the	   negative	   logarithm	   of	   the	  P-­value	   of	   association	   to	   height	   of	  
individual	   SNPs.	   Annotations	   with	   a	   negative	   estimate	   would	   indicate	   the	  
relative	   negative	   influence	   on	   the	   logarithm	  of	   the	  P-­value,	   i.e.,	  a	   reduction	   in	  
significance.	   These	   annotations	   expectedly	   included	   regions	   associated	   with	  
closed	   or	   repressed	   chromatin	   states,	   which	   are	   associated	   with	   little	   to	   no	  
transcriptional	  activity.	  	  
6.4.3 Conclusion	  
In	   conclusion,	   we	   showed	   that	   eSNPs	   had	   a	   genomic	   signature,	   which	   was	  
indicative	   for	   eQTL	   enrichment	   and	   was	   distinctly	   different	   from	   GWAS	   hits.	  
The	   analysis	   also	   showed,	   that	   the	   method	   and	   the	   established	   dataset	   was	  
adaptable	   to	  analyse	  results	   from	  different	  study	   types.	  The	  application	  of	   the	  
linear	   regression	   to	   the	   SNPs	   associated	   to	   height	   highlighted	   another	  way	   of	  
utilizing	   the	  built	  dataset	   for	  different	   studies.	  While	   the	   linear	   regression	  did	  
not	   result	   in	   a	   large	   reduction	   of	   the	   analysed	   genomic	   annotations,	   it	   did	  
highlight	   that	   a	   number	   of	   genomic	   annotations	   were	   influencing	   height-­‐
association.	   The	   result	   could	   either	   be	   due	   to	   the	   analysis	   of	   a	   continuous	  
variable	  or	  could	  underline	  the	  genetic	  complexity	  of	  height.	  It	  needs	  to	  be	  kept	  
in	  mind	  that	  the	  change	  of	  one	  unit	  in	  the	  dependent	  variable	  is	  associated	  with	  
the	  change	  of	  one	  unit	  in	  the	  independent	  variable,	  which	  may	  only	  be	  a	  small	  
increase	   in	   the	   continuous	  P-­value	   of	   height-­‐association,	   but	   significantly	   add	  
towards	  explaining	  the	  observed	  variability	  in	  the	  dataset.	  	  
	   169	  
7 DISCUSSION	  
We	  wanted	  to	  investigate	  the	  distribution	  of	  trait	  associated	  SNPs	  in	  the	  genome	  
with	   respect	   to	   a	   range	   of	   genomic	   annotations,	   which	   covered	   a	   range	   of	  
regulatory	   features	   that	   were	   identified	   by	   experiments	   or	   computer	  
algorithms.	   We	   expanded	   the	   work	   performed	   by	   a	   previous	   study	   [50],	   to	  
address	   some	   flaws	   and	   investigate	   more	   annotations.	   We	   have	   presented	   a	  
statistically	   rigorous	   analysis	   of	   enrichment	   or	   depletion	   of	   trait	   associated	  
variants	   within	   58	   genomic	   annotations	   aimed	   at	   elucidating	   the	   question	   of	  
what	  GWAS	  hits	  coincide	  with	  using	  novel	   techniques	  and	  data	  available	   from	  
the	   NHGRI	   GWAS	   catalogue	   (http://www.genome.gov/gwastudies/).	   The	  
methods	   we	   used	   for	   this	   investigation	   were	   sampling,	   permutations	   and	  
regression,	  which	  are	  summarised	  below.	  We	  have	  further	  applied	  the	  methods	  
presented	   to	   other	   data,	   in	   particular	   the	   results	   of	   a	   GWAS	   analysing	   gene	  
expression	   levels	   and	   a	   meta-­‐analysis	   investigating	   height.	   Here,	   we	   discuss	  
related	  studies	  investigating	  the	  genomic	  context	  of	  trait-­‐associated	  variants.	  
7.1 Summary	  of	  sampling	  method	  
Hindorff	   et	   al.	   performed	   a	   similar	   study	   [50]	  where	   a	   sampling	  method	  was	  
used	   to	   analyse	   the	   distribution	   of	   the	   then-­‐known	  GWAS	   hits	   in	   20	   genomic	  
annotations.	  The	  analysed	  sampling	  method	  set	  out	  to	  create	  a	  null	  distribution	  
against	  which	  the	  observed	  data	  could	  be	  compared	  by	  randomly	  drawing	  many	  
(in	  our	  case	  100)	  sets	  of	  SNPs.	  These	  sets	  of	  SNPs	  were	  drawn	  from	  genotyping	  
arrays	  and	  imputed	  data	  used	  in	  the	  original	  set	  of	  GWA	  studies,	  matching	  the	  
genotyping	   array	   composition	   of	   the	   observed	   trait-­‐associated	   SNPs	   data	  
(GWAS	   hits).	   It	   therefore	   compared	   the	   observed	   hit	   distribution	   to	   a	  
background	  distribution	   to	   assess	   the	   significance	   of	   the	   results.	   This	  method	  
had	  four	  problems	  associated	  with	  it.	  The	  first	  was	  that	  it	  was	  computationally	  
intensive	  and	  took	  one	  day	  for	  the	  analysis	  of	  100	  samples.	  Second,	  information	  
on	  genotyping	  platform	  used	  were	  not	  always	  available	  for	  all	  the	  GWA	  studies	  
recorded	   in	   the	  NHGRI	  GWAS	  catalogue	   [86]	  on	   important	  details	  of	   the	  GWA	  
studies	  curated,	  such	  as	  the	  genotyping	  array	  used	  in	  a	  given	  study.	  Third,	   the	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optimal	   number	   of	   samples	   needed	   to	   appropriately	   describe	   the	   background	  
(null)	   distribution	   of	   SNPs	   is	   unclear	   and	   determined	   by	   computational	  
constraints.	   Fourth,	   this	   method	   ignores	   the	   observed	   clustering	   of	   trait-­‐
associated	  SNPs	  in	  the	  genome,	  as	  such	  SNPs	  will	  often	  co-­‐occur	  with	  regulatory	  
and	  genic	   regions	   [164,	  165].	   It	   is	   therefore	  unlikely	   that	   the	  null	  distribution	  
produced	  by	  the	  samples	  drawn	  would	  reflect	  this	  observed	  clustering,	  and	  this	  
may	  be	  a	  source	  of	  artificial	  enrichments	  or	  depletions	  of	  trait-­‐associated	  SNPs	  
in	   some	   of	   the	   studied	   functional	   annotations.	   Despite	   being	   aware	   of	   these	  
problems,	   the	   first	  analysis	  performed	   in	   this	   thesis	  was	   the	  replication	  of	   the	  
study	   of	   Hindorff	   et	   al.	   [50].	   This	   was	   done	   as	   a	   benchmark	   to	   compare	   the	  
methodology	   we	   developed	   and	   summarise	   below.	   We	   extended	   the	   set	   of	  
annotations	  used	  by	  Hindorff	  et	  al.	   to	   include	  more	  regulatory	  annotations,	  as	  
well	   as	   several	   measures	   of	   conserved	   elements	   and	   regions	   with	   different	  
chromatin	  states.	  
7.2 Summary	  of	  permutation	  method	  
In	  order	  to	  preserve	  the	  observed	  clustering	  of	  SNPs	  and	  functional	  annotations	  
in	  the	  genome,	  we	  developed	  a	  method	  that	  explicitly	  preserves	  that	  structure	  
and	   was	   based	   on	   chromosome-­‐bound	   circular	   permutations.	   The	   method	  
produces	   a	   null	   distribution	   consisting	   of	   the	   20,000	   circularly	   permuted	  
genomes,	  which	  contained	  the	  same	  number	  of	  analysed	  SNPs	  per	  chromosome	  
and	   respected	   the	   clustering	   of	   those	   SNPs	   and	   all	   functional	   elements	   in	   the	  
genome.	  The	  20,000	  permutations	  were	  run	  in	  parallel	  on	  a	  locally	  maintained	  
256	  CPU	   computer	   cluster	   and	   finished	   in	   three	  days	   for	   all	   chromosomes.	   In	  
comparison,	   the	   sampling	   method	   took	   about	   a	   day	   for	   100	   samples.	   It	   will	  
therefore	   likely	   take	  more	   than	   three	   days	   to	   analyse	   20,000	   sets	   of	   samples.	  
Importantly,	  the	  permutation	  method	  is	  readily	  scalable	  to	  very	  large	  numbers	  
of	   trait-­‐associated	   SNPs	   and	   functional	   annotations.	   The	   results	   of	   the	  
permutations	  were	  very	  comparable	  with	  the	  results	  from	  the	  sampling	  method	  
with	  an	  r2	  of	  the	  regression	  of	  their	  odds	  ratios	  of	  0.98.	  The	  confidence	  intervals	  
of	   the	   odds	   ratios	   derived	   by	   permutation	   are	   generally	   slightly	   more	  
conservative	   (i.e.,	   larger)	   than	   those	   from	   the	   sampling	   approach.	   This	   is	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because	  the	  empirically	  calculated	  confidence	  intervals	  use	  information	  on	  the	  
underlying	  distribution	  of	   the	  permuted	  number	  of	   overlaps.	  We	  also	   showed	  
that	   SNPs,	   which	   had	   suggestive	   levels	   of	   trait-­‐association,	   had	   less	   extreme	  
odds	  ratios	  of	  enrichment	  or	  depletion	  than	  significantly	  trait-­‐associated	  SNPs.	  
This	   result	   confirms	   the	   hypothesis	   that	   the	   suggestive	   SNPs	   consist	   of	   true	  
positive	   signals,	   which	   would	   have	   the	   same	   distribution	   as	   the	   significantly	  
associated	   variants,	   and	   false	  positive	   signals,	  which	  would	  be	   expected	   to	   lie	  
outside	   trait-­‐associated	   regions.	   In	   the	   analysis	   above	   one	   of	   the	   parameters	  
was	  the	  LD	  threshold,	  which	  determines	  the	  number	  of	  SNPs	  that	  are	  analysed	  
as	   LD	   partners,	   which	   we	   initially	   set	   at	   0.9.	   A	   second	   LD	   threshold	   was	  
analysed,	   which	   showed	   that	   including	  more	   LD	   partners	   did	   not	   establish	   a	  
clearer	   picture	   of	   enrichment	   versus	   depletion	   of	   trait-­‐associated	   variants.	  
Furthermore,	   we	   analysed	   trait-­‐associated	   variants	   from	   more	   recent	   GWAS	  
and	  showed	  that	  they	  obtained	  less	  extreme	  odds	  ratios	  than	  the	  older	  data;	  see	  
Significant	  SNPs	  (2011)	  compared	  with	  Significant	  SNPs	  (Difference)	  in	  Chapter	  
4.	   This	   means	   that	   the	   newer	   variants	   have	   a	   different	   distribution	   than	   the	  
older	  variants.	  
7.3 Summary	  of	  regression	  models	  
The	   sampling	   and	   permutation	   methods	   analysed	   individual	   genomic	  
annotations	  and	  are	  therefore	  called	  univariate	  analyses.	  We	  wanted	  to	  test	  all	  
genomic	  annotations	  at	   the	   same	   time	  and	   remove	  all	   redundant	   information.	  
For	  this	  we	  used	  a	  multivariate	  logistic	  regression	  model.	  However,	  in	  order	  to	  
allow	   comparisons	   between	   the	   between	   the	   permutations	   and	   sampling	  
methods	   and	   the	   multivariate	   model,	   we	   analysed	   individual	   genomic	  
annotations	   using	   univariate	   logistic	   regression.	   This	   allowed	   comparisons	  
between	   different	   univariate	   analyses	   and	   different	   regression	   methods.	   The	  
weight	   of	   the	   annotation	   was	   an	   outcome	   from	   the	   analysis	   and	   can	   be	  
interpreted	  as	  the	  natural	  logarithm	  of	  an	  odds	  ratio.	  The	  weight	  was	  based	  on	  
the	  presence	  or	  absence	  of	  overlaps	  with	  trait-­‐associated	  variants,	  but	   instead	  
of	  analysing	  100	  samples	  or	  the	  results	  of	  20,000	  permutations	  all	  SNPs	  present	  
in	   the	   background	   data	   were	   analysed.	   This	   method	   is	   exceptionally	   fast,	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finishing	   in	   less	   than	   two	  hours	  when	  run	  on	   the	  computer	  cluster	  mentioned	  
above	  (Chapter	  5).	  The	  null	  distribution	  of	  this	  method	  was	  the	  number	  of	  real	  
non-­‐associated	  SNPs,	  which	  were	  compared	  to	  the	  trait-­‐associated	  SNPs.	  	  
While	  the	  univariate	  methods,	  examining	  annotations	  individually,	  may	  be	  very	  
useful	   for	   investigating	   specific	   genomic	   annotations	   of	   interest,	   the	   overall	  
conclusions	  of	   these	  analyses	  may	  be	  misleading	   (see	  Chapter	  5).	   It	   is	  unclear	  
from	  such	  results,	  which	  of	  the	  overlapping	  and	  often-­‐interdependent	  genomic	  
annotations	  are	  driving	  any	  observed	  enrichment.	  While	  it	  is	  difficult	  to	  identify	  
the	   drivers	   of	   the	   enrichment	   with	   any	   of	   the	   analysed	   methods,	   the	  
multivariate	   approach	   does	   at	   least	   show	   the	   effect	   of	   the	   correlations	   and	  
highlights	   the	   most	   informative	   annotations.	   The	   multivariate	   analysis	  
calculated	   an	   information	   criterion,	   the	   Akaike’s	   Information	   Criterion	   (see	  
Chapter	   5),	   based	   upon	   which	   a	   decision	   was	   taken	   to	   include	   or	   exclude	  
genomic	   annotations	   from	   the	  model.	   This	  was	   a	   comparatively	   slow	  method	  
even	   when	   run	   on	   the	   computer	   cluster	   taking	   up	   to	   ten	   days	   to	   complete.	  
However,	   the	   final	  model	  was	  determined	  by	   the	   amount	   of	   information	   each	  
genomic	   annotation	   carried	   (Chapter	   5)	   and	   the	   method	   had	   the	   added	  
advantage	  that	  the	  effect	  of	  the	  genotyping	  array	  used	  was	  explicitly	  included	  in	  
the	  model,	  unlike	  other	  methods.	  If	  a	  SNP	  was	  represented	  on	  several	  arrays,	  it	  
had	  a	  higher	  chance	  of	  being	  trait-­‐associated	  due	  to	  it	  being	  tested	  more	  often.	  
This	   prior	   probability	   was	   taken	   into	   account	   by	   including	   the	   genotyping	  
arrays	   into	   the	   model.	   A	   possible	   avenue	   that	   could	   be	   taken	   to	   extend	   this	  
method	   is	   by	   including	   additional	   variables	   extra	   annotations	   or	   interactions	  
between	  variables.	  However,	  this	  would	  further	  increase	  the	  running	  time	  of	  the	  
method.	   The	  multivariate	  models	   highlighted	   those	   genomic	   annotations	  with	  
relative	   depletion	   of	   trait-­‐associated	   SNPs,	   which	   obtained	   odds	   ratios	   of	  
enrichment	   in	   the	  univariate	   analyses.	  The	   relative	  depletion	   results	   from	   the	  
comparison	  with	  other	  genomic	  annotations,	  which	  contain	  more	  SNPs	  than	  the	  
depleted	   ones.	   This	   suggests	   that	   the	   univariate	   models	   may	   have	  
overestimated	   the	   importance	   of	   the	   annotations,	   as	   other	   influences	  
contributing	  to	  the	  observed	  enrichment	  were	  not	  taken	  into	  account,	  which	  is	  
an	  important	  finding	  for	  future	  analyses.	  
	   173	  
7.4 Recommendation	  of	  methods	  
We	   have	   analysed	   three	   different	   methods	   of	   investigating	   the	   overlaps	  
between	   trait-­‐associated	   variants	   and	   genomic	   annotations.	   The	   three	  
considered	  univariate	  analyses,	  which	  were	  sampling,	  permutations,	  and	  single	  
variable	   logistic	   regression,	   produced	   remarkably	   similar	   and	   highly	  
comparable	  results.	  However,	  if	  a	  recommendation	  were	  to	  be	  given	  as	  to	  which	  
univariate	  method	  should	  be	  used	  in	  further	  analyses,	  it	  would	  be	  suggested	  to	  
use	   the	   permutation	   method.	   This	   is	   due	   to	   the	   number	   of	   expected	   –	   or	  
background	   –	   overlaps	   against	   which	   the	   real	   trait-­‐associated	   variants	   were	  
compared.	  The	  permutations	  generated	  20,000	  virtual	  genomes	  with	  the	  same	  
number	  of	  variants	  analysed	  per	  chromosome	  producing	  highly	  robust	  results.	  
In	   comparison,	   the	   sampling	   method	   relied	   upon	   100	   samples	   and	   while	   it	  
focussed	  on	  the	  distribution	  of	  the	  variants	  across	  genotyping	  arrays,	  it	  did	  not	  
control	   the	   number	   of	   analysed	   variants	   per	   chromosome.	   Furthermore,	   the	  
sampling	  method	  was	  the	  slowest	  of	  the	  methods	  and	  took	  a	  total	  of	  three	  days	  
for	   an	   analysis.	   While	   the	   logistic	   regression	   using	   single	   variables	   was	   the	  
fastest	   of	   the	   three	   methods,	   it	   produced	   possibly	   inflated	   odds	   ratios.	   The	  
results	  were	  produced	  by	  a	  direct	  comparison	  of	  overlaps	  and	  non-­‐overlaps	  of	  
the	  SNP	  sets	  and	  the	  background.	  However,	  the	  background	  here	  was	  the	  entire	  
genome,	  which	  consisted	  of	  a	  very	  large	  number	  of	  non-­‐associated	  variants	  (i.e.,	  
a	   very	   large	   number	   of	   zeros).	   This	   disproportionate	   separation	   of	   the	   data	  
could	  have	   inflated	   the	   importance	  of	  any	  annotation	   found	   to	  be	  overlapping	  
with	  the	  variants.	  	  
If	  at	  all	  possible,	  however,	  it	  is	  recommended	  to	  use	  the	  multivariate	  analysis	  to	  
analyse	   genomic	   annotations	   overlapping	   with	   associated	   variants.	   This	   is	  
because	   the	  variants	  may	  overlap	  with	  more	   than	  one	  annotation	  at	   the	   time,	  
which	  overestimates	  the	  importance	  of	  individual	  annotations.	  The	  multivariate	  
analysis,	  however,	  takes	  that	  into	  account	  and	  removes	  redundant	  information	  
resulting	   in	  a	  model	   containing	   the	  minimum	  number	  of	   genomic	  annotations	  
explaining	   the	  maximum	   amount	   of	   variation.	   The	   sampling	   and	   permutation	  
methods	  were	  not	  capable	  of	  that,	  so	  the	  logistic	  regression	  was	  used.	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7.5 Summary	  of	  application	  to	  other	  data	  	  
The	   permutation	   and	   multivariate	   regression	   methods	   were	   respectively	  
applied	   to	   two	   different	   datasets,	   a	   gene	   expression	   study	   of	   seven	   different	  
tissues	  in	  myocardial	  infarction	  and	  a	  GWAS	  meta-­‐analysis	  for	  height-­‐associated	  
SNPs,	   to	   demonstrate	   the	   practical	   application	   of	   the	   methods	   described	   in	  
previous	  chapters	  (Chapter	  6).	  The	  permutation	  method	  discovered	  that	  eSNPs,	  
which	  were	  significant	  GWAS	  hits	   in	  an	  analysis	   investigating	  gene	  expression	  
levels,	  are	  more	  enriched	  in	  promoter	  and	  regulatory	  regions	  than	  other	  GWAS	  
hits.	  This	  implied	  that	  eSNPs	  may	  have	  a	  different	  mechanism	  to	  influence	  traits	  
than	   GWAS	   hits,	   as	   would	   have	   been	   expected	   if	   they	   are,	   or	   contain	   a	   high	  
number	   of,	   real	   eQTLs.	   It	   is	   possible	   that	   GWAS	   hits	   affect	   a	   given	   trait	   less	  
subtly	   than	   eQTLs	   do,	   given	   that	   eQTLs	   influence	   traits	   by	   affecting	   gene	  
expression	  levels.	  This	  effect	  could	  be	  quite	  small	  and	  therefore	  not	  immediately	  
noticeable.	  GWAS	  hits,	   however,	   could	  act	  upon	   traits	  by	  disrupting	   coding	  or	  
binding	  regions,	  which	  could	  affect	  phenotypes	  quite	  quickly.	  We	  also	  showed	  
that	  Shared	  eSNPs	  (i.e.,	  eSNPs	  which	  were	  significant	  in	  more	  than	  two	  tissues)	  
have	  more	  extreme	  odds	  ratios	  than	  either	  of	  the	  other	  analysed	  eSNPs	  datasets	  
-­‐	   All	   eSNPs	   or	   Tissue-­‐specific	   eSNPs	   (see	   Chapter	   6).	   A	   linear	   regression	  
investigating	  height-­‐associated	  SNPs	  showed	  that	  51	  of	  54	  genomic	  annotations	  
jointly	   influenced	   the	   P-­value	   of	   height-­‐association.	   While	   this	   is	   a	   very	   high	  
number	  of	  annotations,	  each	  annotation	  influenced	  the	  height-­‐association	  only	  
slightly	  with	  odds	  ratios	  ranging	  from	  0.66	  –	  1.24.	  	  
7.6 Discussion	  of	  genomic	  annotations	  	  
The	  three	  categories	  of	  genomic	  annotations	  had	  different	  relative	  enrichment	  
of	  trait-­‐associated	  variants.	  The	  genic	  category	  included	  regions	  associated	  with	  
genes	   and	   other	   regulatory	   elements,	   such	   as	   eQTLs.	   The	   majority	   of	   the	  
annotations	   included	   in	   this	   category	   were	   enriched	   with	   trait-­‐associated	  
variants.	   The	   enrichment	   signal,	   however,	   could	   possibly	   be	   caused	   by	   the	  
coinciding	   annotations.	   The	   genic	   category	   contained	   genomic	   annotations,	  
which	   ranged	   from	   single	   nucleotides	   to	   full	   genes	   thereby	   introducing	   some	  
heterogeneity	  into	  the	  dataset.	  However,	  the	  impact	  of	  the	  genic	  category	  is	  still	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larger	   than	   the	   conserved	   annotation	   category.	   The	   majority	   of	   the	   genic	  
annotations	   were	   analysed	   previously	   by	   a	   number	   of	   authors	   in	   different	  
studies,	  where	  DNase	   I	  hypersensitive	  sites,	  eQTLs,	  and	  distance	   from	  the	  TSS	  
feature	  the	  most	  often	  [50,	  65,	  110,	  111,	  147,	  166].	  The	  genic	  annotations	  were	  
also	   the	   ones	   that	   were	   included	   most	   frequently	   in	   the	   final	   model	   of	  
multivariate	  analyses	  with	  the	  exception	  of	  the	  Cancer	  SNPs	  set.	  
	  
The	   annotations	   included	   in	   the	   conserved	   region	   were	   slightly	   more	  
comparable	  in	  the	  lengths	  of	  the	  annotated	  genomic	  blocks,	  but	  they	  were	  only	  
modestly	  enriched	  in	  all	  analyses.	  The	  Immune	  SNPs	  and	  Cancer	  SNPs	  were	  the	  
two	   SNP	   sets	   that	   were	   the	   exception	   to	   this,	   as	   conserved	   regions	   were	  
significantly	   and	   consistently	   depleted	   in	   the	   Immune	   SNPs	  while	   the	   Cancer	  
SNPs	  showed	  enrichment	  for	  these	  sites.	  A	  different	  study	  that	  also	  investigated	  
phastCons	  sites	  was	  the	  study	  by	  Gaffney	  et	  al.,	  which	  also	  showed	  only	  modest	  
enrichment	   of	   SNPs	   in	   these	   sites	   [147].	   Hindorff	   et	   al.	   [50]	   also	   investigated	  
conserved	  sites,	  but	  chose	  only	  the	  conserved	  sites	  across	  28	  species.	  The	   low	  
enrichment	   in	   our	   study	   could	   be	   due	   to	   the	   use	   of	   all	   sites	   identified	   by	  
phastCons	   rather	   than	   restricting	   the	  annotation	   to	  only	   those	   sites	  with	  high	  
LOD	   scores.	   This	   could	   have	   reduced	   the	   odds	   ratios	   of	   the	   annotations,	   as	   it	  
could	   be	   possible	   that	   those	   sites	   that	   are	   overlapping	   with	   non-­‐associated	  
variants	  have	   low	   scores	   and	  would	  have	  been	   removed	   from	   the	  dataset	   if	   a	  
threshold	  had	  been	   applied.	  However,	   the	  obtained	  modest	   enrichment	   found	  
by	  Gaffney	  et	  al.	   [147]	  corroborates	  our	  results.	  This	  annotation	  category,	   like	  
the	  chromatin	  states,	  contained	  only	  data	  obtained	  computational	  analyses,	  but	  
had	  very	  different	  enrichment	  and	  depletion	  signals	  than	  the	  chromatin	  states.	  
It	  is	  therefore	  not	  possible	  to	  draw	  a	  line	  between	  the	  quality	  of	  data	  obtained	  
by	  experimental	  or	  computational	  analyses.	  	  
The	  annotations	  in	  the	  third	  category,	  the	  chromatin	  states,	  were	  all	   identified	  
by	  experimental	  data,	  which	  was	  refined	  through	  computational	  analyses.	  This	  
category	  contained	  annotations	  with	  the	  largest	  annotated	  genomic	  blocks	  and	  
could	   potentially	   be	   more	   robust	   to	   shifts	   in	   genomic	   positions	   between	  
genomic	  reference	  maps.	  Furthermore,	   the	  enrichment	  signals	  obtained	   in	   the	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chromatin	  states	  category	  were	  very	  encouraging	  as	   there	  has	  been	  mounting	  
evidence	   [82,	   167,	   168]	   that	   trait-­‐associated	   variants	   preferentially	   lie	   in	  
regions	  that	  can	  be	  identified	  through	  histone	  modifications	  by	  either	  analysing	  
the	  histone	  modifications	  individually	  or	  as	  a	  pattern.	  	  
As	   mentioned	   above,	   none	   of	   the	   analysed	   annotations	   were	   restricted	  
according	   to	   a	   threshold.	   This	   applied	   to	   data	   obtained	   from	   either	  
computational	  analyses	  or	  results	  obtained	  through	  experimental	  analyses,	  like	  
ChIP-­‐seq.	   The	   lack	   of	   threshold	   could	   have	   resulted	   in	   false	   positive	   or	   false	  
negative	  signals,	  depending	  on	  the	  over-­‐	  or	  under-­‐prediction	  of	  the	  annotation	  
in	   the	  observed	  or	  expected	  datasets.	  For	  example,	  a	  genomic	  region	   that	  was	  
falsely	   annotated	   and	   overlapped	   with	   real	   trait-­‐associated	   variants	   but	   not	  
with	   permuted	   variants	   could	   have	   obtained	   a	   higher	   odds	   ratio	   estimate.	  
Alternatively,	  a	  genomic	  region	  that	  was	  falsely	  annotated	  but	  overlapped	  only	  
with	  permuted	  variants	  could	  have	  caused	  a	   falsely	  reduced	  odds	  ratio.	  These	  
are	  caveats	  in	  this	  analysis,	  which	  would	  have	  to	  be	  addressed	  if	  this	  study	  were	  
to	  be	  repeated.	  	  
An	   additional	   caveat,	   which	   could	   have	   caused	   inflated	   odds	   ratios,	   is	   the	  
inclusion	   of	   non-­‐Caucasian	   studies	   into	   the	   analysis.	  While	   the	   percentage	   of	  
studies	   in	   non-­‐Caucasian	   populations	   is	   still	   quite	   small,	   it	   could	   have	  
erroneously	   inflated	   the	  number	  of	  overlaps	   in	  annotations.	  This	   is	  due	   to	   the	  
shorter	   LD	   blocks	   found	   in	   African	   population	   when	   compared	   to	   Caucasian	  
populations.	  For	   future	   studies	   it	  would	  be	   recommended	   to	   remove	   the	  non-­‐
Caucasian	  studies	  from	  further	  analyses.	  	  
	  
7.7 Other	  studies	  investigating	  functional	  annotations	  	  
Many	  recently	  published	  studies	  are	  focussing	  on	  the	  functional	  annotations	  of	  
underlying	   trait-­‐associated	   variants	   to	   inform	   future	   GWAS	   and	   population	  
sequencing	  studies	  [65,	  165,	  169,	  170].	  The	  interest	   in	  regions	  annotated	  with	  
functional	  elements	   is	   largely	  driven	  by	   the	  attempt	   to	   identify	   those	  genomic	  
annotations	   enriched	   for	   GWAS	   hits	   and	   to	   aid	   the	   often-­‐laborious	   search	   for	  
causal	  variants.	  It	  is	  hoped	  that	  a	  separation	  of	  spurious	  associations	  from	  true	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associations	   can	   be	   attempted	   by	   prioritizing	   those	   regions	   that	   were	  
previously	   associated	   with	   trait-­‐associated	   variants.	   This	   could	   potentially	  
increase	   the	   number	   of	   significantly	   trait-­‐associated	   variants	   or	   highlight	  
variants	  with	  a	  higher	   chance	  of	   giving	  a	  positive	   result.	  A	   study	  published	   in	  
2011	   [65]	   suggested	   the	   empirical	   Bayes	   Factors	   for	   three	   annotations	   (cis-­
eQTLs,	  non-­‐synonymous	  SNPs	  and	  promoter	  SNPs)	  for	  prioritisation	  algorithms	  
to	  identify	  candidates	  for	  GWAS	  follow-­‐up	  studies	  to	  be	  4,	  3	  and	  2,	  respectively.	  
This	   implies	   that	   eQTLs	   are	   most	   usually	   enriched	   for	   trait-­‐associated	   SNPs,	  
which	   confirms	   the	   findings	   of	   a	   study	   in	   2010,	   which	   found	   that	   trait-­‐
associated	   variants	   were	   most	   likely	   to	   be	   eQTLs	   [110].	   A	   study	   in	   2013	  
analysed	  a	   genomic	   inflation	   correction	  by	  estimating	  a	   genomic	   control	   from	  
intergenic	  SNPs	  [165]	  while	  also	  identifying	  strong	  enrichment	  in	  5’UTRs.	  Their	  
observations	  of	  strong	  enrichment	  in	  regulatory	  genic	  elements	  agree	  well	  with	  
our	   results,	   but	   they	   only	   analysed	   10	   annotations	   and	   did	   not	   incorporate	  
functional	   regions	   annotated	   by	   chromatin	   states	   [165].	   The	   Encyclopedia	   of	  
DNA	   Elements	   (ENCODE)	   is	   a	   large	   international	   consortium,	   which	   aims	   to	  
categorize	  DNA	  elements.	  The	  publication	  of	  an	  ENCODE	  study	  investigating	  the	  
annotations	  of	  disease-­‐associated	  SNPs	  showed	  that	  ENCODE	  data	  can	  be	  used	  
for	   these	   an	   notational	   studies	   [74].	   This	   finding	   was	   supported	   by	   the	  
publication	   of	   a	   database	   detailing	   regulatory	   and	   rare	   SNPs	   [170].	   An	  
investigation	   also	   using	   multivariate	   logistic	   regression	   to	   identify	   the	  
regulatory	   architecture	   of	   eQTLs	   by	   investigating	   transcription	   factor	   binding	  
sites	  and	  conserved	  sites	  found	  a	  distinct	  enrichment	  of	  eQTLs	  in	  transcription	  
factor	  binding	  sites,	  but	  observed	  only	  showed	  modest	  enrichment	  in	  conserved	  
sites	  [147].	  In	  this	  thesis,	  the	  conserved	  regions	  also	  showed	  modest	  odds	  ratios	  
enrichment	  in	  the	  univariate	  and	  the	  final	  multivariate	  models,	  where	  included.	  
This	   is	   despite	   the	   frequent	   use	   of	   conservation	   measures	   in	   variant	  
prioritization	  methods	   [64],	  which	   implicitly	   suggests	   that	   they	   are	   important	  
for	   trait-­‐associated	   variants.	   But	   here	   it	   appears	   that	   other	   annotations	   are	  
more	   influential.	   It	   appears	   that	   there	   are	  many	   studies	   investigating	   how	   to	  
mine	  the	  existing	  GWAS	  data	  to	  leverage	  more	  information	  from	  them	  to	  aid	  in	  
the	  dissecting	  of	  the	  genetics	  contributing	  to	  complex	  traits.	  While	  all	  studies	  to	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date	   have	   analysed	   different	   genomic	   annotations	   across	   a	   large	   spectrum	   of	  
functional	  elements,	  a	  study	  with	  as	  many	  genomic	  annotations	  as	  analysed	  in	  
this	   thesis	   had	   not	   been	   attempted.	   All	   of	   these	   studies	   suggested	   it	   was	  
worthwhile	  to	  undertake	  a	  more	  comprehensive	  analysis	  of	  functional	  elements	  
and	  to	  examine	  the	  distribution	  of	  GWAS	  hits	  within	  them.	  
7.8 Future	  work	  and	  developments	  and	  their	  impacts	  
There	  has	  been	  a	  substantial	  increase	  in	  the	  number	  of	  studies	  reporting	  on	  the	  
annotations	   of	   trait-­‐associated	   variants	   [167-­‐170]	   since	   the	   original	   study	   by	  
Hindorff	  et	  al.	   in	  2009.	  Furthermore,	  there	  have	  been	  a	  large	  number	  of	  online	  
tools	   investigating	   ways	   of	   easing	   the	   often-­‐laborious	   process	   of	   annotating	  
trait-­‐associated	   variants.	   Among	   these	   are	   HaploReg	   [171]	   and	   RegulomeDB	  
[170],	   which	   aim	   to	   aid	   researchers	   investigating	   the	   underlying	   genomic	  
regions	  of	   trait-­‐associated	  variants.	  This	   could	  potentially	   lead	   to	   a	   faster	   and	  
cheaper	   way	   to	   discover	   the	   underlying	   biological	   causes	   of	   trait-­‐associated	  
variants.	  The	  future	  will	  likely	  see	  more	  online	  tools	  used	  to	  annotate	  variants,	  
as	   there	   is	   an	   ever-­‐increasing	   pressure	   on	   the	   society	   to	   not	   just	   identify	  
associated	  variants.	  The	  tools	  may	  aid	  in	  the	  discovery	  of	  the	  real	  causes	  of	  the	  
associations	  as	  they	  highlight	  which	  annotations	  are	  most	  often	  coinciding	  with	  
trait-­‐associated	  variants.	  The	  future	  will	  tell	  if	  this	  is	  right.	  
	  
During	   the	   course	   of	   the	   research	   presented	   in	   this	   thesis,	   a	   number	   of	   new	  
annotations	  were	  published.	  The	  ENCODE	  data	  was	  released	  over	  the	  past	  few	  
years,	   locating	   a	   large	   number	   of	   transcription	   factor	   binding	   sites	   and	   other	  
sites	  of	  functional	  annotations	  [172-­‐174].	  Before	  2011	  we	  had	  included	  a	  large	  
number	   of	   histone	   modifications,	   which	   were	   identified	   in	   several	   cell	   lines.	  
However,	   in	  2011	  a	  meta-­‐analysis	  of	  histone	  modification	  patterns	   in	  nine	  cell	  
lines	   showed	   that	  particular	   combinations	   (chromatin	   states)	  were	   associated	  
with	  particular	  classes	  of	  functional	  regions	  [82].	  Most	  of	  the	  final	  multivariate	  
regression	  models	  contained	  at	  least	  one	  of	  these	  functional	  classes,	  where	  they	  
were	  influential	  in	  determining	  trait-­‐association	  status.	  One	  can	  only	  expect	  that	  
the	  next	  few	  years	  will	  see	  more	  leaps	  in	  the	  quality	  and	  quantity	  of	  functional	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data	  resulting	  in	  better	  models	  and	  possible	  identification	  of	  highly	  explanatory	  
annotations.	  	  
	  
GWAS	   sample	   sizes	   are	   increasing	   to	   allow	   the	   identification	   of	   variants	  with	  
minor	  allele	  frequencies	  (MAFs)	  of	   less	  than	  1%	  [175]	  to	  be	  detected	  [31]	  and	  
common	  variants	  with	  smaller	  effects.	  Their	  design	  will	  also	  have	   to	   include	  a	  
wider	   range	   of	   different	   populations	   to	   analyse	   diseases	   common	   to	   specific	  
populations	  and	  not	   focus	  on	  mainly	  Caucasian	  populations	   [176,	  177].	  Whole	  
genome	  sequencing	  technologies	  have	  begun	  to	  uncover	  many	  novel	  variations	  
[58,	   178]	   including	   SNPs	   with	   low	   allele	   frequencies	   and	   ‘private’	   mutations,	  
seen	   in	   only	   one	   individual.	   This	   new	  variation	  will	   facilitate	   the	  discovery	   of	  
genetic	  causes,	  as	  a	   large	  proportion	  of	  highly	  deleterious	  SNPs	  [179]	  are	  rare	  
or	   private	   mutations	   [180].	   These	   private	   mutations	   could	   aid	   the	  
understanding	   of	   complex	   traits	   greatly,	   because	   they	   could	   have	   very	   large	  
effects.	   The	   large	   effect	  would	   be	   strongly	   selected	   against,	   therefore	   keeping	  
their	  allele	   frequencies	   low.	  The	  rarity	  of	   these	  mutations	  may	  not	  necessarily	  
be	  matched	  by	  their	  abundance	  in	  certain	  pathways,	  i.e.,	  it	  could	  be	  that	  a	  large	  
number	  of	  rare	  or	  private	  mutations	  disrupt	  the	  same	  pathway	  giving	  the	  same	  
phenotype.	  The	  new	  information,	  which	  will	  be	  discovered,	  might	  also	   include	  
structural	  variants,	  such	  as	  copy	  number	  variants	  (CNVs),	  or	  repetitive	  regions	  
that	   have	   so	   far	   been	   difficult	   to	   assay	   and	   analyse.	   While	   the	   sequencing	  
technologies	  will	  get	  better,	  the	  range	  of	  available	  functional	  genomic	  data	  will	  
also	   be	   improved	   upon.	   These	   annotations	  may	   include	   retrotransposons	   and	  
more	   RNA	  molecules,	   which	   are	   emerging	   as	   functional	   [173,	   181,	   182].	   The	  
emergence	  of	  more	  SNPs	  and	  new	  annotations	  will	  lead	  to	  a	  higher	  demand	  for	  
predictive	   modelling	   of	   variant	   function,	   which	   will	   also	   feed	   back	   into	   the	  
improvement	  of	   future	  models.	  The	  research	  presented	   in	   this	   thesis	   is	  highly	  
adaptable	  and	  can	  be	  easily	  applied	  to	  data	  for	  new	  disease	  associated	  variants	  
and	   new	   functional	   annotation.	   We	   analysed	   a	   broader	   range	   of	   functional	  
annotations	  simultaneously	  than	  other	  studies	  to	  date	  furthermore	  investigated	  
different	   trait-­‐subsets.	   These	   allowed	   the	   drawing	   of	   more	   trait-­‐specific	  
conclusions,	  which	   in	   turn	  may	   feed	   into	  more	   specific	  disease	   risk	  predictive	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models	   and	   say	   something	   about	   the	   architecture	   of	   the	   traits.	   The	   genomic	  
annotations	  from	  the	  multivariate	  models	  used	  here	  (Chapter	  5)	  could	  therefore	  
aid	  the	  calculation	  of	  the	  prior	  probability	  –	  or	   ‘weighing’	  –	  of	  SNPs	  to	  identify	  
those	  variants,	  which	  were	  more	  likely	  to	  affect	  phenotypes.	  	  
	  
Better	   predictive	   models	   and	   the	   ever-­‐decreasing	   cost	   of	   genotyping	   may	  
eventually	   lead	   to	   more	   precise	   disease	   risk	   predictions	   for	   individuals.	  
Companies	   such	   as	   23andme	   (http://www.23andme.com)	   or	   deCODEme	  
(http://www.decodeme.com)	   are	   already	   attempting	   to	  predict	   risk	  of	   certain	  
diseases	   by	   investigating	   the	   genotypes	   of	   a	   number	   of	   SNPs.	   However,	   the	  
results	  produced	  by	  the	  companies	  still	  vary	  greatly	  between	  companies	  as	  they	  
use	   different	   predictive	   algorithms,	   different	   SNP	   sets,	   and	   different	   average	  
population	  risks	  [183].	  Truly	  accurate	  risk	  predictions	  may	  therefore	  be	  out	  of	  
reach	   until	   we	   can	   thoroughly	   comprehend	   environmental	   influences,	   which	  
affect	   genetic	   predisposition,	   and	   include	   them	   in	   our	   analyses.	   It	   might	   be	  
possible	   that	   these	   predictions	   become	   more	   accurate,	   as	   more	   information,	  
such	   as	   environmental	   influences,	   gets	   included	   in	   the	   analysis.	   Such	  
environmental	   influences	   could,	   for	   example,	   be	   modelled	   using	   different	  
histone	  modifications	  known	  to	  respond	  to	  outside	  stimuli.	  However,	  these	  are	  
out	   of	   reach	   at	   present.	   In	   this	   thesis,	   we	   have	   shown	   that	   while	   different	  
combinations	  of	  genomic	  annotations	  influence	  different	  trait-­‐subsets,	  common	  
regulatory	  features	  are	  present	  and	  most	  often	  underlie	  variants	  associated	  to	  a	  
broad	  range	  of	  traits.	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9 APPENDIX	  
9.1 Traits	  divided	  into	  four	  different	  subsets	  
9.1.1 Immune	  traits	  
• Activated	  partial	  thromboplastin	  time	  
• Acute	  anterior	  uveitis	  
• Acute	  chest	  syndrome	  asthma	  
• Acute	  graft-­‐versus-­‐host	  disease	  
• Acute	  renal	  allograft	  rejection	  
• Acute	  respiratory	  distress	  syndrome	  IL*	  production	  
• Addison's	  disease	  
• Aggressive	  periodontitis	  
• AIDS	  
• AIDS	  progression	  
• Airway	  hyperresponsiveness	  atopy	  
• Airway	  hyperresponsiveness,	  methacholine	  induced	  
• Allele	  frequency/	  normal	  
• Allergic	  asthma	  
• Allergic	  bronchopulmonary	  aspergillosis	  abpa	  
• Allergic	  disease	  
• Allergic	  disease,	  ige	  -­‐mediated	  
• Allergic	   diseases	   (bronchial	   asthma.	   Atopic	   dermatitis	   and/or	   food-­‐related	  
anaphylaxis)	  
• Allergic	  rhinitis	  
• Allergic	  rhinitis	  asthma	  
• Allergic	  rhinitis	  dermatitis	  and	  eczema	  fatty	  acid	  
• Allergic	  rhinitis	  IgE	  
• Allergies;	  common	  cold	  
• Allergy	  
• Allergy	  asthma	  
• Allergy	  dermatitis	  and	  eczema	  
• Allergy,	  latex;	  latex	  allergy	  
• Allergy,	  latex;	  latex	  allergy;	  pemphigoid,	  bullous	  
• Allogenic	  stem	  cell	  transplantation	  
• Allograft	  dysfunction,	  renal	  
• Allograft	  outcome	  
• Allograft	  rejection,	  heart	  
• Alopecia	  areata	  
• Altered	  CCR5	  Expression	  or	  coreceptor	  function	  
• Alveolitis,	  extrinsic	  allergic	  
• Alzheimer`s	  disease	  
• ANCA	  positive	  patients	  
• Ankylosing	  spondylitis	  
• Annexin	  A5	  antibodies	  
• Anti-­‐cyclic	  citrullinated	  peptide	  antibodies	  rheumatoid	  arthritis	  
• Anti-­‐GAD65	  antibody	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• Anti-­‐islet	  autoantibodies	  diabetes,	  type	  1	  
• Anti-­‐neutrophil	   cytoplasmic	   antibodies	   kidney	   failure,	   chronic	   polyangiitis	  
wegener's	  granulomatosis	  
• Anti-­‐ro	  52-­‐KD	  autoantibodies	  
• Anti-­‐ro	  autoantibodies	  
• Antibody	  formation	  crohn's	  disease	  ulcerative	  colitis	  
• Anticardiolipin	  antibody	  production	  lupus	  erythematosus	  
• Antineutrophil	  cytoplasmic	  antibody-­‐associated	  vasculitis	  
• Antineutrophil	  cytoplasmic	  antibody;	  (ANCA)-­‐associated	  vasculitis	  
• Antiphospholipid	  syndrome	  
• Aplastic	  anemia,	  acquired	  
• Apolipoprotein	  levels	  
• Arthritis	  
• Arthritis	  (juvenile	  idiopathic)	  
• Arthritis	  lupus	  erythematosus	  
• Aseptic	  abscesses	  crohn's	  disease	  inflammatory	  bowel	  disease	  
• Aspirin-­‐induced	  asthma	  
• Aspirin-­‐intolerant	  asthma	  
• Asthma	  
• Asthma	  (childhood	  onset)	  
• Asthma	  in	  combination	  with	  a	  variety	  of	  other	  diseases	  
• Atherosclerosis,	  coronary	  
• Atopic	  asthma	  
• Atopic	  asthma.	  BHR.	  Total	  IgE.	  SPT	  
• Atopic	  dermatitis	  
• Atopic	  eczema	  
• Atopy	  
• Atopy	  (IgE)	  
• Atopy	  (total	  &	  specific	  IgE)	  
• Atopy	  IgE	  urticaria,	  aspirin-­‐intolerant	  
• Atopy	  vaccine	  response	  
• Atopy-­‐susceptibility	  
• Atopy;	  dermatitis	  and	  eczema	  
• Atopy;	  IgE	  levels	  
• Atopy.	  Airway	  obstruction.	  BHR.	  Asthma	  
• Atopy.	  Asthma	  
• Atopy.	  Asthma.	  Netherton	  
• Atopy.	  BHR	  
• Atopy.	  Spige.	  Total	  IgE.	  Asthma.	  Atopic	  asthma	  
• Atopy/	  asthma	  
• Autoimmunity	  
• Autologous	  mixed	  lymphocyte	  reaction	  
• Bee	  venom	  allergy	  
• Behcet's	  disease	  
• Beta	  cell	  autoimmunity	  
• Β-­‐cell	  function;	  diabetes,	  type	  1	  
• Betacl	  osteocalcin	  
• BHR	  
• Birth	  weight	  bronchopulmonary	  dysplasia	  sepsis	  
• Blau	  syndrome	  
• Bone	  marrow	  transplantation	  
• Bronchial	  asthma	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• Bronchial	  asthma	  (childhood	  &	  adult)	  
• Bronchial	  asthma	  (childhood	  only)	  
• Bronchial	  hyperreactivity	  
• Bronchial	  hyperresponsiveness	  
• Bronchopulmonary	  dysplasia	  respiratory	  distress	  syndrome,	  neonatal	  
• Bullous	  pemphigoid	  
• C-­‐reactive	  protein	  
• Carotid	  atherosclerosis	  in	  HIV	  Infection	  
• CD14	  expression	  
• CD14	  levels	  
• Cedar	  pollinosis	  
• Celiac	  disease	  
• Celiac	  disease	  diabetes,	  type	  1	  
• Celiac	  disease	  gluten	  intolerance	  
• Celiac	  disease	  lupus	  erythematosus	  rheumatoid	  arthritis	  
• Celiac	  disease;	  colitis	  
• Cerebral	  malaria	  
• Childhood	  asthma	  
• Childhood	  atopic	  asthma	  
• Childhood	  atopic	  asthma	  
• Childhood	  B-­‐cell	  non-­‐hodgkin's	  lymphoma	  
• Chinese	  ankylosing	  spondylitis	  patients	  
• Cholangitis,	  sclerosing	  
• Cholangitis,	  sclerosing	  crohn's	  disease	  inflammatory	  bowel	  disease	  
• Cholangitis,	  sclerosing	  crohn's	  disease	  ulcerative	  colitis	  
• Cholesterol,	  LDL;	  cholesterol,	  total;	  C-­‐reactive	  protein;	  APOA2;	  APOB	  
• Chronic	  bronchitis	  
• Chronic	  hepatitis	  C	  infection	  
• Chronic	  immune	  thrombocytopenic	  purpura.	  
• Chronic	  nonproductive	  cough	  
• Chronic	  obstructive	  pulmonary	  disease	  
• Chronic	  pancreatitis	  
• Chronic	  periodontitis.	  
• Chronic	  progressive	  multiple	  sclerosis.	  
• Cirrhosis,	  biliary	  primary	  
• Cirrhosis,	  biliary	  primary	  hepatitis,	  autoimmune	  
• Coeliac	  disease.	  
• Collagen	  disease	  juvenile	  arthritis	  rheumatoid	  arthritis	  still's	  disease	  
• Common	  variable	  immunodeficiency	  
• Congenital	  thrombotic	  thrombocytopenic	  purpura	  
• Contact	  allergy	  
• Contact	  hypersensitivity	  
• Contact	  sensitisation	  
• COPD	  
• Coronary	  heart	  disease	  
• Crohn's	  disease	  
• Cryoglobulinemia	  
• Cutaneous	  neonatal	  lupus	  
• Cytokine	  lung	  function	  
• Cytokine	  release	  
• Cytokine	  release	  mortality	  
• Cytokine	  response	  to	  measles	  vaccine	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• Cytokine	  synthesis	  
• Cytokines;	  tumor	  markers	  
• Decreased	  airway	  responsiveness	  
• Dengue	  shock	  syndrome	  
• Dermatitis	  and	  eczema	  
• Dermatitis	  herpetiformis.	  
• Dermatitis,	  atopic	  
• Dermatomyositis	  myopathy,	  idiopathic	  inflammatory	  polymyositis	  
• Dermatomyositis	  polymyositis	  
• Diabetes	  (gestational)	  
• DRS	  
• Early	  onset	  of	  multiple	  sclerosis.	  
• Early	  onset	  periodontitis	  
• Early	  onset	  psoriasis	  
• Early	  polyarthritis	  
• Early-­‐onset	  periodontitis	  
• Eczema	  
• Eczema	  food	  allergy	  IgE	  
• Emphysema	  
• Eosinophil	  counts	  
• Eosinophilia	  
• Eosinophilic	  esophagitis	  (pediatric)	  
• Epithelial	  neutrophil	  activating	  peptide	  
• Epstein-­‐barr	  virus	  
• Erythema	  nodosum	  
• Familial	  hemophagocytic	  lymphohistiocytosis	  
• Familial	  juvenile	  onset	  psoriasis	  
• Familial	  mediterranean	  fever	  
• FAS	  levels	  
• FEV1	  
• Food	  allergy	  
• Fuchs	  heterochromic	  cyclitis	  
• Glomerulonephritis,	  hepatitis	  B	  virus-­‐associated	  
• Graft	  acceptance,	  liver	  
• Graft	  occlusion,	  atherosclerotic	  
• Graft	  rejection,	  liver	  
• Graft	  versus	  host	  disease	  
• Graves'	  disease	  
• Graves'	  hyperthyroidism	  
• Graves'	  ophthalmopathy	  
• H-­‐thyroiditis	  
• Haemophilia	  with	  chronic	  synovitis	  
• Hashimoto's	  thryoiditis	  
• Hematology	  indices	  
• Hemophagocytic	  lymphohistiocytosis	  
• Henoch-­‐schonlein	  purpura	  
• Hepatitis	  B	  
• Hepatitis	  B	  (viral	  clearance)	  
• Hepatitis	  C	  induced	  liver	  fibrosis	  
• Hepatitis	  type	  1,	  autoimmune	  (AIH-­‐1)	  
• Hepatitis	  type	  2,	  autoimmune	  
• HIV	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• HIV-­‐1	  control	  
• HIV-­‐1	  infection	  
• HLA-­‐associated	  diseases	  
• HPV	  seropositivity	  
• Human	  T-­‐cell	  lymphotropic	  virus	  type	  I	  associated	  myelopathy	  
• Hyper-­‐IgE	  syndrome	  and	  severe	  eczema.	  Atopy	  
• Hyper-­‐IgM	  syndrome	  
• Hyper-­‐IgM	  syndrome	  can	  form	  oligomers	  and	  trigger	  CD40-­‐mediated	  signals	  
• Hyperresponsiveness	  
• Hypothyroidism	  
• Hypothyroidism,	  autoimmune	  
• Hypothyroidism,	  goitrous	  juvenile	  autoimmune	  
• Idiopathic	  chronic	  pancreatitis	  
• Idiopathic	  inflammatory	  myopathies	  
• IgA	  
• IgA	  deficiency	  
• IgA	  deficiency	  and	  common	  variable	  immunodeficiency	  
• IgA	  nephropathy	  
• IgD	  
• IgE	  
• IgE	  grass	  sensitization	  
• IgE	  levels	  
• IgE	  response	  
• IGF-­‐I	  
• IGF-­‐I	  levels;	  IGFBP-­3	  levels	  
• IgG	  
• IgM	  
• IL-­‐18	  concentration	  physical	  functioning	  
• IL-­‐18	  lupus	  erythematosus	  
• IL-­‐1beta	  
• IL-­‐4	  
• IL18	  expression	  level	  
• IL6	  transcription	  
• Immune	  deficiency	  
• Immunoglobulin	  A	  deficiency	  
• Immunoglobulin	  A	  glomerulonephritis	  
• Immunology	  study	  
• Immunotherapy	  response	  
• Improved	  survival	  in	  sepsis	  
• Increased	  expression	  of	  the	  G	  gamma	  and	  A	  gamma	  globin	  
• Increased	  IgE	  
• Increased	  interleukin-­‐10	  (IL-­‐10)	  plasma	  levels	  
• Inflammatory	  bowel	  disease	  
• Inflammation	  
• Inflammation	  oxidative	  stress	  
• Inflammatory	  biomarkers	  
• Inflammatory	  bowel	  disease	  
• Inflammatory	  disease	  
• Inflammatory	  markers	  
• Inflammatory	  myopathies	  
• Inflammatory	  response	  
• Inflammatory	  urogenital	  disease	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• Insulin	  dependent	  diabetes	  
• Interferon	  response	  
• Interleukin-­‐1	  beta	  (IL-­‐1	  beta)	  synthesis	  capacity	  
• Irritable	  bowel	  syndrome	  
• Juvenile	  ankylosing	  spondylitis	  
• Juvenile	  arthritis	  
• Juvenile	  idiopathic	  arthritis	  
• Juvenile	  rheumatoid	  arthritis	  
• Kawasaki	  disease	  
• Kidney	  transplant	  
• Kidney	  transplant	  complications	  
• Kidney	  transplant	  complications;	  lipids	  
• Knee	  osteoarthritis	  
• Latex	  allergy	  
• Leprosy	  
• Leukemia	  virus	  type	  I	  
• Liver	  transplantation,	  immunosuppression	  after	  
• Lung	  function	  
• Lupus	  
• Lupus	  erythematosus	  
• Lupus	  nephritis	  
• Malaria	  
• Measles	  vaccine	  immunity	  
• Microscopic	  polyangiitis	  
• Microsomal	  epoxide	  hydrolase	  
• Mite-­‐sensitive	  asthma	  
• Monocyte	  chemoattractant	  protein-­‐1	  
• Morbidity	  mortality	  
• Multiple	  sclerosis	  
• Myasthenia	  gravis	  
• Myositis	  
• Narcolepsy	  
• Neonatal	  lupus	  
• Nephropathy,	  IgA	  
• Neutrophil	  immunodeficiency	  syndrome	  
• No	  exhalation	  
• Nocturnal	  asthma	  
• Osteoarthritis	  
• Osteomyelitis	  
• Otitis	  media	  
• Pancreatitis	  
• Peanut	  allergy	  
• Pemphigus	  
• Pemphigus	  foliaceus	  
• Pemphigus	  vulgaris	  
• Penicillins	  allergy	  
• Periodontal	  disease	  
• Periodontitis	  
• Physician	  diagnosed	  asthma	  
• Pityriasis	  rosea	  
• Plasma	  IL6	  levels	  
• Plasminogen	  activator	  inhibitor	  type	  1	  levels	  (PAI-­‐1)	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• Pneumoconiosis	  
• Pollen	  allergy	  
• Pollen-­‐induced	  allergic	  rhinitis	  
• Pollinosis,	  cedar	  
• Polymylagia	  rheumatica	  
• Polymyositis	  and	  dermatomyositis.	  
• Polyneuropathy	  vasculitis	  
• Postoperative	  systemic	  inflammatory	  reaction	  
• Postpartum	  thyroiditis	  
• Primary	  biliary	  cirrhosis	  
• Primary	  sclerosing	  cholangitis	  
• Primary	  sjogren's	  syndrome	  
• Psoriasis	  
• Reactive	  arthritis	  
• Reiter's	  syndrome	  
• Renal	  disease	  
• Renal	  transplant	  rejection	  
• Respiratory	  syncytial	  virus	  
• Response	  to	  endotoxin	  
• Retinopathy,	  diabetic;	  nephropathy	  in	  other	  diseases	  
• Rheumatic	  diseases	  
• Rheumatic	  fever	  
• Rheumatic	  heart	  disease	  
• Rheumatoid	  arthritis	  
• Rhinitis	  
• Rickets	  
• Rubella	  vaccine,	  cytokine	  response	  to	  
• Sarcoidosis	  
• Sarcoidosis	  
• Sarcoidosis	  tuberculosis	  
• Sarcoidosis	  uveitis	  
• Scleroderma	  
• Scleroderma;	  jaundice	  
• Sclerosing	  cholangitis	  and	  ulcerative	  colitis	  (combined)	  
• Sclerosis,	  systemic	  
• Semple	  rabies	  vaccine-­‐induced	  autoimmune	  encephalomyelitis	  
• Sepsis	  
• Sepsis	  development	  or	  mortality	  
• Septic	  shock	  
• Serum	  IgE	  levels	  
• Severe	  asthma	  
• Severe	  chronic	  neutropenia	  
• Severe	  combined	  immunodeficiency	  
• Severe	  ulcerative	  colitis	  
• Silicosis	  
• Sinusitis	  
• Sjogren's	  syndrome	  
• SLE	  
• Soluble	  CD14	  plasma	  levels	  
• Specific	  IgE	  
• Spondyloarthropathies	  
• SPT	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• Staphylococcal	  infection	  
• Steroid-­‐dependent	  asthma	  
• Steroid-­‐requiring	  asthma	  in	  sedentary	  women	  
• Stevens-­‐Johnson	  syndrome	  
• Still's	  disease	  
• Sulfasalazine,	  adverse	  effects	  of	  
• Syncytial	  virus	  bronchiolitis	  
• Systemic	  inflammatory	  response	  syndrome	  
• Systemic	  juvenile	  idiopathic	  arthritis	  
• Systemic	  lupus	  erythematosus	  
• Systemic	  scleroderma	  
• Systemic	  sclerosis	  
• Thimerosal	  sensitization	  
• Thrombosis,	  deep	  vein;	  Behcet's	  disease	  
• Thryoiditis,	  chronic	  lymphocytic	  
• Thyroid	  autoimmunity	  
• Thyroiditis,	  chronic	  lymphocytic	  
• Thyroiditis,	  Hashimoto's	  
• Thyrotoxic	  hypokalemic	  periodic	  paralysis	  
• TIgE	  
• TNF-­‐Alpha	  
• Total	  IgE	  
• Total	  serum	  IgE	  
• Tropical	  calcific	  pancreatitis	  
• Tuberculosis	  
• Tumor	  necrosis	  factor	  receptor-­‐associated	  periodic	  syndrome	  
• Type	  1	  diabetes	  
• Type	  1	  diabetes	  autoantibodies	  
• Type	  1	  diabetes	  nephropathy	  
• Type	  2	  diabetes	  
• Type	  2	  diabetes	  and	  other	  traits	  
• Ulcerative	  colitis	  
• Vaspin	  levels	  
• Vitiligo	  
• Vogt-­‐Koyanagi-­‐Harada's	  disease	  
• Wheeze	  
• White	  blood	  cell	  types	  
• X-­‐linked	  lymphoproliferative	  disease	  
• X-­‐linked	  severe	  combined	  immunodeficiency	  
	  
9.1.2 Cancer	  traits	  
• Acute	  lymphoblastic	  leukemia	  (childhood)	  
• Basal	  cell	  carcinoma	  
• Basal	  cell	  carcinoma	  (cutaneous)	  
• Bladder	  cancer	  
• Breast	  cancer	  
• Breast	  cancer	  (male)	  
• Carcinoma	  
• Chronic	  lymphocytic	  leukemia	  
• Chronic	  myeloid	  leukemia	  
• Colorectal	  cancer	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• Endometrial	  cancer	  
• Erectile	  dysfunction	  and	  prostate	  cancer	  treatment	  
• Esophageal	  cancer	  
• Esophageal	  cancer	  (alcohol	  interaction)	  
• Esophageal	  cancer	  (squamous	  cell)	  
• Esophageal	  cancer	  and	  gastric	  cancer	  
• Ewing	  sarcoma	  
• Follicular	  lymphoma	  
• Gastric	  cancer	  
• Glaucoma	  
• Glaucoma	  (exfoliation)	  
• Glaucoma	  (primary	  open-­‐angle)	  
• Glioma	  
• Glioma	  (high-­‐grade)	  
• Hepatocellular	  carcinoma	  
• Hodgkin's	  lymphoma	  
• Lung	  adenocarcinoma	  
• Lung	  cancer	  
• Melanoma	  
• Meningioma	  
• Multiple	  myeloma	  
• Myeloproliferative	  neoplasms	  
• Nasopharyngeal	  carcinoma	  
• Neuroblastoma	  
• Neuroblastoma	  (high-­‐risk)	  
• Non-­‐small	  cell	  lung	  cancer	  
• Ovarian	  cancer	  
• Pancreatic	  cancer	  
• Prostate	  cancer	  
• Renal	  cell	  carcinoma	  
• Testicular	  cancer	  
• Testicular	  germ	  cell	  cancer	  
• Testicular	  germ	  cell	  tumor	  
• Thyroid	  cancer	  
• Upper	  aerodigestive	  tract	  cancers	  
• Urinary	  bladder	  cancer	  
• Wilms	  tumor	  
• YKL-­‐40	  levels	  
• Multiple	  cancers	  (lung	  cancer	  and	  gastric	  cancer	  and	  squamous	  cell	  carcinoma)	  
	  
9.1.3 Normal	  Variation	  traits	  
• Acenocoumarol	  maintenance	  dosage	  
• Activated	  partial	  thromboplastin	  time	  
• Adiponectin	  levels	  
• Aging	  
• Aging	  traits	  
• Alcohol	  and	  nictotine	  co-­‐dependence	  
• Alcohol	  consumption	  
• Amyloid	  A	  levels	  
• Androgen	  levels	  
	   212	  
• Angiotensin-­‐converting	  enzyme	  activity	  
• Ankle-­‐brachial	  index	  
• Anthropometric	  traits	  
• Anticoagulant	  levels	  
• Antipsychotic	  drug-­‐induced	  weight	  gain	  
• Aortic	  root	  size	  
• Aortic	  stiffness	  
• Arterial	  stiffness	  
• Aspartate	  aminotransferase	  
• Bilirubin	  levels	  
• Biochemical	  measures	  
• Birth	  weight	  
• Bitter	  taste	  response	  
• Black	  vs.	  Blond	  hair	  color	  
• Black	  vs.	  Red	  hair	  color	  
• Bleomycin	  sensitivity	  
• Blond	  vs.	  Brown	  hair	  color	  
• Blood	  lipid	  traits	  
• Blue	  vs.	  Brown	  eyes	  
• Blue	  vs.	  Green	  eyes	  
• Body	  mass	  (lean)	  
• Brain	  structure	  
• Breast	  size	  
• Burning	  and	  freckling	  
• Butyrylcholinesterase	  levels	  
• C4B	  binding	  protein	  levels	  
• Caffeine	  consumption	  
• Calcium	  levels	  
• Cannabis	  dependence	  
• Capecitabine	  sensitivity	  
• Cardiac	  hypertrophy	  
• Cardiac	  repolarization	  
• Cardiac	  structure	  and	  function	  
• Carotenoid	  and	  tocopherol	  levels	  
• Carotid	  intima	  media	  thickness	  
• CD4:CD8	  lymphocyte	  ratio	  
• Central	  corneal	  thickness	  
• Cholelithiasis-­‐related	  traits	  in	  sickle	  cell	  anemia	  
• Circulating	  cell-­‐free	  DNA	  
• Coagulation	  factor	  levels	  
• Coffee	  consumption	  
• Cognitive	  decline	  
• Cognitive	  function	  
• Common	  traits	  (other)	  
• Complement	  C3	  and	  C4	  levels	  
• Corneal	  astigmatism	  
• Corneal	  curvature	  
• Corneal	  structure	  
• Cortical	  structure	  
• Cortical	  thickness	  
• Creatinine	  levels	  
• Cutaneous	  nevi	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• Cystatin	  C	  
• D-­‐dimer	  levels	  
• Dehydroepiandrosterone	  sulphate	  levels	  
• Dental	  caries	  
• Diastolic	  blood	  pressure	  
• Drinking	  behavior	  
• Drug-­‐induced	  liver	  injury	  
• Drug-­‐induced	  liver	  injury	  (amoxicillin-­‐clavulanate)	  
• Drug-­‐induced	  liver	  injury	  (flucloxacillin)	  
• E-­‐selectin	  levels	  
• Electrocardiographic	  traits	  
• Electroencephalographic	  traits	  in	  alcoholism	  
• Eosinophil	  counts	  
• Epirubicin-­‐induced	  leukopenia	  
• Erythrocyte	  sedimentation	  rate	  
• Exercise	  (leisure	  time)	  
• Exercise	  treadmill	  test	  traits	  
• Eye	  color	  
• Eye	  color	  traits	  
• F-­‐cell	  distribution	  
• Facial	  morphology	  
• Factor	  VII	  
• Fasting	  glucose-­‐related	  traits	  
• Fasting	  glucose-­‐related	  traits	  (interaction	  with	  BMI)	  
• Fasting	  insulin-­‐related	  traits	  
• Fasting	  insulin-­‐related	  traits	  (interaction	  with	  BMI)	  
• Fasting	  plasma	  glucose	  
• Fetal	  hemoglobin	  levels	  
• Fibrinogen	  
• Folate	  pathway	  vitamin	  levels	  
• Freckles	  
• Freckling	  
• Gamma	  gluatamyl	  transferase	  levels	  
• Gamma	  glutamyl	  transpeptidase	  
• Glycated	  hemoglobin	  levels	  
• Hair	  color	  
• Hair	  morphology	  
• Handedness	  in	  dyslexia	  
• Haptoglobin	  levels	  
• HBA2	  levels	  
• HDL	  cholesterol	  
• HDL	  cholesterol	  -­‐	  triglycerides	  (HDLC-­‐TG)	  
• Head	  circumference	  (infant)	  
• Heart	  failure	  
• Height	  
• Hematocrit	  
• Hematological	  and	  biochemical	  traits	  
• Hematological	  parameters	  
• Hematology	  traits	  
• Hemoglobin	  
• Hemostatic	  factors	  and	  hematological	  phenotypes	  
• Hepatitis	  B	  vaccine	  response	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• Hepcidin	  levels	  
• Hippocampal	  volume	  
• Homocysteine	  levels	  
• HPV	  seropositivity	  
• Hypertension	  
• Hypertension	  risk	  in	  short	  sleep	  duration	  
• IFN-­‐related	  cytopenia	  
• IgE	  levels	  
• IgG	  levels	  
• IgM	  
• Immune	  reponse	  to	  smallpox	  (secreted	  IFN-­‐alpha)	  
• Immune	  reponse	  to	  smallpox	  (secreted	  IL-­‐10)	  
• Immune	  reponse	  to	  smallpox	  (secreted	  IL-­‐12p40)	  
• Immune	  reponse	  to	  smallpox	  (secreted	  IL-­‐1beta)	  
• Immune	  reponse	  to	  smallpox	  (secreted	  IL-­‐2)	  
• Immune	  reponse	  to	  smallpox	  (secreted	  TNF-­‐alpha)	  
• Immune	  response	  to	  smallpox	  vaccine	  (IL-­‐6)	  
• Immunoglobulin	  A	  
• Insulin-­‐like	  growth	  factors	  
• Insulin-­‐related	  traits	  
• Interleukin-­‐18	  levels	  
• Intracranial	  volume	  
• Intraocular	  pressure	  
• Iris	  characteristics	  
• Iris	  color	  
• Iron	  levels	  
• Iron	  status	  biomarkers	  
• Keloid	  
• Left	  ventricular	  mass	  
• Lentiform	  nucleus	  volume	  
• Lipid	  levels	  in	  hepatitis	  c	  treatment	  
• Lipid	  metabolism	  phenotypes	  
• Lipid	  traits	  
• Lipoprotein-­‐associated	  phospholipase	  A2	  activity	  and	  mass	  
• Liver	  enzyme	  levels	  
• Liver	  enzyme	  levels	  (alanine	  transaminase)	  
• Liver	  enzyme	  levels	  (alkaline	  phosphatase)	  
• Liver	  enzyme	  levels	  (gamma-­‐glutamyl	  transferase)	  
• Longevity	  
• LP	  (A)	  levels	  
• Lumiracoxib-­‐related	  liver	  injury	  
• Magnesium	  levels	  
• Major	  depressive	  disorder	  
• Male-­‐pattern	  baldness	  
• Mammographic	  density	  
• Matrix	  metalloproteinase	  levels	  
• Mean	  corpuscular	  hemoglobin	  
• Mean	  corpuscular	  volume	  
• Mean	  platelet	  volume	  
• Menarche	  
• Menarche	  (age	  at	  onset)	  
• Menarche	  and	  menopause	  (age	  at	  onset)	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• Menopause	  
• Menopause	  (age	  at	  onset)	  
• Metabolic	  traits	  
• Monocyte	  chemoattractant	  protein-­‐1	  
• Morbidity-­‐free	  survival	  
• MRI	  atrophy	  measures	  
• N-­‐glycan	  levels	  
• Natriuretic	  peptide	  levels	  
• Neuranatomic	  and	  neurocognitive	  phenotypes	  
• Neutrophil	  count	  
• Nevirapine-­‐induced	  rash	  
• Nicotine	  dependence	  
• Non-­‐albumin	  protein	  levels	  
• Normalized	  brain	  volume	  
• Obesity	  
• Obesity	  and	  blood	  pressure	  
• Obesity-­‐related	  traits	  
• Optic	  disc	  parameters	  
• Optic	  disc	  parameters	  
• Optic	  disc	  size	  
• Optic	  disc	  size	  (disc)	  
• Other	  erythrocyte	  phenotypes	  
• Other	  metabolic	  traits	  
• Pain	  
• Pericardial	  fat	  
• Permanent	  tooth	  development	  
• Personality	  dimensions	  
• Phospholipid	  levels	  (plasma)	  
• Phosphorus	  levels	  
• Phytosterol	  levels	  
• Plasma	  C4B	  binding	  protein	  levels	  
• Plasma	  carotenoid	  and	  tocopherol	  levels	  
• Plasma	  coagulation	  factors	  
• Plasma	  E-­‐selectin	  levels	  
• Plasma	  eosinophil	  count	  
• Plasma	  homocysteine	  
• Plasma	  level	  of	  vitamin	  B12	  
• Plasma	  levels	  of	  liver	  enzymes	  
• Plasma	  levels	  of	  protein	  C	  
• Platelet	  aggregation	  
• Platelet	  counts	  
• PR	  interval	  
• Primary	  sclerosing	  cholangitis	  
• Primary	  tooth	  development	  (number	  of	  teeth)	  
• Primary	  tooth	  development	  (time	  to	  first	  tooth	  eruption)	  
• Progranulin	  levels	  
• Proinsulin	  levels	  
• Prostate-­‐specific	  antigen	  levels	  
• Protein	  biomarker	  
• Protein	  quantitative	  trait	  loci	  
• Prothrombin	  time	  
• Pulmonary	  function	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• Pulmonary	  function	  decline	  
• Pulmonary	  function	  measures,	  QT	  interval	  
• Quantitative	  traits	  
• Reasoning	  
• Recombination	  rate	  (females)	  
• Recombination	  rate	  (males)	  
• Red	  blood	  cell	  traits	  
• Red	  vs.	  Non-­‐red	  hair	  color	  
• Refractive	  error	  
• Renal	  function	  and	  chronic	  kidney	  disease	  
• Renal	  function-­‐related	  traits	  (bun)	  
• Renal	  function-­‐related	  traits	  (EGRFCREA)	  
• Renal	  function-­‐related	  traits	  (SCR)	  
• Renal	  function-­‐related	  traits	  (urea)	  
• Resistin	  levels	  
• Response	  to	  antidepressants	  
• Response	  to	  antipsychotic	  therapy	  (extrapyramidal	  side	  effects)	  
• Response	  to	  antipsychotic	  treatment	  
• Response	  to	  citalopram	  treatment	  
• Response	  to	  clopidogrel	  therapy	  
• Response	  to	  fenofibrate	  
• Response	  to	  gemcitabine	  in	  pancreatic	  cancer	  
• Response	  to	  hepatitis	  C	  treatment	  
• Response	  to	  interferon	  beta	  therapy	  
• Response	  to	  metformin	  
• Response	  to	  statin	  therapy	  
• Response	  to	  statin	  therapy	  (LDL-­‐C)	  
• Response	  to	  tocilizumab	  in	  rheumatoid	  arthritis	  
• Response	  to	  vitamin	  E	  supplementation	  
• Resting	  heart	  rate	  
• Retinal	  vascular	  caliber	  
• Retinol	  levels	  
• Ribavirin-­‐induced	  anemia	  
• RR	  interval	  (heart	  rate)	  
• Select	  biomarker	  traits	  
• Serum	  albumin	  level	  
• Serum	  bilirubin	  levels	  
• Serum	  calcium	  
• Serum	  creatinine	  
• Serum	  dehydroepiandrosterone	  sulphate	  levels	  
• Serum	  IgE	  levels	  
• Serum	  iron	  levels	  
• Serum	  markers	  of	  iron	  status	  
• Serum	  metabolites	  
• Serum	  phosphorus	  levels	  
• Serum	  phytosterol	  levels	  
• Serum	  prostate-­‐specific	  antigen	  levels	  
• Serum	  soluble	  E-­‐selectin	  
• Serum	  total	  protein	  level	  
• Serum	  urate	  
• Serum	  uric	  acid	  
• Sex	  hormone-­‐binding	  globulin	  levels	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• Skin	  pigmentation	  
• Skin	  sensitivity	  to	  sun	  
• Sleepiness	  
• Smoking	  behavior	  
• Soluble	  E-­‐selectin	  levels	  
• Soluble	  leptin	  receptor	  levels	  
• Soluble	  levels	  of	  adhesion	  molecules	  
• Speech	  perception	  in	  dyslexia	  
• Sphingolipid	  levels	  
• Systolic	  blood	  pressure	  
• T-­‐tau	  
• Tanning	  
• Telomere	  length	  
• Testosterone	  levels	  
• Thyroid	  function	  
• Thyroid	  volume	  
• Triglycerides	  
• Triglycerides-­‐blood	  pressure	  (TG-­‐BP)	  
• Two-­‐hour	  glucose	  challenge	  
• Urate	  levels	  
• Uric	  acid	  levels	  
• Urinary	  albumin	  excretion	  
• Urinary	  metabolites	  
• Vascular	  endothelial	  growth	  factor	  levels	  
• Vaspin	  levels	  
• Venous	  thromboembolism	  
• Ventricular	  conduction	  
• Vertical	  cup-­‐disc	  ratio	  
• Visceral	  adipose	  tissue/subcutaneous	  adipose	  tissue	  ratio	  
• Visceral	  fat	  
• Vitamin	  B12	  levels	  
• Vitamin	  D	  insufficiency	  
• Vitamin	  D	  levels	  
• Vitamin	  E	  levels	  
• Volumetric	  brain	  MRI	  
• Waist	  circumference	  
• Waist	  circumference	  -­‐	  triglycerides	  (WC-­‐TGS)	  
• Waist	  circumference	  and	  related	  phenotypes	  
• Waist-­‐hip	  ratio	  
• Warfarin	  maintenance	  dose	  
• Weight	  
• White	  blood	  cell	  count	  
• White	  blood	  cell	  types	  
• White	  matter	  hyperintensity	  burden	  
• Working	  memory	  
• Wrist	  bone	  mass	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9.1.4 Disease	  traits	  
• AB1-­‐42	  
• Abdominal	  aortic	  aneurysm	  
• Acute	  lymphoblastic	  leukemia	  (childhood)	  
• Adiposity	  
• Age-­‐related	  macular	  degeneration	  (wet)	  
• Age-­‐related	  macular	  degeneration	  
• Age-­‐related	  macular	  degeneration	  (CNV	  vs.	  GA)	  
• Age-­‐related	  macular	  degeneration	  (CNV)	  
• Age-­‐related	  macular	  degeneration	  (GA)	  
• Alcohol	  dependence	  
• Alopecia	  areata	  
• Alzheimer's	  disease	  
• Alzheimer's	  disease	  (age	  of	  onset)	  
• Alzheimer's	  disease	  (late	  onset)	  
• Alzheimer's	  disease	  biomarkers	  
• Amyotrophic	  lateral	  sclerosis	  
• Ankylosing	  spondylitis	  
• Arthritis	  (juvenile	  idiopathic)	  
• Asthma	  
• Atrial	  fibrillation/atrial	  flutter	  
• Attention	  deficit	  hyperactivity	  disorder	  
• Autism	  
• Barrett's	  esophagus	  
• Basal	  cell	  carcinoma	  
• Beta	  thalassemia/hemoglobin	  e	  disease	  
• Biliary	  atresia	  
• Biomedical	  quantitative	  traits	  
• Bipolar	  disorder	  
• Bipolar	  disorder	  and	  major	  depressive	  disorder	  (combined)	  
• Bipolar	  disorder	  and	  schizophrenia	  
• Bladder	  cancer	  
• Blood	  pressure	  
• Body	  mass	  in	  chronic	  obstructive	  pulmonary	  disease	  
• Body	  mass	  index	  
• Bone	  mineral	  density	  
• Bone	  mineral	  density	  (hip)	  
• Bone	  mineral	  density	  (spine)	  
• Breast	  cancer	  
• Breast	  cancer	  (male)	  
• C-­‐reactive	  protein	  
• C-­‐reactive	  protein	  and	  white	  blood	  cell	  count	  
• Cardiovascular	  disease	  risk	  factors	  
• Carotid	  atherosclerosis	  in	  HIV	  infection	  
• Celiac	  disease	  
• Celiac	  disease	  and	  rheumatoid	  arthritis	  
• Cholesterol	  (total)	  
• Chronic	  hepatitis	  C	  infection	  
• Chronic	  kidney	  disease	  
• Chronic	  kidney	  disease	  and	  serum	  creatinine	  levels	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• Chronic	  lymphocytic	  leukemia	  
• Chronic	  myeloid	  leukemia	  
• Chronic	  obstructive	  pulmonary	  disease	  
• Cleft	  lip	  
• Colorectal	  cancer	  
• Conduct	  disorder	  (symptom	  count)	  
• Coronary	  artery	  calcification	  
• Coronary	  heart	  disease	  
• Creutzfeldt-­‐Jakob	  disease	  
• Creutzfeldt-­‐Jakob	  disease	  (variant)	  
• Crohn's	  disease	  
• Crohn's	  disease	  and	  celiac	  disease	  
• Crohn's	  disease	  and	  psoriasis	  
• Cystic	  fibrosis	  severity	  
• Diabetes	  (gestational)	  
• Diabetic	  retinopathy	  
• Diastolic	  blood	  pressure	  
• Dilated	  cardiomyopathy	  
• Disc	  degeneration	  (lumbar)	  
• Drinking	  behavior	  
• Duodenal	  ulcer	  
• Dupuytren's	  disease	  
• Electrocardiographic	  traits	  
• End-­‐stage	  renal	  disease	  (non-­‐diabetic)	  
• Endometrial	  cancer	  
• Endometriosis	  
• Eosinophilic	  esophagitis	  (pediatric)	  
• Epilepsy	  
• Epilepsy	  (generalized)	  
• Erectile	  dysfunction	  
• Erectile	  dysfunction	  and	  prostate	  cancer	  treatment	  
• Esophageal	  cancer	  
• Esophageal	  cancer	  (alcohol	  interaction)	  
• Esophageal	  cancer	  (squamous	  cell)	  
• Essential	  tremor	  
• Ewing	  sarcoma	  
• Fasting	  plasmaglucose	  
• Follicular	  lymphoma	  
• Fuchs's	  corneal	  dystrophy	  
• Gallstones	  
• Gamma	  glutamyltranspeptidase	  
• Gastric	  cancer	  
• Glaucoma	  
• Glaucoma	  (primary	  open-­‐angle)	  
• Glioma	  
• Glioma	  (high-­‐grade)	  
• Glomerulosclerosis	  
• Glycated	  hemoglobinlevels	  
• Graves'	  disease	  
• HDL	  cholesterol	  
• HDL	  cholesterol	  -­‐	  triglycerides	  (HDLC-­‐TG)	  
• Hematological	  and	  biochemical	  traits	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• Hepatitis	  B	  
• Hepatocellular	  carcinoma	  
• Hippocampal	  atrophy	  
• Hirschsprung's	  disease	  





• Idiopathic	  pulmonary	  fibrosis	  
• IgA	  nephropathy	  
• IgE	  levels	  
• Infantile	  hypertrophic	  pyloric	  stenosis	  
• Inflammatory	  bowel	  disease	  
• Inflammatory	  bowel	  disease	  (early	  onset)	  
• Intracranial	  aneurysm	  
• Kawasaki	  disease	  
• Kidney	  stones	  
• Knee	  osteoarthritis	  
• LDL	  cholesterol	  
• Leprosy	  
• Lipid	  metabolism	  phenotypes	  
• Lipoprotein-­‐associated	  phospholipase	  A2	  activity	  and	  mass	  
• Liver	  enzyme	  levels	  (alanine	  transaminase)	  
• Liver	  enzyme	  levels	  (alkalinephosphatase)	  
• Liver	  enzyme	  levels	  (gamma-­‐glutamyl	  transferase)	  
• Longevity	  
• Lung	  adenocarcinoma	  
• Lung	  cancer	  
• Major	  depressive	  disorder	  
• Major	  mood	  disorders	  
• Malaria	  
• Melanoma	  
• Menarche	  (age	  at	  onset)	  
• Meningioma	  
• Meningococcal	  disease	  
• Metabolic	  syndrome	  
• Metabolic	  syndrome	  (bivariate	  traits)	  
• Metabolic	  traits	  
• Metabolite	  levels	  
• Migraine	  
• Moyamoya	  disease	  
• Multiple	  cancers	  (lung	  cancer	  and	  gastric	  cancer	  and	  squamous	  cell	  carcinoma)	  
• Multiple	  myeloma	  
• Multiple	  sclerosis	  
• Myasthenia	  gravis	  
• Myeloproliferative	  neoplasms	  
• Myocardial	  infarction	  
• Myocardial	  infarction	  (early	  onset)	  
• Myopia	  (pathological)	  
• Narcolepsy	  
• Nephrolithiasis	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• Nephropathy	  
• Nephropathy	  (idiopathic	  membranous)	  
• Neuroblastoma	  
• Neuroblastoma	  (high-­‐risk)	  
• Non-­‐alcoholic	  fatty	  liver	  disease	  histology	  (other)	  
• Non-­‐obstructive	  azoospermia	  
• Non-­‐small	  cell	  lung	  cancer	  
• Nonalcoholic	  fatty	  liver	  disease	  
• Obesity	  (early	  onset	  extreme)	  
• Obesity	  (extreme)	  




• Ovarian	  cancer	  
• Paget's	  disease	  
• Pancreatic	  cancer	  
• Panic	  disorder	  
• Parkinson's	  disease	  
• Periodontitis	  
• Phospholipid	  levels	  (plasma)	  
• Plasminogen	  activator	  inhibitor	  type	  1	  levels	  (PAI-­‐1)	  
• Polycystic	  ovary	  syndrome	  
• Primary	  biliary	  cirrhosis	  
• Primary	  sclerosing	  cholangitis	  
• Progressive	  supranuclear	  palsy	  
• Proinsulin	  levels	  
• Prostate	  cancer	  
• Protein	  quantitative	  traitloci	  
• Psoriasis	  
• Psoriatic	  arthritis	  
• Pulmonary	  function	  
• Renal	  cell	  carcinoma	  
• Renal	  function	  and	  chronic	  kidney	  disease	  
• Restless	  legs	  syndrome	  
• Rheumatoid	  arthritis	  
• Sarcoidosis	  
• Schizophrenia	  
• Schizophrenia	  and	  bipolar	  disorder	  and	  depression	  (combined)	  
• Sclerosing	  cholangitis	  and	  ulcerative	  colitis	  (combined)	  
• Scoliosis	  
• Soluble	  E-­‐selectin	  levels	  
• Soluble	  levels	  of	  adhesion	  molecules	  
• Stevens-­‐johnson	  syndrome	  and	  toxic	  epidermal	  necrolysis	  (SJS-­‐TEN)	  
• Stroke	  
• Stroke	  (ischemic)	  
• Sudden	  cardiac	  arrest	  
• Suicide	  attempts	  in	  bipolar	  disorder	  
• Systemic	  lupus	  erythematosus	  
• Systemic	  sclerosis	  
• Systolic	  blood	  pressure	  
• Temperament	  (bipolar	  disorder)	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• Testicular	  cancer	  
• Testicular	  germ	  cell	  cancer	  
• Testicular	  germ	  cell	  tumor	  
• Thoracic	  aortic	  aneurysms	  and	  dissections	  
• Thyroid	  cancer	  
• Thyrotoxic	  hypokalemic	  periodic	  paralysis	  
• Tourette	  syndrome	  
• Triglycerides	  
• Tuberculosis	  
• Two-­‐hour	  glucose	  challenge	  
• Type	  1	  diabetes	  
• Type	  1	  diabetes	  autoantibodies	  
• Type	  1	  diabetes	  nephropathy	  
• Type	  2	  diabetes	  
• Type	  2	  diabetes	  and	  othertraits	  
• Ulcerative	  colitis	  
• Urinary	  bladder	  cancer	  
• Uterine	  fibroids	  
• Vitiligo	  
• Wilms	  tumor	  
• YKL-­‐40	  levels	  
• Response	  to	  antipsychotic	  therapy	  (extrapyramidal	  side	  effects)	  
9.2 R	  code	  for	  LogReg2	  model	  
This	  function	  was	  taken	  from	  the R package	  descr [154]	  and	  has	  been	  included	  
here	  for	  reference.	  	  
	  
LogRegR2 = function (model) {# version 2.0, 22-Jan-2012, Dirk Enzmann  
 # Calculates multiple R² analogs (pseudo R²) of logistic regression:  
 
if ((model$family$family != "binomial") | (model$family$link != "logit"))  
{ stop('No logistic regression model, no pseudo R² computed\n') }  
 
 n = dim(model$model)[1]  
 Chi2 = model$null - model$dev  
 Df = model$df.null - model$df.res  
 p = 1-pchisq(Chi2,Df)  
 
 lp = predict(model)  
 var_lp = var(lp)  
 
 RL2 = Chi2/model$null # also called McFaddens R²  
 Cox = 1-exp(-Chi2/n) # Cox & Snell Index  
 Nag = Cox/(1-exp(-model$null/n)) # Nagelkerke Index  
 MZ = var_lp/(var_lp + pi^2/3) # McKelvey & Zavoina's R²  
 
list('Chi2'=Chi2,'df'=Df,'p'=p,'RL2'=RL2,'CoxR2'=Cox,'NagelkerkeR2'=Nag,'McKelvey
_ZavoinaR2'=MZ)  
} 
